Program and Conference Information

25th CROI
Conference on Retroviruses and Opportunistic Infections

Boston
March 4-7, 2018
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CROI FOUNDATION</td>
<td>2</td>
</tr>
<tr>
<td>IAS–USA</td>
<td>2</td>
</tr>
<tr>
<td>CROI 2018 PROGRAM COMMITTEE</td>
<td>3</td>
</tr>
<tr>
<td>Scientific Program Committee</td>
<td>3</td>
</tr>
<tr>
<td>Community Liaison Subcommittee</td>
<td>5</td>
</tr>
<tr>
<td>EXTERNAL REVIEWERS</td>
<td>6</td>
</tr>
<tr>
<td>SCHOLARSHIP Awardees</td>
<td>8</td>
</tr>
<tr>
<td>New Investigator Awardees</td>
<td>8</td>
</tr>
<tr>
<td>International Investigator Awardees</td>
<td>12</td>
</tr>
<tr>
<td>Community Educator Awardees</td>
<td>12</td>
</tr>
<tr>
<td>CONTINUING MEDICAL EDUCATION</td>
<td>13</td>
</tr>
<tr>
<td>GENERAL INFORMATION</td>
<td>15</td>
</tr>
<tr>
<td>Overview</td>
<td>15</td>
</tr>
<tr>
<td>Conference Support</td>
<td>15</td>
</tr>
<tr>
<td>Americans With Disabilities Act</td>
<td>15</td>
</tr>
<tr>
<td>Emergency Services</td>
<td>15</td>
</tr>
<tr>
<td>Embargo Policies and Social Media</td>
<td>16</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>16</td>
</tr>
<tr>
<td>Meals</td>
<td>16</td>
</tr>
<tr>
<td>Overflow Accommodations for Oral Sessions</td>
<td>17</td>
</tr>
<tr>
<td>Mobile App</td>
<td>17</td>
</tr>
<tr>
<td>Website</td>
<td>17</td>
</tr>
<tr>
<td>Webcasts</td>
<td>17</td>
</tr>
<tr>
<td>Affiliated and Proximate Activities Policy</td>
<td>18</td>
</tr>
<tr>
<td>Wi-Fi Access at the Conference</td>
<td>18</td>
</tr>
<tr>
<td>Conference Badges</td>
<td>18</td>
</tr>
<tr>
<td>Child Care</td>
<td>18</td>
</tr>
<tr>
<td>Conference Etiquette</td>
<td>18</td>
</tr>
<tr>
<td>CROI HOTELS</td>
<td>19</td>
</tr>
<tr>
<td>CONFERENCE SERVICES</td>
<td>22</td>
</tr>
<tr>
<td>ABSTRACT PROCESS</td>
<td>24</td>
</tr>
<tr>
<td>PRECONFERENCE AND ORAL SESSIONS</td>
<td>26</td>
</tr>
<tr>
<td>POSTER SESSIONS, BY DAY</td>
<td>64</td>
</tr>
<tr>
<td>POSTER SESSIONS, BY CATEGORY</td>
<td>168</td>
</tr>
<tr>
<td>INDEX OF STUDIES RELATED TO WOMEN</td>
<td>172</td>
</tr>
<tr>
<td>INDEX OF PRESENTING AUTHORS</td>
<td>179</td>
</tr>
<tr>
<td>CONFERENCE SCHEDULE</td>
<td>INSIDE BACK COVER</td>
</tr>
<tr>
<td>CONVENTION CENTER FLOOR PLANS</td>
<td>BACK COVER</td>
</tr>
</tbody>
</table>

Printed in the United States of America.
© Copyright 2018 CROI Foundation/IAS–USA. All rights reserved.
ISBN #978-1-7320053-0-3
CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>President</th>
<th>Kevin M. De Cock, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td></td>
<td>Nairobi, Kenya</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Scott M. Hammer, MD</td>
</tr>
<tr>
<td>Secretary-Treasurer</td>
<td>Columbia University</td>
</tr>
<tr>
<td></td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td>Sharon L. Hillier, PhD</td>
</tr>
<tr>
<td>ICAP at Columbia University</td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td></td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td>John W. Mellors, MD</td>
</tr>
<tr>
<td>San Francisco Department of Public Health</td>
<td>University of Pittsburgh</td>
</tr>
<tr>
<td></td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td>Robert T. Schooley, MD</td>
</tr>
<tr>
<td>University of California Los Angeles</td>
<td>University of California San Diego</td>
</tr>
<tr>
<td>Los Angeles, CA, United States</td>
<td>La Jolla, CA, United States</td>
</tr>
</tbody>
</table>

IAS—USA

The International Antiviral Society—USA is a 501(c)(3) not-for-profit professional education organization. The IAS—USA partners with the CROI PC and Foundation to organize CROI. The mission of the IAS—USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen
Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone: 415-544-9400
Website: www.iasusa.org
CROI 2018 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

- **Judith S. Currier, MD, MSc**
  - CROI 2018 Chair
  - University of California
  - Los Angeles, CA, United States

- **Sharon L. Hillier, PhD**
  - CROI 2018 Vice Chair
  - University of Pittsburgh
  - Pittsburgh, PA, United States

- **Elaine J. Abrams, MD**
  - ICAP at Columbia University
  - New York, NY, United States

- **Adaora Adimora, MD**
  - University of North Carolina at Chapel Hill
  - Chapel Hill, NC, United States

- **Galit Alter, PhD**
  - Ragon Institute of MGH, MIT and Harvard
  - Cambridge, MA, United States

- **Constance A. Benson, MD**
  - University of California
  - San Diego, CA, United States

- **Paul Bieniasz, PhD**
  - The Rockefeller University
  - New York, NY, United States

- **Richard A. Koup, MD**
  - CROI 2018 Vice Chair
  - Vaccine Research Center
  - National Institute of Allergy and Infectious Diseases
  - National Institutes of Health
  - Bethesda, MD, United States

- **Susan P. Buchbinder, MD**
  - San Francisco Department of Public Health
  - San Francisco, CA, USA

- **Connie L. Celum, MD, MPH**
  - University of Washington
  - Seattle, WA, United States

- **Richard E. Chaisson, MD**
  - The Johns Hopkins University
  - Baltimore, MD, United States

- **Nicolas Chomont, PhD**
  - Université de Montréal
  - Montreal, Canada

- **John M. Coffin, PhD**
  - Tufts University
  - Boston, MA, United States

- **Constance A. Benson, MD**
  - University of California
  - San Diego, CA, United States

- **Paul Bieniasz, PhD**
  - The Rockefeller University
  - New York, NY, United States

- **Richard A. Koup, MD**
  - CROI 2018 Vice Chair
  - Vaccine Research Center
  - National Institute of Allergy and Infectious Diseases
  - National Institutes of Health
  - Bethesda, MD, United States

- **Susan P. Buchbinder, MD**
  - San Francisco Department of Public Health
  - San Francisco, CA, USA

- **Connie L. Celum, MD, MPH**
  - University of Washington
  - Seattle, WA, United States

- **Richard E. Chaisson, MD**
  - The Johns Hopkins University
  - Baltimore, MD, United States

- **Nicolas Chomont, PhD**
  - Université de Montréal
  - Montreal, Canada

- **John M. Coffin, PhD**
  - Tufts University
  - Boston, MA, United States
Community Liaison Subcommittee
The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Mark Hubbard
Tennessee Association of People With AIDS
Nashville, TN, United States

Jeff Taylor
AIDS Treatment Activists Coalition
Palm Springs, CA
United States

Morenike Ukpong, FWACS, MBA, BChD
Obafemi Awolowo University
Ile-Ife, Nigeria

Lisa Diane White, MPH
SisterLove, Inc.
Atlanta, GA, United States

The CROI Foundation wishes to thank for their service the following individuals who rotated off the Scientific Program Committee in 2017:

Harold W. Jaffe, MD
Ronald T. Mitsuyasu, MD
Julie M. Overbaugh, PhD
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2018.

Edward P. Acosta, PharmD
University of Alabama at Birmingham
Birmingham, AL, United States

Peter L. Anderson, PharmD
University of Colorado
Aurora, CO, United States

Till Bärnighausen, MD, PhD
Heidelberg University
Heidelberg, Germany

John M. Blandford, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Marta Boffito, MD, PhD
Chelsea and Westminster NHS Foundation Trust
London, United Kingdom

Jacob Bor, ScD
Boston University
Boston, MA, United States

William Borkowsky, MD
New York University
New York, NY, United States

Bruce J. Brew, MD, MBBS
University of New South Wales
Sydney, Australia

Todd T. Brown, MD, PhD
The Johns Hopkins University
Baltimore, MD, United States

Corey Casper, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Ellen G. Chadwick, MD
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL, United States

David B. Clifford, MD
Washington University in St Louis
St Louis, MO, United States

Kelly Dooley, MD, PhD
The Johns Hopkins University
Baltimore, MD, United States

David Evans, PhD
University of Wisconsin-Madison
Madison, WI, United States

Charles W. Flexner, MD
The Johns Hopkins University
Baltimore, MD, United States

Patricia M. Flynn, MD
St. Jude Children's Research Hospital
Memphis, TN, United States

Jennifer Furin, MD, PhD
Case Western Reserve University
Cleveland, OH, United States

Dana H. Gabuzda, MD
Dana-Farber Cancer Institute, Boston, MA, United States

Monica Gandhi, MD, MPH
University of California San Francisco
San Francisco, CA, United States

Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Elvin Geng, MD, MPH
University of California San Francisco
San Francisco, CA, United States

Carlo Giaquinto, MD
University of Padova
Padova, Italy

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, United States

James G. Hakim, MD
University of Zimbabwe
Harare, Zimbabwe

P. Richard Harrigan, PhD
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, Canada

Theodora Hatzioannou, PhD
The Rockefeller University
New York, NY, United States

Priscilla Hsue, MD
University of California San Francisco
San Francisco, CA, United States

Harold W. Jaffe, MD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Angela Kashuba, PharmD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Susan E. Krown, MD
AIDS Malignancy Consortium
New York, NY, United States

Raphael J. Landovitz, MD
University of California Los Angeles
Los Angeles, CA, United States

Bruno Ledergerber, PhD
University of Zurich
Zurich, Switzerland
SCHOLARSHIP Awardees

CROI is committed to supporting new and early career investigators working in HIV research to help them further their education and to network with other researchers in the field. New Investigator Scholarship awardees are presenting authors on accepted abstracts and have been highly recommended by their mentors. In addition, CROI offers scholarships to international researchers and community educators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown that they will greatly benefit from the opportunity to participate in CROI.

New Investigator Awardees

Hadega Aamer
Seattle Children’s Research Institute

Julia A. Aepfelbacher
National Institutes of Health

Abhinav Ajaykumar
University of British Columbia

Raza M. Alvi
Massachusetts General Hospital

Patrizia Amelio
Lausanne University Hospital

Elizabeth M. Anderson
National Cancer Institute

Abigail Armstrong
University of Colorado

Tigran Avoundjian
University of Washington

Nadine Bachmann
University Hospital Zurich

Roger Badia
IRI/CSIC Institute for AIDS Research

Omolara Baiyegunhi
University of Kwazulu-Natal

Kayode Balogun
University Health Network

Kiran Bandi
University of Pittsburgh

Anya Bauer
University of Pennsylvania

Eve-Marie A. Benson
The Johns Hopkins University

Lynn N. Bertagnolli
The Johns Hopkins University

Rachael Billock
University of North Carolina at Chapel Hill

Gilad Bismut
The Johns Hopkins University

Oscar Blanch-Lombarte
IRI/CSIC Institute for AIDS Research

Anne Boerekamps
Erasmus University Medical Center

David C. Boettiger
Kiby Institute

Denali Boon
The Johns Hopkins University

Julie Boucau
Massachusetts General Hospital

Carolyn Boudreau
Ragon Institute of MGH, MIT and Harvard

Kassem Bourgi
Vanderbilt University

Helen J. Box
University of Liverpool

Yann Breton
Laval University

Sarah Bridge
University of Minnesota

Egidio Brocca-Cofano
University of Pittsburgh

Manuela Bullo
University of North Carolina at Chapel Hill

Erin M. Burgunder
University of North Carolina at Chapel Hill

Haotian Cai
Association of Schools and Programs of Public Health

Yanhui Cai
Wistar Institute

Keri Calkins
The Johns Hopkins University

Eugenio N. Cavallari
Sapienza University of Rome

Emily Cedarbaum
University of California San Francisco

Luigi Celani
Sapienza University of Rome

Maddalena Cerrone
St. Stephen’s AIDS Trust—Chelsea and Westminster Hospital

Antoine Chaillon
University of California San Diego

Chloe S. Chaudhury
National Institutes of Health

Sandra E. Chaudron
University of Zurich

Bonnie Chen
Case Western Reserve University

Liang Cheng
University of North Carolina at Chapel Hill

Sukrutha Chettimada
Dana–Farber Cancer Institute

Ryan Cheu
University of Washington

Fatema Z. Chowdhury
The Ragon Institute of MGH, MIT and Harvard

Aaron Christensen-Quick
University of California San Diego

Angelo A. Clemenzia-Alben
University of California San Francisco

Kalysha Clossen
British Columbia Centre for Excellence in HIV/AIDS

Krystal Colon-Rivera
Wistar Institute

Julie Copely
University College London

Bjorn Corleis
Ragon Institute of MGH, MIT and Harvard

César N. Cortés-Rubio
National Institute of Respiratory Diseases

Daniela Angela Covino
Istituto Superiore di Sanità
Morgan L. Craig  
Harvard University

Lize Cuypers  
Katholieke Universiteit Leuven

Weiwei Dai  
University of Massachusetts Medical School

Thibaut Davy-Mendez  
University of North Carolina Chapel Hill

Davide De Francesco  
University College London

Simon de Montigny  
University of Montreal

Valentina De Zan  
Ospedale San Raffaele

Christian Deo T. Deguit  
University of the Philippines Manila

Heloise M. Delagreverie  
Hôpital Saint-Louis

Vincent Desrosiers  
Laval University

Francisco Díez Fuertes  
Instituto de Salud Carlos III

Lourdes Domínguez-Domínguez  
Hospital Universitario 12 de Octubre

Diako Ebrahimi  
University of Minnesota

Ceri Evans  
Queen Mary University of London

Emily Evans  
Emory University

Mary Evans  
Centers for Disease Control and Prevention

Claudia Fabrizio  
University of Bari

Francisco Fanjul  
Hospital Universitario de Son Espases

Shelli Farhadian  
Yale University

Amanda Fernández-Rodríguez  
Instituto de Salud Carlos III

Bridget Fisher  
Center for Infectious Disease Research

Jacob Flynn  
National Institutes of Health

Lindsay T. Fourman  
Massachusetts General Hospital

Chris Fujimirun  
Chulalongkorn University

Hirofumi Fukuda  
Kyoto University

Roberta Gagliardini  
Catholic University of the Sacred Heart

Pierre Gantner  
Hôpitaux Universitaires de Strasbourg

Pilar García Broncano  
Ragon Institute of MGH, MIT and Harvard

Lucio Jesús García-Fraile Fraile  
Hospital Universitario de La Princesa

Rolando Garza  
University of Pennsylvania

Marco Gelpi  
University Hospital Rigshospitalet

Matthew Generoso  
New York University

Jeffrey Gerold  
Harvard University

Melissa Ghulam-Smith  
Boston University

Ana Godinho-Santos  
Universidade de Lisboa

Carmen M. González Domenech  
Hospital Virgen de la Victoria

David Goodman-Meza  
University of California Los Angeles

Bindu P. Gopalan  
St. John's Research Institute

Ria Goswami  
Duke University

Julien Gras  
Hôpital Saint-Louis

Justin Greene  
Oregon Health and Sciences University

Sharon A. Greene  
University of Washington

David C. Griffith  
The Johns Hopkins University

Ahmad Haeri Mazanderani  
National Institute for Communicable Diseases

Megan Halkett  
Northwestern University

Ryan G. Handoko  
Yale University

Laurent Hany  
CHU de Quebec-Université Laval

Tiffany Hensley-McBain  
University of Washington

Lucas E. Hermans  
University Medical Center Utrecht

Akarin Hiransuthikul  
HIV–NAT, Thai Red Cross AIDS Research Centre

Elke Hoornenborg  
Public Health Service Amsterdam

Bethany A. Horsburgh  
The Westmead Institute for Medical Research

Stephane Hua  
Ragon Institute of MGH, MIT and Harvard

Seth C. Insaule  
Amsterdam Institute for Global Health and Development

Sergio Ita  
University of California San Diego

Victoria Iyun  
University of Cape Town

Madeleine Jennewein  
Harvard University

Julie Jesson  
INSERM

Steven W. Jin  
Simon Fraser University

Ana Jordan-Paiz  
Instituto de Salud Carlos III

Claus Kadelka  
University of Zurich

Gerrit Kann  
University Hospital Frankfurt

Sanket Kant  
McGill University

Christina B. Karsten  
Ragon Institute of MGH, MIT and Harvard

Mark D. Kelley  
University of Pittsburgh

Jéromine Klingler  
INSERM

Andreas D. Knudsen  
University of Copenhagen

Yik Lim Kok  
University Hospital Zürich

Xiao Mei T. Kuang  
Simon Fraser University

Hsiao-Hsuan Ku  
Ragon Institute of MGH, MIT and Harvard

Katharina Kusejko  
University Hospital Zurich

Abena Kwaa  
The Johns Hopkins University
General Information

Maria Pino
Vertebrates National Primate Research Center
Micah Piske
University of British Columbia
Alex Pollard
Brighton and Sussex Medical School
Rosalie Ponte
McGill University
Joan T. Price
University of North Carolina at Chapel Hill
Alizé Proust
CHU de Québec-Université Laval
Joel Provost
Laval University
Maria Pyra
University of Washington
Daniel Radwan
The Johns Hopkins University
Mohammad A. Rahman
National Institutes of Health
Rajith Kumar Reddy Rajoli
University of Liverpool
Cláudia Priscila Ramos Muniz
Instituto Nacional de Cancer
Erin Ready
University of British Columbia
Ludy Registre
Boston University
Enrico Richter
University Hospital Essen
Kathryn A. Risher
London School of Hygiene & Tropical Medicine
Muntsa Rocafort
InCaSa Institute for AIDS Research
Marta Rodriguez-Garcia
Dartmouth College
Andreas Ronit
Copenhagen University Hospital
Ofelia M. Rosales Del Real
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubirián
Marina Rubio Garrido
Hospital Ramón y Cajal
Rachel L. Rutishauser
University of California San Francisco
Sahar Saeed
McGill University
Syim Salahuddin
McGill University
Romina Salpini
University of Rome Tor Vergata
Vishal Samboju
University of California San Francisco
Ryan Sanford
Montreal Neurological Institute
Montserrat Sanmartí
Hospital Universitari Mútua de Terrassa
Anamaria D. Sarca
Kyoto University
Mariane H. Schleimann
Aarhus University Hospital
Carla Serra Peinado
Vald d’Hebron Research Institute
Paola Sette
University of Pittsburgh
Radwa Sharaf
Harvard University
Katie Sharp
University of California Los Angeles
Emily Shava
Botswana Harvard AIDS Institute Partnership
Chelsea L. Shover
University of California Los Angeles

Mariya V. Sivay
The Johns Hopkins University
Shayla Smith
Columbia University
Matthew A. Spinelli
University of California San Francisco
Nithya Srinivas
University of North Carolina at Chapel Hill
Carly Elizabeth C. Starke
National Institutes of Health
Melanie Stecher
University of Cologne
Natalia Stella-Ascariz
Hospital La Paz Institute for Health Research
Zachary Strongin
Brigham and Women’s Hospital
Megan M. Stumpf
Fred Hutchinson Cancer Research Center
Jing Sun
The Johns Hopkins University
Nicholas Tan
University of Washington
Shema Tariq
University College London
Lee M. Tatham
University of Liverpool
Bryn C. Taylor
University of California San Diego
Kirk A. Taylor
Imperial College London
Sushama Telwatte
San Francisco VA Medical Center
Richard A. Teran
Columbia University
Rebekka F. Thudium
University of Copenhagen
Phillip Tomezsko
Harvard University
Jessie Torgersen
University of Pennsylvania
Berta Torres
Hospital Clinic of Barcelona
Wim Truyensteer
HIV Cure Research Center, Ghent University
Jonathan Underwood
Imperial College London
Ward P.H. van Bilsen
Public Health Service Amsterdam
Rachel Van Duyn
National Cancer Institute
Clarissa Van Hecke
HIV Cure Research Center, Ghent University
Benni S. Vargas
University of Pittsburgh
Jennifer Velloza
University of Washington
Beate Vestad
Oso University Hospital
Line K. Vibholm
Aarhus University
Alinda Vos
University Medical Center Utrecht
Victoria E. Walker-Sperling
National Cancer Institute
Qi Wang
University of North Carolina at Chapel Hill
Zheng Wang
University of Pittsburgh
Zheng Wang
The Johns Hopkins University
Tomas Raul Wiche Salinas
Centre Hospitalier de l’Université de Montreal
Ingeborg Wijting  
Erasmus University Medical Center  
Nicole E. Winchester  
National Institutes of Health  
Wen Wu  
Oregon Health and Sciences University  
H. Manisha N. Yapa  
University of New South Wales, Australia  
Christine Youn  
National Institute of Allergy and Infectious Diseases  
Yinfeng Zhang  
The Johns Hopkins University

International Investigator Awardees

Clement G. Adu-Gyamfi  
University of the Witwatersrand

Gbolahan Ajibola  
Botswana Harvard AIDS Institute Partnership

Motswedi Anderson  
Botswana Harvard AIDS Institute Partnership

Mariglia B. Antonio  
Universidad de Sao Paulo

Daniel W. Atwine  
Medecins Sans Frontieres-Epicentre

James Ayieko  
Kenya Medical Research Institute

Barbara Castenuovo  
Infectious Disease Institute

Unoda A. Chakalisa  
Botswana Harvard AIDS Institute Partnership

Menard L. Chihana  
Medecins Sans Frontieres-Epicentre

Sergio M. de Almeida  
Universidade Federal do Parana

Kostyantyn Dumchev  
Ukrainian Institute on Public Health Policy

Eduard Grebe  
Stellenbosch University

Etienne Kadima  
Botswana Harvard AIDS Institute Partnership

Makobu Kimani  
Kenya Medical Research Institute

Marina Kornilova  
Alliance for Public Health

Anna Lawino  
Makere University

Wei Lu  
Peking Union Medical College Hospital

Mompati O. Mmalane  
Botswana Harvard AIDS Institute Partnership

Keolebogile N. Mmasa  
Botswana Harvard AIDS Institute Partnership

Sikhulile Moyo  
Botswana Harvard AIDS Institute Partnership

Lydia Nakiyung  
Infectious Disease Institute

Sabin Nsanzimana  
Infectious Disease Institute

Ninutchta Paengsai  
Chiang Mai University

Tamsin K. Phillips  
University of Cape Town

Angsana Phuphuakrat  
Mahidol University

Shanmugam Saravanam  
YR Gaitonde Center for AIDS Research and Education

Kenneth Ssebambulidde  
Infectious Disease Institute

Sarah Jane Steele  
Medecins Sans Frontieres

Birkneh T. Tadesse  
Hawassa University

Vu P. Thao  
Oxford University Clinical Research Unit in Vietnam

Thiago S. Torres  
Instituto Nacional de Infectologia Evandro Chagas (INI/ Fiocruz)

Darlisha A. Williams  
University of Minnesota

Community Educator Awardees

Oluwatosis B. Alaka  
New HIV Vaccine and Microbicide Advocacy Society

David W. Andrist  
The Ohio State University

Giorgio Barbareschi  
European AIDS Treatment Group

Tamás Bereczky  
European AIDS Treatment Group

Charles Brown  
Preventive Care International

Giulio M. Corbelli  
European AIDS Treatment Group

Michael J. Dorosh  
National Institutes of Health

Florita C. Durueke  
New HIV Vaccine and Microbicide Advocacy Society

Daniel K. Gondwe  
Malawi College of Medicine-Johns Hopkins University Research Project

Tian Johnson  
African Alliance for HIV Prevention

Tapiwanashe Kujinga  
Pan-African Treatment Access Movement

Grace Kumwenda  
Pakachere Institute for Health and Development Communication

Maureen Luba  
Centre for the Development of People

Michael Meulbroek  
Asociacion para el trasplante de Organos a Seropositivos

Peter A. Mogere  
Kenya Medical Research Institute-CCR PHRD Thika

Steven S. Muchnick  
Delaney AIDS Research Enterprise to Defeat HIV

Kennedy Mupeli  
Centre for Youth of Hope

Robert E. Newells  
AIDS Project of the East Bay

Joyce W. Ng'ang'a  
WKI Health

Moses S. Nsubuga  
People in Need Agency

Elia F. Phiri  
Addington Afro-Ethnic Health Promotion Group

Ferran Pujol Roca  
Proyecto dels NOMS-Hispanosida

Jorge Saz Berges  
Joves Positius

Pich Seekaew  
Thai Red Cross AIDS Research Centre

Cissy Ssuuna  
Baylor College of Medicine Children’s Foundation-Uganda

Harry C. Tembo  
Zambia Community Advisory Platform
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The IAS–USA designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI 2018, participants will be able to:

• Describe basic science research advances in HIV
• List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
• Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care practitioners, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, and symposia. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions. For physician attendees Board certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation
During the conference, links to the daily and final evaluations will be available at a secure web page on the CROI website at www.croiconference.org/electronic-materials. You will need your e-mail address that you used to register for this conference and your registration ID to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations must be completed by April 9, 2018. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile in the CROI website within 2 to 3 business days.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference, including premeeting workshops, opening session lectures, plenary lectures, and symposia. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended for your certificate.


Disclosure of Financial Relationships
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount.) The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information is detailed in the Abstract eBook.

Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. In 2018, we mark the 25th CROI.

Conference Support
CROI is largely supported by participant registration fees. CROI registration fees cover all hosted attendee meals (including the welcome reception) and travel expenses for invited participants (eg, speakers, leaders, moderators, and CROI PC), as well as selected meeting materials and other conference expenses.
In addition, CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. Commercial support is used to cover some of the costs of the convention center, audiovisual services, and other conference services.
CROI 2018 received grant support commitments from the following commercial companies:

PLATINUM SUPPORTERS
Gilead Sciences
Merck & Co
ViiV Healthcare

GOLD SUPPORTER
Janssen Therapeutics

Additional support has been provided by AbbVie

Americans With Disabilities Act
CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Attendee Services booth on the Plaza level during the conference.

Emergency Services
In the event of an emergency please contact the convention center command center, open 24 hours daily, or notify CROI staff. The command center can be reached at (617) 954-2111 and is located by the Boylston Street entrance to the convention center. In addition, security offices are located throughout the building at each of the building’s entrances. A nurse is available on-site and is accessible by contacting the command center, notifying CROI staff, or visiting the nurse’s office in the registration area.
**Embargo Policies and Social Media**

The research presented at CROI 2018 is embargoed until the conclusion of the session in which it is presented. For example, if a study is presented from 10:15 AM to 10:30 AM as part of a session that ends at 12:00 PM, the embargo on that study lifts at 12:00 PM. Embargoes on poster presentations lift at the conclusion of the session in which the poster is presented. If a study to be presented at CROI 2018 is included in an official CROI press conference and that press conference takes place before the official presentation of the study at the conference, the embargo lifts at the conclusion of the press conference in which the study is featured.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (e.g., blogs) or social media (e.g., Facebook, Twitter). No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

**Welcome Reception**

All registered CROI attendees are invited to the Welcome Reception immediately following the Opening Session on March 4, 2018. The reception will be held in Halls C and D and the corresponding prefunction areas.

The Welcome Reception will offer attendees the opportunity to network with colleagues.

**Meals**

Hosted group morning coffee and light snacks are available to conference registrants from 7:30 AM to 8:30 AM, Monday, Tuesday, and Wednesday, outside of the general session room. An afternoon snack break will be available at 2:30 PM in Poster Hall A. Attendees are on their own for all other meals, including lunch and dinner. Below is a list of food service options located in the Convention Center or within a short walking distance.

**Food Service at the Convention Center**

- **Towne Stove and Spirits**
- **The Capital Grill**

**Food Service at the Prudential Center (adjacent to the Convention Center)**

- Ben & Jerry’s
- Cold Stone Creamery
- Crazy Dough’s Pizza
- DAVIDsTEA
- Dunkin’ Donuts
- Eataly
- Godiva
- Num Pang Kitchen
- Earl’s Kitchen & Bar
- Porto
- The Cheesecake Factory
- Towne Stove & Spirits

**Food Service Within 3 Blocks of the Convention Center**

- Bukowski, 50 Dalton St, 617-437-9999, buckowskitavern.net
- Dillon’s, 955 Boylston St, 617-421-1818, dillonsboston.com
- Boloco, 76 Boylston St, 617-266-2200, boloco.com
- Trader Joe’s, 899 Boylston St, 617-262-6505, traderjoes.com
- The Pour House, 907 Boylston St, 617-236-1767, pourhouseboston.com
- Atlantic Fish Company, 761 Boylston St, 617-267-4000, atlanticfishco.com
- Starbucks, 755 Boylston St, 617-450-0310, starbucks.com
Food Service Within 3 Blocks of the Convention Center (continued)

Dirty Water Dough Co.  222 Newbury St  617-262-0090  dirtywaterdough.com
Summer Shack  50 Dalton St  617-867-9955  summershackrestaurant.com
Whiskey’s  885 Boylston St  617-262-5551  whiskeysboston.com
Lir  903 Boylston St  617-778-0089  lironboylston.com
McGreevy’s Boston  911 Boylston St  617-262-0911  mcgreevysboston.com
Abe & Louie’s  793 Boylston St  617-536-6300  abeandlouies.com
Deluca’s Market  11 Charles St  617-523-4343  delucasmarket.com
Chipotle  553 Boylston St  617-236-1749  chipotle.com
B. Good  655 Boylston St  617-927-8333  bgood.com
Bar 10  10 Huntington Ave  617-424-7488  bar10boston.com
The Huntington at the Westin  10 Huntington Ave  617-262-9600  westincopleyplaceboston.com
Legal Sea Foods  100 Huntington Ave  617-266-7775  legalseafoods.com
Champion’s Sports Bar  110 Huntington Ave  617-927-5304  championsboston.com
Osushi  10 Huntington Ave  617-266-2788  osushiboston.com

Overflow Accommodations for Oral Sessions
If a session room fills to capacity, there will be overflow areas in rooms 302, 311, and 312. There will be signs to direct you to the respective overflow room for the session you would like to attend.

Mobile App
To access the CROI mobile App, use your registration ID number (on your name badge) and the email address you used to register for CROI.

The CROI 2018 mobile App has many features to enhance your conference experience, including to:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- E-mail session notes
- Receive the latest changes to the CROI program
- View electronic posters

The mobile App is compatible with iOS and Android devices. Search “CROI 2018” in your mobile device App store. Access is restricted to registered attendees. Your log-in information and password are provided with the registration materials.

Website
For additional information about the conference and to access electronic materials please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2018 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014, 2015, 2016, and 2017 are available at www.croiconference.org/abstracts/search-abstracts/

Webcasts
Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions are available as webcasts. Webcasts are also available as streaming video for the Apple iPad and iPhone.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts. Webcasts will be available to registered attendees within 24 hours of the end of the relevant session, and publically after the conference ends.
Affiliated and Proximate Activities Policies

The goal of CROI is to promote meaningful, high-level scientific interchange of ideas and debate in order to find better ways to prevent, treat, and cure HIV/AIDS. In keeping with this goal, organizations (commercial companies and their agents, not-for-profit groups, government agencies, etc) must be approved to host affiliated or proximate activities and meetings occurring outside CROI session times. Affiliated activities are not sponsored by, endorsed by, or supported by the IAS—USA, the CROI Foundation, or CROI 2018.

Affiliated or proximate activities are those that are scheduled during or around CROI that involve any CROI attendees. If an activity or meeting is found to have violated the policies for affiliated activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an affiliated activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and damages, and could negatively impact the registration status and attendance of those attending an unapproved affiliated activity.

If you have organized a meeting or activity that includes CROI attendees, as described in the affiliated activity guidelines, and have not completed the Affiliated Activity application, please see an IAS—USA staff member in the IAS—USA office (Room 203) for assistance.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel may not have been approved by CROI, please contact an IAS—USA staff member in the IAS—USA office.

WiFi Access at the Conference

Complimentary wireless internet is provided at the Hynes Convention Center. As a courtesy to your fellow attendees, please disable the WiFi function on your unused devices. For example, if you have a tablet, laptop, and a WiFi enabled phone, please use one device at a time to access WiFi and disable the others.

WiFi Log-in Information

Network: CROI2018    Password: CROI2018
Note: the password is case sensitive; you will need to log in each day as the building resets the network each night.

Conference Badges

You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. **DO NOT LOSE YOUR BADGE. Payment of US $850 will be required to replace a lost badge.**

Child Care

Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel.

Conference Etiquette

In consideration of the work of presenters at CROI, and the CROI copyright policy, attendees should not photograph posters, record parts of talks, or post other people's data. Please ensure all cell phones and pagers are off or are set on SILENT mode. No photography is permitted in session rooms.
Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Boston area (ie, within a 50-mile radius of the Hynes Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI Hotel Reservation System. Please inform the Conference Organizers if you have inadvertently booked a hotel stay outside of the CROI Hotel Reservation System.

CROI 2018 hotels are listed below.

<table>
<thead>
<tr>
<th>Hotel Name</th>
<th>Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Marriott Copley Plaza</td>
<td>110 Huntington Ave.</td>
<td>617-236-5800</td>
</tr>
<tr>
<td>Boston Park Plaza</td>
<td>50 Park Plaza at Arlington St.</td>
<td>617-426-2000</td>
</tr>
<tr>
<td>The Charlesmark at Copley</td>
<td>655 Boylston St.</td>
<td>617-247-1212</td>
</tr>
<tr>
<td>The Colonnade Hotel</td>
<td>120 Huntington Ave.</td>
<td>617-424-7000</td>
</tr>
<tr>
<td>Copley Square Hotel</td>
<td>47 Huntington Ave.</td>
<td>617-536-9000</td>
</tr>
<tr>
<td>Fairmont Copley Plaza</td>
<td>138 St. James Ave.</td>
<td>617-267-5300</td>
</tr>
<tr>
<td>Hilton Boston Back Bay</td>
<td>40 Dalton St.</td>
<td>617-236-1100</td>
</tr>
<tr>
<td>Mandarin Oriental</td>
<td>776 Boylston St.</td>
<td>617-535-8888</td>
</tr>
<tr>
<td>The MidTown Hotel</td>
<td>220 Huntington Ave.</td>
<td>617-262-1000</td>
</tr>
<tr>
<td>Sheraton Boston</td>
<td>39 Dalton St.</td>
<td>617-236-2000</td>
</tr>
<tr>
<td>Taj Boston</td>
<td>15 Arlington St.</td>
<td>617-536-5700</td>
</tr>
<tr>
<td>Westin Copley Place</td>
<td>10 Huntington Ave.</td>
<td>617-262-9600</td>
</tr>
</tbody>
</table>
CROI HOTELS

★ The John B. Hynes Memorial Convention Center
1 Boston Marriott Copley Place
2 Boston Park Plaza Hotel
3 The Charlesmark at Copley
4 The Colonnade Hotel
5 Copley Square Hotel
6 Fairmont Copley Plaza
7 Hilton Boston Back Bay
8 Mandarin Oriental
9 The Midtown Hotel
10 Sheraton Boston
11 Taj Boston
12 Westin Copley Place
# CONFERENCE SERVICES

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
</table>
| **Boston Information**            | Registration Area on the Plaza Level | Saturday: 2:30 PM – 7:30 PM  
                          |                           | Sunday: 8:30 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 8:00 AM – 6:30 PM |
| **Bag and Coat Check**            | Plaza Level Room 109      | Sunday: 8:00 AM – 9:30 PM  
                          |                           | Monday to Wednesday: 7:30 AM – 6:30 PM |
| **Cyber Cafe**                    | Plaza Level: Outside Poster Hall A 2nd Floor: Outside the General Session Room | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday: 7:00 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 7:30 AM – 6:00 PM |
| **Media Center**                  | Room 210                  | Sunday: 10:00 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 8:00 AM – 6:30 PM |
| **Badge Pickup**                  | Registration Area on the Plaza Level | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday: 7:00 AM – 7:00 PM  
                          |                           | Monday: 7:00 AM – 6:00 PM  
                          |                           | Tuesday and Wednesday: 8:00 AM – 6:00 PM |
| **IAS–USA Office**                | Room 203                  | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday to Wednesday: 7:00 AM – 6:00 PM |
| **Speaker Ready Room**            | Room 200                  | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday to Wednesday: 6:00 AM – 6:00 PM |
| **Personal Considerations Room**  | Room 308                  | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday: 9:00 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 8:00 AM – 6:00 PM |
| **New Mother's Room**             | Room 307                  | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday: 9:00 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 8:00 AM – 6:00 PM |
| **Networking Areas**              | Cafeteria, Rooms 303, 305, 309, 310, and Poster Halls A, B, D | Saturday: 3:00 PM – 6:00 PM  
                          |                           | Sunday: 9:00 AM – 7:00 PM  
                          |                           | Monday to Wednesday: 8:00 AM – 6:00 PM |
CONFERENCE SERVICES

Notes

Local Information and reservations assistance.

Bag and coat check are free of charge.

Computers with internet access are available for webcasts and abstract searches.

The Media Center is a work space with Wi-Fi and is the location of the daily press conferences open exclusively to registered, accredited media.

Badges and conference material can be picked up at this location.

The conference organizers are available to answer questions or concerns regarding the conference.

Oral abstract, invited, and themed discussion session speakers must drop off presentations here at least 24 hours before their presentation. Poster presenters should submit an electronic version of their poster through the abstract submission website before the start of the conference.

The Personal Considerations Room is set aside for those who require a short-term private space for personal health needs. Use of this room is available on a first-come, first-served basis.

The New Mothers’ Room is set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis.

These areas are set up with tables and chairs for attendees to gather and network with colleagues.
ABSTRACT PROCESS

Scientific Categories
A. Virology
B. Pathogenesis: Human Studies and Animal Models
C. Host Immune Responses to Infection, Vaccines, and Immunotherapy
D. HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy
E. Neuropathogenesis and Central Nervous System Complications
F. Clinical Pharmacology
G. Antiretroviral Therapy: Pre-Clinical and Randomized Trials
H. Antiretroviral Therapy: Efficacy and Effectiveness Studies
I. HIV Drug Resistance
J. HIV Diagnostics
K. Hepatitis Viruses and Liver Complications
L. Malignancies
M. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
N. Other Complications of HIV Infection and Antiretroviral Therapy
O. Tuberculosis and Other Opportunistic Infections
P. Maternal and Fetal HIV
Q. Pediatrics and Adolescents
R. Epidemiology
S. Testing
T. Prevention Interventions
U. Contraceptive and Reproductive Health in Women
V. Implementation and Scale-Up of Treatment and Care
W. Population and Cost Modeling

Abstract Content
Author names, institutions, titles, and abstracts in the Abstract eBook and other materials are presented as submitted by the corresponding author.

Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed more than 2000 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise. PC members and external experts in the field reviewed the abstracts for the quality and originality of the work and scored them numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate. Scores ranged from 1 (definite oral presentation) to 5 (rejected).

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores are identified and censored. Abstracts with high variability in scores were discussed individually during a series of conference calls. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (versus just being a late submission).
Common Reasons for Abstract Rejection

- Information is not new enough
- Methodology is inadequate or insufficient to support conclusions
- Background does not summarize the hypothesis
- Submission is poorly written
- Abstract is duplicative of other submissions
- Abstract is not appropriate for CROI
- Controls are absent or inadequate
- Statistical evaluation is inadequate or absent
- Summary of essential results is inadequate or absent
- Data are inadequate or insufficient to support conclusions
- Submission reports clinical trial and data from unplanned analysis or incomplete or ongoing studies
- Format does not follow guidelines (eg, section[s] missing, more than 1 graphic, table, or figure submitted)

Statistics for Abstracts

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>General abstract submitted</td>
<td>1960</td>
</tr>
<tr>
<td>General abstracts accepted</td>
<td>1061</td>
</tr>
<tr>
<td>General oral abstracts</td>
<td>95</td>
</tr>
<tr>
<td>General poster abstracts</td>
<td>966</td>
</tr>
<tr>
<td>Late-breaking abstracts submitted</td>
<td>203</td>
</tr>
<tr>
<td>Late-breaking abstracts accepted</td>
<td>44</td>
</tr>
<tr>
<td>Late-breaking oral abstracts</td>
<td>19</td>
</tr>
<tr>
<td>Late-breaking poster abstracts</td>
<td>25</td>
</tr>
<tr>
<td>Total abstracts submitted</td>
<td>2163</td>
</tr>
<tr>
<td>Total abstract accepted</td>
<td>1105</td>
</tr>
</tbody>
</table>

All Authors on Accepted Abstracts

<table>
<thead>
<tr>
<th>Region</th>
<th>N</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>101</td>
<td>9.1</td>
</tr>
<tr>
<td>Asia</td>
<td>35</td>
<td>3.2</td>
</tr>
<tr>
<td>Australia</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Europe</td>
<td>226</td>
<td>20.5</td>
</tr>
<tr>
<td>Latin and South America</td>
<td>12</td>
<td>1.1</td>
</tr>
<tr>
<td>North America</td>
<td>720</td>
<td>65.2</td>
</tr>
</tbody>
</table>
Preconference Sessions

SUNDAY, MARCH 4, 2018

Workshop W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
CME
Ballroom BC
9:00 AM - 12:15 PM

Target Audience: This workshop is directed toward new trainees (e.g., undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic). However, it is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:
- Describe the current state of the art of selected areas of HIV basic and clinical research
- List the leading research themes being presented at CROI 2018
- Navigate CROI 2018, maximize the knowledge gained, and interact with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and CROI 2018 overall

Conveners
Serena S. Spudich, Yale University, New Haven, CT, USA
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA

PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES

SEEING HIV: THE VIRAL LIFECYCLE ANIMATED
Janet Iwasa, University of Utah, Salt Lake City, UT, USA

ADVANCES IN MOLECULAR VIROLOGY
Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany

ADVANCES IN IMMUNOLOGY
Alexandra Trkola, University of Zurich, Zurich, Switzerland

ADVANCES IN TUBERCULOSIS TREATMENT AND PREVENTION
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, USA

ADVANCES IN HIV PREVENTION
Wafaa M. El-Sadr, ICAP at Columbia University, New York, NY, USA

ADVANCES IN HIV CURE
Huldrych F. Günthard, University of Zurich, Zurich, Switzerland
LUNCH AND MARTIN DELANEY PRESENTATION
WOMEN IN RESEARCH: SCIENCE IS BETTER
WHEN WOMEN ARE REPRESENTED

Ballroom BC 12:30 PM – 1:30 PM

Description: The Martin Delaney Presentation is held annually during the workshops for Young Investigators, International Scholars, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945-2009). It recognizes the important contributions of community advocacy and engagement in research.

Target Audience: This session is directed toward new trainees (e.g., undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic.) Attendance is mandatory for all community educator scholarship recipients. It is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for less than 1 year.

Objectives: After attending this lecture, participants will be able to:
• Describe the importance of women as activists in research
• Explain the importance of women as researchers
• Describe the importance of mentorship in encouraging women to contribute as the next generation of HIV researchers

Introduction
Sharon L. Hillier, University of Pittsburgh, Pittsburgh, PA, USA

Moderator
Lisa Diane White, SisterLove, Inc, Atlanta, GA, USA

2 WOMEN IN RESEARCH: SCIENCE IS BETTER
WHEN WOMEN ARE REPRESENTED

WOMEN AS ACTIVISTS IN RESEARCH
Dázon Dixon Diallo, SisterLove, Inc, Atlanta, GA, USA

WOMEN CONDUCTING RESEARCH
Tonia Poteat, The Johns Hopkins University, Baltimore, MD, USA

IMPORTANCE OF MENTORSHIP IN DEVELOPING THE NEXT GENERATION OF INVESTIGATORS
Monica Gandhi, University of California San Francisco, San Francisco, CA, USA
Workshop W-2 FRONTIERS IN LABORATORY SCIENCE
Room 304-306 2:00 PM – 4:00 PM

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning about hot new technologies that are influencing HIV research or hold a substantial potential for research.

Level of Knowledge: It is assumed that the participants are familiar with the main technological and data analysis approaches used in HIV research.

Objectives: At the completion of the session, participants will be able to:
- Describe new approaches to designing synthetic nanocarrier systems for drug delivery based on principles of virus assembly and entry
- Describe state of the art imaging technologies enabling the visualization of single HIV particle dissemination through tissues and cells
- Describe emerging opportunities to exploit single cell transcriptomic and sequencing technologies to probe opportunities to interfere with the cellular viral reservoir

Conveners
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany

3 VIRUS-LIKE NANOCARRIER FOR DELIVERY OF BIOMOLECULES BETWEEN CELLS
Joerg Votteler, University of Utah, Salt Lake City, UT, USA

4 3D AND MULTI-SCALE IMAGING OF HIV-1 SPREAD IN TISSUES
Pamela J. Bjorkman, California Institute of Technology, Pasadena, CA, USA

5 SINGLE CELL VIRAL AND RECEPTOR BAR CODES: BEYOND THE SINGLE CELL TRANSCRIPTOME
Eli A. Boritz, NIAID, Bethesda, MD, USA

Workshop W-3 CLINICAL TRIAL DESIGN AND ANALYSIS
Ballroom A 2:00 PM – 4:00 PM

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and with basic HIV epidemiology.

Objectives: At completion of the session, participants will be able to:
- Describe how phylogenetic studies can inform interventions at a population level
- Assess strategies for measuring the population-level impact of interventions
- Distinguish pragmatic trials from controlled trials and describe the methodological challenges of each

Conveners
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, USA

6 SEEING THE FOREST THROUGH THE TREES: USING PHYLOGENETICS TO IMPACT THE EPIDEMIC
Susan J. Little, University of California San Diego, San Diego, CA, USA
7 MEASURING THE POPULATION-LEVEL IMPACT OF INTERVENTIONS
Jessica E. Justman, ICAP at Columbia University, New York, NY, USA

8 PRAGMATIC TRIALS
Alison Grant, London School of Hygiene & Tropical Medicine, London, UK

Workshop W-4 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C
Ballroom BC  2:00 PM – 4:00 PM

Target Audience: This session is directed to persons interested in the management of hepatitis C virus (HCV) infection.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV treatment and the medications used.

Objectives: At completion of the session, participants will be able to:
• Describe the management of HCV infection in pregnancy, childhood, and adolescence
• Distinguish between HCV reinfection and relapse and describe the management strategies for acute HCV infection
• Identify when HCV resistance testing is necessary and describe approaches to HCV retreatment after treatment failure
• Describe the diagnostic modalities of and treatment for steatosis in the context of HCV, including post-HCV treatment

Conveners
Debika Bhattacharya, University of California Los Angeles, Los Angeles, CA, USA
Arthur Kim, Harvard Medical School, Boston, MA, USA

9 INTERACTIVE CASE-BASED WORKSHOP ON HEPATITIS C

HCV PREVENTION AND TREATMENT IN CHILDREN
Ravi Jhaveri, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

ACUTE HCV INFECTION WITH REINFECTION
Christoph Boesecke, University of Bonn, Bonn, Germany

HCV RESISTANCE AND RETREATMENT
Pablo Ryan, Hospital Universitario Infanta Leonor, Madrid, Spain

STEATOSIS: TESTING AND TREATMENT
Kathleen E. Corey, Massachusetts General Hospital, Boston, MA, USA
Opening Session

Auditorium / Hall C / Auditorium Balcony
5:00 PM – 7:00 PM

Session Hosts

Judith S. Currier
CROI 2018 Chair
University of California Los Angeles, Los Angeles, CA, USA

Richard A. Koup,
CROI 2018 Vice Chair
Vaccine Research Center; National Institute of Allergy and Infectious Diseases National Institutes of Health; Bethesda, MD, United States

Sharon L Hillier
CROI 2018 Vice Chair
University of Pittsburgh, Pittsburgh, PA, USA

Bernard Fields Lecture

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the Opening Session, usually by a basic scientist recognized for his or her important and relevant contributions to the fields of virology and viral pathogenesis.

10 THE POTENTIAL OF INTERNATIONAL COLLABORATIONS FOR HIV PREVENTION: STUDIES OF MOTHER-TO-CHILD-TRANSMISSION

Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

N’Galy-Mann Lecture

The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research. The lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

11 MICH MAR GENO - THE GIFT OF HOPE

Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya

YOU SHALL LHiv 2:ZERO

A performance of personal testimonies, dance, music, and song
MONDAY, MARCH 5, 2018

Oral Sessions

Plenary PL-1 MONDAY PLENARY SESSION
Auditorium / Hall C / Auditorium Balcony 8:30 AM – 9:30 AM

12  THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD
8:30  Harold W. Jaffe, Centers for Disease Control and Prevention, Atlanta, GA, USA

13  PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION
9:00  JoAnne L. Flynn, University of Pittsburgh, Pittsburgh, PA, USA

Oral Abstract 0-01 VIRUS AND HOST DETERMINANTS OF HIV/SIV PATHOGENESIS
Ballroom A 10:00 AM – 12:00 PM

Oral Abstract Moderators
Jacob D. Estes, Oregon Health and Sciences University, Beaverton, OR, USA
Sandhya Vasan, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

14  IDENTIFICATION OF A NOVEL LOCUS OF HIV REGULATION IN POPULATIONS OF AFRICAN DESCENT
10:00  Paul J. McLaren, Deepti Gurdassani, Manj Sandhu, Jacques Fellay

15  HOST FACTORS ASSOCIATED WITH BNAB DEVELOPMENT IN HIV-1 CONTROLLERS

16LB  INTERDOMAIN STABILIZATION IMPAIRS CD4 BINDING AND IMPROVES IMMUNOGENICITY OF SOSIPS
10:30  Peng Zhang, Jason Gorman, Hui Geng, Yin LIN, Yaroslavl Tsybovsky, Huiyi Miao, Qingbo Liu, Tsion Andine, Alice Kwon, Ferzan Uddin, Mit Patel, Christina Guzzo, John R. Mascola, Peter D. Kwong, Paolo Lusso

17  EQUAL DISTRIBUTION OF SIV DNA IN MEMORY T HELPER CELL SUBSETS OF Rhesus Macaques
10:45  Stephen Lai, Joseph Mudd, Jason Brenchley

18  KINETICS OF GASTROINTESTINAL DYSFUNCTION IN ACUTE SIV INFECTION OF MACAQUES
11:00  Tiffany Hensley-McBain, Alicia Berard, Charlene J. Miller, Jennifer A. Manuzak, Alexander S. Zevin, Patricia Polacino, Brian Agricola, Mark Cameron, R. Keith Reeves, Jeremy Smedley, Shiu-Lok Hu, Brandon Keele, Adam Burgener, Nichole Klatt

19  PROGRESSIVE LYMPH NODE DYSFUNCTION DURING SIV INFECTION IS NOT REVERSED WITH ART
11:15  Claire Deleage, Ismail B. Turkbey, Peter L. Choyke, Yanling Liu, Gregory Q. Del Prete, Brandon Keele, Jeffrey D. Lifson, Jacob D. Estes
Oral Sessions

20 P38 MAPK IN VIVO INHIBITION IMPACTS SIV-MEDIATED IMMUNE ACTIVATION & CD4 T-CELL LOSS
11:30 Omkar Chaudhary, Felipe Lelis, Ronald Veazey, Anna Aldovini

21 INTRON—CONTAINING HIV-1 RNA ACTIVATES TYPE I INTERFERON AND INFLAMMATORY CYTOKINES
11:45 Sean McCauley, Kyusik Kim, Anetta Nowosielska, Ann Dauphin, William E. Diehl, Jeremy Luban

Oral Abstract O-02 ART: NEW DATA AND NEW INSIGHTS
Auditorium 10:00 AM – 12:00 PM

Oral Abstract Moderators
Giovanni Di Perri, University of Torino, Torino, Italy
Michelle S. Cespedes, Icahn School of Medicine at Mt Sinai, New York, NY, USA

22 SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC

23 IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL
10:15 Diana Gibb, Alexander J. Szubert, Ennie Chidziva, Abbas Lugemwa, Shalton Mwaringa, Abraham Siika, Jane E. Mallewa, Mutsa Bwakura-Dangarembizi, Sheila Kabahenda, Andrew Reid, Keith Baleeta, Sarah Walker, Sarah Pett, for the REALITY trial team

24 HAIR ANTIRETROVIRAL LEVELS STRONGLY PREDICT VIROLOGIC OUTCOMES IN ACTG’S A5257 TRIAL
10:30 Monica Gandhi, Igho Ofotukun, Peter Bacchetti, Chengshi Jin, Heather Ribaudo, David Haas, Anandi N. Sheth, Howard Horng, Nhi Phung, Karen Kuncze, Alexander Louie, Hideaki Okochi, Raphael J. Landovitz, Jeffrey J. Lennox, Judith S. Currier, for the A5257 Study Team

25 TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS IS A STRONG PREDICTOR OF VIRAL SUPPRESSION
10:45 Jose R. Castillo-Mancilla, Mary Morrow, Ryan P. Coyle, Stacey Coleman, Edward M. Gardner, Jia-Hua Zheng, Lucas Ellison, Lane R. Bushman, Jennifer J. Kiser, Samantha MaWhinney, Peter L. Anderson

26 MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV
11:00 Randolph P. Matthews, Deanne J. Rudd, Vanessa Levine, Sandra Zhang, Laura Sterling, Jay Grobler, Ryan Vargo, S. Aubrey Stoch, Marian Iwamoto

27 COMPARATIVE LYMPHOID TISSUE PHARMACOKINETICS (PK) OF INTEGRASE INHIBITORS (INSTI)
11:15 Courtney V. Fletcher, Ann Thorkelson, Lee Winchester, Timothy Mykris, Jon Weinhold, Kayla Campbell, Jodi Anderson, Jacob Zulk, Puleng Moshele, Timothy Schacker

28LB RIFAMPIN EFFECT ON TENOFOVIR ALAFENAMIDE (TAF) PLASMA/INTRACELLULAR PHARMACOKINETICS
11:30 Maddalena Cerrone, Omamah Alfarisi, Megan Neary, Mark A. Marzinke, Teresa Parsons, Andrew Owen, Gary Maartens, Anton Poziak, Charles W. Flexner, Martha Boffito
29LB  SYSTEMATIC VS TEST-GUIDED TUBERCULOSIS TREATMENT: DATA OF THE STATIS RANDOMIZED TRIAL
François-Xavier Blanc, Anani D. Badje, Maryline Bonnet, Delphine Gabillard, Eugene Messou, Conrad Muzoora, Sovannarith Samreth, Duc Bang Nguyen, Laurence Borand, Anais Domergue, Naome Natukunda, Serge Eholie, Serge Domoua, Xavier Anglaret, Didier Laureillard

30LB  RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES
Beatriz Grinsztejn, Michael D. Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda Wieclaw, Robert Gross, Catherine Godfrey, Ngalingeswaran Murumasa, Cecilia Kanyama, John W. Mellors, Carole Wallis, Ann Collier, for the A5288 Study Team

Questions for the final 3 presentations will be held until the conclusion of the sessions.

Oral Abstract 0-03 ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION

Oral Abstract Moderators
Vidya Mave, Byramjee Jeejeebhoy Government Medical College, Pune, India
Thomas Harrison, St. George’s University of London, London, United Kingdom

31  EFFECT OF TB SCREENING AND RETENTION INTERVENTIONS ON EARLY ART MORTALITY IN BOTSWANA
Andrew F. Auld, Tefera Agizew, Anikie Mathoma, Rosanna Boyd, Anand Date, Sherri Pals, Christopher Serumola, Unami Mathebula, Heather Alexander, Todd V. Ellerbrock, Gaobaone Rankgoane-Pono, Pontsho Pono, Katherine Fielding, Alison Grant, Alyssa Finlay

32  A CLUSTER-RANDOMIZED TRIAL OF SYMPTOM VS TST SCREENING TO IMPROVE CHILD IPT UPTAKE
Nicole Salazar-Austin, Silvia Cohn, Grace Barnes, Molefi Tladi, Katlego Matlaoleng, Catharina Swanepeol, Zarina Motala, Ebrahim Variava, Neil A. Martinson, Richard E. Chaisson

33  SAFETY AND EFFICACY OF DOLUTEGRAVIR-BASED ART IN TB/HIV COINFECTED ADULTS AT WEEK 24
Kelly Dooley, Richard Kaplan, Noluthando Mwelase, Beatriz Grinsztejn, Eduardo Ticona, Marcus Lacerda, Pedro Cahn, Elena Belonosova, Mounir Ait-Khaled, Kostas Angelis, Dannae Brown, Rajendra P. Singh, Christine Talgaro, Allan-Raymond Tenorio, Michael Aboud

34  PHARMACOKINETICS OF BICTEGRAVIR ADMINISTERED TWICE DAILY IN COMBINATION WITH RIFAMPIN
Joseph M. Custodio, Steve K. West, Sean Collins, Amanda Yu, Deqing Xiao, Hal Martin, Erin Quirk, Brian P. Kearney, Anita Mathias

35  HIGHER HIGH DOSE FLUCONAZOLE FOR THE TREATMENT OF CRYPTOCOCCAL MENINGITIS
Umesh G. Laloo, Richard Larsen, Judith Aberg, Evelyn Hogg, Lauren Komarow, David B. Clifford, Sandy Pillay, Deborah Langat, Agrey Bukuru, Vidya Mave, Khuanchai Supparatpinyo, Wadzani Samaneka

36  ADJUNCTIVE SERTRALINE IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS
Joshua Rhein, Kathy Huppler Hullsiek, Lillian Tugume, Edwin Nuwagira, Edward Mpoza, Reuben Kiggundu, Kenneth Ssebambulidide, Darlisha A. Williams, Ananta Bangdiwala, Mahsa Aabasi, Abdu Musubiire, Conrad Muzoora, David Meya, David R. Boulware, for the ASTRO-CM Study Team
Oral Sessions

Oral Sessions • Monday

37LB  ONE MONTH OF RIFAPENTINE/ISONIAZID TO PREVENT TB IN PEOPLE WITH HIV: BRIEF-TB/A5279
11:30
Susan Swindells, Ritesh Ramchandani, Amita Gupta, Constance A. Benson, Jorge T. Leon-Cruz, Ayoibunda Omoz-Oarhe, Marc Antoine Jean Juste, Javier R. Lama, Javier A. Valencia, Sharlaa Badal-Faesae, Laura E. Moran, Courtney V. Fletcher, Eric Nueremberger, Richard E. Chaisson, for the ACTG 5279/BRIEF TB Study Team (Brief Rifapentine/Isoniazid Efficacy for TB Prevention)

38LB  URINE-BASED SCREENING FOR TUBERCULOSIS: A RANDOMIZED TRIAL IN HIV-POSITIVE INPATIENTS
11:40

39LB  A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS
11:50

Questions for the final 3 presentations will be held until the conclusion of the session.

Oral Abstract O-04 SURVEILLANCE AND EPIDEMIOLOGY: NEW APPROACHES
Ballroom B  10:00 AM – 12:00 PM

Oral Abstract Moderators
Alexandra M. Oster, CDC, Atlanta, GA, USA
Robin Wood, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

40  RAPIDLY GROWING HIV TRANSMISSION CLUSTERS IN THE UNITED STATES, 2013–2016
10:00
Anne Marie France, Nivedha Panneer, Cheryl B. Ocemia, Neeraja Sadauvala, Ellsworth Campbell, William M. Switzer, Joel O. Wertheim, Alexandra M. Oster

41  CLUSTER ANALYSIS REVEALS IMPORTANT SHIFT OF DRIVERS OF THE HIV EPIDEMIC IN SWISS MSM
10:15
Nadine Bachmann, Claus Kadelka, Teja Turk, Katharina Kusejko, Jürg Böni, Vincent Aubert, Sabine Yerly, Thomas Klimkait, Huldrych F. Günthard, Roger Kουyos, for the Swiss HIV Cohort Study

42  PHYLOGENETIC PATTERNS OF HIV TRANSMISSION AMONG TRANSGENDER WOMEN IN LOS ANGELES
10:30
Manon Ragonnet-Cronin, Yunyin W. Hu, Sheldon Morris, Zhijuan Sheng, Kathleen Poortinga, Joel O. Wertheim

43  ASSESSING THE ROLE OF GEOGRAPHICAL HIV HOT-SPOTS IN THE SPREAD OF THE EPIDEMIC
10:45
Diego F. Cuadros, Tiago Graf, Tulio de Oliveira, Till Bärnighausen, Frank Tanser

44  USING SUCCESSIVE SURVEYS TO CALCULATE INCIDENCE AMONG AT-RISK POPULATIONS IN THE US
11:00
Janet C. Burnett, Qian An, Dita Broz, Cyprian Wejnert, for the NHBS Study Group
**Themed Discussion TD-01 EARLY EVENTS: METHODS AND MECHANISMS**

**Ballroom A**  
1:30 PM – 2:30 PM

**Themed Discussion Leader**  
Viviana A. Simon, Icahn School of Medicine at Mt Sinai, New York, NY, USA

186 NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS  
Rodrigo Matus-Nicodemos, Daniel Douek, Richard A. Koup

185 HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET  
Anamaria D. Sarca, Hirofumi Fukuda, Luca Sardo, Jessica Smith, Kotaro Shirakawa, Kazuki Honkawa, Taisuke Izumi, Akifumi Takaori-Kondo

187 VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY  
Flore De Wit, Frauke Christ, Sambasivarao Pillalamarri, Akkadeevi Venkatesham, Arthur Van Aerschot, Zeger Debyser

189 UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1  
Edmund Osei-Kuffour, Kerstin Schott, Philipp A. Lang, Karl S. Lang, Renate König, Dieter Häussinger, Carsten Münk

190 VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER  
Sarah B. Nodder, Caitlin Miller, Hisashi Akiyama, Chelsea R. Ettinger, Rahm Gummuluru

**Themed Discussion TD-02 CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION**

**Room 304-306**  
1:30 PM – 2:30 PM

**Themed Discussion Leader**  
Gary Maartens, University of Cape Town, Cape Town, South Africa

455 EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE  

---

**Oral Sessions**

**Oral Sessions**  
**CROI 2018**  
**35**

**Oral Sessions**  
**CROI 2018**  
**35**

**Oral Sessions**  
**CROI 2018**  
**35**

**Oral Sessions**  
**CROI 2018**  
**35**

**Oral Sessions**  
**CROI 2018**  
**35**
456 EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS

Daniel W. Atwine, Elisabeth Baudin, Thibaut Gelé, Winnie R. Muyindike, Mworoi Keneth, Rachele Kyohairwe, Kenneth Kananura, Dan Nyehangane, Patrick Orikiriza, Valérie Furlan, Anne-Marie Taburet, Aurélie Barrail-Tran, Maryline Bonnet, for the ANRS12292 Rifaviren study group

457 PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/ RIFAMPICIN IN PEOPLE WITH HIV

Maddalena Cerrone, Xinzhu Wang, Megan Neary, Christine Weaver, Serge Fedele, Isaac Day-Weber, Andrew Owen, Andrew Hill, Myra McClure, Marta Boffito

458 IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN

Rajith Kumar Reddy Rajoli, Paul Curley, David Back, Charles W. Flexner, Andrew Owen, Marco Siccardi

Themed Discussion TD-03 THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA

Auditorium 1:30 PM – 2:30 PM

Themed Discussion Leader

Satish Gopal, University of North Carolina Project–Malawi, Lilongwe, Malawi

649 HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA

Scott Dryden-Peterson, Neo Tapela, Isaac Nkele, Oaitse John, Gita Sunjea, Surbhi Grover, Memory Bvochora-Nsingo, Malebogo Pusoentsi, Joseph Makhema, Mompati O. Mmalane, Mukendi Kayembe, Shahin Lockman

650 SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH

Mazvita Sengayi, Wenlong C. Chen, Adrian Spoerri, Elvira Singh, Matthias Egger, Julia Bohlius

658LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN

Sharon A. Greene, Hillary M. Topazian, Hugo De Vuyst, Christine J. McGrath, Barbara A. Richardson, Grace John-Stewart, Anthony Cagle, Evans Nyongesa-Malava, Nelly Yatich, Catherine Kiptinness, Sameh Sakr, Nelly R. Mugo, Michael H. Chung

659GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+

Emmanouil Papasavvas, Andrew V. Kossenkov, Livio Azzoni, Nicola M. Zetola, Agnieszka Mackiewicz, Brian Ross, Matthew Fair, Surya Vadrevu, Doreen Ramogola-Masire, Cindy Finhaber, Luis Montaner

655KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE

Suzanne P. Fiorillo, Francis Jaji, Maxwell Matimba, Thomas Campbell, Margaret Borok
Themed Discussion TD-04 HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?

Ballroom C 1:30 PM – 2:30 PM

Themed Discussion Leader
Jennifer Jao, Icahn School of Medicine at Mt Sinai, New York, NY, USA

878  LOPINAVIR/РИТОНАВИР INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN
Audrey Monnin, Nicolas Nagot, Marianne Periès, Roselyne Vallo, Nicolas Meda, Mandisa Singata, James Tumwine, Pascal Reynier, Thorkild Tylleskär, Philippe Van de Perre, Jean-Pierre Molès, for the PROMISE PEP consortium ANRS 12174

879  HEU BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)
Abhinav Ajaykumar, Mayanne Zhu, Hugo Soudéyns, Fatima Kakkar, Jason Brophy, Ari Bitnun, Ariane Alimenti, Deborah M. Money, Helene C. Cote, for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

880  INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS
Marisa M. Mussi-Pinhata, Adriana Weinberg, Qilu Yu, Rachel A. Cohen, Sahera Dirajlal-Fargo, Nicholas Funderburg, Emily Bowman, Nahida Chakhtoura, Grace A. McComsey

881  INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA
Pilar Garcia Broncano, Samuel W. Kgole, Gosego Masasa, Terence Mohammed, Sikuhiile Mayo, Joseph Makhema, Xu G. Yu, Jennifer Jao, Roger L. Shapiro, Mathias Lichterfeld, Kathleen M. Powis

882  MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS
Charles D. Mitchell, Sady Dominguez, Varghese George, Eddy Perez-Then, Carlos V. Castillo, Juan L. Santana-Guerrero, Jeannette Baez, Margaret Roach, William Walters, Qiaojuan Shi, Shao-Pei Chou, Ruth Ley, Savita Pahwa

Themed Discussion TD-05 HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE

Ballroom B 1:30 PM – 2:30 PM

Themed Discussion Leader
Adeeba Kamarulzaman, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

970  HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS — UNITED STATES, 2010-2015
Sheryl Lyss, Tianchi Zhang, Alexandra M. Oster

971  CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US
Johanna Chapin-Bardales, Silvina Masciotra, Amanda Smith, Brooke Hoots, William M. Switzer, Wei Luo, S. Michele Owen, Gabriela Paz-Bailey

973  NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016
Lucia V. Torian, Jasmine Abdelnabi, Lisa A. Forgione, Joel O. Wertheim
974 **DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015**
Sarah L. Braunstein, Rebekkah S. Robbins, Demetre C. Daskalakis

975 **3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS**

**Symposium S-1 STOP IT NOW: TARGETING EARLY INFECTION EVENTS**
**Ballroom A**

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding emerging themes in HIV-1 pathogenesis and recent models showing how targeted interventions during primary HIV-1 infection have led to virological control.

**Level of Knowledge:** It is assumed that the participants are familiar with the basic concepts of HIV pathogenesis and have some familiarity with B cell and T cell immunology.

**Objectives:** At the completion of the session, participants will be able to:
- Describe how CD8 T cells can inhibit HIV-1 replication during acute infection and appreciate new models showing how this can lead to immunologic control of viral replication
- Describe how neutralizing antibodies to HIV-1 and antibodies to host proteins (alpha-4 beta-7) can directly and indirectly limit HIV dissemination during acute infection and lead to viral control
- Outline different clinical strategies now under investigation that are aimed at modulating early events in HIV infection in humans and appreciate how they may lead to HIV-1 control without a need for antiretroviral drug therapy

**Conveners**
Brandon Keele, National Cancer Institute, Frederick, MD, USA
Michaela Müller-Trutwin, Institute Pasteur, Paris, France

48 **MECHANISMS OF EARLY CD8+ T CELL CONTROL**
**4:00**
Jonah Sacha, Oregon Health and Sciences University, Portland, OR, USA

49 **EARLY BROADLY NEUTRALIZING ANTIBODY TREATMENT LEADING TO T-CELL CONTROL**
**4:30**
Malcolm Martin, NIAID, Bethesda, MD, USA

50 **ANTI-ALPHA-4/BETA-7 ANTIBODY-MEDIATED CONTROL: UNDERSTANDING THE MECHANISM**
**5:00**
James Arthos, NIH, Bethesda, MD, USA

51 **EARLY INTERVENTION THERAPIES IN HUMANS: ART, ANTIBODIES, AND VACCINES**
**5:30**
Eugène Kroon, Thai Red Cross AIDS Research Center, Bangkok, Thailand
Symposium S-2 BREAST IS BEST, BUT IT’S A VIRAL MILKSHAKE!
Room 304-306
4:00 PM – 6:00 PM

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning more about transmission of retroviruses through breast feeding.

Level of Knowledge: It is assumed that the participants are familiar with the basic epidemiology of breast milk transmission of HIV and HTLV-1.

Objectives: At the completion of the session, participants will be able to:

- Describe infant gut immunology and its ontogeny, microbiome, and host susceptibility to viral infection through breast milk
- Describe the epidemiology, virology, pathophysiology and risk to the infant of breast milk exposure to HIV and HTLV-1
- Explain the efficacy of prevention of transmission of breast milk viruses
- Explain the pharmacology of breast milk excretion of antiretrovirals, optimal antiretroviral therapy (ART) combinations for breast feeding, and risk of ART toxicity to the infant

Conveners
Ruth Nduati, University of Nairobi, Nairobi, Kenya
Philippe Van de Perre, CHU de Montpellier, Montpellier, France

52 THE INFANT GUT: A GREAT DEFENSE SYSTEM?
4:00 Andrew Prendergast, Queen Mary University of London, London, UK

53 MOTHER-TO-CHILD TRANSMISSION OF HTLV-1
4:30 Antoine Gessain, Institut Pasteur, Paris, France

54 CAN WE ELIMINATE BREASTMILK TRANSMISSION OF HIV?
5:00 Ameena Goga, South African Medical Research Council, Cape Town, South Africa

55 ART IN BREASTMILK: DEFINING THE RISK-BENEFIT RATIO
5:30 Catriona Waitt, University of Liverpool, Liverpool, UK
**Oral Sessions**

**CROI 2018**

**Symposium S-3 OBSTACLES TO THE GLOBAL CONTROL OF TUBERCULOSIS**

**Ballroom C**

4:00 PM – 6:00 PM

**Target Audience:** This session is directed to clinicians and researchers interested in the pathogenesis, clinical manifestations, diagnosis, treatment and prevention of tuberculosis (TB) and its complications, including HIV and TB co-infection.

**Level of Knowledge:** It is assumed that participants are familiar with basic TB biology, epidemiology, clinical features and treatment.

**Objectives:** At the completion of the session, participants will be able to:

- Describe the changing epidemiology of TB and the global burden of TB disease
- Describe new approaches for identifying and tracking TB transmission
- Identify new regimens and strategies for treatment of drug-resistant TB

**Conveners**

David Alland, Rutgers New Jersey Medical School, Newark, NJ, USA

Mina C. Hosseinipour, University of North Carolina Project–Malawi, Lilongwe, Malawi

---

56

**THE GLOBAL BURDEN OF TUBERCULOSIS AND MODELING CONTROL STRATEGIES**

Nimalan Arinaminpathy, Imperial College London, London, UK

4:00

57

**USING WHOLE GENOME SEQUENCING TO BETTER UNDERSTAND TB TRANSMISSION DYNAMICS**

Neel R. Gandhi, Emory University, Atlanta, GA, USA

4:30

58

**UNDIAGNOSED TUBERCULOSIS: PROMISE FOR PREVENTION**

Neil A. Martinson, Perinatal HIV Research Unit, Soweto, South Africa

5:00

59

**NEW DEVELOPMENTS IN THE MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS**

Serena Koenig, Brigham and Women’s Hospital, Boston, MA, USA

5:30
Symposium S-4 STRATEGIES FOR IMPROVING THE US CARE CASCADE: CONFRONTING A FRAGMENTED HEALTH SYSTEM

Ballroom B 4:00 PM – 6:00 PM

Target Audience: This session is directed to students, researchers, and clinicians who are interested in learning about the current status of the US HIV epidemic, challenges to delivering comprehensive care, and strategies for improving care delivery and addressing disparities.

Level of Knowledge: It is assumed that the participants are familiar with basic HIV epidemiology.

Objectives: At the completion of the session, participants will be able to:

- Describe the epidemiology of the US epidemic with a focus on most heavily affected populations
- Review challenges in HIV testing and strategies to improve HIV testing uptake
- Describe challenges to retention in care and strategies for improving it
- Discuss how the fragmented health system in the US negatively affects provision of comprehensive continuity care and list ways to promote solutions for reaching and retaining vulnerable populations

Conveners
Ank E. Nijhawan, University of Texas Southwestern, Dallas, TX, USA
Darrell Wheeler, University at Albany, New York, NY, USA

60 THE EVOLVING HIV EPIDEMIC IN THE UNITED STATES 4:00
Carlos del Rio, Emory University, Atlanta, GA, USA

61 HIV TESTING AND LINKAGE: THE GATEWAY TO TREATMENT AND PREVENTION 4:30
Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA

62 HIV CARE ENGAGEMENT: MAXIMIZING INDIVIDUAL AND POPULATION HEALTH 5:00
Michael J. Mugavero, University of Alabama at Birmingham, Birmingham, AL, USA

63 SYSTEMS OF CARE FOR VULNERABLE POPULATIONS IN THE UNITED STATES 5:30
Julia C. Dombrowski, University of Washington, Seattle, WA, USA
TUESDAY, MARCH 6, 2018

**Oral Sessions**

**Plenary PL-2 TUESDAY PLENARY SESSION**

**Auditorium / Hall C / Auditorium Balcony**

8:30 AM – 9:30 AM

64  **THE VAGINAL MICROBIOME AND ACQUISITION OF HIV INFECTION**

Nichole Klatt, University of Washington, Seattle, WA, USA

65  **ADDRESSING MENTAL HEALTH: A CRUCIAL COMPONENT TO ENDING THE HIV EPIDEMIC**

Robert H. Remien, New York State Psychiatric Institute and Columbia University, New York, NY, USA

**Oral Abstract 0-05 THE HIV RESERVOIR AND VIRAL REPLICATION**

**Auditorium**

10:00 AM – 12:00 PM

66  **PERSISTENT DETECTION OF HIV RNA+ CELLS WITH ART STARTED IN FIEBIG 1&2 VS FIEBIG 3-5**

Eugène Kroon, Mark de Souza, Suthat Chottanapund, Jodi Anderson, Sopark Manasnayakorn, Siri Jorstad, Caitlin David, Adam Conner, Erika Helgeson, Cavan Reilly, Merlin L. Robb, Daniel Douek, Jintanat Ananworanich, Timothy Schacker, for the RV254/SEAEC010 Study Group

67  **CD8+ T CELL RESPONSES IN TREATED HYPERACUTE HIV INFECTION LIMIT HIV RESERVOIR SIZE**

Zaza Ndhlovu, Samuel W. Kazer, Thandeka Nkosi, Funsho Ogunshola, Amber D. Moodley, Krista Dong, Alex K. Shalek, Thumbi Ndungú, Bruce D. Walker

68  **EXPANDED CLONES HARBORING REPLICATION-COMPETENT VIRUS WAX AND WANE OVERTIME**

Zheng Wang, Mithra R. Kumar, Janet Siliciano, Robert Siliciano, for the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

69LB  **DETERMINANTS OF HIV-1 RESERVOIR SIZE AND LONG-TERM DYNAMICS UNDER SUPPRESSIVE ART**

Nadine Bachmann, Chantal von Siebenthal, Valentina Vongrad, Kathrin Neumann, Teja Turk, Niko Beerenwinkel, Jasmina Bogojeska, Jacques Fellay, Volker Roth, Roger Koyou, Karin Metzner, Huldrych F. Günthard, for the Swiss HIV Cohort Study

70  **NO EVIDENCE FOR ONGOING HIV REPLICATION IN LYMPH NODES DURING SUPPRESSIVE ART**

William R. McManus, Michael J. Bale, Jonathan Spindler, Ann Wiegand, Andrew Musick, Xiaolin Wu, David Wells, Stephen H. Hughes, Brandon Keele, Rebecca Hoh, Jeffery Milush, John M. Coffin, John W. Mellors, Steven G. Deeks, Mary F. Kearney

**Oral Sessions • Tuesday**
Oral Sessions

71  NO RESIDUAL VIRUS REPLICATION IN A RANDOMISED TRIAL OF DOLUTEGRAVIR INTENSIFICATION
11:15

72  SINGLE RIMIDEPSIN INFUSIONS DO NOT INCREASE HIV EXPRESSION IN PERSONS ON ART (A5315)
11:30

73LB  PGT121 COMBINED WITH GS-9620 DELAYS VIRAL REBOUND IN SHIV-INFECTED RHESUS MONKEYS
11:45
Erica Borducchi, Peter Abbink, Joseph Nkolola, Mark G. Lewis, Romas Gelezijunas, Dan Barouch

Oral Abstract O-06 NON-AIDS COMPLICATIONS
Ballroom A 10:00 AM – 12:00 PM

Oral Abstract Moderators
Mosepele Mosepele, University of Botswana, Gaborone, Botswana
Helen Kovari, University Hospital Zurich, Zürich, Switzerland

74  IL-6, D-DIMER OR T-CELLS: WHICH BEST PREDICT EVENTS OR EXPLAIN BENEFITS OF EARLY ART?
10:00
Jason V. Baker, Birgit Grund, Shweta Sharma, Abdel Babiker, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group

75  SERIOUS CLINICAL OUTCOMES IN HIV-POSITIVE PERSONS WITH CHRONIC KIDNEY DISEASE (CKD)
10:15

76  INCREASED RISK OF PERIPHERAL ARTERY DISEASE IN PERSONS WITH HIV COMPARED TO CONTROLS
10:30
Andreas D. Knudsen, Jens D. Lundgren, Marco Gelpi, Ashley Roen, Amanda Mocroft, Shoaib Afzal, Børge Nordestgaard, Henrik Sillesen, Andreas Ronit, Anne-Mette Lebech, Lars Køber, Klaus F. Kofoed, Susanne D. Nielsen

77  HIV INFECTION IS ASSOCIATED WITH PROGRESSION OF HIGH RISK CORONARY PLAQUE IN THE MACS
10:45
Wendy Post, Sabina Haberlen, Long Zhang, Mallory Witt, Lisa Jacobson, Todd T. Brown, Frank J. Palella, Lawrence Kingsley, Matthew Budoff

78  CAROTID ARTERY ATHEROSCLEROSIS IS ASSOCIATED WITH MORTALITY IN HIV+ WOMEN AND MEN
11:00
David B. Hanna, Jee-Young Moon, Kathryn Anastos, Sabina Haberlen, Audrey French, Frank J. Palella, Stephen J. Gange, Mallory Witt, Seble Kassaye, Jason Lazar, Phyllis Tien, Lawrence Kingsley, Wendy Post, Robert C. Kaplan, Howard Hodis

79  IMPACT OF LDMTX ON IMMUNE ACTIVATION AND ENDOTHELIAL FUNCTION IN TREATED HIV
11:15
Oral Sessions

80  PLATELET FUNCTION UPON SWITCHING TO TAF VS CONTINUING ABC: A RANDOMIZED SUBSTUDY
   11:15  Patrick W. Mallon, Alan Winston, Frank Post, Dermot Kenny, Colm Bergin, Robert T. Maughan, Elena Alvarez-Barco, Willard Tinago, Eimear Dunne, Mingjin Yan, Moupali Das, Martin Rhee, for the GS-US-311-1717 Platelet Sub Study Team

81LB  A TREATMENT AS PREVENTION TRIAL TO ELIMINATE HCV IN HIV+ MSM: THE SWISS HCVREE TRIAL
   11:45  Dominique L. Braun, Benjamin H. Hampel, Huyen Nguyen, Markus Flepp, Marcel Stoeckle, Charles Bèguegin, Patrick Schmid, Julie Delaloye, Mathieu Rougemont, Enos Bernasconi, Dunja Nicca, Roger Koyous, Jürg Böni, Huldrych F. Günthard, Jan S. Fehr, for the Swiss HIV Cohort Study

Oral Abstract 0-07 OF MICE, MONKEYS, AND MEN: PrEP FROM PRECLINICAL TO POPULATION LEVEL IMPACT

Ballroom B  10:00 AM – 12:00 PM

Oral Abstract Moderators
Craig W. Hendrix, Johns Hopkins University, Baltimore, MD, USA
Elske Hoornenborg, Public Health Service Amsterdam, Amsterdam, Netherlands

82  PROTECTION AGAINST REPEATED VAGINAL SHIV CHALLENGES BY BNAB 3BNC117 AND 10-1074
   10:00  David A. Garber, Debra Adams, James Mitchell, Shanon Ellis, Till Schoofs, Michael S. Seaman, Janet McNicholl, Michel Nussenzweig, Walid Heneine

83  LONG-ACTING CABOTEGRAVIR PROTECTS MACAQUES AGAINST REPEATED PENILE SHIV EXPOSURES

84  GRIFFITHSIN/CARRAGEENAN INSERTS PREVENT SHIV, HSV-2, AND HPV INFECTIONS IN VIVO

85  ORAL FTC/TAF COMBINATION PREVENTS VAGINAL SHIV INFECTION IN PIGTAIL MACAQUES

86  BY RACE/ETHNICITY, BLACKS HAVE HIGHEST NUMBER NEEDING PrEP IN THE UNITED STATES, 2015
   11:00  Dawn K. Smith, Michelle Van Handel, Jeremy A. Grey

87  GETTING TO ZERO NEW HIV DIAGNOSES IN SAN FRANCISCO: WHAT WILL IT TAKE?
   11:15  Susan P. Buchbinder, Stephanie E. Cohen, Jen Hecht, Ling Hsu, Robert P. Kohn, Henry F. Raymond, Albert Y. Liu, Hyman Scott, Oliver Bacon, Tracey Packer, Susan Philip, Diane V. Havlir, Susan Scheer

88  RAPID REDUCTION IN HIV DIAGNOSES AFTER TARGETED PrEP IMPLEMENTATION IN NSW, AUSTRALIA
   11:30  Andrew Grulich, Rebecca J. Guy, Janaki Amin, Heather-Marie Schmidt, Christine Selvey, Jo Holden, Karen Price, Robert Finlayson, Mark Bloch, Iryna Zablotska, Fengyi Jin, David Smith, Anna McNulty, David A. Cooper, for the EPIC-NSW research team
Oral Sessions

Oral Abstract O-08 90:90:90: PROGRESS, CHALLENGES, AND NEW TOOLS

Ballroom C 10:00 AM – 12:00 PM

Oral Abstract Moderators

Mauro Schechter, Projeto Praca Onze, Rio de Janeiro, Brazil
Glenda E. Gray, Perinatal HIV Research Unit, Soweto, South Africa

90 HIV TREATMENT, PREVENTION, AND INCIDENCE IN A HYPERENDEMIC UGANDAN FISHING COMMUNITY
10:00
Joseph Kagaayi, Gertrude Nakigozi, Godfrey Kigozi, Mary K. Grabowski, Victor Ssemplija, Fred Nalugoda, Ronald H. Gray, Robert Ssekubugu, Caitlin E. Kennedy, Thomas C. Quinn, David Serwadda, Maria Wawer, Steven J. Reynolds, Larry W. Chang

91 PROGRESS TOWARD 90-90-90: 2016 LESOTHO POPULATION-BASED HIV IMPACT ASSESSMENT RESULTS
10:15
Kyaw Thin, Koen Frederix, Stephen McCracken, Andrea Low, Hetal Patel, Nahima Ahmed, Bharat S. Parekh, Jessica E. Justman, Amee M. Schwitters

92 THE RAPID ART PROGRAM INITIATIVE FOR HIV DIAGNOSES (RAPID) IN SAN FRANCISCO
10:45
Oliver Bacon, Jennie C. Chin, Ling Hsu, Stephanie E. Cohen, Darpan Sachdev, Diane Jones, Jonathan Fuchs, Susan Scheer, Susan P. Buchbinder, Diane V. Havlir

93 SAME-DAY ART INITIATION AFTER HOME-BASED HIV TESTING: A RANDOMIZED CONTROLLED TRIAL
11:00
Niklaus D. Labhardt, Isaac Ringera, Thabo I. Lejone, Thomas Klimkait, Josephine Muhairwe, Alain Amstutz, Tracy R. Glass

94 EXTENDED-RELEASE NALTREXONE IMPROVES VIRAL SUPPRESSION IN HIV+ PRISONERS
11:30
Sandra Springer, Marwan Azar, Angela DiPaola, Russell Barbour, Breanne Biondi, Maua Herme, Frederick Altice

95 HIGHER MORTALITY IN HIV- INFECTED VS.- UNINFECTED ADULTS DESPITE ART, BOTSWANA
11:45
Tendani Gaolathe, Kathleen Wirth, Molly Pretorius Holme, Etienne Kadima, Unoda A. Chakalisa, Kuto Manyake, Joseph Makhma, Mompati O. Mmalane, Jean Leidner, Scott Dryden-Peterson, Kathleen M. Powis, Mosepele Mosepele, Relefetswe Lebelonyane, Lisa A. Mills, Shahin Lockman
Themed Discussion TD-06 ROLE OF THE MICROBIOME IN HIV INFECTION (AND VICE-VERSA)
Room 304-306 1:30 PM – 2:30 PM

Themed Discussion Leader
Roger Paredes, IrsiCaixa Institute for AIDS Research, Badalona, Spain

271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN
Laura Noël-Romas, Michelle Perner, Alicia Berard, Ann M. Carias, Kenzie Birse, John Schellenberg, Melissa Lemke, Annelie Tjernlund, Garrett Westmacott, Douglas Lauffenburger, Kristina Broliden, Lyle McKinnon, Kelly Arnold, Thomas Hope, Adam Burgener

272 IMPAIRED GUT TIGHT JUNCTION BUT PRESERVED TΔ AND MICROBIAL TRANSLLOCATION IN ACUTE HIV
Elvira S. Cannizzo, Giuseppe Ancona, Delfina Tosi, Federica Savi, Camilla Tincati, Antonella D’Arminio Monforte, Giulia Marchetti

273 MICROBIAL DYSBIOSIS DOES NOT ALTER DISEASE PROGRESSION IN SIV-INFECTED ASIAN MACAQUES
Alexandra Ortiz, Sarah DiNapoli, Jacob Flynn, Carly Elizabeth C. Starke, Stephen Lai, Mackenzie Long, Ornella Sortino, Carol Vinton, Joseph Mudd, Jacob D. Estes, Jason Brenchley

274 EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S
Rachel Presti, Douglas W. Kitch, Adriana Andrade, Alan Landay, Jeffrey Jacobson, Cara Wilson, Eunice Yeh, Jacob D. Estes, Claire Deleage, Karin L. Klingman, Netanya S. Utay, Edgar T. Overton, Jason Brenchley, Brett Williams, for the A5352S Clinical Trial Team

275 THE IMPACT OF SYNBIOTICS IN ADVANCED HIV DISEASE: A RANDOMIZED CLINICAL TRIAL
Sergio Serrano-Villar, Maria Lagarde, Nadia Madrid, Jose I. Bernardo, Alejandro Vallejo, Carolina Gutiérrez, Alfonso Cabello, Mariano Mataarranz, Judit Villar, Alberto Díaz de Santiago, Jose-Ramón Blanco, Talia Sainz, Federico Pulido, Santiago Moreno, Vicente Estrada

Themed Discussion TD-07 AGING BRAIN AND HIV: BEFORE AND AFTER
Room 302 1:30 PM – 2:30 PM

Themed Discussion Leader
Linda Chang, University of Maryland, Baltimore, MD, USA

437 CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART
Napapon Sailasuta, Jennifer Daniels, Phillip Chan, Carlo Sacdalan, Merlin L. Robb, Somporn Tipsuk, Jintanat Ananworanich, Duanghathai Suttichom, Robert Paul, Nisakorn Ratnaratorn, Mantana Pothisiril, Netsiri Dumrongpisutikul, Serena S. Spudich, Victor Varcour, for the SEARCH 010/ RV254 and RV304 Study Team

438 AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS
Ned Sacktor, Richard Skolasky, Heidi Roosa, Cornelia Demsky, Yun Zhou, Weiguo Ye, Noble George, Peter B. Barker, Dean Wong, Mona Mohamed

439 NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV
Jeremy Strain, Robert S. Smith, Sarah Cooley, Beau M. Ances
SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS

Dima A. Hammoud, Sanhita Sinharay, Sally Steinbach, Paul Wakim, Katrina Geannopoulos, Katherine Traino, Amit Dey, Stanley Rapoport, Edmund C. Tramont, Joseph Snow, Nehal N. Mehta, Bryan Smith, Avindra Nath

BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART

Ignacio Pérez-Valero, Lucia Bailon, Alicia Gonzalez, Belen Alejos, Helena Melero, Norberto Malpica, Jose I. Bernardino, Juan González-Garcia, Jose R. Arribas, for the La Paz HIV Group

Themed Discussion TD-08 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?

Ballroom C 1:30 PM – 2:30 PM

Themed Discussion Leader

Gerardo García-Lerma, Centers for Disease Control and Prevention, Atlanta, GA, USA

LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA

Simani Gaseitsiwe, Sikhulile Moyo, Melissa Zahralban-Steele, Dorcas Maruapula, Baitshepi Mokaleng, Terence Mohammed, Shenaaz El-Halabi, Elliot G. Raizes, Tendani Gaolathe, Shahin Lockman, Max Essex, Vlad Novitsky

HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION

Safia S. Kuriakose, Jomy M. George, Nicola Dee, Pam Stoll, Brian K. Agan, Robin L. Dewar, Alice K. Pau, Frank Maldarelli

UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE

Isabelle Malet, Frédéric Subra, Hervé Leh, Charlotte Charpentier, Gilles Collin, Diane Descamps, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis

PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS


INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1

Kristen Andreatta, Silvia Chang, Ross Martin, Madeleine Willkom, Kirsten L. White
Themed Discussion TD-09 BONES OF CONTENTION
Auditorium
1:30 PM – 2:30 PM

Themed Discussion Leader
Eugènia Negredo, Fundació Lluita Contra la Sida, Badalona, Spain

720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY
Nicolas Salvadori, Bo Fan, Waralee Teeyasoonthranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Sirirongpotong, Chaiwat Putiyunun, Athena Kourtis, Marc Bulterys, George K. Siberry, Gonzague Jourdain, for the iTAP Study Group

721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN
Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary G. Fowler, Josaphat Byagumisha, Adeodata Kekitiinwa, Gail R. Goldberg

722 RATES OF BONE LOSS SLOW AFTER THE FIRST YEAR OF ART: START BMD SUBSTUDY FINAL RESULTS
Andrew Carr, Birgit Grund, Ann V. Schwartz, Anchealé Avihingsanon, Sharlaa Badal-Faesen, Jose I. Bernadino, Patrick W. Mallon, Vicente Estrada, Alberto M. La Rosa, Sanjay Pujari, David White, Nicole Wyman Engen, Kristine E. Ensrud, Jennifer Hoy, for the START Bone Mineral Density Substudy Group

723 GREATER BONE TURNOVER MARKER DECLINE WITH ZOLEDRONIC ACID THAN WITH TDF-SWITCHING
Andrew Carr, Robyn Richardson, Stephen J. Kerr, Peter R. Ebeling, Nicholas Pocock, Jhon Rojas, Esteban Martinez, Jennifer Hoy, for the ZeST Study Group

724 COMBINED EFFECTS OF BISPHOSPHONATES & TDF→TAF SWITCH IN HIV+ ADULTS WITH LOW BMD
Todd T. Brown, Michael T. Yin, Samir K. Gupta, William R. Short, Melanie Thompson, Daniel Podzamczer, Giovanni Di Perri, Cheryl McDonald, Matthias Cavassini, Pablo Tebas, Ya-Pei Liu, Scott McCallister, Andrew Cheng, Moupali Das

Themed Discussion TD-10 EXPANDING PrEP IN WOMEN
Ballroom A
1:30 PM – 2:30 PM

Themed Discussion Leader
Quarraisha Abdool Karim, CAPRISA, Durban, South Africa

1048 PREDICTORS OF PrEP ELIGIBILITY AMONG AT–RISK WOMEN IN THE SOUTHERN UNITED STATES
Anar S. Patel, Lakshmi Goparaju, Jessica M. Sales, Cyra Christina Mehta, Oni J. Blackstock, Dominika Seidman, Igbo Ototokun, Mirjam-Colette Kempf, Margaret Fischl, Elizabeth T. Golub, Adaora Adimora, Audrey French, Gina Wingood, Seble Kassaye, Anandi N. Sheth

1045 PREDICTORS OF WILLINGNESS TO TAKE PrEP AMONG BLACK AND LATINA TRANSGENDER WOMEN
Tonia Poteat, Erin Cooney, Mannat Malik, Thespina Yamanis, Maren Lujan, Andrea L. Wirtz

1046 PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT
Robyn Eakle, Gabriela Gomez, Niven Naicker, Rutendo Bothma, Judie Mbohua, Maria A. Cabrera Escobar, Elaine Saayman, Michelle A. Moorhouse, Willem D. Venter, Helen Rees
1049 RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082

1043 PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN
Maria Pyra, Elizabeth Brown, Jessica E. Haberer, Renee Heffron, Elizabeth A. Bukusi, Stephen Asiiimwe, Connie L. Celum, Elly T. Katabira, Nelly R. Mugo, Jared Baeten, for the Partners Demonstration Project Team

1047 HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE
John Kinuthia, Jillian Pintye, Kenneth K. Mugwanya, Marline Serede, Joseph Sila, Felix Abuna, Harrison Lagat, Julia Dettinger, Tina Schuh, Jared Baeten, Grace John-Stewart

**Themed Discussion TD-11 THE PERSISTENT CHALLENGE OF LATE PRESENTATION AND MORTALITY**

**Ballroom B**

**1:30 PM – 2:30 PM**

**Themed Discussion Leader**
Nathan Ford, WHO, Geneva, Switzerland

903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA

901 LONG-TERM MEASURES OF HIV EXPOSURE AND MORTALITY IN THE HIV OUTPATIENT STUDY

891 SHIFTING MORTALITY TRENDS AMONG PERSONS WITH HIV AND INJECTION DRUG USE OVER 30 YEARS
Jing Sun, Damani A. Piggott, Abimereki D. Muzaale, Jacquie Astemborski, Shruti H. Mehta, Gregory D. Kirk

902 POST-HOSPITAL MORTALITY AND READMISSION AMONG HIV-INFECTED ADULTS IN SOUTH AFRICA
Chris Hoffmann, Minja Milovanovic, Deanne Kerrigan, Neil A. Martinson, Ebrahim Variava

898 PERSONS LIVING WITH HIV (PLHIV) WITH ADVANCED HIV DISEASE: NEED FOR NOVEL CARE MODELS
Wafa M. El-Sadr, Chloe A. Teasdale, Katharine Yuengling, Peter Preko, Maureen Syowai, Felix Ndagije, Miriam Rabkin, Elaine J. Abrams
Symposium S-5 MOLECULAR MACHINES  
Ballroom A  
4:00 PM – 6:00 PM

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding key stages in the HIV replication cycle, both from a basic science perspective and to advance the development of new therapeutics and more effective vaccines.

**Level of Knowledge:** It is assumed that the participants are familiar with the different stages of the viral life cycle and have a basic understanding of molecular biology.

**Objectives:** At the conclusion of this session, learners will be able to describe:

- The structures and mechanisms of viral and cellular machines that perform or block key stages of HIV replication
- HIV envelope protein structure and transformations, inhibition by drugs and antibodies, and progress toward an envelope-based vaccine.
- The molecular architecture and regulation of the RT-RNA complex that initiates HIV reverse transcription
- The structure and mechanism of SAMHD1, a host restriction factor that inhibits retroviral replication by depleting cytoplasmic dNTP pools
- The structure and mechanism of the Vps4 ATPase, the host machine that powers HIV budding

**Conveners**

- **Zandrea Ambrose,** University of Pittsburgh, Pittsburgh, PA, USA
- **A Bing Chen,** Boston Children’s Hospital/Harvard Medical School, Boston, MA, USA
- **Peter D. Kwong,** National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
- **Elisabetta Viani Puglisi,** Stanford University, Stanford, CA, USA
- **Ian A. Taylor,** The Francis Crick Institute, London, UK
- **Christopher P. Hill,** University of Utah, Salt Lake City, UT, USA

**Program**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>98</td>
<td>HIV ENV: STRUCTURE, FUNCTION, AND INHIBITION THEREOF</td>
<td>Peter D. Kwong, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA</td>
</tr>
<tr>
<td>99</td>
<td>ARCHITECTURE OF THE HIV-1 REVERSE TRANSCRIPTASE INITIATION COMPLEX</td>
<td>Elisabetta Viani Puglisi, Stanford University, Stanford, CA, USA</td>
</tr>
<tr>
<td>100</td>
<td>STRUCTURE AND MECHANISM OF THE SAMHD1 HIV-1 RESTRICTION FACTOR</td>
<td>Ian A. Taylor, The Francis Crick Institute, London, UK</td>
</tr>
<tr>
<td>101</td>
<td>STRUCTURE AND MECHANISM OF VPS4, THE ENZYME THAT DRIVES HIV BUDDING</td>
<td>Christopher P. Hill, University of Utah, Salt Lake City, UT, USA</td>
</tr>
</tbody>
</table>
Target Audience: This session is directed to clinicians and scientists who are interested in understanding the degree to which HIV contributes to increased morbidity and mortality in the modern ART era and potential intervention strategies to improve health beyond ART alone.

Level of Knowledge: It is assumed that participants are familiar with the general epidemiology of HIV infection and basic concepts in HIV pathogenesis, including immune activation.

Objectives: At the completion of the session, participants will be able to:

- Explain the degree to which HIV is associated with excess morbidity and mortality in the modern ART era, and subgroups of HIV-infected individuals that are at particularly high risk
- Describe the potential contribution of health-related behaviors and treatable noncommunicable chronic disease to this excess morbidity and mortality
- Describe the potential contribution of persistent immune activation and inflammation to morbidity and mortality during treated HIV infection as well as possible intervention targets

Conveners

Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA
Dominique Costagliola, Pierre and Marie Curie University, Paris, France

102 LIFE EXPECTANCY IN THE MODERN ART ERA
4:00 Caroline Sabin, University College London, London, UK

103 IMPACT OF PHYSICAL AND MENTAL COMORBIDITIES ON LIFE EXPECTANCY
4:30 Keri N. Althoff, Johns Hopkins University, Baltimore, MD, USA

104 INFLAMMATION AND DISEASE RISK AMONG HIV-SEROPOSITIVE INDIVIDUALS
5:00 Jason V. Baker, Hennepin County Medical Center, Minneapolis, MN, USA

5:30 – 6:00 Moderated discussion with the speakers
Symposium S-7 PrEP WORKS, NOW WHAT?  
Ballroom B  
4:00 PM – 6:00 PM

**Target Audience:** This session is directed to clinicians and scientists who are interested in understanding the challenges and opportunities of preexposure prophylaxis (PrEP) as a treatment strategy.

**Level of Knowledge:** It is assumed that the participants are familiar with basic HIV epidemiology and prevention strategies.

**Objectives:** At the completion of the session, participants will be able to:
- Describe the correlation between the uptake of PrEP and high rates of STIs
- Explain how PrEP could impact HIV incidence globally
- Describe the current challenges in PrEP scale-up and the various strategies to guide PrEP scale up

**Conveners**

Elizabeth M. Irungu, Kenya Medical Research Institute, Nairobi, Kenya

Leandro A. Mena, University of Mississippi Medical Center, Jackson, MS, USA

---

**105**  
4:00  
**THE INTERSECTION OF PrEP AND SEXUALLY TRANSMITTED INFECTIONS**  
Julia A. Schillinger, CDC, Atlanta, GA, USA

---

**106**  
4:30  
**IMPACT OF PrEP ON HIV INCIDENCE**  
Roel Coutinho, University Medical Center Utrecht, Utrecht, Netherlands

---

**107**  
5:00  
**FIVE CONTROVERSIES IN PrEP SCALE-UP**  
Linda-Gail Bekker, University of Cape Town, Cape Town, South Africa

---

**108**  
5:30  
**TAKING THE LEAP IN PrEP SCALE-UP: A GOOD TYPE OF CHALLENGE**  
Nelly R. Mugo, Kenya Medical Research Institute, Nairobi, Kenya
WEDNESDAY, MARCH 7, 2018

Oral Sessions

Plenary PL-3 WEDNESDAY PLENARY SESSION
Auditorium / Hall C / Auditorium Balcony 8:30 AM – 9:30 AM

109 GROWING UP WITH HIV
8:30 Patricia M. Flynn, St. Jude Children’s Research Hospital, Memphis, TN, USA

110 ARE WE ON THE FAST TRACK TO “BEND AND END” THE HIV EPIDEMICS?
9:00 Helen A. Weiss, London School of Hygiene & Tropical Medicine, London, UK

Oral Abstract 0-09 HIV REPLICATION, INHIBITION, AND RESTRICTION
Ballroom A 10:00 AM – 12:00 PM

Oral Abstract Moderators
Rahm Gummuluru, Boston University, Boston, MA, USA
Brandon Keele, National Cancer Institute, Frederick, MD, USA

111 IDENTIFICATION OF HIV-1 ENV MUTATIONS THAT CONFER BROAD RESISTANCE TO ARVS IN VITRO
10:00 Rachel Van Duyne, Phuong Pham, Eric O. Freed

112 STRAIN-DEPENDENT ACTIVATION AND INHIBITION OF HIV-1 ENTRY BY A PF-68742 DIASTEREOISOMER
10:15 Connie A. Zhao, Amy Princiotto, Mark Farrell, Amos B. Smith, Navid Madani, Joseph G. Sodroski

113LB TRISPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV-1 INFECTION
10:30 Amarendra Pegu, Zhi-yong Yang, Ling Xu, Ercole Rao, Nicole Doria-Rose, Jochen Benninga, Krisha McKee, Dana M. Lord, Ronnie R. Wei, Gejing Deng, Stephen Schmidt, Wang Keyun, Mario Roederer, John R. Mascola, Gary Nabel

114 MOLECULAR DETERMINANTS OF HIV HYPERMUTATION
10:45 Diako Ebrahimi, Christopher Richards, Michael A. Carpenter, Jennifer McCann, Adam Cheng, Terumasa Ikeda, Daniel Salamango, Reuben S. Harris

115 HIV-1 SPLICING SUPPRESSION AS A POSSIBLE THERAPEUTIC TARGET
11:00 Ann Emery, Matthew Takata, Jeffery Levengood, John Collins, Alice Telesnitsky, Blanton Tolbert, Paul Bieniasz, Ronald Swanstrom

116 A LONG INTERNAL LOOP GOVERNS THE SENSITIVITY OF THE ANTI-HIV PROTEIN SERINC5 TO NEF
11:15 Weiwei Dai, Yoshiko Usami, Yuanfei Wu, Heinrich Gottlinger

117 PROTECTIVE GENE EXPRESSION SIGNATURE IN RESPONSE TO RHCMOV/SIV VACCINE VECTORS
11:30 Connor Driscoll, Richard Green, Fredrik Barrenas, Jean Chang, Elise Smith, Lynn Law, Scott Hansen, Louis J. Picker, Michael Gale
118 CROSS-SPECIES CMV VACCINATION REVEALS DETERMINANTS OF NON-CLASSICAL T CELLS


Oral Abstract 0-10 THE CNS RESERVOIR(S), REBOUND, AND BRAIN INJURY

Ballroom B 10:00 AM – 12:00 PM

Oral Abstract Moderators
Lishomwa Ndhlovu, University of Hawaii, Honolulu, HI, USA
Christina Marra, University of Washington/ Harborview Medical Center, Seattle, USA

119 HIV-1 PERSISTS IN CSF CELLS IN HALF OF INDIVIDUALS ON LONG-TERM ART

10:00

Serena S. Spudich, Rajesh T. Gandhi, Joshua C. Cyktor, Christina Lalama, Ronald Bosch, Bernard J. Macatangay, Charles Rinaldo, Kevin Robertson, Ann Collier, Catherine Godfrey, Evelyn Hogg, Joseph J. Eron, Deborah McMahon, John W. Mellors, for the A5321 Study Team

120 LONGITUDINAL TRAJECTORY OF BRAIN VOLUME AND CORTICAL THICKNESS IN PRIMARY INFECTION

10:15

Ryan Sanford, Beau M. Ances, Richard W. Price, Dieter Meyerhoff, Serena S. Spudich, Louis Collins

121 HIV AND BRAIN ATROPHIC SIGNATURE IN ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT

10:30

Lucette A. Cysique, Madeline Nichols, Thomas Gates, James Soares, Kirsten Moffat, Caroline Rae, Bruce J. Brew

122 LONGITUDINAL COGNITIVE OUTCOMES AFTER TREATMENT IN ACUTE HIV INFECTION

10:45

Phillip Chan, Umit Tokac, Joanna Hellmuth, Eugène Kroon, Donn Colby, Carlo Sacdalan, James L. Fletcher, Somporn Tipsuk, Suteeraporn Pinyakorn, Merlin L. Robb, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, Robert Paul, for the RV254/SEARCH 010 Study Team

123 IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS

11:00

Shibani S. Mukerji, Vikas Misra, David Lorens, Hajime Uno, Susan Morgello, Donald Franklin, Ronald J. Ellis, Scott L. Letendre, Dana H. Gabuzda

124 SIV REBOUND IN THE SPINAL CORD AFTER STOPPING ART: A NOVEL CNS RESERVOIR

11:15

Megan E. McCarroll, Lisa Mangus, Samuel A. Brill, Sarah E. Beck, Kelly A. Metcalf Pate, Suzanne E. Queen, Joseph Mankowski

125 IDENTIFICATION OF BRAIN INJURY USING A NOVEL DEFINITION OF COGNITIVE IMPAIRMENT

11:30

Jonathan Underwood, James H. Cole, Davide De Francesco, Caroline Sabin, Alan Winston, for the CHARTER group

126 HEME OXYGENASE-1 POLYMORPHISM ASSOCIATES WITH NEUROIMMUNE ACTIVATION IN HIV SUBJECTS

11:45

Alexander J. Gill, Rolando Garza, Suren A. Ambegaokar, Patricia J. Vance, Benjamin B. Gelman, Dennis L. Kolson
Oral Abstract O-11 HEPATITIS C VIRUS / HIV-ASSOCIATED MALIGNANCIES

Room 304-306 10:00 AM – 12:00 PM

Oral Abstract Moderators
Milosz Parczewski, Pomeranian Medical University, Szczecin, Poland
Meredith S. Shiel, National Cancer Institute, Rockville, MD, USA

127  
RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHO FAILED GLECAPREVIR/PIBRETASVIR
10:00
David L. Wyles, Ola Weiland, Betty Yao, Robert Reindollar, Frank Weillert, Jean-Francois Dufour, Stuart Gordon, Fred Poodrad, Albrecht Stoehr, Ashley Brown, Stefan Mauss, Suvajit Samanta, Tami Pilott-Matias, Lino Rodrigues, Roger Trinh

128  
8 WEEKS OF GRAZOPREVIR/ELBASVIR FOR ACUTE HCV: A MULTICENTER CLINICAL TRIAL (DAHHS 2)
10:15
Anne Boerekamps, Anja De Weggheleire, Guido van den Berk, Fanny Lauw, Mark Claassen, Dirk Posthouwer, Wouter Bierman, Sebastiaan Hullegie, Eric Florence, Anton Dofferhoff, Joop E. Arends, Bart Rijnders

129  
FUELING THE EPIDEMIC: LOW RATES OF SPONTANEOUS CLEARANCE OF ACUTE HCV INFECTION
10:30
Christoph Boesecke, Elena Muller Martinez, Mark Nelson, Patrick Ingiliz, Thomas Lutz, Stefan H. Scholten, Christiane Cordes, Heribert Knechten, Maria Martinez-Rebollar, Christoph D. Spinner, Michael Rausch, Thomas Reiberger, Stefan Mauss, Jürgen K. Rockstroh, for the PROBE-C study group

130  
INTERNATIONAL VERSUS DOMESTIC HCV TRANSMISSION IN MSM: A PERSPECTIVE FOR THE DAA ERA
10:45
Luisa Salazar-Vizcaya, Roger Kouyos, Karin Metzner, Kamila Caraballo, Cyril Shah, Jürg Böni, Manuel Battegay, Enos Bernasco, Alexandra Calmy, Matthias Cavassini, Herbert A. Mbunkah, Olivia Keiser, Andri Rauch, for the Swiss HIV Cohort Study

131  
ITAP TRIAL: MATERNAL AND INFANT EFFICACY AND SAFETY RESULTS 12 MONTHS AFTER DELIVERY
11:00
Gonzague Jourdain, Linda J. Harrison, Nicole Ngo-Giang-Huong, Tim R. Cressey, Luc Decker, Camlin Tierney, Jullapong Achalapong, Prateep Kanjanavikai, Anita Luvira, Ussanee Srirompotong, Trudy V. Murphy, Noelle Nelson, George K. Siberry, Stanislas Pol, for the ITAP Study Group

132  
STATIN EXPOSURE IS ASSOCIATED WITH DECREASED RISK OF CANCER
11:15
Roger Bedimo, Fatma Shebl, Keith M. Sigel, Sheldon T. Brown, Kristina Crothers, Matthew B. Goetz, Amy C. Justice, Janet Tate, for the VA Aging Cohort Study

133  
PREDICTORS OF KS-IRIS IN MILD/MODERATE AIDS-KS DURING ART IN LOW-RESOURCE SETTINGS
11:30
Thomas Campbell, Minhee Kang, Trijn Umbleja, Susan E. Krown, Agrey Bukuru, Jeffrey N. Martin, Catherine Godfrey, Mulinda Nyirenda, Naftali Busakhala, Margaret Borok, Deborah Langat, Brenda Hoagland, Noluthando Mwelase, Mina C. Hosseinipour, for the ACTG A5264 Protocol Team

134  
ACTG 5282: HPV TEST&TREAT VS CYTOLOGY-BASED CERVICAL CANCER PREVENTION IN HIV+ WOMEN
11:45
Timothy Wilkin, Roy Matining, Vikrant Sahasrabuddhe, Huichao Chen, Reena Masih, Rosie Mngqibisa, Mohammed Rassool, Yamikani Mbilizi, Tsitsi M. Magure, Cynthia Riviere, Aida Asmelash, Ramesh BhoSale, Pamela Michelow, Catherine Godfrey, Cindy Firnhaber
Oral Abstract 0–12 CRITICAL ISSUES IN WOMEN’S HEALTH AND EARLY TREATMENT OF PEDIATRIC HIV INFECTION

Ballroom C 10:00 AM – 12:00 PM

Oral Abstract Moderators
Catherine Orrell, Desmond Tutu HIV Foundation, Cape Town, South Africa
Linda Barlow-Mosha, Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

135  ARV PROPHYLAXIS/ART INITIATION AT BIRTH LIMITS THE SIZE OF THE RESERVOIR IN CHILDREN
10:00
Marta Massanella, Jintanat Ananworanich, Louise Leyre, Thidarut Jupimai, Panadda Sawangsingth, Mark de Souza, Suteeporn Pinyakorn, Piyarat Suntrattwiwong, Pope Kosalaraksa, Thitiporn Borkird, Kulkanya Chokephaibulkit, Suparat Kanjanavanit, Thanyawee Puthanakit, Nicolas Chomont, for the HIVNET209 and HIVNET194 study groups

136  LOW HIV RESERVOIR AT 84 WEEKS IN VERY EARLY TREATED HIV-INFECTED CHILDREN IN BOTSWANA
10:15
Roger L. Shapiro, Mathias Lichterfeld, Michael D. Hughes, Kara Bennett, Kenneth Mswabw, Gbolahan Ajibola, Pilar Garcia-Broncano, Sikhulile Moyo, Terence Mohammed, Patrick Jean-Philippe, Maureen Sakoi, Oganee Batlang, Shahn Lockman, Joseph Makhema, Daniel R. Kuritzkes

137  TIME TO VIRAL REBOUND AFTER STOPPING ART IN CHILDREN TREATED FROM INFANCY IN CHER
10:30
Avy Violari, Man Chan, Kennedy N. Otowome, Ravindre Panchia, Patrick Jean-Philippe, Diana Gibb, Mark Cotton, Abdel Babiker, for the CHER Study Team and EPICAL Consortium

138  SIMILAR CLINICAL OUTCOMES BETWEEN FORMULA AND BREASTFEEDING WOMEN IN PROMISE
10:45
Risa M. Hoffman, Konstantia Angelidou, Sean Brummel, Friday Saidi, Dingase E. Dula, Vidyia Mave, Lee Fairlie, Gerhard Theron, Moreen Kamateeka, Tsungai Chipato, Avy Violari, Nahida Chakhtoura, Judith S. Currier, Mary Glenn Fowler, for the IMPAACT PROMISE 1077BF/FF Team

139  PROMISE TRIAL: RESULTS OF CONTINUED VS DISCONTINUED ART AFTER END OF BREASTFEEDING
11:00
Taha E. Taha, Sean Brummel, Konstantia Angelidou, Mary Glenn Fowler, Patricia M. Flynn, Cornelius Mukuuzunga, Dingase E. Dula, Maxensia Owor, Dhayendre Moodley, Tsungai Chipato, Amy J. Loftis, Nahida Chakhtoura, Katie McCarthy, Judith S. Currier, for the IMPACT PROMISE Study Team15

140  ART DETECTION AND RESISTANCE DURING VIRAEMIC EPISODES IN PREGNANCY AND BREASTFEEDING
11:15
Landon Myer, Andrew D. Redd, Elton Mukonda, Briana Lynch, Tamsin K. Phillips, Anna Eisenberg, Allison Breaud, Nie-Yuan M. Hsiao, Craig Martens, Maia Lesosky, James A. McIntyre, William Clarke, Elaine J. Abrams, Steven J. Reynolds

141  VAGINAL CONTRACEPTIVE HORMONE EXPOSURE PROFOUNDLY ALTERED BY EFV- AND ATV/R-BASED ART
11:30
Kimberly K. Scarsi, Yoninah S. Cramer, David Gingrich, Susan L. Rosenkranz, Francesca Aweeka, Robert Coombs, Carmen D. Zorrilla, Kristine Coughlin, Laura E. Moran, Baiba Berzins, Catherine Godfrey, Susan E. Cohn, for the AIDS Clinical Trials Group A5316 Study Team
**142LB**  
**11:45**  
**RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY**  
Amita Gupta, Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Carolyne Onyango-Makumbi, Tsungai Chipato, Gaerolwe Masheto, Katherine Shin, Bonnie Zimmer, Timothy R. Sterling, Nahida Chakhtoura, Patrick Jean-Philippe, Adriana Weinberg, for the IMPAACT P1078/TB APPRISE Study Team

---

**Oral Abstract 0-13**  
**IMPROVING USE OF THE TOOLS WE HAVE: HIV TESTING AND VAGINAL RINGS**  
Auditorium  
**10:00 AM – 12:00 PM**

**Oral Abstract Moderators**  
**Euphemia Sibanda**, Centre for Sexual Health and HIV AIDS Research, Harare, Zimbabwe  
**Rachel Baggaley**, World Health Organization, Geneva, Switzerland

**143LB**  
**10:00**  
**HIGH UPTAKE AND REDUCED HIV-1 INCIDENCE IN AN OPEN-LABEL TRIAL OF THE DAPIVIRINE RING**  
Jared Baeten, Thesla Palanee-Phillips, Nyaradzo Mgodi, Ashley Mayo, Annalene Nel, Zeda Rosenberg, Sharon L. Hillier, Elizabeth Brown, for the MTN-025/HOPE Study Team

**144LB**  
**10:15**  
**HIV INCIDENCE AND ADHERENCE IN DREAM: AN OPEN-LABEL TRIAL OF DAPIVIRINE VAGINAL RING**  
Annalene Nel, Nelettie Van Niekerk, Ben Van Baelen, Zeda Rosenberg, for the The IPM 032/DREAM Study Team

**145**  
**WHO REMAINS UNTESTED FOLLOWING NEAR-UNIVERSAL (≥95%) POPULATION HIV TESTING?**  
Dalsone Kwarisima, Jane Kabami, Norton Sang, Kevin Kadede, Atukunda Mucunguzi, Katherine Snyman, Tamara D. Clark, Elizabeth A. Bukusi, Teri Liegler, Edwin D. Charlebois, Laura B. Balzer, Maya L. Petersen, Moses R. Kamya, Diane V. Havlir, Gabriel Chami

**146**  
**10:45**  
**EXPANDED HIV TESTING ELIGIBILITY INCREASES DETECTION OF HIV INFECTIONS, WESTERN KENYA**  
Rachael Joseph, Paul K. Musingila, Fredrick Miruka, Lucy Ng’ang’a, Hellen Muttai, Kevin M. De Cock, Felix M. Mulama, Caroline O. Dande, Polycarp Musee, Stella Wanjohi

**147**  
**11:00**  
**OPTIMAL HIV TESTING STRATEGIES TO INCREASE HIV DIAGNOSIS IN SOUTH AFRICA**  
Leigh F. Johnson, Gesine Meyer-Rath, Craig Van Rensburg, Caroline Govathson

**148**  
**11:15**  
**EFFECT OF HIV SELF-TESTING ON SEXUAL PARTNER NUMBERS FOR ZAMBIAN FEMALE SEX WORKERS**  
Catherine E. Oldenburg, Michael M. Chanda, Katrina F. Ortblad, Magdalene Mwale, Steven Chongo, Nyambe Kamungoma, Catherine Kanchele, Andrew Fullem, Guy Harling, Till Bärnighausen

**149**  
**11:30**  
**HIV SELF-TEST DISTRIBUTION INCREASES TEST FREQUENCY IN SOUTH AFRICAN MSM**  
Sheri A. Lippman, Tim Lane, Oscar Rabede, Hailey Gilmore, Yea-Hung Chen, Nkull Mlotshwa, Kabelo Maleke, Alexander Marr, James A. McIntyre
150LB  LINKAGE TO CARE AFTER HIV SELF-TESTING IN ZIMBABWE: A CLUSTER-RANDOMISED TRIAL
Euphemia Sibanda, Melissa Neuman, Mary Tumushime, Karin Hatzold, Constanza Wadadzaushe, Miriam H. Mutseta, Jeffrey Dirawo, Sue Napierala, Getrude Ncube, Miriam Taegtmeyer, Cheryl Johnson, Katherine Fielding, Helen A. Weiss, Elizabeth L. Corbett, Frances Cowan

Themed Discussion TD-12  T AND B CELL INTERACTIONS IN LYMPH NODES
Ballroom A  1:30 PM – 2:30 PM

Themed Discussion Leader
Michael R. Betts, University of Pennsylvania, Philadelphia, PA, USA

284  FREQUENCIES AND DISTRIBUTION OF ENV-SPECIFIC B CELLS IN BLOOD VERSUS LYMPH NODES
Alessandra Noto, Andrew McDavid, Phu Van, Madeleine Suffiotti, Agostino Riva, Jean-Marc Corpataux, Song Ding, Craig Fenwick, Raphael Gottardo, Giuseppe Pantaleo

285  T AND B CELL ALTERATIONS IN PERIPHERAL BLOOD AND LYMPH NODE IN ACUTE HIV INFECTION
Supranee Buranapraditkun, Hiroshi Takata, Carlo Sacdalan, Sopark Manasnayakorn, Suthat Chottanapund, Pattarawat Thantivorasit, Peeriya Prueksaakaew, Khunthalee Benjapornpong, Bessara Nuntapinit, Timothy Schacker, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Lydie Trautmann, for the RV254/SEARCH010

286  CYTOLYTIC CD4+ T CELLS WITH FOLLICULAR HOMING PROPERTIES IN CHRONIC HIV INFECTION
Enrico Richter, Johanna Eberhard, Marek Korencak, Bruce T. Schultz, Britta Flach, Stefan Esser, Julian Schulze zur Wiesch, Hendrik Streeck

287  TFC CELLS INTERACT WITH OTHER FOLLICULAR T CELLS TO CONTROL SIV VIREMIA
Mohammad Arif Rahman, Katherine M. McKinnon, Tatiana S. Karpova, David A. Ball, David Venzon, Wenjin Fan, Guobin Kang, Qingsheng Li, Marjorie Robert-Guroff

Themed Discussion TD-13  BIG APPLICATIONS OF LITTLE RNAs
Ballroom C  1:30 PM – 2:30 PM

Themed Discussion Leader
Raymond T. Chung, Massachusetts General Hospital, Boston, MA, USA

637  POTENTIAL FOR SERUM MICRO-RNAs TO PREDICT FIBROSIS REGRESSION DURING HBV TREATMENT
Cody Orr, Rob Myers, David Gong, Biao Li, Zhaoshi Jiang, John Flaherty, Anuj Gagger, G. Mani Subramanian, Eric G. Meissner

638  HEPATIC EXPRESSION OF HSA-MIR-125A-5P AND FIBROSIS IN OVERT AND OCCULT HBV INFECTION
Lorenzo Onorato, Aniello Russo, Giorgio de Stefano, Carmine Minichini, Mario Starace, Pietro Filippini, Loredana Alessio, Nunzia Farella, Nicoletta Potenza, Evangelista Sagnelli, Nicola Coppola

639  CIRCULATING MICRORNAs IN HIV PATIENTS REVEAL SPECIFIC SIGNATURES FOR LIVER DAMAGE
Miguel Angel Martinez, Sandra Franco, Daniela Buccione, Beatriz Mothe, Lidia Ruiz, Maria Nevot, Ana Jordan-Paiz, Raquel Pluvinet, Susanna Aussó, Rosa M. Morillas, Lauro Sumoy, Cristina Tural
Oral Sessions

Oral Sessions

Oral Sessions

Oral Sessions

Oral Sessions

Oral Sessions

Oral Sessions

Themed Discussion TD-14 OUTCOMES OF PREVENTION STRATEGIES FOR CRYPTOCOCCAL MENINGITIS

Ballroom B
1:30 PM – 2:30 PM

Themed Discussion Leader
Graeme Meintjes, University of Cape Town, Cape Town, South Africa

784 CRAG STATUS AND EFFECT ON BENEFITS FROM ENHANCED PROPHYLAXIS IN THE REALITY TRIAL
Sarah Pett, Lewis Haddow, Ruth Nhema, Moira J. Spyer, Laura Benjamin, Grace Najiku, Ibrahim Daud, Jay Berkley, Juliet Kitabalwa, James G. Hakim, Rob Heyderman, Sarah Walker, Diana Gibb, for the REALITY trial team

785 EVALUATION OF A CRYPTOCOCCAL SCREENING AND TREATMENT PROGRAM IN HIV CLINICS IN UGANDA
Elizabeth Nalintya, David Meya, Sarah Lofgren, Kathy Huppler Hullsiek, David R. Boulware, Radha Rajasingham

786 CLINIC-BASED LATERAL FLOW CRYPTOCOCCAL ANTIGEN TESTING AT HIV DIAGNOSIS, SOUTH AFRICA
Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunus Moosa, Connie L. Celum

787 SYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA PRESENTING AS EARLY CRYPTOCOCCAL MENINGITIS
Kenneth Ssebambulidde, Mahsa Abassi, Joshua Rhein, Ananta Bangdiwala, Darlisha A. Williams, Edward Mpoza, Lillian Tugume, Richard Kwizera, Abdu Musubire, Fiona Cresswell, Sarah Lofgren, Kathy Huppler Hullsiek, David R. Boulware, David Meya, for the ASTRO-CM

788 POSTMORTEM CRYPTOCOCCAL MENINGITIS FOLLOWING TREATMENT FOR CRYPTOCOCCAL ANTIGENAEMIA
Rachel M. Wake, Tanvier Omar, Aaron S. Karat, Joseph N. Jarvis, Nelesh P. Govender, Thomas S. Harrison

Themed Discussion TD-15 PHYLOGENETICS FOR PUBLIC HEALTH INTERVENTION

Room 302
1:30 PM – 2:30 PM

Themed Discussion Leader
Andrew Leigh Brown, University of Edinburgh, Edinburgh, United Kingdom

953 PHYLOGENETIC METHODS OF IDENTIFYING FOCI OF HIV-1 TRANSMISSION
Angela McLaughlin, P. Richard Harrigan, Jean A. Shoveller, Jeffrey Joy

957 HIV TRANSMISSION CLUSTER DYNAMICS THAT INFORM PUBLIC HEALTH INTERVENTION IN ILLINOIS
Manon Ragonnet-Cronin, Joel O. Wertheim, Christina S. Hayford, Richard D'Aquila, Fangchao Ma, Cheryl Ward, Nanette Benbow

miRNA PROFILE OF HCV SPONTANEOUS CLEARANCE INDIVIDUALS SHOW PREVIOUS HCV INFECTION
Óscar Brochado Kith, Alicia Gómez Sanz, Luis M. Real, Javier Crespo, Pablo Ryan, Juan Macías, Joaquín Cabezas, Juan A. Pineda, María T. Arias-Loste, Isabel Cuesta, Sara Monzón-Fernández, Luz M. Medrano, María A. Jimenez-Sousa, Salvador Resino, Amanda Fernández-Rodríguez

Themed Discussion TD-14 OUTCOMES OF PREVENTION STRATEGIES FOR CRYPTOCOCCAL MENINGITIS

Ballroom B
1:30 PM – 2:30 PM

Themed Discussion Leader
Graeme Meintjes, University of Cape Town, Cape Town, South Africa

784 CRAG STATUS AND EFFECT ON BENEFITS FROM ENHANCED PROPHYLAXIS IN THE REALITY TRIAL
Sarah Pett, Lewis Haddow, Ruth Nhema, Moira J. Spyer, Laura Benjamin, Grace Najiku, Ibrahim Daud, Jay Berkley, Juliet Kitabalwa, James G. Hakim, Rob Heyderman, Sarah Walker, Diana Gibb, for the REALITY trial team

785 EVALUATION OF A CRYPTOCOCCAL SCREENING AND TREATMENT PROGRAM IN HIV CLINICS IN UGANDA
Elizabeth Nalintya, David Meya, Sarah Lofgren, Cathy Huppler Hullsiek, David R. Boulware, Radha Rajasingham

786 CLINIC-BASED LATERAL FLOW CRYPTOCOCCAL ANTIGEN TESTING AT HIV DIAGNOSIS, SOUTH AFRICA
Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunus Moosa, Connie L. Celum

787 SYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA PRESENTING AS EARLY CRYPTOCOCCAL MENINGITIS
Kenneth Ssebambulidde, Mahsa Abassi, Joshua Rhein, Ananta Bangdiwala, Darlisha A. Williams, Edward Mpoza, Lillian Tugume, Richard Kwizera, Abdu Musubire, Fiona Cresswell, Sarah Lofgren, Kathy Huppler Hullsiek, David R. Boulware, David Meya, for the ASTRO-CM

788 POSTMORTEM CRYPTOCOCCAL MENINGITIS FOLLOWING TREATMENT FOR CRYPTOCOCCAL ANTIGENAEMIA
Rachel M. Wake, Tanvier Omar, Aaron S. Karat, Joseph N. Jarvis, Nelesh P. Govender, Thomas S. Harrison

Themed Discussion TD-15 PHYLOGENETICS FOR PUBLIC HEALTH INTERVENTION

Room 302
1:30 PM – 2:30 PM

Themed Discussion Leader
Andrew Leigh Brown, University of Edinburgh, Edinburgh, United Kingdom

953 PHYLOGENETIC METHODS OF IDENTIFYING FOCI OF HIV-1 TRANSMISSION
Angela McLaughlin, P. Richard Harrigan, Jean A. Shoveller, Jeffrey Joy

957 HIV TRANSMISSION CLUSTER DYNAMICS THAT INFORM PUBLIC HEALTH INTERVENTION IN ILLINOIS
Manon Ragonnet-Cronin, Joel O. Wertheim, Christina S. Hayford, Richard D'Aquila, Fangchao Ma, Cheryl Ward, Nanette Benbow
959  PREDICTIVE MODEL FOR HIV TRANSMISSION CLUSTER GROWTH IN NORTH CAROLINA

955  ASSOCIATION BETWEEN VIRAL SUPPRESSION AND MOLECULAR CLUSTER GROWTH, UNITED STATES
Nivedha Panneer, Alexandra M. Oster, Cheryl B. Ocfemia, Sheryl Lyss, Joel O. Wertheim, Anne Marie France

956  HIGH VIRAL LOAD ACROSS STAGE OF INFECTION ASSOCIATED WITH CLUSTERING IN US NETWORK
Joel O. Wertheim, Alexandra M. Oster, Nivedha Panneer, Chenhua Zhang, Neeraja Saduvala, Ellsworth Campbell, Jeffrey A. Johnson, William M. Switzer, Walid Heneine

960  AGE DISPARITIES IN EUROPEAN HIV TRANSMISSION PAIRS UNCOVERED WITH VIRAL SEQUENCE DATA
Matthew D. Hall, Chris Wyman, Oliver Ratmann, Jan Albert, Norbert Bannert, Anne-Marie Bakken Kren, Marion Cornelissen, Kate Grabowski, Huldrych F. Günthard, Laurence Meyer, Kholoud Porter, Matti Ristola, Guido Vanham, Christophe Fraser, for the BEEHIVE Collaboration

Themed Discussion TD-16 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING INTO HIV PREVENTION AND CARE
Room 304-306 1:30 PM – 2:30 PM

Themed Discussion Leader
Renee Heffron, University of Washington, Seattle, WA, USA

1068  INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA
Wangui Muthigani, Emily R. Begnel, Dunstan Achwoka, Tai Ho Chen, John Kinuthia, Christine J. McGrath, Alison L. Drake, for the FP Working Group

1069  MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO
Shino Arikawa, Cécile Cazes, Anne Thomas, Thierry Tiendrebeogo, Benjamin G. Kariyiare, Vincent Pitche, Didier K. Ekouevi, Renaud Becquet

1070  CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLISH, AND CLIENT VIEWS
Ingrid V. Bassett, Ai Xu, Sabina Govere, Hilary Thulare, Simone C. Frank, Christina Psaros, Robert A. Parker

1071  PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI’S PMTCT PROGRAM
Deus Thindwa, Megan Landes, Monique van Lettow, Annie Kanyemba, Ernest Nkhoma, Thokozani Kalua, Happy Phiri, Joep J. van Oosterhout, for the NEMAPP consortium
Oral Abstract O-14 DEFINING THE HIV RESERVOIR
Ballroom A 4:00 PM – 6:00 PM

Oral Abstract Moderators
Sara Gianella, University of California San Diego, La Jolla, CA, USA
Eli A. Boritz, NIH, Bethesda, MD, USA

151 NOVEL PARADIGM FOR MEASURING HIV-1 RESERVOIR ALLOWS QUANTITATION OF INTACT PROVIRUSES
4:00
Katherine Bruner, Alexandra J. Murray, Ya-Chi Ho, Gregory Laird, Zheng Wang, Kyungyoon J. Kwon, Subul A. Beg, Andrew Timmons, Sarah B. Laskey, Janice E. Clements, Janet Siliciano, Robert Siliciano

152LB CLONES OF CD4 T CELLS WITH UNIQUE GENE SIGNATURE CONTRIBUTE TO HIV-1 PERSISTENCE
4:15
Lillian B. Cohn, Israel T. da Silva, Renan Valerios, Amy Huang, Julio C. Lorenzi, Yehuda Z. Cohen, Joy A. Pai, Allison Butler, Marina Caskey, Mila Jankovic, Michiel Nussenzweig

153 IDENTIFICATION OF INTEGRATION SITES OF INDUCIBLE HIV-1 USING HIV-1 RNA SORTSEQ
4:30
Ales Varabyou, C. Conover Talbot, Hao Zhang, Subul A. Beg, Ross Pollack, Haiping Hao, Joseph B. Margolick, Robert Siliciano, Mihaela Pertea, Ya-Chi Ho

154LB HERITABLE CLONE-SPECIFIC DIFFERENCES IN HIV-1 GENE EXPRESSION
4:45
Edmond A. Atindaana, David Read, Kalyani Pyaram, Sarah Emery, Cheong-Hee Chang, Jeffrey Kidd, Alice Telesnitsky

155 CD32+PD-1+ TFH CELLS ARE THE MAJOR HIV RESERVOIR IN LONG-TERM ART-TREATED INDIVIDUALS
5:00
Alessandra Noto, Francesco Procopio, Jean-Marc Corpatiaux, Giuseppe Pantaleo

156 MAJORITY OF THE LATENT RESERVOIR RESIDES IN CD32A NEGATIVE CD4 T CELLS
5:15

157 CD32 DOES NOT MARK THE HIV-1/SIV LATENT RESERVOIR
5:30
Christa E. Osuna, Richard Apps, So-Yon Lim, Jessica L. Kublin, Rasmie Thomas, Yangin Ren, Nathaniel D. Bachtel, Margaret Ackerman, Jintanat Ananworanich, Dan Barouch, Nelson L. Michael, R. Brad Jones, Douglas Nixon, James Whitney, for the BELIEVE study

158 CD32+ CD4+ T CELLS ARE HIV TRANSCRIPTIONALLY ACTIVE RATHER THAN A RESTING RESERVOIR
5:45
Mohamed Abdel-Mohsen, Costin Tomescu, Surya Vadrevu, Adam M. Spivak, Leticia Kuri-Cervantes, Guoxin Wu, Kara Cox, Maria J. Buzón, Michael R. Betts, Vicente Planelles, Karam Mounzer, Bonnie J. Howell, Daria Hazuda, Pablo Tebas, Luis Montaner
Symposium S-8 ART: THE NEXT 25 YEARS
Ballroom B  4:00 PM – 6:00 PM

This session is dedicated to the memory of Dr. Mark Wainberg

Target Audience: This session is directed to clinicians and scientists who are interested in understanding advances in antiretroviral therapy.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of antiretroviral therapy in clinical practice.

Objectives: At the completion of the session, participants will be able to:
• Integrate new antiretroviral therapy into clinical practice
• Identify challenges and opportunities for new antiretroviral therapy in children
• Describe new generic antiretrovirals that are entering care in Sub-Saharan Africa

Conveners
Eric Arts, Western University, London, Ontario, Canada
Marta Boffito, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom

159 INTEGRATING NEW ANTIRETROVIRAL THERAPIES  
4:00  Chloe Orkin, Barts Health NHS Trust, London, UK

160 BROADLY NEUTRALIZING ANTIBODIES FOR HIV PREVENTION AND TREATMENT: DREAM OR PIPE DREAM?  
4:30  Daniel R. Kuritzkes, Brigham and Women’s Hospital, Boston, MA, USA

161 ANTIRETROVIRAL THERAPY IN CHILDREN: PRESENT CHALLENGES, FUTURE OPPORTUNITIES  
5:00  Helena Rabie, Stellenbosch University, Cape Town, South Africa

162 TRANSITIONING TO NEW GENERIC ANTIRETROVIRALS IN SUB-SAHARAN AFRICA  
5:30  Tendani Gaolathe, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana

CME
Symposium S-9 EMERGING PRIORITIES IN LIVER DISEASE
Ballroom C
4:00 PM – 6:00 PM

Target Audience: This session is directed to clinicians and scientists interested in the management of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections.

Level of Knowledge: It is assumed that participants are familiar with the general principles of HCV and HBV prevention and management.

Objectives: At the completion of the session, participants will be able to:
- Recognize the impact of the opioid epidemic on the spread of infectious diseases
- Compare the opportunities and challenges in the plans to eliminate HCV by 2030
- Recognize the rising epidemic of liver cancer and compare the impacts of HBV and HCV
- Describe the benefits and risks of transplanting organs infected with HIV or HCV

Conveners
Benjamin Linas, Boston University Medical Center, Boston, MA, USA
Gail Matthews, Kirby Institute, Sydney, Australia

163 THE OPIOID EPIDEMIC AND INFECTIOUS DISEASES: A PUBLIC HEALTH CRISIS
4:00
Sally Hodder, West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA

164 GLOBAL ELIMINATION OF HEPATITIS C
4:30
Jordan Feld, Toronto General Hospital, Toronto, ON, Canada

165 THE RISING CHALLENGE OF LIVER CANCER
5:00
Massimo Colombo, University of Milan, Milan, Italy

166 EXPANDING HOPE: ORGAN TRANSPLANTS FROM DONORS WITH HIV OR HCV INFECTION
5:30
Christine Durand, Johns Hopkins Hospital, Baltimore, MD, USA
POSTER SESSIONS BY DAY
MONDAY, MARCH 5, 2018

Poster P-A1 MOLECULAR VIROLOGY
Poster Hall A 2:30 PM – 4:00 PM

167  RHESUS PRIMARY CELL IN VITRO SHIV INFECTION ASSAY CORRELATES WITH IN VIVO REPLICATION
Adrienne E. Swanstrom, Sean O’Brien, Paul Bieniasz, Theodora Hatzioannou, Mario Roederer, Brandon Keele, Gregory Q. Del Prete, Jeffrey D. Lifson

168  FIRST REPORT OF A SUBTYPE B CONTAINING HIV-1 RECOMBINANT OF SUB-SAHARAN AFRICA ORIGIN
Gustavo Kijak, Erik Billings, Eric Sanders-Buell, Anne Marie O’Sullivan, Nicoise Ndemb, Sylvia Adebajo, Afoke Kokogho, Mark Milazzo, Merlin L. Robb, Nelson L. Michael, Sodsai Tovanabutra, Man Charurat, Trevor Crowell, Julie Ake, for the MHRP Viral Sequencing Core and the TRUST/RV368 Study Group

169  PHYLOGENETIC CLUSTERS OF HIV-1 REVEAL POTENTIAL VIRAL GENETIC IMPACT ON COMORBIDITIES
Katharina Kusejko, Dominique L. Braun, Manuel Battegay, Enos Bernasconi, Alexandra Calmy, Matthias Cavassini, Matthias Hoffmann, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Andri Rauch, Roger Kouyos, Huldrych F. Günthard, for the Swiss HIV Cohort Study

170  IS FITNESS RESPONSIBLE FOR POORER ART RESPONSE IN HIV-1 SUBTYPE F INFECTED PATIENTS?
Eva Poveda, Dane Winner, Samira Joussef, Berta Pernas, Marta Grandal, Antonio Aguilar, Angeles Castro, Alvaro Mena, Miguel E. Quinones-Nateu

171  DETECTION OF ANTI-ASP ANTIBODIES IN SERA OF HIV+ INDIVIDUALS
Antonio Mancarella, Elisa De Crignis, Giampietro Corradin, Craig Fenwick, Matthieu Perreau, Giuseppe Pantaleo, Cecilia Graziosi

172  STO-609 INHIBITS P24 RELEASE FROM GAG-EXPRESSING CELLS
Antonio Valentino, Sue Crawford

173  PROGRESS IN DEVELOPING HIGHLY POTENT SECOND-GENERATION MATURATION INHIBITORS
Phuong Pham, Emiko Urano, Sherimay Ablan, Justin A. Kaplan, T.J. Nitz, David E. Martin, Carl Wild, Ritu Gaur, Eric O. Freed

174  THE VIROME OF A NEW WORLD PRIMATE UNVEILS A RETROVIRUS THAT CAUSES IMMUNOSUPPRESSION
Cláudia Priscila Ramos Muniz, Dawn M. Dudley, Liliane T. Cavalcante, Gislaine Curty, Stefanie V. Santos, Aldìes Pissinatti, David H. O’Connor, Marcelo Alves Soares, André Felipe Andrade dos Santos

175LB  PRIMER ID SEQUENCING TO STUDY THE DEVELOPMENT OF CXCR4- USING HIV-1 VARIANTS
Shuntai Zhou, Ean Spielvogel, Sabrina Clark, Adaora Adimora, Catalina Ramirez, Andrew Edmonds, Igho Ofotokun, Seble Kassaye, Margaret Fischl, Stephen J. Gange, Alan Landay, Maria Villacres, Jack DeHovitz, Kathryn Anastos, Ronald Swanstrom
<table>
<thead>
<tr>
<th>Poster P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION</th>
<th>Poster Hall A</th>
<th>2:30 PM – 4:00 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>203</strong> HSV-1/HSV-2 INFECTION IN MACAQUES AND REACTIVATION AFTER EXPOSURE TO HETEROLOGOUS HSV</td>
<td>Priya Srinivasan, Jining Zhang, Clare Burn, Tyana Singletary, Dawn Little, Lara Pereira, Pedro Mesquita, Betsy Herold, James M. Smith</td>
<td></td>
</tr>
<tr>
<td><strong>204</strong> ASSESSING BIOLOGIC RISK FOR HIV TRANSMISSION IN TRANSGENDER WOMEN</td>
<td>Alexandra Schuetz, Carlo Sacdalan, Nisakorn Ratnaratorn, Yuwadee Phuang-Ngern, Eugène Kroon, Rungsun Rerknimitr, Suthat Chottanapund, Denise C. Hsu, Tanyaporn Wansom, Nelson L. Michael, Merlin L. Robb, Robert J. O’Connell, Jintanat Ananworanich, Sandhya Vasan, for the RV304 Study Group</td>
<td></td>
</tr>
<tr>
<td><strong>207</strong> CELL RECRUITMENT EVENTS DURING THE MENSTRUAL CYCLE ASSOCIATE WITH SHIV SUSCEPTIBILITY</td>
<td>Alison S. Kohlmeier, Ivana Massud, Susan Ruone, Mian-er Cong, James Mitchell, Frank Deyounks, Gerardo Garcia-Lerma</td>
<td></td>
</tr>
<tr>
<td><strong>208</strong> DETERMINANTS OF SUBOPTIMAL IMMUNOLOGICAL RESPONSE AFTER ART INITIATION IN ACUTE HIV</td>
<td>Ryan C. Handoko, Donn Colby, Eugène Kroon, Mark de Souza, Suteeraporn Pinyakorn, Peeriya Prueksakaew, Jennifer Chiarella, Shelly J. Krebs, Irini Sereti, Victor Valcour, Nelson L. Michael, Nittaya Phanuphak, Jintanat Ananworanich, Serena S. Spudich, for the SEARCH 010/RV254 Study Team</td>
<td></td>
</tr>
<tr>
<td><strong>209</strong> CD4 INCREASE &lt;100 CELLS/MM³ DURING 2 YEARS OF ART IS ASSOCIATED WITH WORSE OUTCOMES</td>
<td>Sol Aldrete, Kirk A. Easley, Jeong H. Jang, Tian Dai, Yi No Chen, Jason Okulicz, Brian K. Agan, Mirko Paiardini, Vincent C. Marconi</td>
<td></td>
</tr>
<tr>
<td><strong>210</strong> EFFECTS OF LONG-TERM ART ON SIVAGMSAB-INFECTED PIGTAILED MACAQUES</td>
<td>Benjamin Policicchio, Paola Sette, Ranjit Sivanandam, Cui Ling Xu, Tianyu He, Egidio Brocca-Cofano, Kevin D. Raehet, Ellen P. Penn, Tammy Dunsmore, George S. Haret-Richter, Russell Tracy, Cara Wilson, Alan Landay, Cristian Apetrei, Ivona Pandrea</td>
<td></td>
</tr>
<tr>
<td><strong>211</strong> EFFECTS OF SUBCLINICAL CMV REPLICATION ON T-CELL ACTIVATION DURING EARLY ART</td>
<td>Aaron Christensen-Quick, Marta Massanella, Andrew Frick, Celsa A. Spina, Milenka Vargass, Masato Nakazawa, Christy M. Anderson, Sara Gianella</td>
<td></td>
</tr>
</tbody>
</table>
212 SPECT/CT IMAGING OF CD4-POOL SUGGESTS A NOVEL CORRELATE OF BENIGN DISEASE PROGRESSION
Sharat Srinivasula, Jorge Carrasquillo, Insook Kim, Chang Paik, H. Clifford Lane, Michele Di Mascio

213 INFECTIOUS MONOCYTES CONTRIBUTE TO IMPAIRED INFLUENZA VACCINE RESPONSES IN AGING
Varghese George, Suresh Pallikkuth, Rajendra Pahwa, Lesley R. de Armas, Stefano Rinaldi, Margaret Roach, Li Pan, Maria F. Pallin, Celeste Sanchez, Margaret Fischl, Gordon Dickinson, Allan Rodriguez, Maria L. Alcaide, Savita Pahwa

214 TRANSCRIPTOME PROFILING AND DATA MINING: PREDICTIVE GENES OF HIV DISEASE PROGRESSION
Francisco Diez Fuertes, Esther Calonge, Maria Pernas, Humberto Erick De La Torre Tarazona, Isabelle Casademont, Anavaj Sakuntabhai, José Alcamí Pertejo

215 CD4 T CELL DEPLETION IN PRIMATES IS ASSOCIATED WITH LOSS OF INNATE LYMPHOID CELLS
Joseph Mudd, Kathleen Busman-Sahay, Sarah D’Napoli, Stephen Lai, Virginia Sheikh, Andrea Lisco, Claire Deleage, Brian Richardson, David J. Palesch, Mirko Paiairdini, Mark Cameron, Irini Sereti, R. Keith Reeves, Jacob D. Estes, Jason Brenchley

Poster P-C3 NEUTRALIZING ANTIBODIES
Poster Hall A
2:30 PM – 4:00 PM

288 CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION
Deogratius Ssemwanga, Nicole Doria-Rose, Andrew D. Redd, Andrea R. Shiakolas, Andrew Longosz, Rebecca N. Nsubuga, Gershim Asiki, Janet Seeley, Amy Ransier, Sam Darko, Daniel Douek, Stephen Porcella, Thomas C. Quinn, John R. Mascola, Pontiano Kaleebu

289 BROAD SPECTRUM OF NEUTRALIZATION-ENHANCEMENT BY NOVEL CD4MIMIC COMPOUND YIR-821
Shokichi Takahama, Kazuki Tanaka, Hasan Zahid, Alam Muntasir, Takeo Kuwata, Ami Masuda, Kohei Takahashi, Takuya Kobayakawa, Takuya Yamamoto, Tomoyuki Miura, Liye He, Hirokazu Tamamura, Shilei Ding, Andrés Finzi, Shuzo Matsushita

290 A 2-DIMENSIONAL APPROACH TO ANALYZING BROADLY NEUTRALIZING ANTIBODY COMBINATIONS
Nicholas E. Webb, Colin M. Sevaried, Nicole Tobin, Grace M. Aldrovandi

291 OPTIMIZING HIV-1 VIRUS TEST PANELS FOR EFFECTIVE DETECTION OF NEUTRALIZATION BREADTH
Claus Kadelka, Peter Ruster, Roger Koyous, Huldrych F. Günthard, Alexandra Trkola, for the Swiss HIV Cohort Study

292 HIV RECEPTOR USAGE IMPACTS SENSITIVITY TO V1-V3 LOOP BROADLY NEUTRALIZING ANTIBODIES
Ludy Registre, Yvetane Moreau, Sila Ataca, Manish Sagar

293 USE OF PROMISCUOUS GLYCAN AT V3 REGION CORRELATES WITH ELITE NEUTRALIZATION RESPONSE
294  ENV STRUCTURE IS EVOLVING AT DIFFERENT RATES IN DIVERSE CLADES OF HIV-1
Raghavendranath Kandula, Hagit Hodis, Yunxia O’Malley, Kallin Khan, Hillel Haim

295  OPENPRIMER, A PRIMER DESIGN TOOL FOR AMPLIFYING B CELL CDNA ENCODING HUMAN ANTIBODIES
Matthias Döring, Christoph Kreer, Nathalie Lehnen, Nico Pfeifer, Florian Klein

296LB  STRUCTURE-GUIDED IMPROVEMENT OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES
Qingbo Liu, Yen-Ting Lai, Peng Zhang, Peter D. Kwong, Paolo Lusso

Poster P-C4 NON-NEUTRALIZING ANTIBODIES
Poster Hall A  2:30 PM – 4:00 PM

297  THE CODEVELOPMENT OF ANTIBODY GLYCOSYLATION AND FUNCTIONALITY IN HIV INFECTION
Madeleine Jennewein, Jennifer Mabuka, Bruce D. Walker, Thumbi Ndungú, Galit Alter

298  GP41—SPECIFIC ANTIBODIES MEDIATE POTENT ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
Megan M. Stumpf, Katherine L. Williams, Nicole Naiman, Meghan Garrett, Nitya Ramadows, Peter Kim, Julie Overbaugh

299  DISSECTING THE PHENOTYPE AND TRANSCRIPTOME OF IGG3+ B CELLS
Saheli Sadanand, Wen-Han Yu, Dario Garcia-Dominguez, Galit Alter

300  DEFINING CORRELATES OF ANTIBODY-POLYFUNCTIONALITY IN RV144 VACCINEES
Stephanie Fischinger, Todd J. Suscovich, Hendrik Streeck, Galit Alter

301  DEFINING CORRELATES OF HUMORAL IMMUNE PROTECTION AGAINST EBV
Christina B. Karsten, Sally A. Shin, Howard M. Heller, Kumaran Kolandaivelu, Jaap Middeldorp, Bruce D. Walker, Boris Julg, Galit Alter

302  LEVERAGING NEUTROPHILS TO CONTROL HIV VIA IGA
Nickita Mehta, Magdalena Sips, Jishnu Das, Marina Krykbaeva, Anne-Sophie Dugast, Fernanda Cerqueira, Galit Alter

Poster P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL
Poster Hall A  2:30 PM – 4:00 PM

320  TRANSCRIPTIONAL BLOCKS UNDERLYING HIV LATENCY DIFFER BETWEEN GUT AND BLOOD IN VIVO
Sushama Telwatte, Sulggi Lee, Ma Somsouk, Hiroyu Hatano, Christopher Baker, Peggy Kim, Tsui-Hua Chen, Jeffery Milush, Peter W. Hunt, Steven G. Deeks, Joseph K. Wong, Steven A. Yuki

321  PATTERN RECOGNITION RECEPTOR AGONISTS INDUCE HIV IN ART SUPPRESSED HIV+ DONOR CELLS
Jasmine Kaur, Angela Tsai, George Kukolj, Tomas Cihlar, Jeffrey Murry

322  TRANSCRIPTIONAL REPROGRAMMING IN CCR5+ MEMORY CD4+ T CELLS PROMOTES HIV-1 LATENCY
Liang Shan, Kai Deng, Adam Capoferrer, Robert Siliciano
323 LTR METHYLATION AND RESIDUAL VIREMIA IN INDIVIDUALS ON SUPPRESSIVE ART
César N. Cortés-Rubio, Santiago Avila-Rios, Gonzalo Salgado-Montes de Oca, Margarita Matías-Florentino, Christopher E. Ormsby, Ana P. Carranco-Arenas, Gustavo Reyes-Terán

324 SYNTHETIC INGENOLS MAXIMIZE PROTEIN KINASE C-INDUCED HIV-1 LATENCY REVERSAL
Adam M. Spivak, Racheal Nell, Paul Sebahar, Mark Petersen, Ryan Looper, Vicente Planelles

325 EXOSOMAL TAT REACTIVATES LATENT HIV-1
Xiaoli Tang, Huafei Lu, Stacey Chapman, Bharat Ramratnam

326 SINGLE-CELL TRANSCRIPTOMICS TO EVALUATE HIV LATENCY ESTABLISHMENT IN CD4 T CELLS
Lesley R. de Armas, Kyle Russell, Sion Williams, Robert K. Suter, Stefano Rinaldi, Li Pan, Suresh Pallikkuth, Rajendra Pahwa, Ramzi T. Younis, Savita Pahwa

327 BCL6 INHIBITION REPRESSIONS THF/NON-TFH HIV INFECTION AND T-CELL/MEYOLOID ACTIVATION
Yanhui Cai, Mohamed Abdel-Mohsen, Costin Tomescu, Matthew Fair, Livio Azzoni, Emmanouil Papasavvas, Fengtian Xue, Jie Sun, Neil D. Romberg, Carole Le Coz, Luis Montaner

328 IDENTIFICATION OF SMALL MOLECULES THAT INHIBIT REACTIVATION OF LATENT HIV-1
Benni S. Vargas, Fang Han, Nicholas S. Giacobbi, Phalguni Gupta, Nicolas Sluis-Cremer

329 CONTRIBUTION OF LNCRNAs IN ESTABLISHMENT OF HIV LATENCY IN CENTRAL MEMORY CD4 T CELLS
Wim Trypsteen, Cory White, Alberto Bosque, Pieter Mestdagh, Steve Lefever, Celsa A. Spina, Linos Vandenkerckhove, Nadejda Beliakova-Bethell

330 TRANSLATION EFFICIENCY LIMITS HIV-1 LATENCY REVERSAL
Phillip Tomezsko, Daniel R. Kuritzkes, Silvi Rouskin, Athi Tsibris

331 LRA TREATMENT ALTERS ANTIGEN PROCESSING AND PEPTIDE PRESENTATION IN CD4 T CELLS
Julie Boucau, Alvaro Sanchez Bernabeu, Sylvie Le Gall

332 SPONTANEOUS REACTIVATION OF LATENT HIV-1 PROMOTERS IS LINKED TO THE CELL CYCLE
Yik Lim Kok, Stefan Schmutz, Anne Inderbitzin, Kathrin Neumann, Audrey Kelley, Lisa Jörimann, Mohaned Shilaih, Valentina Vongrad, Roger Kouyos, Huldrych F. Günthard, Christian Berens, Karin Metzner

333 CYTOSINE METHYLATION OF THE HIV LTR WHEN STARTING ART IN ACUTE VS CHRONIC INFECTION
Sarah LaMere, Sara Gianella, Antoine Chaillon, Christina Huynh, Susan J. Little, Davey M. Smith

Poster P-D02 INSIGHTS FROM HIV REBOUND
Poster Hall A 2:30 PM – 4:00 PM

334 IMPACT OF TREATMENT INTERRUPTION ON HIV RESERVOIRS AND IMMUNOLOGIC PARAMETERS
Katherine Clarridge, Jana Blazkova, Kevin Einaufr, Marissa Hand, Mary Petrone, Eric Reisland, Jesse Justement, Victoria Shi, Erin Huiting, Catherine Seamon, Susan Moir, Michael Sneller, Mathias Lichterfeld, Tae-Wook Chun
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>335</td>
<td><strong>SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA</strong></td>
<td>Zachary Strongin, Radwa Sharaf, Jake VanBelzen, Jeffrey Jacobson, Elizabeth Connick, Paul Volberding, Daniel Skiest, Rajesh T. Gandhi, Daniel R. Kuritzkes, Una O’Doherty, Jonathan Z. Li</td>
</tr>
<tr>
<td>337</td>
<td><strong>HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN</strong></td>
<td>Catherine N. Le, Paula Britto, Sean Brummel, Risa M. Hoffman, Patricia M. Flynn, Taha E. Taha, Anne Coletti, Mary Glenn Fowler, Karin L. Kligman, James A. McIntyre, Jonathan Z. Li, Judith S. Currier</td>
</tr>
</tbody>
</table>

**Poster P-D03 HIV RESERVOIRS IN ACUTE INFECTION**

<table>
<thead>
<tr>
<th>Poster Hall A</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>339</td>
<td><strong>HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION</strong></td>
<td>Guinevere Q. Lee, Kavidha Reddy, Kevin Einauf, Kamini Gounder, Krista Dong, Bruce D. Walker, Xu G. Yu, Thumbi Ndungu, Mathias Lichterfeld</td>
</tr>
<tr>
<td>340</td>
<td><strong>MOLECULAR PROFILE OF HIV-1 RESERVOIRS IN EARLY-TREATED INFANTS FROM BOTSWANA</strong></td>
<td>Pilar Garcia Broncano, Kevin Einauf, Ce Gao, Guinevere Q. Lee, Kenneth Maswabi, Gbolahan Ajibola, Sihkhulle Moyo, Terence Mohammed, Thabani Ncub, Joseph Makhema, Kathleen M. Powis, Xu G. Yu, Daniel R. Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld</td>
</tr>
<tr>
<td>341</td>
<td><strong>HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I</strong></td>
<td>Omolare Baiyegunhi, Funsho Ogunshola, Nasreen Ismail, Krista Dong, Bruce D. Walker, Thumbi Ndungu, Zaza Ndholovu</td>
</tr>
<tr>
<td>342</td>
<td><strong>THE HIV RESERVOIR DURING EARLY ANTIRETROVIRAL THERAPY AND MARAVIROC INTENSIFICATION</strong></td>
<td>Antoine Chaillon, Sara Gianella, Steven Lada, Maile Karris, Douglas D. Richman, Sanjay R. Mehta, Susan J. Little, Joel O. Wertheim, Davey M. Smith</td>
</tr>
<tr>
<td>343</td>
<td><strong>HIV SEROLOGY FOLLOWING TREATMENT INTERRUPTION IN VERY EARLY TREATED PEOPLE</strong></td>
<td>Rapee Trichavaroj, Supanit Pattanachaiwit, Sasiwimol Ubolyam, Panadda Sawangsinth, Jintana Intasan, Eugène Kroon, Donn Colby, Robert J. O’Connell, Sandhya Vasan, Praphan Phanuphak, Nittaya Phanuphak, Jintanat Ananworanich, Mark de Souza, Siriwat Akapirat, for the SEARCH019/RV409 &amp; SEARCH022/RV411 Study Groups</td>
</tr>
</tbody>
</table>
**Poster Sessions**

**Poster P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS**

**Poster Hall A**  
2:30 PM – 4:00 PM

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>344</td>
<td>REEVALUATING SIGNALS OF VIRAL REPLICATION &amp; EVOLUTION IN LYMPHOID TISSUE DURING ART</td>
<td>Daniel S. Rosenbloom, Alison L. Hill, Sarah B. Laskey, Robert Siliciano</td>
</tr>
<tr>
<td>345</td>
<td>MONITORING THE IMPACT OF ART MODIFICATION WITH LONGITUDINAL FDG-PET IN SIV-MODEL</td>
<td>Sanhita Sinharay, Sharat Srinivasula, William T. Schreiber-Stainthorp, Swati Shah, Paula DeGrange, Andrew Bonvillain, Jing Wang, Lori E. Dodd, H. Clifford Lane, Dina A. Hammoud, Michele Di Mascio</td>
</tr>
<tr>
<td>346</td>
<td>SPREAD OF HIV-DNA IN CD4+ T-CELL SUBSETS DEPENDS ON ART INITIATION TIMING</td>
<td>Pierre Gantner, Cindy Barnig, Marialuisa Partisani, Geneviève Beck-Wirth, Jean-Pierre Faller, Martin Martinotin, Mahsa Mohseni-Zadeh, Christine Cheneau, Marie-Laure Batard, Patricia Fischer, Béatrice Uring-Lambert, Siamak Bahram, David Rey, Samira Fafi-Kremer</td>
</tr>
</tbody>
</table>

**Poster P-E1 NEUROCOGNITIVE CORRELATES, INCLUDING ANTIRETROVIRAL THERAPY AND VASCULAR DISEASE**

**Poster Hall A**  
2:30 PM – 4:00 PM

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>400</td>
<td>CLASSIFYING COGNITIVE STATUS IN HIV-INFECTED MEN BY MULTIVARIATE NORMATIVE COMPARISON</td>
<td>Zheng Wang, Yu Cheng, Samantha A. Molsberry, Lawrence Kingsley, Andrew Levine, Eileen Martin, Eric N. Miller, Cynthia Munro, Ann B. Ragin, Ned Sacktor, Eric C. Seaberg, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study</td>
</tr>
<tr>
<td>401</td>
<td>USE OF NON-ANTIRETROVIRAL MEDICATIONS THAT MAY IMPACT NEUROCOGNITION</td>
<td>Kendra K. Radtke, Peter Bacchetti, Leah H. Rubin, Kathryn Anastos, Howard Crystal, Daniel Merenstein, Roksana Karim, Kathleen M. Weber, Andrew Edmonds, Anandi N. Sheth, Margaret Fischl, David Vance, Ruth Greenblatt</td>
</tr>
<tr>
<td>402</td>
<td>BRAIN NEUROTRANSMITTER GENOMICS AND EFAVirenZ CENTRAL NERVOUS SYSTEM (CNS) EFFECTS</td>
<td>David Haas, Yuki Bradford, Anurag Verma, Shefali S. Verma, Sarah A. Pendergrass, Joseph J. Eron, Roy M. Gulick, Sharon Riddler, Paul E. Sax, Thomas Campbell, Eric Daar, Gene D. Morse, Edward P. Acosta, Marylyn D. Ritchie, for the AIDS Clinical Trials Group</td>
</tr>
<tr>
<td>403LB</td>
<td>POOREr NEUROCOGNITIVE PERFORMANCE ASSOCIATED WITH CSF HIV DNA DESPITE LONG-TERM ART</td>
<td>Kevin Robertson, Ronald Bosch, Serena S. Spudich, Rajesh T. Gandhi, Joshua C. Ckytor, Hanna Mar, Bernard J. Macatangay, Christina Lalama, Charles Rinaldo, Ann Collier, Catherine Godfrey, Joseph J. Eron, Deborah McMahon, John W. Mellors, for the ACTG A5321 team</td>
</tr>
</tbody>
</table>
404 DETERMINANTS OF COGNITIVE FUNCTION DIFFER IN A EUROPEAN AND A KOREAN COHORT
Davide De Francesco, Alan Winston, Jun Yong Choi, Rosan van Zoest, Jonathan Underwood, Judith Schouten, Nam Su Ku, Wook Joo Kim, Peter Reiss, Caroline Sabin, for the ComorBidity in Relation to Aids (COBRA) Collaboration and the Korean NeuroAIDS Project

405 HIV SUBTYPE AND RISK OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER IN RAKAI, UGANDA
Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Kate Grabowski, Noeline Nakasuujia, Xiangrong Kong, Kevin Robertson, Ronald H. Gray, Maria Wawer

406 VITAMIN D IS NOT ASSOCIATED WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER IN UGANDA
Deanna Saylor, Gertrude Nakigozi, Noeline Nakasuujia, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ned Sacktor

407 VACS INDEX PREDICTS SYMPTOMATIC HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS IN UGANDA
Deanna Saylor, Gertrude Nakigozi, Noeline Nakasuujia, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ned Sacktor

408 NEUROPSYCHOLOGICAL PHENOTYPES IN THE MACS
Samantha A. Molsberry, Yu Cheng, Lawrence Kingsley, Lisa Jacobson, Andrew Levine, Eileen Martin, Eric N. Miller, Cynthia Munro, Ann B. Ragin, Ned Sacktor, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study

409 PREVALENCE OF HIV NEUROCOGNITIVE IMPAIRMENT IN A RURAL TANZANIAN COHORT
Montserrat Sanmartí, Ana-Claire Meyer, Angels Jaen, Kevin Robertson, Nora Tan, Leila Samson, Regina Ndaki, Marcel Tanner, Manuel Battegay, David Dalmau, Emilio Letang

410 PREDICTORS OF HIV-RELATED COGNITIVE IMPAIRMENT IN EAST AFRICA
Benedetta Milanini, Isabel E. Allen, Emmanuel Bahemana, Yakubu Adamu, Francis Kiwewwa, Jonah Jonath Maswai, John Owuoth, Christina Polyak, Julie Ake, Victor Valcour, for the AFRICOS study Team

411 PLASMA D-DIMER RELATES TO PHYSICAL HEALTH AND MOTOR SKILLS ACROSS THE AGE SPAN IN HIV
Jessica L. Montoya, Scott L. Letendre, Ronald J. Ellis, Dilip V. Jeste, David J. Moore

412 CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT DIFFER BY SEX
Felicia C. Chow, Kunling Wu, Katherine Tassiopoulos, Baiba Berzins, Kevin Robertson, Babafemi Taiwo

413 IMPACT OF DETERMINANTS OF INCREASED VASCULAR RISK ON NEUROCOGNITION IN HIV+ PATIENTS
Ilaria Mastorosso, Patrizia Lorenzini, Carmela Pinnetti, Alessandra Vergori, Gabriele Fabbri, Raffaella Libertone, Maria Maddalena Plazzi, Pietro Balestra, Martina Ricottini, Rita Bellagamba, Mauro Zaccarelli, Adriana Ammassari, Stefania Cicalini, Andrea Antinori

414 BIOMARKERS OF ENDOTHELIAL ACTIVATION IN HIV-ASSOCIATED ISCHEMIC STROKE
415  **HAND IMPROVEMENT IS ASSOCIATED WITH INCREASED CPE SCORE AFTER ARV INTENSIFICATION**


416  **CROSS-SECTIONAL AND CUMULATIVE LONGITUDINAL CPE SCORES ARE NOT ASSOCIATED WITH HAND**

Galia Santos, Katharine Darling, Isabella Locatelli, Melanie Metral, Alexandra Calmy, Thanh Doco-Lecompte, Christoph Hauser, Helen Kovari, Philip E. Tarr, Marcel Stoeckle, Caroline Di Benedetto, Patrick Schmid, Renaud Du Pasquier, Matthias Cavassin, for the NAMACO study group

417  **EXOSOMAL MICRO-RNA EXPRESSION ASSOCIATES WITH NEUROPSYCHOLOGICAL FUNCTION DURING ART**

Tess O’Meara, Yong Kong, Brinda Emu, Kevin Robertson, Richard W. Price, Sarah Yosief, Xinran N. Liu, Rabib Chaudhury, Serena S. Spudich, Lingeng Lu

418  **NO CHANGE IN NEUROCOGNITIVE FUNCTION AFTER SWITCHING FROM EFAVIRENZ TO RILPIVIRINE**

Giuseppe Lapadula, Davide P. Bernasconi, Francesca Bai, Antonio Di Biaggio, Emanuele Focà, Stefano Bonora, Francesco Castelli, Claudio Viscoli, Alessandra Bandera, Antonella D’Arminio Monforte, Andrea Gori, for the SWEAR Study Group

---

**Poster Sessions**

**Poster P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION**

**Poster Hall A** 2:30 PM – 4:00 PM

419  **BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPOTOMATIC NEUROCOGNITIVE IMPAIRMENT**

Luigi Celani, Eugenio Nelson Cavallari, Mariangela Fratino, Claudia Pinacchio, Giuseppe Corano Scheri, Gabriella De Girolamo, Giancarlo Cecarelli, Claudio M. Mastroianni, Carolina Scagnolari, Vincenzo Vullo, Gabriella d’Ettorre

420  **LOW DOSE HYDROCORTISONE ENCHANCES COGNITIVE FUNCTIONING IN HIV-INFECTED WOMEN**

Leah H. Rubin, Luan Phan, Pauline M. Maki

421  **ORAL MGBG WITH cART BLOCKS AIDS AND SIVE, AND REDUCES CNS INFECTION AND CAROTID IMT**

Jaclyn Mallard, Jamie Schafer, Kevin White, Arianna Noggle, Joseph Enders, Cecily Midkiff, Xavier Alvarez, Tricia H. Burdo, Kenneth C. Williams

---

**Poster P-E3 NEUROCOGNITIVE CORRELATES: TREATMENT STRATEGIES AND ADJUNCTIVE TREATMENT**

**Poster Hall A** 2:30 PM – 4:00 PM

422  **DEPRESSION IS COMMON AND ASSOCIATED WITH COGNITIVE FUNCTION IN WELL-TREATED HIV**

Åsa Mellgren, Maria Jivegård, Magnus Gisslén

423  **DEPRESSION SYMPTOM CHANGES OF HIV-POSITIVE INDIVIDUALS IN THE RAKAI COHORT**

Noeline Nakasuji, Gertrude Nakigozi, Deanna Saylor, Kevin Robertson, Ronald H. Gray, Maria Wawer, Ned Sacktor

---

CROI 2018
Poster Sessions

424 CNS TOXICITY OF DTG IS NOT ASSOCIATED WITH PSYCHIATRIC CONDITIONS OR PLASMA EXPOSURE

Poster P-F1 ANTIRETROVIRAL, ANTITUBERCULAR, AND ANTIMALARIAL PHARMACOKINETICS
Poster Hall D 2:30 PM – 4:00 PM

455 EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE

456 EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS
Daniel W. Atwine, Elisabeth Baudin, Thibaut Gelé, Winnie R. Muyindike, Mworozi Kenneth, Racheal Kyohairwe, Kenneth Kanamura, Dan Nyehangane, Patrick Orikiriza, Valérie Furlan, Anne-Marie Taburet, Aurélie Barrail-Tran, Maryline Bonnet, for the ANRS12292 Rifavirenz study group

457 PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/ RIFAMPICIN IN PEOPLE WITH HIV
Maddalena Cerrone, Xinzhu Wang, Megan Neary, Christine Weaver, Serge Fedele, Isaac Day-Weber, Andrew Owen, Andrew Hill, Myra McClure, Marta Boffito

458 IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN
Rajith Kumar Reddy Rajoli, Paul Curley, David Back, Charles W. Flexner, Andrew Owen, Marco Siccardi

459 DOLUTEGRAVIR INTERACTIONS WITH ARTEMETHER-LUMEFANTRINE AND AMODIAQUINE-ARTESUNATE
Stephen I. Walimbwa, Mohammed Lamorde, Catriona Waitt, Julian P. Kaboggoza, Laura Else, Pauline Byakika-Kibwika, Aliu Amara, Joshua Gini, Markus Winterberg, Joel Tarning, Saye Khoo, for the DolACT Research Group

Poster Sessions - Monday

460 TENOFOVIR HIV-1 PLASMA PROPHYLACTIC CONCENTRATION: iPREX,VOICE,PARTNERS META-ANALYSIS
Katarina Vuicevic, Craig W. Hendrix, Robert M. Grant, Connie L. Celum, Jared Baeten, Jeanne Marrazzo, Peter L. Anderson, David Glidden, Radojka M. Savic

461 PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH LOW PROTEASE INHIBITOR LEVELS IN HAIR
EFAVIRENZ LEVEL IN HAIR PREDICTS VIROLOGIC RESPONSE BETTER THAN LEVEL IN BLOOD
Laura Dickinson, Marco Siccardi, Kathryn Anastos, Mardge H. Cohen, Deborah Gustafson, Gerald Sharp, Stephen J. Gange, Seble Kassaye, Peter Bacchetti, Ruth Greenblatt, for the Women’s Interagency HIV Study

PHARMACOLOGIC MEASURES OF PrEP ADHERENCE AMONG HIGH-RISK MSM IN HPTN 067
Jennifer Velloza, Monica Gandhi, Craig W. Hendrix, Peter Bacchetti, Pamela Murnane, James P. Hughes, Maoji Li, Marcel Curnin, Timothy H. Holtz, Sharon Mannheimer, Mark A. Marzinke, K. Rivet Amico, Estelle Piwowar-Manning, Susan H. Eshleman, Robert M. Grant

Poster P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES
Poster Hall D 2:30 PM – 4:00 PM

DRV/R/3TC FDC FOR HIV-1 TREATMENT-NAIVE PATIENTS: WEEK 48 RESULTS OF THE ANDES STUDY
Maria I. Figueroa, Omar G. Sued, Ana M. Gun, Waldo Belloso, Diego M. Cecchini, Gustavo Lopardo, Daniel Pryluka, Maria J. Rolon, Valeria I. Fink, Santiago Perez Lloret, Pedro Cahn

MORTALITY/MORBIDITY AFTER INITIATING ART WITH CD4 <100 CELLS/UL IN THE REALITY TRIAL
Frank Post, Alexander J. Szubert, Andrew Prendergast, Victoria Johnston, Hermione Lyall, Felicity Fitzgerald, Peter Muygrenyi, James G. Hakim, Priscilla Chepkorir, Clara Agutu, Sronym Kaunda, Sarah Walker, Diana Gibb, Sarah Pett, for the REALITY trial team

SIMILAR EFFICACY & SAFETY BY SUBGROUP IN DRIVE-AHEAD: DOR/3TC/TDF VERSUS EFV/FTC/TDF
Chloe Orkin, Kathleen E. Squires, Jean-Michel Molina, Paul E. Sax, Wing-Wai Wong, Otto Sussmann, Richard Kaplan, Anthony Rodgers, Xia Xu, Gina Lin, Sushma Kumar, George G. Hanna, Carey Hwang, Elizabeth Martin, for the DRIVE-AHEAD Study Group

AGE, GENDER, AND RACE ANALYSES OF D/C/F/TAF IN HIV-1 TREATMENT NAÏVE PATIENTS
Bruce Rashbaum, Cheryl McDonald, Cristina Mussini, Christoph D. Spinner, John Jeozorwski, Eric Y. Wong, Kimberley Brown

DURABILITY OF INITIAL REGIMENS WHEN STARTING ART WITH ~200 CD4 AND +5HLOG HIV-RNA
Nicola Gianotti, Patrizia Lorenzini, Alessandro Cozzi-Leplri, Andrea De Luca, Giordano Madeddu, Laura Sighinolfi, Carmela Pinnetti, Carmen Santoro, Paola Meraviglia, Cristina Mussini, Andrea Antonini, Antonella D’Arminio Monforte, for the ICONA Foundation Study Group

Poster P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS
Poster Hall D 2:30 PM – 4:00 PM

SAFETY PROFILE OF DOLUTEGRAVIR: REAL-LIFE DATA OF LARGE SCALE IMPLEMENTATION IN BRAZIL
Poster Sessions

495 ARE INTEGRASE INHIBITORS A RISK FACTOR FOR IRIS IN THE ANRS 146 OPTIMAL TRIAL?
Jean-Daniel Lelievre, Lambert Assoumou, Esther Aznar, Federico Pulido, Giuseppe Tambussi, Manuel Crespo, Agnes Meybeck, Jean-Michel Molina, Fanny Cardon, Constance Delaugerre, Rémi Lancar, Lydie Béniguel, Yves Levy, Dominique Costagliola, for the the ANRS 146 - GeSIDA 7211 study group

496 RALTEGRAVIR-BASED ART IS EFFECTIVE AND SAFE IN HIV+ LIVER TRANSPLANT RECIPIENTS
Christian Manzardo, Lucia Serrano, Jesús Fortún, Marino Blanes, Montserrat Tuset, Miguel Montejo, Miguel Jiménez, Elisa Cordero, Raquel Lastras, Esteban Ribera, Maria Luisa Gonzalez-Dieguez, Asunción Moreno, Antoni Rimol, Jose M. Miro, for the FIPSE Cohort Investigators

497 INSTI-BASED INITIAL ART IN A US COHORT OF HIV-INFECTED ADULTS
Stockton Mayer, Nabil Rayeed, Rachel Hart, Richard Novak, Bienvenido Yangco, Frank J. Palella, Benjamin Young, Kate Buchacz

Poster P-H3 ANTIRETROVIRAL SWITCH STUDIES
Poster Hall D
2:30 PM – 4:00 PM

498 IMPACT OF PREVIOUS M184V ON VIROLOGICAL OUTCOME OF SWITCH TO 3TC-BASED DUAL THERAPIES
Robertagagliardini, Arturo Ciccullo, Alberto Borghetti, Franco Maggiolo, Dario Bartolozzi, Vanni Borghi, Monica Pecorari, Antonio Di Biagio, Anna Paola Callegaro, Blanca Bruzzzone, Francesco Saladini, Stefania Paolucci, Lara Bellazzi, Simona Di Giambenedetto, Andrea De Luca

499 HIV TREATMENT EXPERIENCED PATIENTS SWITCHED TO D/C/F/TAF: AGE, GENDER, RACE ANALYSES
Gregory D. Huhn, Edwin DeJesus, Pierre-Marie Girard, Romana Petrovic, Eric Y. Wong, Kimberly Brown

500 EFFECT OF SWITCHING TO INTEGRASE INHIBITOR ON THE HIV RESERVOIR IN ILEUM BIOPSIES
Sara Moron-Lopez, Victor Urrea, Jordi Navarro, Maria C. Puertas, Ariadna Torrella, Maria Salgado, Cristina Gálvez, Bibiana Planas, Línos Vardakerkhove, Juliá Blanco, Manuel Crespo, Javier Martínez-Picado

502 ANALYSIS OF HIV PATIENTS SWITCHING TO D/C/F/TAF BY PRIOR ARV TREATMENT EXPERIENCE

503 WHO WANTS TO SWITCH? GAUGING INTEREST IN POTENTIAL NEW ANTIRETROVIRAL THERAPIES
Jan Ostermann, Caroline Derrick, Amy Hobbie, Andrew Weinhold, Noor Al-Shareef, Valerie Yelverton, Sharon Weissman, Helmut Albrecht, Nathan Thielman
504  SWITCHING TO RPV/FTC/TAF FROM RPV/FTC/TDF OR EFV/FTC/TDF: WEEK 96 RESULTS
Anthony Mills, Cynthia Brinson, Claudia Martorell, Gordon Crofoot, Eric Daar, Olayemi Osiyemi, Bruce Rashbaum, David Shamblaw, Hans-Jürgen Stellbrink, Daniel Podzamczer, Hui Liu, Ya-Pei Liu, Danielle Porter, Sean Collins, Devi SenGupta

505  FACTORS PREDICTING VIROLOGICAL FAILURE DURING DOLUTEGRAVIR MAINTENANCE MONOTHERAPY
Ingeborg Wijting, Sofie L. Rutsaert, Casper Roxy, David M. Burger, Elrozy Andrinopoulou, Linos Vandekerckhove, Bart Rijnders

506  RESISTANCE ANALYSES OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE SWITCH STUDIES
Kristen Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Hal Martin, Hiba Graham, Erin Quirk, Kirsten L. White

507  IN SILICO CLINICAL TRIALS FOR EVALUATION OF HIV SHORT-CYCLE STRATEGIES
Melanie Prague, Chloé Pasin, Linda Wittkop, Pierre Duffau, Estibaliz Lazaro, Charles Cazanave, Marc Vareil, Fabrice Bonnet, Rodolphe Thiébaut

---

Poster P-K01 HCV DIAGNOSIS AND TESTING
Poster Hall D 2:30 PM – 4:00 PM

576  EFFECTIVENESS OF BEST PRACTICE ALERT AND PROVIDER EDUCATION FOR HEP C SCREENING
Mamta K. Jain, Joanne Sanders, Lisa Quirk, Brian Adamson, Barbara J. Turner, Amit G. Singal

577  CHANGES IN HEPATITIS C VIRUS (HCV) TESTING AWARENESS IN MASSACHUSETTS, 2015-2016
Monina Klevens, Monica Morrison, Liisa Randall, H D. Fukuda, Daniel Church, Shauna Onofrey, Kevin Cranston, Alfred DeMaria

578  LINKAGE TO CARE FOR PREVIOUSLY DIAGNOSED HCV-INFECTED EMERGENCY DEPARTMENT PATIENTS
Yu-Hsiang Hsieh, Anuj Patel, Danielle Signer, Erica Shelton, Jacob Cohen, Mustapha Saheed, David L. Thomas, Richard Rothman

579  VERY LOW HEPATITIS C VIRAL LOADS IN ABSENCE OF THERAPY: IMPACT ON HCV ANTIGEN TESTING
Barbara Bertisch, Matteo Brezzi, Francesco Negro, Beat Muellhaupt, Patrizia Kuenzler-Heule, Patrick Schmid, Olivier Clerc, Alberto Moriggia, Darius Moradpour, Olivia Keiser, for the Swiss Hepatitis C Cohort Study

580  EVALUATION OF DBS HCV RNA QUANTIFICATION AND GENOTYPING IN RESOURCE LIMITED SETTINGS

---

Poster P-K02 MOLECULAR EPIDEMIOLOGY OF HCV NETWORKS
Poster Hall D 2:30 PM – 4:00 PM

581  CLUSTERING OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS IN BALTIMORE
Oluwaseun Falade-Nwulia, Shruti H. Mehta, Mark Sulkowski, Carl A. Latkin, David L. Thomas, Zach Downing, Rachel Latanich, Gregory D. Kirk, Rebecca Rose, Stuart C. Ray, Oliver Laeyendecker
582 UNRAVELLING HCV1A WHEREABOUTS IDENTIFIES A NEED FOR A PAN-EUROPEAN PREVENTION PROGRAM
Lize Cuypers, Bram Vrancken, Lavinia Fabeni, Velia C. Di Maio, Milosz Parczewski, Vladimir Chulanov, Perpetua Gomes, Anna Maria Geretti, Christoph Sarrazin, Cillian De Gascun, Saleta Sierra, Federico García, Anne-Mieke Vandamme, Francesca Ceccherini Silberstein

583 NSSA RESISTANCE ASSOCIATES WITH ADVANCED LIVER FIBROSIS BUT NOT TRANSMISSION CLUSTERS
Milosz Parczewski, Ewa Janczewska, Justyna Kordek, Iwona Cielniak, Arkadiusz Pisula, Monika Bociąga-Jasik, Władysław Łojewski, Aleksandra Szymczak, Łukasz Socha, Magdalena Leszczyszyn-Pyńka, Anna Urbańska, Ewa Siwak, Nadine Lübbe

584 GENETIC CORROBORATION OF HCV TRANSMISSION AMONG YOUNG ADULT INJECTING PARTNERSHIPS
Damien C. Tully, Judith Hahn, David J. Bean, Jennifer Evans, Kimberly Page, Todd M. Allen

Poster P-K03 NEW HCV INFECTIONS
Poster Hall D
2:30 PM – 4:00 PM

585 HCV RNA AND ANTIGEN DETECTION FOR DIAGNOSIS OF ACUTE HEPATITIS C AMONG MSM ON PrEP
Julien Gras, Nadia Mahjoub, Isabelle Charrueau, Laurent Cotte, Cécile Tremblay, Julie Chas, François Raffi, Eric Cua, Brigitte Guillou, Nicolas Guigue, Marie-Laure Chaix Baudier, Laurence Meyer, Jean-Michel Molina, Constance Delaugerre, for the ANRS IPERGAY study group

586 ESTIMATING HIV, HCV AND HSV-2 INCIDENCE FROM EMERGENCY DEPARTMENT SEROSURVEYS

587 ESTIMATING HIV AND HCV INCIDENCE AMONG PERSONS WHO INJECT DRUGS IN INDIA
Denali Boon, Sunil S. Solomon, Aylur K. Srikrishnan, Allison M. McFall, Pachamuthu Balakrishnan, Syed Iqbal, Gregory M. Lucas, Oliver Laeyendecker, Thomas C. Quinn, Shruti H. Mehta

588 HIV-1 ENHANCES SEXUAL TRANSMISSION OF HEPATITIS C VIRUS BY HUMAN LANGERHANS CELLS
Bernadien Nijmeijer, Ramin Sarrami Forooshani, Gaby Steba, Richard Molenkamp, Renee Schreurs, Matthijs Siegenbeek van Heukelom, Marc van der Valk, Carla Ribeiro, Teunis Geijtenbeek

589 CHANGE IN HIV RISK BEHAVIOR IN PWID ON HCV TREATMENT WITH OR WITHOUT OAT AND PREP
Sarah Kattakuzhy, Laura Nussdorf, Kristi Hill, Rachel Silk, Chloe Gross, Elizabeth Akoth, Poonam Mathur, Benjamin Emmanuelle, Nadeera Sidique, Chloe S. Chaudhury, David Sternberg, Henry Masur, Shyam Kottili, Elana S. Rosenthal

590 HCV INCIDENCE IN HIV-INFECTED AND IN PrEP-USING MSM
Laurent Cotte, Eric Cua, Jacques Reynes, François Raffi, David Rey, Pierre Delobel, Amandine Gagneux–Brunon, Christine Jacomet, Romain Palich, Hélène Laroche, André Cabié, Bruno Hoen, Christian Chidiac, Pierre Pradat, for the DatAIDS Study Group
591 HCV INCIDENCE IS STILL INCREASING IN FRENCH HIV-INFECTED MSM
Laurent Cotte, Thomas Huleux, François Raffi, Pierre Delobel, Jacques Reynes, Pascal Puglièse, David Rey, Firouze Bani-Sadr, Isabelle Poizot-Martin, André Cabié, Antoine Chéret, Claudine Duvivier, Marc-Antoine Valantin, Pierre Pradat, for the DatAIDS Study Group

592 LOW PREVALENCE OF HEPATITIS C VIRUS AMONG NYC MSM INITIATING PREP AND PEP, 2016-2017
Tarek Mikati, Kelly Jamison, Christine M. Borges, Demetre C. Daskalakis

593 ASSESSING DIFFERENCES IN HISTORIC AND RECENT HIV/HCV COINFECTION IN PHILADELPHIA
Dana Higgins, Danica Kuncio, Kathleen Brady, Coleman Terrell

649 HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA
Scott Dryden-Peterson, Neo Tapela, Isaac Nkele, Oaitse John, Gita Suneja, Surbhi Grover, Memory Bvochora-Nsingo, Malebogo Pusoentsi, Joseph Makhema, Mompati O. Mmalane, Mukendi Kayembe, Shahin Lockman

650 SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH
Mazvita Sengayi, Wenlong C. Chen, Adrian Spoerri, Elvira Singh, Matthias Egger, Julia Bohlius

651 STILL HIGH RISK OF VIRUS-RELATED CANCER DESPITE 20 YEARS OF cART IN ICONA COHORT
Pierluca Piselli, Diego Serraino, Alessandra Bandera, Andrea Antinori, Enrico Girardi, Claudia Cimaglia, Alessandro Tavelli, Francesca Bai, Gianmario Baldin, Andrea Calcagno, Antonella D’Arminio Monforte, Antonella Cingolani, for the Icona Foundation Study Group

652 CANCER STAGE, TREATMENT, AND SURVIVAL COMPARING HIV CLINIC ENROLLEES AND SEER
Keri Calkins, Geetanjali Chander, Corinne Joshu, Anthony T. Fojo, Richard D. Moore, Bryan Lau

653 RISK OF NON-AIDS-DEFINING CANCERS AMONG VETERANS WITH WELL-CONTROLLED HIV INFECTION
Aaron P. Thrift, Kathryn E. Royse, Peter A. Richardson, Suchismita Raychaudhury, Roxanne Desiderio, Donna L. White, Jennifer R. Kramer, Elizabeth Chiao

654 TRENDS IN INCIDENCE OF KAPOSI SARCOMA AMONG MALES IN ALL 50 UNITED STATES, 2000-2013
Aaron P. Thrift, Donna L. White, Harrison Nguyen, Kathryn E. Royse, Jennifer R. Kramer, Elizabeth Chiao

655 KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE
Suzanne P. Fiorillo, Francis Jaji, Maxwell Matimba, Thomas Campbell, Margaret Borok
**Poster P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS**  
**Poster Hall D**  
**2:30 PM – 4:00 PM**

### 703  
**THE MEDITERRANEAN PORTFOLIO DIET IN HIV DYSLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL**  
Clare Stradling, G N. Thomas, Karla Hemming, Shahrad Taheri, Stephen Taylor, Jonathan Ross, Satyajit Das

### 704  
**BIOMARKERS AND GENETICS OF CELL CHOLESTEROL DYSREGULATION IN HIV NONPROGRESSORS**  
Giovanna Rappocciolo, Diana Campbell DeLucia, Jeremy J. Martinson, Stacy Wendell, Charles Rinaldo, for the Multicenter AIDS Cohort Study (MACS)

### 705  
**STATIN USE AND CARDIOVASCULAR DISEASE MITIGATION AMONG PERSONS LIVING WITH HIV**  
Derek T. Larson, Seung Hyun Won, Anuradha Ganesan, Ryan Maves, Jason Okulicz, Karl Kronmann, Xiuping Chu, Christina Schofield, Thomas O'Bryan, Brian K. Agan, Robert Deiss

### 706  
**INCREASED RISK OF LOW ADIPOSECTIN AND ATEROGENIC DYSLIPIDEMIA IN HIV INFECTION**  
Marco Gelpi, Shoaib Afzal, Ashley Roen, Amanda Mcroft, Anne-Mette Lebech, Birgitte Lindegaard, Klaus F. Kofoed, Borge Nordestgaard, Jens D. Lundgre, Susanne D. Nielsen

### 707  
**NON-CLASSICAL MONOCYTE AND CD4/CD8 RATIO PREDICTS ANKLE BRACHIAL INDEX IN TREATED HIV**  
Dominic Chow, Nattawat Klonmit, Louie M. Ganguanlco, Scott A. Souza, Sean Terada, Lindsay Kohorn, Lishomwa C. Ndhlovu, Cecilia Shikuma

### 708  
**MICROBIAL-RELATED METABOLITE TMAO AND CAROTID ARTERY ATHEROSCLEROSIS IN HIV INFECTION**  
Zhilei Shan, David B. Hanna, Clary Clish, Justin M. Scott, Robert Burk, Sabina Haberlen, Sanjiv J. Shah, Joseph B. Margolick, Wendy Post, Howard Hodis, Alan Landay, Kathryn Anastos, Robert C. Kaplan, Qibin Qi

### 709  
**IL-32 ISOFORMS AS NOVEL BIOMARKERS FOR CVD IN HIV-INFECTED INDIVIDUALS**  
Mohamed El-Far, Sarah M. Zaidan, Carl Chartrand-Lefebvre, Petronela Ancuta, Nicolas Chomont, Etienne Larouche-Anctil, Jean-Pierre Routy, Benoit Trottier, Jean-Guy Baril, Paul MacPherson, Sylvie Trottier, Robert C. Kaplan, Alan Landay, Madeleine Durand, Cécile Tremblay, for the Canadian HIV and Aging Cohort Study

---

**Poster P-M8 CARDIAC AND PULMONARY COMPLICATIONS IN LOW- AND MIDDLE-INCOME SETTINGS**  
**Poster Hall D**  
**2:30 PM – 4:00 PM**

### 710  
**INTEGRATED VS REFERRED MANAGEMENT OF CVD RISK FACTORS FOR HIV+ PATIENTS IN SWAZILAND**  
Miriam Rabkin, Anton M. Palma, Margaret McNairy, Samkelo Simelane, Averie B. Gachuh, Raymond A. Bitchong, Harriet Nuwagaba-Bibirbonwoha, Pido Bongomin, Velephi Okeke, Wafaa M. El-Sadr
711  HIGH PREVALENCE OF HYPERTENSION IN HIV-INFECTED AND HIV-UNINFECTED ADULTS IN BOTSWANA
Mosepele Mosepele, Kara Bennett, Tendani Gaolathe, Joseph Makhema, Mompati O. Mmalane, Molly Pretorius Holme, Refeletswe Lebelonyane, Kathleen M. Powis, Jean Leidner, Joseph N. Jarvis, Neo Tapela, Tiny Masupe, Lucky Mokgathe, Kathleen Wirth, Shahin Lockman

712  HYPERTENSION AND DIABETES CONTROL ALONG THE HIV CARE CASCADE IN SOUTH AFRICA

713  PREVALENCE OF NON-COMMUNICABLE DISEASES IN LONG-TERM AIDS SURVIVORS IN HAITI
Samuel Pierre, Vanessa Rivera, Grace Seo, Benedict Charles, Gaetane Julmiste, Alexandra Apollon, Emelyne Dumont, Molene Cadet, Myung Hee Lee, Katey Walsh, Adias Marcelin, Patrice Severe, Daniel Fitzgerald, Jean W. Pape, Margaret McNairy

714  PAN AFRICAN PULMONARY HYPERTENSION COHORT COMPARING RISK AND SURVIVAL OF HIV+/HIV-
Friedrich Thienemann, Vitaris Kodogo, Feriel Azibani, Karen Sliwa, for the Pan African Pulmonary Hypertension Cohort (PAPUCO) Study Group

716  SIGNS OF CARDIOVASCULAR DISEASE IN A RURAL AFRICAN POPULATION; DOES HIV PLAY A ROLE?
Alinda Vos, Kerstin Klipstein-Grobusch, Hugo Tempelman, Diederick Grobbee, Roel Coutinho, Walter Devillé, Roos Barth, for the Ndlovu Research Consortium

717  HYPERTENSION AND HIV AS COMORBIDITIES IN SOUTH AFRICA: MODELING THE DUAL BURDEN
Brianna Osetinsky, Omar Galarraga, Mark Lurie, Stephen McGarvey, Till Bärnighausen, Sake de Vlas, Jan A. Hontelez

718  CORONARY ARTERY CALCIFICATION IN VIROLOGICALLY SUPPRESSED AGING HIV-INFECTED THAIS
Pairoj Chattranukulchai, Monravee Tumkosit, Sarawut Siwamogsatham, Tanakorn Apornpong, Sivaporn Gatechompl, Akarin Hiransuthikul, Win M. Han, Stephen J. Kerr, Opas Putcharoen, Smonporn Boonyaratavej, Kiat Ruxrunghatham, Praphan Panuphak, Anchalee Avihingsanon, for the HIV-NAT 006 and HIV-NAT 207 study groups

719  ARV-NAIVE HIV-INFECTED ADULTS HAD LOWER BONE FORMATION MARKERS THAN HIV-UNINFECTED
Lalita Wattanachanya, Jureeporn Jantarapakde, Anchalee Avihingsanon, Reshmie Ramautarsing, Stephen J. Kerr, Deondara Trachunthong, Thanaporn Mansawat, Kanitta Pussadee, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Tawatchai Chaiwatanarat, Nittaya Panuphak, Sarat Sunthornyothin, Praphan Panuphak, for the TNT 003 and TNT 003.1 study team
TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY
Nicolas Salvadori, Bo Fan, Waralee Teeyasoontranon, Nicole Ngo-Giang-Huong, Siriluk Phanomcheong, Anita Luvira, Achara Puangsombat, Arunrat Suwannarat, Ussanee Sirimompotong, Chaiwat Putiyunun, Athena Kourtis, Marc Butlers, George K. Siberry, Gonzague Jourdain, for the iTAP Study Group

OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN
Florence Nabwire, Ann Prentice, Matthew M. Hamill, Mary G. Fowler, Josaphat Byagumisha, Adeodata Kekitiinwa, Gail R. Goldberg

RATES OF BONE LOSS SLOW AFTER THE FIRST YEAR OF ART: START BMD SUBSTUDY FINAL RESULTS
Andrew Carr, Birgit Grund, Ann V. Schwartz, Anchalee Avihingsanon, Sharlaa Badal-Faesen, Jose I. Bernadino, Patrick W. Mallon, Vicente Estrada, Alberto M. La Rosa, Sanjay Pujari, David White, Nicole Wyman Engen, Kristine E. Ensrud, Jennifer Hoy, for the START Bone Mineral Density Substudy Group

GREATER BONE TURNOVER MARKER DECLINE WITH ZOLEDRONIC ACID THAN WITH TDF-SWITCHING
Andrew Carr, Robyn Richardson, Stephen J. Kerr, Peter R. Ebeling, Nicholas Pocock, Jhon Rojas, Esteban Martinez, Jennifer Hoy, for the ZeST Study Group

COMBINED EFFECTS OF BISPHOSPHONATES & TDF→TAF SWITCH IN HIV+ ADULTS WITH LOW BMD
Todd T. Brown, Michael T. Yin, Samir K. Gupta, William R. Short, Melanie Thompson, Daniel Podzamczer, Giovanni Di Perri, Cheryl McDonald, Matthias Cavassini, Pablo Tebas, Ya-Pei Liu, Scott McCallister, Andrew Cheng, Moupali Das

BONE, RENAL, AND INFLAMMATION MARKERS IN THE DOLUTEGRAVIR MONOTHERAPY (DOMONO) STUDY
Ingeborg Wijting, Casper Rokx, Sandra A. Smits, M. C. Zillikens, Theodora de Vries-Sluijs, Karin Schurink, Hannelore Bax, Maarten Derksen, Eloyz Andrinopoulou, Ineke van der Ende, Eric van Gorp, Jan Nouwen, Annelies Verbon, Wouter Bierman, Bart Rijnbers

OMEGA-3 FATTY ACID SUPPLEMENTATION IN HIV PATIENTS: A RANDOMIZED CLINICAL TRIAL
Juan M. Tiraboschi, Antonio Navarro-Alcaraz, Elena Ferrer, Carmen Gomez-Vaquero, Dolors Giralt, Arkaitz Imaz, Maria Saumoy, Daniel Podzamczer

HYPERKYPHOSIS AND AGING IN THE WOMEN’S INTERAGENCY HIV STUDY
Anne M. Ritchie, Wendy B. Katzman, Yifei Ma, Rebecca Scherzer, Mardge H. Cohen, Michael T. Yin, Phyllis Tien
THE ASSOCIATION OF PAIN AND LONG-TERM OPIOID THERAPY WITH HIV TREATMENT OUTCOMES

MOBILITY PREDICTS INCIDENT TB INFECTION IN CHILDREN & ADULTS IN RURAL UGANDA
Carina Marquez, Atukunda Mucunguzi, Gabriel Chamie, Laura B. Balzer, Joel Kiroonde, Theodore Ruel, Bridget Nzarubara, Dalsone Kwarisima, Edwin D. Charlebois, Maya L. Petersen, Diane V. Havlir, for the SEARCH Collaboration

IMPROVED SENSITIVITY OF A NOVEL RECOMBINANT PROTEIN SKIN TEST FOR THE DIAGNOSIS OF TB
Roberto Badaro, Corey Casper, Rhea Coler, C. A. Araujo-Neto, Diana B. Pedral-Sampaio, Maria Nakatani, Antonio Campos Neto, Steven Reed

HIV-ASSOCIATED TB IN A LOW BURDEN COUNTRY: IS SCREENING FOR LATENT TB STILL NEEDED?
Enrico Girardi, Alessandro Cozzi-Lepri, Andrea Gori, Annalisa Saracino, Antonio Di Biagio, Giuseppe Lapadula, Giancarlo Orofino, Miriam Lichtner, Sergio Lo Caputo, Andrea Antinori, Antonella D'Arminio Monforte, Cristina Mussini, for the Icona Foundation Study Group

A PILOT RCT OF GENEXPERT MTB/RIF ON A MOBILE HIV TESTING UNIT IN SOUTH AFRICA
Ingrid V. Bassett, Leah S. Forman, Sabina Govere, Hilary Thulare, Simone C. Frank, Bright Mhlongo, Elena Losina

TRENDS IN HIV- AND SEX-STRATIFIED TUBERCULOSIS CASE NOTIFICATIONS IN BLANTYRE, MALAWI
Mariott Nliwasa, Augustine Choko, Mphatso Mwapasa, Daniel Grint, Peter MacPherson, Elizabeth L. Corbett

ROLE OF CHEST X-RAY IN DIAGNOSIS OF HIV-ASSOCIATED SMEAR-NEGATIVE TB IN UGANDA
Lydia Nakiyingi, John Mark Bwanika, Willy Ssengooba, Frank Mubiru, Harriet Mayanja-Kizza, Jerrold Ellner, Susan E. Dorman, Yukari C. Manabe

C-REACTIVE PROTEIN TO SCREEN FOR HIV-ASSOCIATED TUBERCULOSIS IN SOUTH AFRICA
Adrienne E. Shapiro, Ting Hong, Sabina Govere, Dumezweni Ntshangase, Hilary Thulare, Mahomed-Yunus Moosa, Afton Dorasamy, Connie L. Celum, Jacques H. Grosset, Paul K. Drain

PLASMA INDOLEAMINE 2, 3-DIOXYGENASE, A BIOMARKER FOR TUBERCULOSIS IN HIV INFECTION
Clement G. Adu-Gyamfi, Tracy Snyman, Chris Hoffmann, Neil A. Martinson, Richard E. Chaisson, Jaya A. George, Melinda S. Suchard
774  **HIV INFECTION IMPAIRS MYCOBACTERIUM TUBERCULOSIS-SPECIFIC CD4 T-CELL RESPONSES**

Patrizia Amelio, Jerry Hella, Klaus Reither, Lujeko Kamwela, Omar Lweno, Anneth Tumbo, Linda Geoffrey, Song Ding, Giuseppe Pantaleo, Claudia Daubenberger, Matthieu Perreau

775  **VARIATION IN THE NLRP3 GENE IS ASSOCIATED WITH INFLAMMATION AND MORTALITY IN HIV/TB**

Shruthi Ravimohan, Kebatsabile Ngoni, Neo Tamuahla, Caroline Tiemessen, Drew Weissman, Gregory Bisson

776  **DECAY OF INFLAMMATION MARKERS IN HIV-1/TB COINFECTED INDIVIDUALS INITIATING ART**

Heloise M. Delagreverie, Claire Bauduin, Nathalie De Castro, Beatriz Grinsztejn, Marc Chevrier, Samia Mourah, Issa Kalidi, Jose H. Pilotto, Carlos Brites, Nemora T. Barcellos, Genevieve Chene, Linda Wittkop, Jean-Michel Molina, Constance Delaugerre, for the ANRS study group RELATE-TB ANRS 12-180

777  **ANALYSIS OF PHAGOCYTE FUNCTION IN HIV/TB CO-INFECTION USING A NOVEL WHOLE BLOOD ASSAY**

Ankur Gupta-Wright, Dumiszulu Tembo, kondwani C. Jambo, Elizabeth Chimbayo, David G. Russell, Henry Mwandumba

---

**Poster P-03 TUBERCULOSIS TRANSMISSION DYNAMICS, DRUG RESISTANCE, AND TREATMENT ISSUES**

**Poster Hall D**

2:30 PM – 4:00 PM

778  **SPATIAL OVERLAP LINKS SEEMINGLY UNCONNECTED GENOTYPE-MATCHED TB CASES IN RURAL UGANDA**

Gabriel Chamie, Midori Kato-Maeda, Devy Emperador, Bonnie Wandera, John Crandall, Michael Janes, Carina Marquez, Moses R. Kamya, Edwin D. Charlebois, Diane V. Havlir

779  **SPATIAL DISTRIBUTION OF RIFAMPICIN-RESISTANT TB IN WESTERN CAPE, SOUTH AFRICA**

Avery McIntosh, Helen E. Jenkins, Laura F. White, Elizabeth J. Ragan, Tania Dolby, John Simpson, Megan B. Murray, Rob Warren, Karen R. Jacobson

780  **TREATING RIFAMPICIN-RESISTANT TB WITH DELAMANID IN A HIGH HIV PREVALENCE SETTING**

Erika K. Mohr, Anja Reuter, Jennifer Hughes, Justine Fargher, Johnny Daniels, Borgani Chabalala, Gabriella Ferlazzo, Virginia de Azevedo, Amir Shroufi, Laura Trivino Duran, Petros Isaakidis

781  **PHARMACOKINETICS OF RIFABUTIN 150 MG QD VS 300 MG TIW WITH LPV/R IN HIV/TB PATIENTS**

Chris Fujitmirun, Weerawat Manosuthi, Sivaporn Gatechompol, Phornchai Pingsasena, Narukjai Thammajaruk, Angela Colbers, Rob Aarnoutse, Kiat Ruxrungtham, David M. Burger, Anchalee Avihingsanond, Opas Putcharoen

782  **WIRELESSLY OBSERVED THERAPY VS DIRECTLY OBSERVED THERAPY FOR TB MEDICATION ADHERENCE**

Sara H. Browne, Charles A. Peloquin, Amanda J. Tucker, Kathleen Moser, Julie Low, Anya Umlauf, Florin Vaida, Constance A. Benson
Poster Sessions

Poster P-P1 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND STRATEGIES DURING PREGNANCY

Poster Hall D  2:30 PM – 4:00 PM

803 INCREASED RISK OF HYPERTENSION IN PREGNANCY AMONG WOMEN ON NEVIRAPINE-BASED REGIMENS
Rebecca Zash, Paige L. Williams, Denise Jacobson, Modiegi Diseko, Gloria Mayondi, Judith Mabuta, Katherine Johnson, Mompati O. Mmalane, Max Essex, Shahin Lockman, Joseph Makhema, Chipo Petlo, Roger L. Shapiro

804 DOES CHANGING ART IN EARLY PREGNANCY FOR FETAL RISKS DESTABILIZE VIRAL SUPPRESSION?
Violaine Peyronnet, Josiane Warszawski, Jeanne Sibiude, Catherine Dollfus, Christine Rouzioux, Jérôme Le Chenadec, Albert Faye, Roland Tubiana, Laurent Mandelbrot, for the ANRS Inserm EPF C001 cohort study group

805 COMPARISON OF FOUR CLASSICAL PI- AND Raltegravir-based Regimens During Pregnancy
Jeanne Sibiude, Olivia Dialla, Roland Tubiana, Stephane Blanche, Catherine Dollfus, Pierre Frange, Jérôme Le Chenadec, Laurent Mandelbrot, Josiane Warszawski, for the ANRS-EPF-C01 Research Group

806 Raltegravir in Pregnancy: Patterns of Use and Birth Outcomes in the UK and Ireland
Rebecca Sconza, Virginia Rasi, Helen Peters, Mario Cortina-Borja, Claire Thorne

807 DolPHIN-1: Dolutegravin vs Efavirenz When Initiating Treatment in Late Pregnancy
Catriona Waitt, Stephen I. Walimbwa, Catherine Orrell, Mohammed Lamorde, Christie Heiberg, Ushma Mehta, Julian P. Kaboggoza, Julie Anne Coombs, Josaphat Byagumisha, Aliu Amara, Thoko Malaba, Laura Else, Landon Myer, Saye Khoo, for the DolPHIN-1 Study Group

808 Dipsticks Proteinuria to Predict Renal Dysfunction in HIV-Infected Pregnant Women
Mwangelwa Mubiana-Mbewe, Bridget Mugisa, Bernadette Ngeno, Paul R. Young, Jillian L. Kadota, Benjamin H. Chi, Charles B. Holmes, Michael Vinikoor

809 Concentrations of TFV-DP During Pregnancy Among Women Using PrEP
Maria Pyra, Peter L. Anderson, Kenneth K. Mugwanya, Jessica E. Haberer, Renee Heffron, Stephen Asilimwe, Elly T. Kataibira, Nelly R. Mugo, Elizabeth A. Bukusi, Connie L. Celum, Jared Baeten, for the Partners Demonstration Project Team

810 Ex Vivo Cotyledon Perfusion Fairly Predicts in Vivo Arv Human Placental Transfer
Vincent Madelein, Minh Le, Agnes Bourgeois Moine, Sophie Matheron, Diane Descamps, Laurent Mandelbrot, Gilles Peytavin

Poster P-P2 ADHERENCE, VIRAL SUPPRESSION, AND RETENTION IN PREGNANT AND POSTPARTUM WOMEN

Poster Hall D  2:30 PM – 4:00 PM

811 Cabergoline for Lactation Suppression Among HIV+ and HIV–Women
Sarah Humphrey, Maeve Baechler, Melissa Schiff, Jane Hitti
812  PREDICTORS OF VIROLOGIC FAILURE IN POSTPARTUM WOMEN ON ART IN PROMISE 1077HS
Risa M. Hoffman, Meredith G. Warshaw, K. Rivet Amico, Jose H. Pilotto, Gaerolwe Masheto, Jullapong Achalapong, Elizabeth S. Machado, Kulkanya Chokephaibulkit, Geraldo Duarte, Anne Coletti, Renee Browning, Nahida Chakhtoura, Karin L. Klingman, Judith S. Currier, for the IMPAACT PROMISE 1077HS Team

813  DISPARITIES IN ANTENATAL VIROLOGIC FAILURE AMONG WOMEN RECEIVING OPTION B+ IN KENYA
Keshet Ronen, Brian Khasimwa, Bhavna Chohan, Daniel Matemo, Jennifer Unger, Alison L. Drake, John Kinuthia, Grace John-Stewart

814  ART ADHERENCE AMONG PREGNANT AND NON-PREGNANT WOMEN IN SOUTH AFRICA AND UGANDA
Lynn T. Matthews, Catherine Orrell, Bosco M. Bwana, Stephen Asiiomwe, Gideon Amanyire, Nicholas Musinguzi, Anna Cross, Kathleen Bell, Alexander C. Tsai, Christina Psaros, David R. Bangsberg, Jessica E. Haberer, for the META Study Team

815  EARLY CLINICAL EVENTS AFTER ART INITIATION IN PREGNANCY INFLUENCE VIRAL LOAD OUTCOMES

816  WITHDRAWN

817  QUANTIFYING VISIT ADHERENCE IN PREGNANT WOMEN INITIATING ART IN SWAZILAND

818  TEXT MESSAGING FOR RETENTION IN PMTCT: A STEPPED-WEDGE CLUSTER-RANDOMIZED TRIAL
Thomas A. Odeny, James P. Hughes, Elizabeth A. Bukusi, Eluud Akama, Elvin Geng, King Holmes, R. Scott McClelland

819  DOES QI IMPROVE PMTCT PROCESSES IN RURAL SOUTH AFRICA? A STEPPED-WEDGE CLUSTER RCT
H. Manisha N. Yapa, Jan-Walter De Neve, Terusha Chetty, Carina Herbst, Frank Post, David A. Cooper, Awanchana Jiamsakul, Pascal Geldsetzer, Guy Harling, Philippa Matthews, Frank Tanser, Kobus Herbst, Dickman Gareta, Deenan Pillay, Till Bärnighausen

820  IMPROVED POSTPARTUM HIV OUTCOMES AFTER CARE COORDINATION TEAM INTERVENTION
Anandi N. Sheth, Stephanie Hackett, Christina M. Meade, Jennifer M. Davis, Joy Ford, Jeromia Blue, Lisa Curtin, Andres Camacho-Gonzalez, Ann Chahroudii, Rana Chakraborty, Melody P. Palmore, Martina L. Badell
837  EFFECT OF ANTITUBERCULOSIS THERAPY ON THE PHARMACOKINETICS OF EFAVIRENZ IN CHILDREN

838  PHARMACOKINETICS OF 8-HOURLY LOPINAVIR/RTONOVIR IN CHILDREN ON RIFAMPICIN
Helena Rabie, Holly Rawizza, Peter Zuidewind, Jana L. Winckler, Heather Zar, Annelies Van Rie, Jennifer Norman, Helen Mcilleron

839  TUBERCULOSIS DISEASE AND ISONIAZID USE IN SOUTH AFRICAN CHILDREN LIVING WITH HIV
Gloria E. Anyalechi, Chloe A. Teasdale, Emilia M. Rivadeneira, Rommel Bain, Gurpreet Kindra, Mary Mogashoa, Stephen M. Arpadi, Elaine J. Abrams

840  TEMPORAL TRENDS IN GLOBAL PEDIATRIC COTRIMOXAZOLE USE AND IMPACT ON MORTALITY
David C. Boettiger, Matthew Law, Annette H. Sohn, Mary-Ann Davies, Kara K. Wools-Kaloustian, Valériane Leroy, Marcel Yotebieng, Michael J. Vinikoor, Rachel Vreeman, Andrew Edmonds, Azar Kariminia, for the IeDEA global consortium

841  PHARMACOKINETICS AND SAFETY OF LOPINAVIR/RTONAVIR SOLUTION IN HIV-INFECTED NEWBORNS
Adrie Bekker, Nathan Hanan, Mae Cababasay, Jiajia Wang, Firdose Nakwa, Elizabeth Smith, Jack Moye, Avy Violari, Mark Cotton, Lubbe Wiesner, Jennifer Norman, Barend Fourie, Edmund V. Capparelli, Mark Mirochnick, for the IMPAACT P1106 team

842  EFFECTIVENESS AND SAFETY OF LPV/R PELLETS-BASED ART IN CHILDREN: 48-WEEK ANALYSIS
Isabelle Andreux-Meyer, Olawale Salami, Raymond Omollo, Dalton Wamalwa, Elizabeth Maleche Obimbo, Adeodata Kekitiinwa, Juliet Mwanga-Amumpaire, Patrick Oyaro, Elizabeth A. Bukusi, Moses Waweru, Monique Wasunna, Janice Lee, François Simon, Marc Lallemant, for the LIVING STUDY GROUP

843  SAFETY, PK, & EFFICACY OF FTC/TAF IN HIV-INFECTED ADOLESCENTS (12-18 YRS)

844  BICTEGRAVIR/FTC/TAF SINGLE-TABLET-REGIMEN IN ADOLESCENTS: WEEK 24 RESULTS
P1101: PHASE I/II STUDY OF RALTEGRAVIR CONTAINING REGIMEN IN HIV-TB COTREATED CHILDREN

Poster P-Q3 AGING UP WITH HIV INFECTION: HEALTH OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS
Poster Hall D
2:30 PM – 4:00 PM

MILESTONES AND OUTCOMES OF YOUNG ADULTS WITH PERINATAL HIV INFECTION OR EXPOSURE
Elaine J. Abrams, Claude A. Mellins, Amelia Bucek, Curtis Dolezal, Jeannette Raymond, Andrew Wiznia, Cheng-Shiu Leu

SELF-HARM IN ADOLESCENTS WITH PERINATAL HIV AND HIV-AFFECTED ADOLESCENTS IN ENGLAND
Julie Copelyn, Lindsay Thompson, Marthe Le Prevost, Kate Sturgeon, Katie Rowson, Susie Brice, Ali Judd

MONITORING THE 3rd 90: ARE WE ON TRACK WITH ADOLESCENTS AND YOUTH?
Evelyne Ngugi, Agnes Natukunda, Tai Ho Chen, Kenneth Masamaro, Lucy Ng’ang’a, Jonathan Mwangi, Immaculate Mutisya, Abraham Katana, Peter W. Young

STUNTING AND GROWTH OF HIV-INFECTED ADOLESCENTS: HOW TO INTERPRET PROGRAMMATIC DATA?
Julie Jesson, Michael Schomaker, Karen Malatest, Dewi K. Wati, Azar Kariminia, Mariam Sylla, Kouakou Koudio, Shobna Sawry, Michael J. Vinikoor, Samuel Ayaya, Rachel Veerman, Mary-Ann Davies, Valérie Leroy, for the leDEA global cohort consortium

PREVALENCE OF GLOMERULAR DYSFUNCTION AMONG PERINATALLY HIV-INFECTED THAI ADOLESCENTS
Tavitiya Sudjaritruk, Suparat Kanjanavanit, Linda Aurpibul, Tawalchaya Chotecharoentanan, Saowalak Sarachai, Kamolrawee Sintupat, Ratchaneekorn Khampam, for the NEPHRO study team

Poster P-R1 LATE PRESENTATION AND MORTALITY
Poster Hall B
2:30 PM – 4:00 PM

TRENDS IN CAUSE-SPECIFIC MORTALITY ON THE HIV CARE CASCADE, SOUTHERN & EASTERN AFRICA
Kathryn A. Risher, Clara Calvert, Basia Zaba, Emma Slaymaker, Kobus Herbst, Jessica Nakiyangi-Mirollo, Amelia C. Crampin, Mark Urassa, Baltazar Mtenga, Georges Reniers

ADVANCED HIV AND THE CARE CASCADE IN THE BOTSWANA COMBINATION PREVENTION PROJECT
Refeletswe Lebelonyane, Lisa A. Mills, Chipo Mogorosi, Shenaaz El-Halabi, Janet Moore, Lisa Block, Huisheng Wang, Joe Theu, Joseph Makhema, Stembile Matambo, Tafariyzi Marukutira, Etienne Kadima, Max Kapanda, Pamela J. Bachanas, Joseph N. Jarvis

IMPROVED VIRAL SUPPRESSION BUT STABLE MORTALITY IN PEOPLE WHO INJECT DRUGS, 1997–2015
Becky L. Genberg, Gregory D. Kirk, Jacquie Astemborski, Hana Lee, Shruti H. Mehta
889  FACTORS ASSOCIATED WITH DELAYED HIV DIAGNOSES IN WASHINGTON, DC, 2006-2015
Rupali K. Doshi, Jessica Li, Kerri Dorsey, Auntre D. Hamp

890  LOWER MITOCHONDRIAL DNA COPY NUMBER IS ASSOCIATED WITH HIV & PREDICTIVE OF MORTALITY
Jing Sun, Ryan Longchamps, Damani A. Piggott, Jason A. Sumpter, Shruti H. Mehta, Dan Arking, Gregory D. Kirk, for the the ALIVE study

891  SHIFTING MORTALITY TRENDS AMONG PERSONS WITH HIV AND INJECTION DRUG USE OVER 30 YEARS
Jing Sun, Damani A. Piggott, Abimereki D. Muzaale, Jacquie Astemborski, Shruti H. Mehta, Gregory D. Kirk

892  INDIVIDUAL AND SITE-LEVEL FACTORS ASSOCIATED WITH RISK OF DEATH AMONG PEOPLE WITH HIV
Amanda D. Castel, Lindsey Powers Happ, Anne K. Monroe, Maria Jaurrette, Arpi Terzian, Alan Greenberg, for the DC Cohort Executive Committee

893  MORTALITY IS HIGHER AMONG SUCCESSFULLY TREATED PWH COMPARED TO MATCHED CONTROLS
Veronica Svedhem-Johansson, Zaake de Coninck, Laith Hussain-Alkhateeb, Anna Mia Ekström, Göran Bratt, Magnus Gisslén, Max Petzold

894  RATES OF MORTALITY AMONG SCHIZOPHRENIC PEOPLE LIVING WITH AND WITHOUT HIV
Kalysha Closson, Kate Salters, Thomas L. Patterson, Oghenowede Eyawo, William Chau, Monica Ye, Mark Hull, Viviane D. Lima, Julio S. Montaner, Robert S. Hogg, for the Comparative Outcomes Service Utilization Trends (COAST) Cohort Study

895  CAUSES OF DEATH AND EARLY MORTALITY IN PEOPLE WITH HIV IN MEXICO (2004-2015)
Yanink Caro-Vega, Pablo F. Belaunzaran-Zamudio, Jesús Alegre-Díaz, Brenda Crabtree-Ramírez, Raul Ramírez-Reyes, Pablo Kuri-Morales, Malaquias Lopez-Cervantes, Juan Sierra-Madero

896  LATE PRESENTATION WITH HIV IN AFRICA: PHENOTYPES, RISK AND RISK STRATIFICATION
Abraham Siika, Leanne McCabe, Mutsa Bwakura-Dangarembizi, Cissy Kityo, Jane E. Malleva, Kath Maitland, Anna Griffiths, Keith Baleeta, Shepherd Mudzingwa, James Abach, Kusum Nathoo, Andrew Prendergast, Sarah Walker, Diana Gibb, for the REALITY trial team

897  SMOKING, CHRONIC DISEASES, AND MORTALITY OF PEOPLE RECEIVING ART IN BRITISH COLUMBIA
Erin Ready, Monica Ye, William Chau, Viviane D. Lima, Paul Sereda, Katherine Lepik, Robert S. Hogg, Rolando Barrios, Julio S. Montaner, David Moore

898  PERSONS LIVING WITH HIV (PLHIV) WITH ADVANCED HIV DISEASE: NEED FOR NOVEL CARE MODELS
Wafaa M. El-Sadr, Chloé A. Teasdale, Katharine Yuengling, Peter Preko, Maureen Syowai, Felix Ndagiije, Miriam Rabkin, Elaine J. Abrams

899  HIGH MORTALITY AMONG PLHIV WITH TB IN LESOTHO DESPITE HIGH ART UPTAKE
Andrea Howard, Kieran Hartsough, Kathryn Curran, Koen Frederix, Fred Asimwe, Llang Maama-Maime, Simon G. Marealle, Eric Pevzner
900 SUBSTANTIAL MORTALITY AND LOSS PRIOR TO TREATMENT IN ART-ELIGIBLE PATIENTS IN ZAMBIA
Aaloke Mody, Izukanji Sikazwe, Theodora Savory, Kombatende Sikombe, Paul Somwe, Mwanza wa Mwanza, Carolyn Bolton Moore, Nancy Padian, Charles B. Holmes, Elvin Geng

901 LONG-TERM MEASURES OF HIV EXPOSURE AND MORTALITY IN THE HIV OUTPATIENT STUDY

902 POST-HOSPITAL MORTALITY AND READMISSION AMONG HIV-INFECTED ADULTS IN SOUTH AFRICA
Chris Hofmann, Minja Milovanovic, Deanne Kerrigan, Neil A. Martinson, Ebrahim Varia

903 LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA

Poster P-R2 EPIDEMIOLOGY AND RISK FACTORS
Poster Hall B 2:30 PM – 4:00 PM

904 RATE AND RISK OF TRANSMISSIBLE HIV RNA (>1500 COPIES/ML) AMONG ADULTS ON ART

905 INFECTION PRESSURE IN MEN WHO HAVE SEX WITH MEN AND THEIR SUITABILITY TO DONATE BLOOD
Ward P. van Bilsen, Hans L. Zaaijer, Amy Matser, Katja van den Hurk, Maarten F. Schim van der Loeff, Ed Slot, Maria Prins, Thijs J. Van de Laar

906 INDIVIDUAL AND NETWORK DRIVERS OF RACIAL DISPARITIES AMONG YMSM
Brian Mustanski, Ethan Morgan, Richard D’Aquila, Michelle Birkett, Patrick Janulis, Gregory Phillips, Michael E. Newcomb

907 HIV DIAGNOSES AND TRENDS IN THE SOUTHERN UNITED STATES, 2010-2015
Meg Watson, Andre Dailey, Alexandra M. Oster

908 DEGREE OF HOUSING INSTABILITY SHOWS INDEPENDENT “DOSE-RESPONSE” WITH HIV SUPPRESSION
Angelo A. Clemenzi-Allen, Elvin Geng, Katerina A. Christopoulos, Hali Hammer, Susan P. Buchbinder, Diane V. Havlir, Monica Gandhi

909 ONGOING NEED FOR BEHAVIORAL HIV PREVENTION INTERVENTIONS FOR HIV-POSITIVE MSM OVER 50
Mary Ann Chiasson, Martin J. Downing, Irene Yoon, Steven Houang, Sabina Hirshfield
910 UNDISCLOSED HIV INFECTION AMONG MSM IN NATIONAL HIV BEHAVIORAL SURVEILLANCE
Brooke Hoots, Cyprian Wejnert, Amy Martin, Richard Haaland, Silvina Masciotra, Catlann Sionean, Amanda Smith, William M. Switzer, Gabriela Paz-Bailey, for the NHBS Study Group

911 HIV TRANSMISSION BETWEEN MEN WHO HAVE SEX WITH MEN AND HETEROSEXUAL WOMEN
Alexandra M. Oster, Nivedha Panneer, Sonia Singh

912 RELIABILITY OF SELF-REPORTED HIV STATUS AMONG AFRICAN MSM SCREENED FOR HPTN 075
Jessica M. Fogel, Yinfeng Zhang, Xu Guo, William Clarke, Autumn Breaued, Vanessa Cummings, Erica Hamilton, Arthur Ogendo, Noel Kayange, Ravindre Panchia, Karen Dominguez, Ying Q. Chen, Theodorus Sandfort, Susan H. Eshleman, for the HPTN 075 Study Team

913 FACTORS ASSOCIATED WITH VIRAL SUPPRESSION AMONG MSM IN WASHINGTON, DC
Auntre D. Hamp, Jenevieve Opoku, Adam Allston

914 RACIAL DIFFERENCES IN EGOCENTRIC NETWORK PROPERTIES AMONG GAY, BISEXUAL AND OTHER MSM
Meagan Zarwell, William T. Robinson

915 ECONOMIC DEPENDENCE AND HIV RISK AMONG YOUNG, BLACK MEN WHO HAVE SEX WITH MEN
Kalysha Closson, Gbolahan Olarewaju, Richard Crosby

916 WITHDRAWN

917 HIV DIAGNOSES AMONG WOMEN IN RURAL VS NON-RURAL AREAS, UNITED STATES, 2010-2016
Ndidi Nwangwu-Ike, Neeraja Saduvala, Meg Watson, Alexandra M. Oster

918 FACTORS ASSOCIATED WITH HIV INFECTION AMONG FEMALES AGED 15-24 IN ZAMBIA
Haotian Cai, Danielle T. Barradas, Sundeep Gupta, Kathy Hageman, Andrea Low, Nzali Kancheya, Katrina Sleeman, Dan B. Williams, Karampreet Sachathep, Hetal Patel, Omega Chituwo, Lloyd Mulenga, for the ZAMPHIA Project Team

919 WITHDRAWN

920 HIV PREVALENCE AMONG WOMEN WHO EXCHANGE SEX RECRUITED IN 4 US CITIES, 2016
Senad Handanagic, Brooke Hoots, Kristen Leigh Hess, Emily Higgins, Paige Padgett, Sarah L. Braunstein, Sara N. Glick, Dita Broz, Gabriela Paz-Bailey, Cyprian Wejnert, Lina Nerlander, for the NHBS High Risk Women Study Group

921 TRANSACTIONAL SEX MEASUREMENT AND ASSOCIATION WITH HIV INCIDENCE AMONG WOMEN
Mary K. Grabowski, Virginia Burke, Gertrude Nakigozi, Fred Nalugoda, Robert Seekubugu, Larry W. Chang, Godfrey Kigozi, Deanne Kerrigan, David Serwadda, Betty Nantume, Darix K. Ssebagala, Ronald H. Gray, Joseph Kagayi, Maria Wawer, Caitlin E. Kennedy

922 VIOLENCE AND HIV RISK FACTORS AMONG WOMEN WHO EXCHANGE SEX FOR MONEY OR DRUGS
Christine Agnew-Brune, Lina Nerlander, Dita Broz, Zaida Lopez, Stephanie Schuette, Vivian Griffin, Alexis Rivera, Sara N. Glick, Gabriela Paz-Bailey
923 SEXUAL PARTNER TYPE AND INCIDENT HIV-INFECTION AMONG ADOLESCENT GIRLS IN HPTN 068

Nadia Nguyen, Kimberly A. Powers, Annie Green Howard, William C. Miller, Carolyn T. Halpern, Yaw Agyei, Catherine MacPhail, Kathleen Kahn, Audrey Pettifor

924 AN AGE-STRATIFIED RISK SCORE TO PREDICT HIV ACQUISITION IN YOUNG SOUTH AFRICAN WOMEN

Emma K. Burgess, Nonhlanhla Yende-Zuma, Delivette Castor, Quarraisha Abdool Karim

925 SEROSORTING FOR CONJUGAL RELATIONSHIP FORMATION IN HETEROSEXUAL COUPLES, SOUTH AFRICA

Hae-Young Kim, Alain Vandormael, Andrew Tomita, Till Bärnighausen, Frank Tanser

926 SELF-REPORTED RISKY SEXUAL PRACTICES AMONG ADOLESCENTS AND YOUNG ADULTS IN BOTSWANA

Unoda A. Chakalisa, Kathleen Wirth, Kara Bennett, Etienne Kadima, Kutlo Manyake, Tendani Gaolathe, Pamela J. Bachanas, Tafireyi Marukutira, Scott Dryden-Peterson, Mompazi O. Mmalane, Joseph Makhema, Molly Pretorius Holme, Max Essex, Shahin Lockman, Kathleen M. Powis

927 HIGH PREVALENCE OF CONCURRENT SEXUAL PARTNERSHIPS IN A LARGE POPULATION SURVEY

Etienne Kadima, Kathleen Wirth, Kara Bennett, Tendani Gaolathe, Jean Leidner, Unoda A. Chakalisa, Erik VanWidenfelt, Pamela J. Bachanas, Refleetswe Lebelonyane, Mompazi O. Mmalane, Joseph Makhema, Molly Pretorius Holme, Shahin Lockman, Max Essex, Sikhulile Moyo

928 ARE FISHERFOLK AT HIGHER RISK THAN THEIR NEIGHBORS: FINDINGS FROM WESTERN KENYA, 2015

Emily Zielinski-Gutierrez, Sifunjo F. Odongo, Daniel Kwaro, Kennedy Mutai

929 NATIONAL TRENDS IN HIV PREVALENCE IN 3 KEY POPULATIONS IN UKRAINE

Kostyantyn Dumchev, Yana Sazonova, Tetiana Salyuk, Olga Varetska


Andrew J. Mitsch, Xiao Wang, Dean Seneca, Sonia Singh, Donald Warne

931 COMPLEX HIV EPIDEMIC DYNAMICS IN MIGRANTS IN EUROPEAN UNION/ECONOMIC AREA (EU/EEA)

Julia Del Amo, Inma Jarrin, Victoria Hernando, Cristina Moreno, Belen Alejos, Anastasia Pharris, Teymur Noori

932 HIV TESTING AND US ACQUISITION AMONG AFRICAN IMMIGRANTS LIVING WITH HIV IN THE US

Roxanne P. Kerani, Amanda Lugg, Baiba Berzins, Oumay Gaye, Lauren Lipira, Camille Bundy, Helena Kwakwa, King Holmes, Matthew R. Golden

933 NO CHANGE IN THE FREQUENCY OF AGE DISPARATE RELATIONSHIPS OR IMPACT ON HIV STATUS

George Mwinnyaa, Oliver Laeyendecker, Kate Grabowski, Joseph Ssekasanvu, Anthony Ndyanabo, Robert Ssekubugu, Joseph Kagayi, Godfrey Kigozi, Gertrude Nakigozi, David Serwadda, Ronald H. Gray, for the for the Rakai Health Sciences Program
934  HIGH INCIDENCE AND BURDEN OF HIV INFECTION IN EAST LONDON, SOUTH AFRICA
Bhakti Hansoti, Anna Eisenberg, David Stead, Nomzamo Mvandaba, Eshan U. Patel, Andy Parrish, Madeleine Whalen, Reinaldo Fernandez, George Mwinnyaa, Steven J. Reynolds, Andrew D. Redd, Stewart Dandorf, Richard Rothman, Oliver Laeyendecker, Thomas C. Quinn

935  ARE HIV PREVALENCE ESTIMATES FOR WESTERN KENYA TOO HIGH?
Peter W. Young, Emily C. Zielsinski-Gutierrez, Daniel Kwaro, Martien W. Borgdorff, Joshua Gitonga, Joyce Wamicwe, Samuel M. Mwalili, Rachel Joseph, Kevin M. De Cock

936  ASSOCIATION OF MOBILITY WITH HIV RECENT INFECTIONS AND VIREMIA IN BOTSWANA
Mompati O. Mmalane, Sikhulile Moyo, Baraedi W. Sento, Jean Leidner, Kara Bennett, Thandie Phindela, Kutlo Manyake, Ernest Moseki, Tendani Gaolathe, Joseph Makhema, Molly Pretorius Holme, Janet Moore, Max Essex, Shahin Lockman, Kathleen Wirth

937  NEW METHOD FOR RAPID DETECTION OF HIV TIME-SPACE CLUSTERS FOR PUBLIC HEALTH ACTION
Laurie Linley, Arthur Fitzmaurice, Meg Watson, Chenhua Zhang, Riuguang Song, Anne Marie France, Alexandra M. Oster

938  EPIDEMIOLOGICAL STUDY OF TRANSMISSION CLUSTERS IN A LOCAL HIV-1 COHORT
Carmen M. González Domenech, Isabel Viciana-Ramos, Gabriel Sena-Corrales, Laura Mora Navas, Guillermo Ojeda, Enrique Nuño, Encarnación Clavijo, Rosario Palacios, Jesus Santos

939  AGE-DEPENDENT RACIAL/ETHNIC DISPARITIES IN LONGITUDINAL HIV CARE INDICATORS
Fidel A. Desir, Catherine R. Lesko, Richard D. Moore, Michael J. Silverberg, Peter F. Rebeiro, Michael A. Horberg, Mari Kitahata, Stephen Crystal, Angel Mayor, Marina Klein, Amy C. Justice, Michael John Gill, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

940  HIV VIRAL SUPPRESSION ASSESSED BY TWO METRICS IN NORTH CAROLINA DURING 2016
Manuela Bullo, Erika Samoff, Nicole Dzialowy Adams, Brad Wheeler, Kimberly A. Powers, Anna Cope

941  UNDISCLOSED ANTIRETROVIRAL DRUG USE IN BOTSWANA – IMPLICATIONS FOR NATIONAL ESTIMATES

942  CONCOMITANTLY SUPPRESSED SYSTEMIC AND IMBALANCED MUCOSAL IMMUNITY INCREASE HIV RISK

943  RELATIONSHIP BETWEEN DEPRESSION AND RISK BEHAVIORS IN A US MILITARY HIV COHORT
Brandon W. Carney, James White, Xiaohe Xu, Thankam Sunil, Colton Daniels, Morgan Byrne, Anuradha Ganesan, Robert Deiss, Grace E. Macalino, Brian K. Agan, Jason Okulicz
Poster P-T01 BARRIERS AND FACILITATORS OF PrEP
Poster Hall B
2:30 PM – 4:00 PM

1005 DISTANCE TO CLINIC IS A BARRIER TO PrEP UPTAKE & RETENTION IN UGANDA SEARCH COMMUNITY
Christopher Mayer, Asiphas Owaraganise, Jane Kabami, Dalsone Kwarisima, Catherine A. Koss, Edwin D. Charlebois, Moses R. Kamya, Maya L. Petersen, Diane V. Havlir, Britta Jewell

1006 GEOGRAPHIC ACCESS TO PrEP CLINICS AMONG US MSM: DOCUMENTING PrEP DESERTS
Kevin Weiss, Anna Bratcher, Patrick S. Sullivan, Aaron J. Siegler

1007 THE PrEP CASCADE AT NYC SEXUAL HEALTH CLINICS: NAVIGATION IS THE KEY TO UPTAKE
Preeti Pathela, Kelly Jamison, Susan Blank, Tarek Mikati, Trevor Hedberg, Sarit A. Golub, Lena Saleh, Christine M. Borges

1008 OUT-OF-POCKET COSTS IMPED PrEP USE AMONG YOUNG MSM IN THE PRIVATE HEALTHCARE SYSTEM

1009 HIGH DISCONTINUATION OF PRE-EXPOSURE PROPHYLAXIS WITHIN SIX MONTHS OF INITIATION
Chelsea L. Shover, Marjan Javanbakht, Steven Shoptaw, Robert Bolan, Pamina Gorbach

1010 PrEP IMPLEMENTATION AND PERSISTENCE IN A COUNTY HEALTH DEPARTMENT IN ATLANTA, GA
Charlotte-Paige M. Rolle, Udodirim Onwubiko, Jennifer Jo, Anandi N. Sheth, Colleen F. Kelley, David P. Holland

1011 HIV PREEXPOSURE PROPHYLAXIS AS A GATEWAY TO PRIMARY CARE

1012 TRENDS IN PrEP UPTAKE, ADHERENCE, AND DISCONTINUATION AMONG YMSM IN CHICAGO
Ethan Morgan, Daniel T. Ryan, Kevin Morgan, Richard D’Aquila, Michael E. Newcomb, Brian Mustanski

1013 PATTERNS AND CORRELATES OF PARTICIPANT RETENTION IN THE US PrEP DEMO PROJECT
Susanne Doblecki-Lewis, Daniel Feaster, Albert Y. Liu, Stephanie E. Cohen, Richard A. Elion, Oliver Bacon, Gabriel Cardenas, Michael Kolber, Megan Coleman

1014 INCREASING PrEP UPTAKE, PERSISTENT DISPARITIES IN AT-RISK PATIENTS IN A BOSTON CENTER
Kenneth H. Mayer, Chris Grasso, Kenneth Levine, Douglas Krakower, Victoria Powell, Stephen L. Boswell, Julia L. Marcus

1015 DISPARITIES IN PrEP UPTAKE AMONG PRIMARY CARE PATIENTS SCREENED FOR HIV/STIs IN SF
Hyman Scott, Anne Hirozawa, Miranda Nordell, Monica Gandhi, Catherine James, Hali Hammer, Susan Scheer, Susan P. Buchbinder
1016 EARLY ADOPTERS OF PrEP AMONG MSM IN INDIA AND DETERMINANTS OF EMERGING DISPARITIES
Viraj V. Patel, Alpana Dange, Sarit A. Golub, Shrutha Neytra, Yashesh Parekh, Christopher Pina, Julia H. Arnsten, Jack Harrison-Quintana, Kenneth H. Mayer

1017 ACCEPTABILITY OF PrEP AMONG A LARGE COHORT OF YOUNG TRANSGENDER WOMEN IN 2 US CITIES
Arjee J. Restar, Lisa Kuhns, Sari Reisner, Robert Garofalo, Matthew J. Mimiga

1018 AUTOMATED IDENTIFICATION OF POTENTIAL PrEP CANDIDATES USING ELECTRONIC HEALTH DATA
Douglas Krakower, Susan Gruber, John T. Menchaca, Sharon Ulery, Ira B. Wilson, Kenneth H. Mayer, Michael Klompas

1019 MONITORING PrEP USE AMONG WASHINGTON STATE MSM: RESULTS OF AN INTERNET SURVEY
Darcy W. Rao, Jason Carr, Kelly Naismith, Julia Hood, James P. Hughes, Matthew R. Golden

1020 COMPARING THE CHARACTERISTICS OF BRAZILIAN MSM USING APP FOR SEXUAL ENCOUNTERS
Thiago S. Torres, Raquel B. De Boni, Mauricio Vasconcelos, Paula M. Luz, Brenda Hoagland, Ronaldo I. Moreira, Alex Garner, Valdilea Veloso, Beatriz Grinsztejn

1021 HIV RISK PERCEPTION AMONG MEN WHO HAVE SEX WITH MEN: A RANDOMIZED CONTROLLED TRIAL
Jill Blumenthal, Donald E. Mulvihill, Sonia Jain, Sara Graber, Marvin Hanashiro, Eric Ellorin, Xiaoying Sun, Richard Haubrich, Sheldon Morris

Aaron J. Siegler, Farah Mouhanna, Robertino Mera Giler, Scott McCallister, Howa Yeung, Jeb Jones, Jodie L. Guest, Michael Kramer, Cory Woodyatt, Elizabeth Pembleton, Patrick S. Sullivan

Poster P-T08 MUCOSAL SAFETY STUDIES OF VAGINAL, RECTAL RING, AND ORAL PrEP
Poster Hall B 2:30 PM – 4:00 PM

1055 TDF/FTC PrEP, LUBRICANT USE, AND THE RECTAL MUCOSAL MICROBIOTA AMONG HIV-NEGATIVE MSM
Colleen F. Kelley, Jeffrey Fountain, Angela Holder, Chuong Dinh, LaShonda Hall, Sheila Heeke, Yingtian Hu, Colleen S. Kraft, Nicole A. Pescatore, Yijuian Hu, Clyde Hart, Richard Haaland

1056 GENDER-SPECIFIC RECTAL PROTEOME CHANGES WITH ORAL AND TOPICAL MARAVIROC USE AS PrEP
Sarah Mutch, Laura Noël-Romas, Jarret C. Engstrom, Rhonda M. Brand, Aaron Siegel, Ross Cranston, Ian McGowan, Adam Burgener

1057 MICROBIOME AND PROTEOME ALTERATIONS WITH DAPIVIRINE RING USE IN ADOLESCENT GIRLS
Christina Farr Zuend, Laura Noël-Romas, Jeanne Marrazzo, Sharon L. Hillier, Charlene S. Dezzutti, Kathleen E. Squires, Katherine Bunge, Adam Burgener
1058 **ACTIVITY OF GRIFFITHSIN-M78Q: AN HIV ENTRY INHIBITOR IN THE RECTAL ENVIRONMENT**

*Henry Nabeta, Sanet Steyn, Amanda Lasnik, Ian McGowan, Joshua Fuqua, Joseph C. Koukam, Kenneth E. Palmer*

1059LB **EARLY TERMINATION OF A PHASE 1 TRIAL OF TENOFOVIR DISOPROXIL FUMARATE VAGINAL RING**

*Maria J. Keller, Laurie Ray, Jessica M. Atrio, Lilia Espinoza, Shada Sinclair, Jessica Goymer, Mark A. Marzinke, Bruce Frank, Peter L. Anderson, Jeanne Marrazzo, Nelly R. Mugo, Craig W. Hendrix, Betsy Herold*

1060LB **HYPO-OSMOLAR RECTAL ENEMA TFV FORMULATION PREVENTS SHIV ACQUISITION**

*Peng Xiao, Sanjeev Gumber, Mark A. Marzinke, Abhijit Date, Thuy Hoang, Justin Hanes, Laura Ensign, Lin Wang, Lisa C. Rohan, Richard Cone, Edward J. Fuchs, Craig W. Hendrix, Francois Villinger*

**Poster P-U2 CARING FOR WOMEN LIVING WITH HIV: MENOPAUSE AND CONTRACEPTION**

**Poster Hall B**

2:30 PM – 4:00 PM

1072 **HIV-1 RESERVOIR DYNAMICS IN MENOPAUSAL WOMEN DURING HORMONE THERAPY**

*Stephanie Banning, Olivia Roberts-Sano, Emanuele Mazzola, Qianjing He, Stacey Chapman, Rebecca Gelman, Susan Cu-Uvin, Atie Tsibris*

1073 **ASSOCIATION OF HIV STATUS WITH SEXUAL FUNCTION IN WOMEN AGED 45-60**

*Nasreen Toorabally, Cath Mercer, Kirstin Mitchell, Fiona Burns, Caroline Sabin, Richard Gilson, Shema Tariq*

1074 **MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN HIV+ WOMEN**

*Shema Tariq, Fiona Burns, Lorraine Sherr, Richard Gilson, Alexandra Rolland, Caroline Sabin*

1075 **REPRODUCTIVE TRACT INFECTION RISK-BASED SCREENING FOR IUD INSERTION IN HIV+ WOMEN**

*Nontokozo Langwenya, Catherine Todd, Heidi Jones, Donald R. Hoover, Agnes Ronan, Landon Myer*

**Poster P-W2 MODELING ANTIRETROVIRAL THERAPY INTERVENTIONS AND OUTCOMES**

**Poster Hall B**

2:30 PM – 4:00 PM

1155 **ASSESSING THE UTILITY OF THE TIPPING POINT RATIO FOR MONITORING ART PROGRAM SUCCESS**

*Simon de Montigny, Marie-Claude Boily, Benoit R. Masse, Kate M. Mitchell, Dobromir Dimitrov*

1156 **PREDICTING THE PROBABILITY AND TREATMENT COSTS OF ELIMINATING HIV IN BOTSWANA**

*Katie Sharp, Sally Blower*

1157 **COST-EFFECTIVENESS OF MEDICAL CARE COORDINATION FOR HIGH-RISK PWH IN LA COUNTY**

*Moses J. Flash, Wendy H. Garland, Bruce R. Schackman, Sona Oksuzyan, Justine A. Scott, Philip J. Jeng, Emily B. Martin, Marisol Mejia, Elena Losina, Emily P. Hyle, Sonali P. Kulkarni, Kenneth Freedberg*

1158 **220 VULNERABLE COUNTIES: ONE YEAR LATER**

*Alana Sharp, Brian Honermann, Austin Jones, Gregorio A. Millett*
TUESDAY, MARCH 6, 2018

Poster P-A2 HOST CELL PATHWAYS AND VIRAL REPLICATION
Poster Hall A 2:30 PM – 4:00 PM

176 IDENTIFICATION OF FASNALL, A NOVEL FASN INHIBITOR THAT ATTENUATES HIV-1 REPLICATION
Manjusha Kulkarni, Annette Burkhouse, Menakshi Bhat, Yazan Alwarawrah, Phillip Hughes, Jesus Arcos, David Loiselle, Jordi Torrelles, Nicholas Funderburg, Timothy Haystead, Jesse Kwiek

177 EXPRESSION OF MDM2 IN MACROPHAGES FAVORS HIV-1 INTEGRATION THROUGH INHIBITION OF PS3
Yann Breton, Vincent Desrosiers, Michel Ouellet, Michel J. Tremblay

178 INTERPLAY BETWEEN FOLATE CYCLE AND HIV-1 INFECTION IN MONOCYTE-DERIVED MACROPHAGES
Vincent Desrosiers, Yann Breton, Michel Ouellet, Michel J. Tremblay

179 LOXL3 REGULATES HIV-1 INFECTION IN HUMAN PRIMARY MACROPHAGES
Laurent Hany

180 SYNONYMOUS RECODED ENV GENE INDUCE LETHALITY AND LOSS OF PROTEIN EXPRESSION IN HIV-1
Ana Jordan-Paiz, Maria Nevot, Sandra Franco, Miguel Angel Martinez

181 ENHANCEMENT OF HIV-1 INFECTION BY BUPRENORPHINE
German G. Gornalusse, Lucia Vojtech, Claire Levy, Rogelio M. Valdez, Urvashi Pandey, Julie McElrath, Florian Hladik

182LB EBV BORF2 INHIBITS AND SEQUESTERS HUMAN APOBEC3B TO PROTECT VIRAL GENOME INTEGRITY
Adam Cheng, Jaime Yockteng Melgar, Lori Frappier, Reuben S. Harris

Poster P-A3 EARLY EVENTS: METHODS AND MECHANISM
Poster Hall A 2:30 PM – 4:00 PM

183 R5X4 EVOLVE DISTINCT GP41 ACTIVATION PATHWAYS TO SENSE ALTERNATE CORECEPTOR BINDING
Annemarie Laumaea, Benjamin K. Dickerman, Jacqueline K. Flynn, Paul R. Gorry, Jason M. Mackenzie, Heidi E. Drummer, Pantelis Poub mourios

184 VARIABILITY OF HIV-1 V2 ENV DOMAIN FOR INTEGRIN BINDING: CLINICAL CORRELATES
Claudia Fabrizio, Davide F. Bavaro, Luciana Lepore, Antonella Lagioia, Gioacchino Angarano, Laura Monno, Annalisa Saracino

185 HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET
Anamaria D. Sarca, Hirofumi Fukuda, Luca Sardo, Jessica Smith, Kotaro Shirakawa, Kazuki Horikawa, Taisuke Izumi, Akifumi Takaori-Kondo

186 NEF UPREGULATES FASL EARLY WHILE MHCs ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS
Rodrigo Matus-Nicodemos, Daniel Douek, Richard A. Koup

187 VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY
Flore De Wit, Frauke Christ, Sambasivarao Pillalamarri, Akkadevi Venkatesham, Arthur Van Aerschot, Zeger Debyser
188 HIV RT STRAND TRANSFER AND NONTEMPLATED BASE ADDITION ARE MECHANISTIcALLY INDEPENDENT
Joanna Luczkowiak, Tania Matamoros, Luis Menéndez-Arias

189 UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1
Edmund Osei-Kuffour, Kerstin Schott, Philipp A. Lang, Karl S. Lang, Renate König, Dieter Häussinger, Carsten Münk

190 VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER
Sarah B. Nodder, Caitlin Miller, Hisashi Akiyama, Chelsea R. Ettinger, Rahm Gummuluru

191LB A NOVEL MODE OF RNA BINDING ASSISTS APOBEC3H IN THE MOLECULAR ARMS RACE AGAINST HIV
Jennifer Bohn, Keyur Thummar, Ashley York, Alice Raymond, William C. Brown, Paul Bieniasz, Theodora Hatzioannou, Janet L. Smith

216 HIV UNSPliced RNA EXPRESSION INDUCES INNATE IMMUNE ACTIVATION AND T CELL DYSFUNCTION
Hisashi Akiyama, Caitlin Miller, Chelsea R. Ettinger, Anna C. Belkina, Jennifer Snyder-Cappione, Rahm Gummuluru

217 INSULIN-LIKE GROWTH FACTOR 1 INVERSELY RELATES TO MONOCYTE ACTIVATION MARKERS IN HIV
Lindsay T. Fourman, Natalia Czerwonka, Sofia D. Shaikh, Takara L. Stanley, Kathleen V. Fitch, Janet Lo, Steven K. Grinspoon

218 EXOSOMES ARE ASSOCIATED WITH IMMUNE ACTIVATION AND OXIDATIVE STRESS IN HIV PATIENTS
Sukrutha Chettimada, David Lorenz, Vikas Misra, Dara H. Gabuzda

219 CONTROLLED STUDY TO EVALUATE IMMUNOLOGIC EFFECT OF ISOTRETINOIN ON HIV-1 INFECTION
Nina Lin, Bernard J. Macatangay, Ellen S. Chan, Heather Ribaudo, Karin L. Klingman, Linda Boone, Jonathan Z. Li, Maureen A. Kane, Francesca Aweeka, Charles Rinaldo, Ian McGowan, Douglas Kwon, for the ACTG A5325/A5330s team

220 HIV-1 UNMASKS THE PLASTICITY OF INNATE LYMPHOID CELLS
Yetao Wang, Kyle Gellatly, Alan Derr, Smita Jaiswal, Alper Kucukural, Patrick McDonel, Thomas Greenough, Jean Marie Houghton, Manuel Garber, Jeremy Luban

221 SYSTEMATIC ACTIVATION OF NOVEL IGA+ NATURAL KILLER-LIKE B CELLS IN HIV/SIV INFECTIONS
Chidikia Nwanze, Cordelia Manickam, R. Keith Reeves

222 IL-15 DRIVES THE GENERATION AND SURVIVAL OF SENESCENT CD8 T CELLS IN HIV INFECTION
Stephen R. Morris, Bonnie Chen, Soumya Panigrahi, Scott F Sieg, Souheil A Younes, Sara Gianella, Michael M. Lederman, Michael L. Freeman

223 REGULATION OF B CELLS BY IGg3 IN HIV-INFECTED INDIVIDUALS
Christine Youn, Lela Kardava, Haewon Sohn, James W. Austin, Wei Wang, Clarisa M. Buckner, Marissa Hand, Kathleen Gittens, Richard Kwan, Michael Sneller, Tae-Wook Chun, Susan K. Pierce, Susan Moir
224LB  RESISTANCE OF HIV-INFECTED MACROPHAGES TO CTL KILLING DRIVES IMMUNE ACTIVATION

Kiera L. Clayton, David R. Collins, Joshua Lengieza, Farokh Dotiwala, Judy Lieberman, Bruce D. Walker

225  SPECIFIC CTFH FREQUENCY CORRELATES WITH MEMORY B CELL RESPONSES IN HIV CONTROLLERS

Lisa A. Chakrabarti, Mathieu Claireaux, Moran Galperin, Daniela Benati, Alexandre Nouel, Madhura Mukhopadhyay, Pierre de Truchis, David Zucman, Samia Hendou, Faroudy Boufassa, Olivier Lambotte

226  INTERACTION OF HOST AND VIRAL GENOMICS ON HIV DISEASE PROGRESSION IN RAKAI UGANDA

Genevieve L. Wojcik, Michael A. Eller, David Serwadda, Kate Grabowski, Fred Wabwire-Mangen, Anthony Ndyanabo, Merlin L. Robb, Nelson L. Michael, Leigh Anne Eller, Ronald H. Gray, Thomas C. Quinn, Oliver Laeyendecker, for the for the Rakai Health Sciences Program

227  FC DEPENDENT ANTI-HIV-SPECIFIC ANTIBODY FUNCTIONALITY DISTINGUISHES HIV CONTROLLERS

Sanket Kant, Franck P. Dupuy, Chris Leeks, Alexandre Barbe, Ningyuo Zhang, Cindy X. Zhang, Jean-Pierre Routy, Petronela Ancuta, Cécile Tremblay, Nicole Bernard

228  TEMPORAL VARIATION OF IGG SUBCLASSES DIFFERENTIATES HIV CONTROLLERS AND PROGRESSORS

Jishnu Das, Saheli Sadanand, Amy Chung, Todd J. Suscovich, Hendrik Streeck, Davey M. Smith, Susan J. Little, Douglas Lauffenburger, Douglas D. Richman, Galit Alter

229  ART REDUCES T CELL ACTIVATION AND IMMUNE EXHAUSTION MARKERS IN HIV CONTROLLERS

Jonathan Z. Li, Florencia P. Segal, Ronald Bosch, Christina Lalama, Randall Tressler, Cornelius N. Van Dam, Michael Keefer, Mary Carrington, Mathias Lichterfeld, Daniel R. Kuritzkes, Xu G. Yu, Alan Landay, Paul E. Sax, for the AIDS Clinical Trials Group A5308 Study Team

230  EFFICIENT ANTIBODY PROFILE IN HLA-B*57+ HIV CONTROLLERS

Jéromine Klingler, Angeline Rouers, Géraldine Laumond, Sylvie Schmidt, Camille Ducloy, Luzia Mayr, Thomas Decoville, Nathalie Salomé, Assia Samri, Veronique Avettand-Fenoel, Faroudy Boufassa, Christine Rouzioux, Olivier Lambotte, Arnaud Moris, Christiane Moog, for the ANRS CO21 Cohort

231  THE CHAMP COHORT: POST-TREATMENT CONTROLLERS IDENTIFIED FROM 9 CLINICAL STUDIES

Golnaz Namazi, Jesse Fajnzylber, Evgenia Aga, Ronald Bosch, Edward P. Acosta, Jeffrey Jacobson, Paul Volberding, Daniel Skiest, Ronald T. Mitsuysasu, Robert T. Schooley, Ann Collier, Jean-Pierre Routy, Bruce D. Walker, Jonathan Z. Li, for the CHAMP Study Team

232LB  TARGETING HIGHLY NETWORKED CTL EPITOPIES AS A MECHANISM OF ELITE HIV-1 CONTROL

Gaurav D. Gaiha, Elizabeth Rossin, Christian Landeros, Ita Muzhingi, Chioma A. Nwonu, Bruce D. Walker

Poster Session: Tuesday
233LB  WOUND HEALING MECHANISMS REQUIRED IN PATHOGENESIS CONTROL OF SIV IN NATURAL HOST
Fredrik Barrenas, Kevin D. Raehlt, Lynn Law, Richard Green, Guido Silvestri, Steven E. Bsoinger, Qingsheng Li, Matthew Thomas, Jean Chang, Elise Smith, Reem A. Dawoud, Cristian Apetrei, Ivona Pandrea, Michael Gale

Poster P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION
Poster Hall A  2:30 PM – 4:00 PM

234  PERSISTENT DYSREGULATION OF HIV-SPECIFIC T FOLLICULAR HELPER CELLS DURING ART
Julia Niessl, Amy E. Baxter, Antigoni Morou, Elsa Brunet-Ratnasingham, Madeleine Lindqvist, Parsia A. Vagefi, Eileen P. Scully, Jean-Pierre Routy, Daniel E. Kaufmann

235  NEUTROPHIL DYNAMICS IN SIV-INFECTED PIGTAILED MACAQUES BEFORE AND AFTER ART
Egidio Brocca-Cofano, Tianyu He, Ranjit Sivanandham, Benjamin Policicchio, Paola Sette, Tammy Dunsmore, George S. Haret-Richter, Alan Landay, Cristian Apetrei, Ivona Pandrea

236  CHARACTERIZATION OF FDC-BOUND VIRAL PRODUCTS DURING HIV/SIV INFECTION
Matthew Bronnimann, Joy M. Folkvord, Pamela Skinner, Eva Rakasz, Elizabeth Connick

237  HIV-2 IMPACT ON LYMPHOID ORGANS: EVIDENCE OF VIRAL REPLICATION AND TISSUE DISRUPTION
Ana Antão, Ana Pires, Cristina Ferreira, Helena Nunes-Cabaço, Sandra Maurício, Cheila Rocha, Paula Matoso, Rui M. Victorino, Susana M. Fernandes, Ana E. Sousa

238  CD163+ LYMPH NODE MACROPHAGES ARE CORRELATED WITH LYMPH NODE FIBROSIS IN CHRONIC HIV
Brooks I. Mitchell, Fredrick Yost, Glen M. Chew, Michelle L. D’Antoni, Ashley Marumoto, Jodi Anderson, Caitlin David, Nancy Hanks, Dominic Chow, Timothy Schacker, Lishomwa C. Ndholu, Cecilia Shikuma

239  GUT HOMING DEFECTS AND EXHAUSTION OF BLOOD TH17 AND TH1 CELLS IN HIV INFECTION
Stephanie Dillon, Allison J. Christians, Kejun Guo, Gregory Austin, Alan Landay, Mario Santiago, Cara Wilson

240  VARIOUS SUBSETS OF CCR6+ CD4+ T CELLS ARE DIFFERENTIALLY TARGETED BY HIV-1 IN THE GUT
Manon Nayrac, Mary Requena, Claire Loiseau, Fatima L’Faqhi, Michelle Cazabat, Nicolas Carrere, Bertrand Suc, Jacques Izopet, Pierre Delobel

241  SHIV/SIV INFECTION PROMOTES CD8 T CELL VASCULAR INFILTRATION BY CX3CL1 AND IL-15
Bonnie Chen, Soumya Panigrahi, Jonathan Wyrick, Stephen R. Morris, Scott F Sieg, Nicholas Funderburg, David A. Zidar, Mirko Paiardini, Francois Villinger, Souheil A Younes, Michael M. Lederman, Michael L. Freeman

242  SMOKING INHIBITS HIV-1 INDUCED CD8+ T CELL INFILTRATION INTO THE ALVEOLAR SPACE
Bjorn Corleis, Josalyn Cho, Samantha J. Gates, Antonella C. Lisanti, Puja Kohli, Amy K. Dickey, Abigail Schiff, Scott R. Harris, Benjamin Medoff, Douglas Kwon
243 **INCREASES IN TH17 CELL DENSITY AT MUCOSAL SURFACES IN STATES OF ELEVATED PROGESTINS**
Megan Halkett, Ann M. Carias, Thomas Hope

244 **IDENTIFICATION OF NK CELL SUBSETS CORRELATING WITH HIV DNA IN HIV-INFECTED SUBJECTS**
Christopher Pohlmeyer, Veronica Gonzalez, Alivelu Irrinki, Ricardo Ramirez, Li Li, Andrew Mulato, Jeffrey Murry, Aaron Arvey, Rebecca Hoh, Steven G. Deeks, Garry Nolan, George Kukolj, Tomas Cihlar, Stefan Pflanz, Gundula Min-Oo

245 **CHARACTERIZATION OF NKG2C+ MEMORY NK CELLS IN SIV INFECTION BY FISH-FLOW CYTOMETRY**
Daniel Ram, R. Keith Reeves

---

### Poster P-B5 COMPARTMENTS FOR HIV REPLICATION
**Poster Hall A**
2:30 PM – 4:00 PM

246 **INNATE LYMPHOID CELLS IN ENDOCERVICAL MUCOSA OF HIV INFECTED WOMEN**
Natasa Strbo, Maria L. Alcaide, Laura Romero, Denisse Garcia, Margaret Fischl

247 **HIV-1 VPR SUSTAINS IL-6 PRODUCTION TO PROMOTE HIV-1 REPLICATION IN MACROPHAGES**
Qi Wang, Lishan Su

248 **T FOLLICULAR HELPER CELLS ARE MAJOR HIV-2 RESERVOIRS AND SUPPORT PRODUCTIVE INFECTION**
Ana Godinho-Santos, Ana Antão, Bárbara Tavares, Tiago Ferreira, Ana Serra-Caetano, Paula Matoso, Cheila Rocha, Russell B. Foxall, Ana E. Sousa

249 **NEUTROPHIL EXTRACELLULAR TRAPS PREVENT HIV INFECTION IN THE GENITAL TRACT**
Fiona D. Barr, Christina Ochsenbauer, Charles Wira, Marta Rodriguez-Garcia

250 **COMPARTMENTALIZED HIV-1 IS FOUND IN THE SEMEN OF MEN WITH AND WITHOUT URETHRITIS**
Olivia Council, Lihua Ping, Chase McCann, Gerald Tegha, Irving Hoffman, Debbie Kamwendo, Mitch Matoga, Myron S. Cohen, Ronald Swanstrom

251LB **WITHDRAWN**

---

### Poster P-CS VACCINE DESIGN AND TESTING
**Poster Hall A**
2:30 PM – 4:00 PM

303 **THE DEVELOPMENT OF A NOVEL MACHINE-LEARNING-GUIDED HIV IMMUNOGEN DESIGN**
Wen-Han Yu, Galit Alter, Christina B. Karsten, Douglas Lauffenburger, Daniel Lingwood, Dan Barouch

304 **DEFINING THE COMMON CORRELATES OF HIV VACCINE TRIALS CROSS-PREDICTS VACCINE EFFICACY**
Wen-Han Yu, Dan Barouch, Douglas Lauffenburger, Margaret Ackerman, Caitlyn Linde, Thomas Broge, Galit Alter
305 **VACCINATION WITH MF59 INDUCES DISTINCT VACCINE-SPECIFIC ANTIBODY FUNCTIONALITY**
Carolyn Boudreau, Todd J. Suscovich, Galit Alter

306 **ADDITIONAL BOOST OF AIDSVAX B/E FURTHER INCREASED RV305 IGG BUT NOT IGA ANTIBODIES**

307 **INCREASE IN B CELL RESPONSES UPON LATE BOOST STRATEGIES OF ALVAC-HIV/AIDSVAX B/E**

308 **EPITOPES ASSOCIATED WITH HIV-1 DYNAMICS AFTER DC-BASED THERAPEUTIC VACCINATION**
Mathieu Surenaud, Laura Richert, Monica Montes, Sandy Zurawski, Karolina Palucka, Jacques Banchereau, Rodolphe Thiébaut, Jean-Daniel Lelievre, Christine Lacabarat, Yves Levy

309 **SIV REBOUND KINETICS FOLLOWING TLR7-AGONIST & THERAPEUTIC VACCINE ADMINISTRATION**
Jeffrey Gerold, So-Yon Lim, Christa E. Osuna, Dan Barouch, James Whitney, Alison L. Hill

310 **IPROTECT1: A VAC-3S VACCINE PHASE II STUDY IN HIV-INFECTED PATIENTS**
Christine Katlama, Gilles Pialoux, Laurent Cotte, Pierre-Marie Girard, Anne Simon, Jacques Reynes, Jürgen K. Rockstroh, Jose M. Gatell, Alain Devidas, Yazdan Yazdanpanah, Odile Launay, Laurence Weiss, Gerd Fäkhenheuer, Béhazine Combadière, Vincent Vieillard

311 **PHASE I CLINICAL TRIAL OF AN MRNA-BASED THERAPEUTIC VACCINE AGAINST HIV-1 INFECTION**
Lorna Leal, Alberto C. Guardo, Sara Moron-Lopez, Maria Salgado, Beatriz Mothe, Carlo Heirman, Kris Thielemans, Pieter Pannus, Christian Brander, Rob Gruters, Arno Andeweg, Javier Martinez-Picado, Montserrat Plana, Felipe Garcia, for the iHIVARNA consortium

312 **HIV ANTIBODY GLYCOFORMS MODULATE IMMUNE COMPLEX-DRIVEN INNATE AND ADAPTIVE IMMUNITY**
Giuseppe Lofano, Wen-Han Yu, Margaret Ackerman, Todd J. Suscovich, Galit Alter

---

**Poster P-C6 NOVEL INTERVENTIONAL STRATEGIES**
Poster Hall A

313 **RIFAXIMIN USE DOES NOT ALTER SCD14 LEVELS IN HIV-INFECTED PERSONS ON SUPPRESSIVE ART**
Anuradha Ganesan, Deborah McMahon, Netanya S. Utay, Jennifer Bell, Heather Burris, Timothy Whitman, Jing Qin, Jeffrey Laczek, Patrick Young, Brian K. Agan, Sheila Kumar, Dean Follmann, Stephen Wank, Frank Maldarelli, for the Gut –Check Rifaximin Team
314 EFFECT OF SWITCHING TO RALTEGRAVIR AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION

Berta Torres, Alberto C. Guardo, Amanda Fabra, Lorna Leal, Cristina Rovira, Carmen Hurtado, MANELE. BARGALLÓ, Constanza Lucero, Irene Fernandez, Flor Etcheverry, Jose M. Gatell, Montserrat Plana, Felipe Garcia

315 TLR9 AGONIST ENHANCES B CELL DIFFERENTIATION AND ANTIBODY PRODUCTION IN HIV+ ADULTS

Mariane H. Schleimann, Line K. Vibholm, Maria-Louise R. Kobberø, Manuel Schmidt, Burghardt Wittig, Tine Dansgaard, Peter Ahlborg, Michel Hellfritzsch, Rikke Olesen, Lars Østergaard, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard

316 A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY

Debbie S. Ruelas, Yanyan Zheng, Laura Garvin-Queen, Fahimeh Raoufi, Laurence Fayadat-Dilman, Yuan Li, Julie Strizki, Richard Barnard, Steven G. Deeks, Mohammad Tabrizifard, Daniel Gorman

317 HIV INFECTION OF TARGET CELLS IN PEDIATRIC TONSIL IS INHIBITED BY AN HSP90 INHIBITOR

Ria Goswami, Holly A. Heimsath, Riley J. Mangan, Joshua A. Eudailey, Guido Ferrari, Timothy Haystead, Barton F. Haynes, Sallie Permar

318 ALTERED AND INCOMPLETE IMMUNE RECONSTITUTION IN HIV+ STEM CELL TRANSPLANT RECIPIENTS

Daniel D. Murray, John Zaunders, Carole Ford, Kersten Koelsch, Samuel T. Milliken, Orla Morrissey, Sharon Avery, Joseph Sasaudeusz, Matthew Law, Anthony Kelleher, Sharon R. Lewin, David A. Cooper, John Moore, Mark Polizotto

319LB Α4Β7-BLOCKADE COMBINED WITH VRC01 MODULATES IMMUNE RESPONSES TO SHIV-AD8 INFECTION


Poster Sessions - Tuesday

Poster P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE
Poster Hall A
2:30 PM – 4:00 PM

348 IL-21 PLUS IFNA LIMITS VIRAL PERSISTENCE AND REBOUND IN SIV-INFECTED RHEUS MACAQUES

Maria Pino, Luca Micci, Justin L. Harper, Colin T. King, Guido Silvestri, Jeffrey D. Lifson, Mirko Paiardini

349 CD4 DEPLETION IN SIV-INFECTED MACAQUES ON EARLY ART HAS NO IMPACT ON VIRAL REBOUND

Adrienne E. Swanson, Taina T. Immonen, Claire Deleage, Kelli Oswald, William J. Bosch, Douglas K. Schneider, Sirish Khanal, James A. Thomas, Cathi Pyle, Charles M. Trubey, Jacob D. Estes, Jeffrey D. Lifson, Brandon Keele, Gregory Q. Del Prete

350 SIV PERSISTS IN LYMPHOID TISSUES DESPITE ALEMUTUMAB-INDUCED CD4+ T CELL DEPLETION

351 ΔCCRS ANTI-HIV CAR T CELLS ENGRAFT AND PERSIST IN SHIV-INFECTED PIGTAIL MACAQUES
Thor A. Wagner, Christopher Peterson, Brenda Seymour, Taylor Mesojednik, Jeb English, Bryan Sands, Courtnee Clough, Karsten Eichholz, Larry Corey, Hans-Peter Kiem, David J. Rawlings

352 FULLY MHC-MATCHED ALLOGENEIC HSCT IN SIV-INFECTED, ART-SUPPRESSED MACAQUES
Helen Wu, Benjamin Burwitz, Shaheed Abdulhaqq, Christine Shriver-Munsch, Tonya Swanson, Alfred Legasse, Katherine Hammond, Jason Reed, Mina Northrup, Stephanie Junell, Gabrielle Meyers, Richard Maziarz, Jeffrey Stanton, Jonah Sacha

353LB IL-15 TREATMENT INCREASES CYTOTOXIC LYMPHOCYTES IN LN FOLLICLES AND REDUCES SHIV RNA
George N. Pavlakis, Dionysios C. Watson, Eirini Moysi, Antonio Valentin, Cristina Bergamaschi, Santhi Devsundaram, Sotirios Fortis, Claire Deleage, Jacob D. Estes, Elena Chertova, Jeffrey D. Lifson, Constantinios Petrovas, Barbara K. Feibler

354 GAMMA/Delta Cells Target the HIV Reservoir: Immunotherapeutic Potential for HIV Cure
Chloe Whitworth, Carolina Garrido, Katherine Sholtis, Matthew Clohosey, Nancie Archin, David M. Margolis, Natalia Soriano-Sarabia

355 Blockade of IFNAR Rescues Anti-HIV-1 CD8 T Cell Functions to Reduce HIV-1 Reservoir
Liang Cheng, Jianping Ma, Guangming Li, Zhiyuan Hu, Liguang Zhang, Lishan Su

356 A Phase 1 Study of ALT-803 (IL-15 Superagonist) to Clear Latent HIV Reservoirs
Zachary Davis, Ann Thorkelson, Jodi Anderson, Hing C. Wong, Jonathan Karn, Curtis Dobrowelski, Jeffrey S. Miller, Sarah Cooley, Daniel Douek, Timothy Schacker

357 Effect of 24 Weeks TLR9 Agonist Therapy on CTL Responses and Viral Rebound During ATI
Line K. Vibholm, Giacomo Frattari, Mariane H. Schleimann, Rikke Olesen, Mathias Lichterfeld, Anni Winckelmann, Christina V. Konrad, Vibeke Klstrup, Thomas A. Rasmussen, Manuel Schmidt, Burghardt Wittig, Lars Østergaard, Paul W. Denton, Martin Tolstrup, Ole S. Søgaard

358 IFN-α Induces NK-Dependent HIV DNA Decline in ART-Treated HIV/HCV Coinfected Patients
Stephane Hua, Selena Viganò, Samantha Tse, Zhengyu Ouyang, Sean Harrington, Jordi Negron, Pilar Garcia-Broncano, Giulia Marchetti, Miguel Genebat, Manuel Leal, Salvador Resino, Ezequiel Ruiz-Mateos, Mathias Lichterfeld, Xu G. Yu

359 The Therapeutic Vaccine VACC-4X Targets Gag CTL Epitopes with Preexisting Mutations
Anni Winckelmann, Vincent Morcila, Wei Shao, Lars Østergaard, Ole S. Søgaard, Martin Tolstrup, Sarah Palmer

Poster Sessions

Poster P-D06 Novel Interventions to Target HIV Reservoirs
Poster Hall A 2:30 PM – 4:00 PM
SEX-BASED DIFFERENCES IN TRANSCRIPTOMIC PROFILES AND HIV RESERVOIR CORRELATES
Eileen P. Scully, Khader Ghneim, Ashish Sharma, Ainsley Lockhart, Rowena Johnston, Monica Gandhi, Rebecca Hoh, Sharon R. Lewin, Nicolas Chomont, Steven G. Deeks, Rafick-Pierre Sekaly

THE IMPACT OF ART DURATION ON THE INFECTION OF T CELLS WITHIN ANATOMIC SITES
Eunok Lee, Susanne von Stockenstrom, Vincent Morcilla, Wei Shao, Wendy Hartogensis, Peter Bacchetti, Jeffery Milush, Rebecca Hoh, Ma Somsouk, Peter W. Hunt, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

PERSISTENCE OF CD4+PD-1HIGH T CELLS DESPITE LONG-TERM SUPPRESSIVE ART
Bernard J. Macatangay, Rajesh T. Gandhi, Deborah McMahon, Christina Lalama, Ronald Bosch, Joshua C. Cyktor, Christopher Hensel, Evelyn Hogg, Luann Borowski, Joseph J. Eron, John W. Mellors, Charles Rinaldo, for the ACTG A5321

PROVIRAL LANDSCAPE IN HIV-1 POST-TREATMENT CONTROLLERS AND NON-CONTROLLERS
Radwa Sharaf, Guinevere Q. Lee, Xiaoming Sun, Evgenia Aga, Ronald Bosch, Rajesh T. Gandhi, Jeffrey Jacobson, Edward P. Acosta, Daniel R. Kuritzkes, Michael M. Lederman, Xu G. Yu, Mathias Lichterfeld, Jonathan Z. Li, for the AIDS Clinical Trials Group (ACTG) NWCS 380 Study Team

HIV VIREMIA IS THE PRODUCT OF A SMALL FRACTION OF HIV INFECTED CELLS
Elizabeth M. Anderson, Shawn Hill, Jennifer Bell, Catherine A. Rehm, Sara Jones, Rob Gorelick, Mary F. Kearney, John M. Coffin, Frank Maldarelli

THE GENETIC TRAITS OF FULL-LENGTH HIV SEQUENCED FROM MEMORY T CELL SUBSETS
Bethany A. Horsburgh, Bonnie Hiener, Eunok Lee, John-Sebastian Eden, Timothy E. Schlub, Susanne von Stockenstrom, Jeffery Milush, Teri Liegler, Elizabeth Sinclair, Rebecca Hoh, Rémi Fromentin, Nicolas Chomont, Steven G. Deeks, Frederick M. Hecht, Sarah Palmer

PULMONARY MUCOSAL T CELLS AS POTENTIAL HIV RESERVOIRS DURING LONG-TERM ART
Syim Salahuddin, Omar Farnos, Ron Olivenstein, Aurelie Le Page, Amelie Pagliuzza, Christina de Castro, Jean Bourbeau, Petronela Ancuta, Bertrand Lebouché, Jean-Pierre Routy, Nicolas Chomont, Cecilia Costiniuk, Mohammad-Ali Jenabian

THE BIRC5/OX40 PATHWAY MAINTAINS SURVIVAL OF HIV-1-INFECTED CD4 T CELLS
Hsiao-Hsuan Kuo, Rushdy Ahmad, Guinevere Q. Lee, Hsiao-Rong Chen, Matthew J. Szucs, Atte Tsibris, Eric Rosenberg, Steven Carr, Xu G. Yu, Mathias Lichterfeld

HIV-2 RESERVOIR DISTRIBUTION IN CD4 T CELLS RELATED TO CXCR6 AND TRIM-5 EXPRESSION
Assia Samri, Charlotte Charpentier, Mélanie Bertine, Mariama S. Diallo, Sophie Even, Veronique Morin, Anne Oudin, Gilles Collin, Sophie Matheron, Rodolphe Thibault, Rima Zoorob, Brigitte Autran, Françoise Brun-Vezinet, for the ANRS COS IMMUNOVIR-2 study group
370 EFFECTOR MEMORY T CELLS CONTRIBUTE TO X4 MONOTYPIC RESIDUAL PLASMA VIRUS PRODUCTION
Hadega Aamer, Sherry McLaughlin, Michael Dapp, Sheila Styrchak, Ana Gervassi, Janine Maenza, Ann Collier, James Mullins, Lisa Frenkel

371 TESTICULAR IMMUNE PRIVILEGE AND HIV-1 PERSISTENCE
Rosalie Ponte, Franck P. Dupuy, Zabrina Brumme, Natalie Kinloch, Art Poon, Pierre Brassard, Maud Bélanger, Vikram Mehraj, Reina Bendayan, Mohammad-Ali Jenabian, Jean-Pierre Routy

372 RECONSTRUCTING INTEGRATION DATES OF LATENT HIV SEQUENCES WITHIN-HOST
Bradley R. Jones, Natalie Kinloch, Joshua J. Horacek, Bruce Ganase, Marianne Harris, P. Richard Harrigan, R. Brad Jones, Mark Brockman, Jeffrey Joy, Art Poon, Zabrina Brumme

373 IDENTIFICATION OF MACROPHAGE RESERVOIRS THROUGH TROPISM OF HIV-1 ENVELOPES
Viviane Machado, Thaisa Alvarado, Mario Stevenson, Labelle Barrios, Aubrey Morales, Mark Sharkey, Marco Salemi, Carla Mavian, Timothy J. Henrich

374LB HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE A UNIQUE FUNCTIONAL HIV RESERVOIR
Thomas D. Zaikos, Valeri Terry, Nadia T. Sebastian Kettinger, Andrew J. Neevel, Ryan Yucha, Kathleen L. Collins

Poster P-E4 NEUROIMAGING AND ASSOCIATED BIOMARKERS
Poster Hall A 2:30 PM – 4:00 PM

425 BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART
Ignacio Pérez-Valero, Lucía Bailón, Alicia Gonzalez, Belen Alejos, Helena Melero, Norberto Malpica, Jose I. Bernardino, Juan González-García, Jose R. Arribas, for the La Paz HIV Group

426 LONGITUDINAL PET IMAGING OF THE SEROTONERGIC SYSTEM IN SIV-INFECTED NONHUMAN PRIMATES

427 IMMUNOLOGICAL AND NEUROMETABOLITE CHANGES ASSOCIATED WITH SWITCH FROM EFV TO AN INSTI
Nina Lin, Yvonne Robles, Alan Landay, Tyler Starr, Jennifer Kinslow, Joshua Ladner, Rebeca M. Plank, Laura F. White, Kathy Melbourne, Alexander Lin, Daniel R. Kuritzkes

428 CHANGES IN BRAIN VOLUME AND COGNITION IN MICE EXPOSED IN UTERO TO ABC/3TC-ATV/RTV
Kayode Balogun, Monica Guzman Lenis, Lindsay Cahill, Howard Mount, John Sled, Lena Serghides

429 BRAIN 18F-FDG PET OF SIV-INFECTED MACAQUES AFTER TREATMENT INTERRUPTION OR INITIATION
William T. Schreiber-Stainthorpe, Sharat Srinivasula, Sanhita Sinharay, Swati Shah, Jing Wang, Lori E. Dodd, H. Clifford Lane, Michele Di Mascio, Dima A. Hammoud
430 INTACT STRUCTURAL AND FUNCTIONAL BRAIN IMAGING IN ACUTE HIV
Vishal Samboju, Carissa Philippi, Phillip Chan, Yann Cobigo, James L. Fletcher, Merlin L. Robb, Joanna Hellmuth, Khunthalee Benjapornpong, Netsiri Dumrongpisutkul, Mantana Pothisiri, Robert Paul, Jintanat Ananworanich, Serena S. Spudich, Victor Valcour, for the SEARCH 010/ RV254 and RV304 protocol team

431 HIV INFECTION AND AGE HAVE INDEPENDENT EFFECTS ON BRAIN GRAY MATTER VOLUME
Erin O’Connor, Thomas Zeffiro, Melissa F. Murray, Donna Martineck, James T. Becker

432 MULTIMODAL BRAIN IMAGING PREDICTS NEUROCOGNITIVE IMPAIRMENT IN CHRONIC HIV
Talia M. Nir, Hei Y. Lam, Chris R. Ching, Neda Jahanshad, Jaroslaw Harezlak, Kenia Martinez, Tong Zhu, Giovanni Schifitto, Ronald Cohen, Paul M. Thompson, Bradford A. Nava, for the HIV Neuroimaging Consortium

433 LESION LOAD IS ASSOCIATED WITH NEUROCOGNITIVE DEFICITS IN HIV-INFECTED INDIVIDUALS

434 ANALYSIS OF THE EFFECTS OF HIV DISEASE ON FUNCTIONAL NEUROMAGNETIC CONNECTIVITY
Mark D. Kelley, Melissa F. Murray, Donna Martineck, Ricardo Bruna, Anto Bagic, James T. Becker

435 BRAIN WHITE MATTER HYPERINTENSITIES, HIV DISEASE, COGNITION AND DIABETES
Minjie Wu, Omalara Fatukasi, Shaolin Yang, Jeffry Alger, Peter B. Barker, Tae Kim, Andrew Levine, Eileen Martin, Cynthia Munro, Todd B. Parrish, Ann B. Ragin, Ned Sacktor, Eric C. Seaberg, James T. Becker, for the Neuropsychology Working Group of the Multicenter AIDS Cohort Study

436 MULTIVARIATE PATTERN ANALYSIS OF VOLUMETRIC NEUROIMAGING DATA IN TREATED HIV- Disease
Jonathan Underwood, James H. Cole, Robert Leech, Alan Winston, for the CHARTER group

437 CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART
Napapon Sailasuta, Jennifer Daniels, Phillip Chan, Carlo Sacdahan, Merlin L. Robb, Sompong Tipsuk, Jintanat Ananworanich, Duangthai Suttichom, Robert Paul, Nisakorn Ratnaratorn, Mantana Pothisiri, Netsiri Dumrongpisutkul, Serena S. Spudlich, Victor Valcour, for the SEARCH 010/ RV254 and RV304 Study Team

438 AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS
Ned Sacktor, Richard Skolasky, Heidi Roosa, Cornelia Demsky, Yun Zhou, Weiquo Ye, Noble George, Peter B. Barker, Dean Wong, Mona Mohamed

439 NEUROIMAGING CORRELATES OF FRAILTY, COGNITION AND HIV
Jeremy Strain, Robert S. Smith, Sarah Cooley, Beau M. Ances
Poster Sessions

440  SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS
Dima A. Hammoud, Sanhita Sinharay, Sally Steinbach, Paul Wakim, Katrina Geannopoulos, Katherine Traino, Amit Dey, Stanley Rapoport, Edmund C. Tramont, Joseph Snow, Nehal N. Mehta, Bryan Smith, Avindra Nath

441LB  BRAIN PET IMAGING OF MICROGLIA IN MACAQUES WITH SIV ENCEPHALITIS

Poster P-F3  ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
Poster Hall D  2:30 PM – 4:00 PM

464  HIGHER NRTI METABOLITE:ENDOGENOUS NUCLEOTIDE RATIOS IN OLDER HIV+ WOMEN ON TDF/FTC
Julie B. Dumond, Camden Bay, Julie A. Nelson, Craig Sykes, Kathryn Anastos, Roopali Sharma, Seble Kassaye, Maria Villacres, Ruth Greenblatt, Audrey French, Stephen J. Gange, Igho Ofotokun, Margaret Fischl, David Vance, Adaoa Adimora

465  ETRAVIRINE PHARMACOKINETICS IN TREATMENT-EXPERIENCED CHILDREN AGES 1 -<6 YEARS
Christine E. MacBrayne, Richard Rutstein, Ram Yoge, Andrew Wizia, Lee Fairlie, Bobbie Graham, Carmelita Alvero, Jack Moye, Ellen Towney, Herta Crawuels, Xavier Woot de Trixhe, Lotke Tambuyzer, Simon Vanvegge, Magda Opsomer, Jennifer J. Kiser

466  CYP2B6 VARIANTS ALTER ETONOGESTREL PHARMACOKINETICS WHEN COMBINED WITH EFAVIRENZ
Megan Neary, Catherine Chappell, Kimberly K. Scarsi, Shadia Nakalema, Joshua Matovu, Sharon L. Achilles, Beatrice A. Chen, Marco Siccardi, Andrew Owen, Mohammed Lamorde

467  NR1I2 RS2472677 AND ABCG2 RS2231142 INFLUENCE DOLUTEGRAVIR CONCENTRATIONS IN PLASMA
Emilie R. Elliot, Megan Neary, Laura Else, Saye Khoo, Graeme Moyle, Daniel F. Carr, Xinzhui Wang, Myra McClure, Andrew Owen, Marta Boffito

468  PHARMACOKINETICS OF DOLUTEGRAVIR WITH AND WITHOUT DARUNAVIR/COBICISTAT
Emilie R. Elliot, Maddalena Cerrone, Laura Else, Alieu Amara, Elisa Bisdomini, Saye Khoo, Marta Boffito

469  PHARMACOKINETICS (PK) OF ETHINYLESTRADIOL/LEVONORGESTREL WITH ATAZANAVIR/COBICISTAT
Emilie R. Elliot, Elisa Bisdomini, Laura Else, Sujan Dilly Penchala, Saye Khoo, Graeme Moyle, Nneka Nwokolo, Marta Boffito

470  THE EFFECT OF ANTACIDS AND MULTIVITAMINS ON RALTEGRAVIR
Helen Reynolds, Joseph Lewis, Deidre Egan, Mas Chaponda, Laura Else, Justin Chiong, Darren M. Moss, David Back, Andrew Owen, Saye Khoo
471 RAVIDASVIR PHARMACOKINETICS AND ARV DRUGS INTERACTIONS IN HCV+/−HIV INFECTED ADULTS
Tim R. Cressey, Soek-Siam Tan, Hajjah Rosaida Hj Mohd Said, Muhammad Radzi Abu Hassan, Haniza Omar, Tee Hoi Poh, Chan Wah Kheong, Suresh Kumar, Satawat Thongsawat, Kanawee Thetket, Suparat Khemnark, Anhalee Avihingsanon, Francois Simon, Isabelle Andrieux-Meyer, Marc Lallemant

Poster P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS
Poster Hall D 2:30 PM – 4:00 PM

472 MAPPING THE DISTRIBUTION OF EFAVIRENZ WITH BRAIN TISSUE CELLS
Nithya Srinivas, Elias Rosen, Gabriela D. Cruz, Craig Sykes, Amanda Schauer, Lourdes Adamson, Paul Luciw, Angela Kashuba

473 SWITCHING TO TAF IN EVG-BASED REGIMENS: CSF PHARMACOKINETICS AND ANTIVIRAL ACTIVITY
Qing Ma, Andrew Ocque, Gene D. Morse, Chelsea Sanders, Alina Burgi, Susan J. Little, Scott L. Letendre

474 DIFFERENTIAL BRAIN TISSUE PENETRATION OF ANTIRETROVIRALS AND FLUCONAZOLE
Melanie Nicol, Jonne Taylor, Katelyn Pastick, James Fisher, Carol Karuganda, Joshua Rhein, Darlisha A. Williams, David Meya, David R. Boulware, Robert Lukande

475 MASS SPEC IMAGING REVEALS ASSOCIATIONS BETWEEN ARVs, VIRUS, AND CELLS IN LYMPH NODES
Elias Rosen, Claire Deleage, Nicole White, Craig Sykes, Lourdes Adamson, Yuri Fedoriw, Jacob D. Estes, Paul Luciw, Angela Kashuba

476 EFFECT OF SEX, SHIV, AND DRUG TRANSPORTERS ON LYMPH NODE ANTIRETROVIRAL PENETRATION
Erin M. Burgunder, John K. Fallon, Nicole White, Amanda Schauer, Craig Sykes, Lourdes Adamson, Jason R. Pirone, Paul Luciw, Philip C. Smith, Angela Kashuba

477 HIV TARGET CELL DISTRIBUTION AND TFV PENETRATION IN FORESKIN AND URETHRA
Alison S. Kohlmeier, Kenji Nishiura, Natalia Makarova, Jessica Radzio-Basu, Gerardo Garcia-Lerma, Charles Dobard

478 SEMINAL TENOFOVIR CONCENTRATIONS, VIRAL SUPPRESSION AND SEMEN QUALITY WITH TAF VS TDF
Arkaitz Imaz, Jordi Niubo, Mackenzie L. Cottrell, Emilia Perez, Angela Kashuba, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia, Daniel Podzamczer

Poster P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN
Poster Hall D 2:30 PM – 4:00 PM

523 PRETREATMENT HIV DRUG RESISTANCE SPREAD WITHIN TRANSMISSION CLUSTERS IN MEXICO CITY
Margarita Matías-Florentino, Antoine Chaillon, Santiago Avila-Rios, Verónica Ruiz, Silvia del Arenal, Manuel A. Becerril-Rodríguez, Alicia Piñeirúa, Florentino Badian Hernandez, Andrea Gonzalez Rodriguez, Sanjay R. Mehta, Gustavo Reyes-Terán
524  SPREAD OF HIV-1 PRE-TREATMENT DRUG RESISTANCE IN THE COLOGNE-BONN REGION, GERMANY
Melanie Stecher, Martin Hoenigl, Anna-Maria Eis-Huebinger, Clara Lehmann, Gerd Fätkenheuer, Jan-Christian Wasmuth, Rolf Kaiser, Sanjay R. Mehta, Joerg Janne Vehreschild, Antoine Chaillon

525  IMPACT OF TRANSMITTED RESISTANCE ON CLINICAL OUTCOMES IN THE VMVN TRIAL IN VIETNAM
Vu P. Thao, Cuong D. Do Duy, Thanh Thuy Pham Thi, Duong T. Hao, Bui T. That, Donn Colby, Todd Pollack, Thuy Le

526  PREVALENCE OF HIV-1 ANTIRETROVIRAL DRUG RESISTANCE IN FLORIDA, 2015-2016
Karalee Poschman, Emma C. Spencer

527  PRETREATMENT HIV DRUG RESISTANCE IN THE START STUDY USING NEXT GENERATION SEQUENCING
John D. Baxter, David Dunn, Rasmus L. Marvig, Marc Bennedbaek, Alessandro Cozzi-Lepri, Shweta Sharma, Anna Tostevin, Michael Koziel, Mark Gompels, Angie N. Pinto, Jens D. Lundgren, for the INSIGHT START Study Group

528  DECLINE IN CLINICALLY RELEVANT RESISTANCE TO FIRST LINE ARV REGIMENS IN SPAIN
Marta Alvarez, José Ángel Fernández-Caballero, Ana B. Perez, Nuria Espinosa, Silvia García-Bujalance, Maria Jesus Perez-Elias, Rafael Delgado, José A. Iribarren, Isabel Viciana, David Dalmau, Antonio Aguilar, Maria Masia, Victoria Hernandez, Federico Garcia, for the CoRIS Resistance Study Group

529  HIGH PREVALENCE OF NNRTI AND INI-RESISTANT POLYMORPHIC VIRUS IN PRIMARY HIV INFECTION

---

Poster P-12 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY
Poster Hall D  2:30 PM – 4:00 PM

530  HIV DRUG RESISTANCE AS A SIGNIFICANT DRIVER OF FIRST-LINE TREATMENT FAILURE IN UGANDA

531  EFFECT OF 12-WEEK RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON HIV RESISTANCE

532  POOLED WEEK 48 EFFICACY AND BASELINE RESISTANCE: B/F/TAF IN TREATMENT-NAIVE PATIENTS
Kirsten L. White, Rima Kulkarni, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Devi SenGupta, Hal Martin, Erin Quirk, Andrew Cheng
**533** HIV DRUG RESISTANCE WITH EARLY VS DELAYED ANTIRETROVIRAL TREATMENT (HPTN 052)

Phil J. Palumbo, Jessica M. Fogel, Ethan A. Wilson, Sarah E. Hudelson, Stephen Hart, Laura Hovind, Estelle Piwowar-Manning, Maria Papathanasopoulos, Mariza Morgado, Shanmugam Saravanan, Srikanth Tripathy, Ying Q. Chen, Myron S. Cohen, Susan H. Eshleman, for the HPTN 052 Study Team

**534** DEFINING CLINICALLY RELEVANT THRESHOLD FOR ULTRASENSITIVE HIV RESISTANCE TESTING

Seth C. Inzaule, Raph L. Hamers, Marc Nguerra-Julian, Maria Casadella, Mariona Parera, Bonaventura Clotet, Tobias F. Rinke de Wit, Roger Paredes, for the PanAfrican Studies to Evaluate Resistance (PASER)

**535** PROVIRAL DRUG RESISTANCE ACQUIRED DURING EARLY THERAPY PREDICTS VIROLOGICAL OUTCOME

Bindu P. Gopalan, Reena Dsouza, Karthika Arumugam, Niharika Rajnala, Udaykumar Ranga, Anita Shet

**Poster P-I3 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS!**

**Poster Hall D**

**2:30 PM – 4:00 PM**

**536** RARE HIV VARIANTS WITH LINKED DUAL-CLASS RESISTANCE ARE ASSOCIATED WITH ART FAILURE

Valerie F. Boltz, Wei Shao, Elias K. Halvas, James A. McIntyre, Robert T. Schooley, Shahin Lockman, Judith S. Currier, Fredrick Sawe, Evelyn Hogg, Michael D. Hughes, Mary F. Kearney, John M. Coffin, John W. Mellors

**537** ACCUMULATION OF HIV DRUG RESISTANCE ON FAILING FIRST-LINE ART IN LUSAKA, ZAMBIA

Parker Hudson, Lloyd Mulenga, Andrew Westfall, Ranjit Warrier, Aggrey Wmeemba, Michael Saag, Jeffrey S. Stringer, Joseph J. Eron, Benjamin H. Chi

**538** IMPACT OF FIRST-LINE ART CHOICE AND DURATION OF VIRAL FAILURE ON SECOND-LINE OPTIONS

Seema T. Meloni, Chika K. Onwuumah, Oche Agbaji, Beth Chaplin, David O. Olaleye, Rosemary Audu, Ezechi C. Oliver, Godwin Imade, Adesola Z. Musa, Georgina N. Odaibo, Holly Rawizza, Prosper Okonkwo, Emmanuel O. Idigbe, Phyllis J. Kanki, for the Nigeria Drug Resistance Research Team

**539** GENOTYPIC RESISTANCE PROFILES IN HIV-INFECTED CHILDREN WITH TREATMENT FAILURE

Birkneh T. Tadesse, Byron A. Foster, Deger Jerene, Kyle Cobarrubias, Bemuluyiga Baraki, Natalie Kinloch, Mark Brockman, Eyuas Makonnen, Eleni Akillil, Zabrina Brumme

**540** FIRST-LINE HIV TREATMENT FAILURE IN NON-B SUBTYPES AND RECOMBINANTS IN UGANDA

Art Poon, Emmanuel Ndashimuye, Mariano Avino, Richard Gibson, Fred Kyeyune, Immaculate Nankya, Miguel E. Quinones-Nateu, Eric Arts, for the Ugandan Drug Resistance Study

**541** HIGH LEVELS OF HIV DRUG RESISTANCE AMONG ADULTS FAILING SECOND-LINE ART IN NAMIBIA

Michael R. Jordan, Ndapewa Hamunime, Souleymane Sawadogo, Simon Agolory, Andreas Shiningawamwe, Taffa Negussie, Christa L. Fischer Walker, Elliot G. Raizes, Nicholas Mutenda, Christian Hunter, Natalie Dean, Kim Steegen, Vibha Kana, Chunfu Yang, Steven Y. Hong
Poster Sessions

Poster P-I4 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?
Poster Hall D 2:30 PM – 4:00 PM

542 LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA
Simani Gaseitsiwe, Sikhulle Moyo, Melissa Zahralban-Steele, Dorcas Maruapula, Baitshepi Mokaleng, Terence Mohammed, Shenaa El-Halabi, Elliot G. Raizes, Tendani Gaolathe, Shahin Lockman, Max Essex, Vlad Novitsky

543 HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION
Safia S. Kuriakose, Jomy M. George, Nicola Dee, Pam Stoll, Brian K. Agan, Robin L. Dewar, Alice K. Pau, Frank Maldarelli

544 UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE
Isabelle Malet, Frédéric Subra, Hervé Leh, Charlotte Charpentier, Gilles Collin, Diane Descamps, Eric Deprez, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis

545 PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS

546 INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1
Kristen Andreatta, Silvia Chang, Ross Martin, Madeleine Willkom, Kirsten L. White

547 157Q INTEGRASE POLYMORPHISM: IN VITRO PHENOTYPIC IMPACT AND IN VIVO VIROLOGIC OUTCOME
Charlotte Charpentier, Isabelle Malet, Audrey Rodallec, Laurence Bocket, Corinne Amiel, Laurence Morand-Joubert, Pantxika Bellecave, Thuy T. Nguyen, Anne Maillard, Brigitte Montes, Marie Leoz, Constance Delaugerre, Vincent Calvez, Anne-Geneviève Marcelin, Diane Descamps

548 CHARACTERIZATION OF THE DOLUTEGRAVIR MONOTHERAPY-ACQUIRED S230R RESISTANCE MUTATION
Hanh T. Pham, Ingeborg Wijting, Lydia Labrie, Said Hassounah, Ineke van der Ende, Bluma G. Brenner, Bonnie Spira, Charles Boucher, Bart Rijnders, Jeroen J. van Kampen, Thibault Mesplede, Mark A. Wainberg

549 IN VITRO SELECTED RESISTANCE TO NEW INTEGRASE INHIBITORS BY B & NON-B SUBTYPE VIRUSES
Bluma G. Brenner, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, Bonnie Spira, Thibault Mesplede, Jean-Pierre Routy

Poster P-J1 HIV DIAGNOSTICS
Poster Hall D 2:30 PM – 4:00 PM

563 FIELD EVALUATION OF A DUAL HIV/SYPHILIS TEST IN A COMMUNITY-BASED CLINIC, LOS ANGELES
Chrysovalantis Stafylis, Lauren J. Natoli, Katheryn Salow, Emma Davidson, Yancy Granados, Mark R. McGrath, Jeffrey D. Klausner
FIELD EVALUATION OF A DUAL ANTIGEN RAPID TEST FOR HIV/SYPHILIS INFECTION, VIETNAM
Keenan Withers, Minh D. Nguyen, Chrysovalantis Stafylis, Loc Pham, Le Minh Giang, Jeffrey D. Klausner

TIME FROM HIV INFECTION TO EARLIEST DETECTION FOR 4 FDA-APPROVED POINT-OF-CARE TESTS
Kevin P. Delaney, Lauren Violette, George A. Ure, Andy M. Cornelius-Hudson, Lisa Niemann, Laura Wesolowski, Pollyanna Chavez, Steven Ethridge, Vanessa McMahon, Hollie Clark, David A. Katz, Joanne Stekler

UTILITY OF POC XPERT HIV-1 TESTS FOR DETECTION-QUANTIFICATION OF COMPLEX RECOMBINANTS
Marina Rubio Garrido, Adolphe Ndarabu, Gabriel Reina, David Barquin, Silvia Carlos, Africa Holguin

RELATIVE SENSITIVITIES OF 4TH AND 5TH GEN COMBO HIV AG/AB, P24 AND VIRAL LOAD ASSAYS
Mars Stone, John Bainbridge, Ana M. Sanchez, Andrea Pappas, Mark M. Manak, Robert Coombs, M Kathleen Shriver, Paul Contestable, Sangeetha Vijaysri Nair, David H. Wilson, Martin Stengelin, Gary Murphy, Indira Hewlett, Thomas M. Denny, Michael P. Busch

INCREASING POSITIVITY FOR NON-PLASMA SAMPLES USING THE ABBOTT REALTIME HIV-1 ASSAY
Ming Chang, Junhui Wang, Jared Baeten, Andrew Mujugira, Robert Coombs

EVALUATION OF THE CDC/APHL HIV DIAGNOSTIC ALGORITHM WITH RECENTLY FDA-APPROVED ASSAYS

PERFORMANCE EVALUATION OF THE APTIMA HIV-1 QUANT ASSAY ON THE PANTHER SYSTEM
Silvina Masciotra, Wei Luo, Tara Smith, Vickie Sullivan, William Fowler, Steven Ethridge, Laura Wesolowski, Kevin P. Delaney, William M. Switzer, S. Michele Owen

EVALUATION OF THE APTIMA HIV-1 QUANT DX ASSAY FOR MONITORING OF HIV-1 VIRAL LOAD
Mónica García-Álvarez, Sagrario Zurita, Francisca Gutiérrez, Paula Aranguren, Samanta Aparicio, Rafael Delgado

CEPHEID XPERT HIV-1 VIRAL LOAD ASSAY PERFORMANCE EVALUATION
Laura Wesolowski, William Fowler, Wei Luo, Silvina Masciotra, Kevin P. Delaney, Emeka Oraka, Pollyanna Chavez, Steven Ethridge, William M. Switzer, S. Michele Owen

CELLULAR HIV-1 NUCLEIC ACID DETECTION IN CASES WITH UNDETECTABLE PLASMA VIRAL LOAD
Linda Jagodzinski, Holly R. Hack, Ying Liu, Jennifer Malia, Mark M. Manak, Nittaya Phanuphak, Mark de Souza, Eugène Kroon, Donn Colby, Nitiya Chomchey, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Sheila A. Peel, for the RV254/SEARCH010

QUANTIFICATION OF UNDETECTABLE PLASMA HIV RNA (≤20 COPIES/ML) WITH SINGLE-COPY ASSAY
Nicolas A. Margot, Dianna L. Koontz, Scott McCallister, John W. Mellors, Christian Callebaut
575  **REPLICATE APTIMA VL TESTING DETECTS RESIDUAL VIREMIA IN MOST ART-TREATED ADULTS**  
Sonia Bakkour, Sheila M. Keating, Xutao Deng, Mars Stone, Andrew Worlock, Steven G. Deeks, Peter Bacchetti, Melanie Dimapazos, Joseph Lau, Leilani Montalvo, Scott Hauenstein, Douglas D. Richman, **Michael P. Busch**, for the Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group

---

**Poster Sessions - Tuesday**

**Poster P-K04 HCV CASCADE**
**Poster Hall D**  
2:30 PM – 4:00 PM

594  **ACTIVE-C: A COMMUNITY-BASED PROGRAM TO TEST AND CURE HEPATITIS C IN ALABAMA**  

595  **MASSACHUSETTS HEPATITIS C CARE CASCADE, 2007-2015**  
**Quynh Vo**, Shauna Onofrey, Daniel Church, Kevin Cranston, Alfred DeMaria, Monina Klevens

596  **THE HEPATITIS C CONTINUUM OF CARE AMONG HIV INFECTED INDIVIDUALS IN AUSTRIA**  
Michaela Rappold, Armin Rieger, Martin Gisinger, Mario Sarcelatti, Brigitte Schmied, Maria Geit, Alexander Zoufaly, Bernhard Haas, Ninon Taylor, Manfred Kanatschnig, Laura Simula, Sara Krüger, Bruno Ledergerber, **Robert Zangerle**, for the AHIVCOS Group

597  **THE HCV DIAGNOSIS AND TREATMENT UPTAKE AMONG PATIENTS IN HIV CARE**  

598  **HEPATITIS C CARE CASCADE IN JAIL: IMPLICATIONS FOR HARD-TO-REACH POPULATIONS**  
Caroline Abe, Esmaeil Porsa, **Ank E. Nijhawan**

599  **OPERATIONALIZING ELIMINATION: CURING HEPATITIS C IN THE PATIENT-CENTERED MEDICAL HOME**  
Sarah Rojas, Lisa Asmus, Christopher Cavanaugh, Maureen Khasira, Stephanie Constantine, Christian B. Ramers

---

**Poster P-K05 HCV CASCADE: TREATMENT AND BEYOND**
**Poster Hall D**  
2:30 PM – 4:00 PM

600  **INCREASING INCIDENCE OF DENIAL OF DAA THERAPY FOR CHRONIC HCV BY INSURANCE TYPE**  
Charitha Gowda, Stephen Lott, Matthew Grigorian, Dena M. Carbonari, M. Elle Saine, Stacey Trooskin, Jason A. Roy, **Jay Kostman**, Paul N. Urick, Vincent Lo Re

601  **HEPATITIS C TREATMENT UPTAKE AMONG INSURED HIV/HCV-COINFECTED PATIENTS**  
Jennifer O. Lam, Leo Hurley, Scott Chamberland, Jamila Champs, Laura C. Gittleman, Daniel G. Korn, Jennifer B. Lai, Charles P. Quesenberry, Joanna Ready, Varun Saxena, Suk Seo, David J. Witt, Michael J. Silverberg, Julia L. Marcus
602 TREATMENT OF CHRONIC HEPATITIS C GT1,2,4 IN AFRICA: FINAL RESULTS OF ANRS TACTRIAL
Karine Lacombe, Raoul Moh, Corine Chazzallon, Babacar Sylla, Maud Lemoine, Charles Kounafack, Eric Tchoumi Leuwat, Magloire Biwole Sida, Fatoumata Fadiga, Michèle Tagni-Sartre, Viviane Marie Pierre Cisse, Lawson-Ananissoh Latè Mawuli, Pierre-Marie Girard, Alain Attia, for the ANRS12311 TAC TRIAL

603 DAA IMPLEMENTATION RATE IN HIV/HCV PATIENTS IN SPAIN: 2 YEARS OF UNRESTRICTED ACCESS

604 MULTICENTER REGISTRY IN HIV/HCV CO-INFECTED PATIENTS INITIATING LEDIPASVIR/SOFOSBUVIR
Kristen M. Marks, Nwora L. Okeke, Lawrence Park, Cody A. Chastain, Kimberly Workowski, Chris Woods, Kenneth E. Sherman, Gregory K. Robbins, Stefan Mauss, Jürgen K. Rockstroh, Susanna Naggie

605 UNREPORTED ALCOHOL USE WAS COMMON BUT DID NOT IMPACT HCV CURE IN HIV-INFECTED PWID
Risha Irvin, Geetanjali Chander, Kathleen Ward, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz, Kayla Herne, Lilian Arteaga, David L. Thomas, Shruti H. Mehta, Mark Sulkowski

606 HIGH EFFICACY OF 8 WEEKS OF LEDIPASVIR/SOFOSBUVIR IN AFRICAN AMERICANS WITH HCV
Whitney Nichols, Alexander Geboy, Cathy Gurgol, Chinyere Ukaegbu, Nicole Brown, Dawn Fishbein

607 HIV PREDICTS FAILURE OF LDV/SOF IN HCV G1 TREATMENT-NAÏVE NON-CIRRHOTIC PATIENTS
Juan Berenguer, José L. Calleja, Marisa Montes, Ángela Gil-Martin, Ana Moreno, Rafael Bañares, Teresa Aldamíz-Echevarría, Agustin Albillos, Maria J. Téllez, Antonio Olveira, Lourdes Domínguez-Domínguez, Javier Garcia-Samaniego, Inma Jarrín, María J. Calvo, Juan González-García

608 PREDICTIVE FACTORS OF INTERFERON-FREE THERAPY FAILURE IN HIV/HCV COINFECTION
Lourdes Domínguez-Domínguez, Maria Lagarde, Otilia Bisbal, Mariano Matarranz, Carlos Lumbrales, Ásunción Hernando, Rafael Rubio, Federico Pulido

609 PREDICTORS OF LACK OF HEPATITIS C ERADICATION USING DIRECT-ACTING ANTIVIRALS
Edward R. Cachay, Alvaro Mena, Laura Benitez, Ivana Maida, Carmen de Mendoza Fernández, Angeles Castro, Elena Dore, Craig Ballard, Vincent Soriano, W. C. Mathews, for the HCV-HIV Transatlantic Research Network (HCV-TREN)

610 DAA TREATMENT RESPONSE AMONG HIV/HCV-COINFECTED PATIENTS IN THE CNICS COHORT
611 REDUCTIONS IN HEALTHCARE SERVICE USAGE FOLLOWING DIRECT ACTING ANTIVIRAL THERAPY
Sahar Saeed, Erica E. Moodie, Mark Hull, Sharon Walmsley, Curtis Cooper, Alexander Wong, Michael John Gill, Valerie Martel-Laferriere, Erin C. Strumpf, Marina Klein, for the Canadian HIV–HCV Co-Infection Cohort Study

612 HIGH INCIDENCE OF HCV REINFECTION IN MSM IN THE DAA ERA
Patrick Ingiliz, Malte Wehmeyer, Stefan Christensen, Thomas Lutz, Knud Schewe, Axel Baumgarten, Dietrich Hueppe, Karl-Georg Simon, Jürgen K. Rockstroh, Christoph Boesecke, Stefan Mauss

613 PREVALENCE OF ACTIVE HEPATITIS B AMONG NEW YORK CITY MSM, PreP AND PEP, 2016-2017
Tarek Mikati, Kelly Jamison, Christine M. Borges, Demetra C. Daskalakis

614 PREVALENCE AND PREDICTORS OF HEP B INFECTION AND HEP B/HIV CO-INFECTION, ZAMBIA 2016
Karampreet Sachathpe, Kumbusto Dzekedeke, Lloyd Mulenga, Nichimunya Nkombo, Webster Kasongo, Andrea Low, Suzue Saito, Stanley Kamocha, Kathy Hageman, Gina Mulundu, Eysu Teshale

615 NEAR FULL LENGTH GENOMES OF CHRONIC AND OCCULT HBV FROM HIV PATIENTS IN BOTSWANA

616 IN SILICO ANALYSIS OF OCCULT HBV ASSOCIATED MUTATIONS IN BOTSWANA

617 HIGHER RATES OF HBSAG CLEARANCE WITH TDF-CONTAINING THERAPY IN HBV/HIV COINFECTION
Pierre Gantner, Laurent Cotte, Clotide Allavena, Firouze Bani-Sadr, Thomas Huleux, Claudine Duvivier, Marc-Antoine Valantin, Christine Jacomet, Veronique Joly, Antoine Chéret, Pascal Puglièse, Pierre Delobel, André Cabié, David Rey, for the dat’aids

618 HIGH HBV AND HIV SUPPRESSION WITH TREATMENT OF HIV/ HBV COINFECTION IN B/F/TAF STUDIES

619 PROGRESSIVE HBSAG LOSS IN HIV-HBV COINFECTED INDIVIDUALS ON TDF-INCLUSIVE CART
Jennifer Audsley, Anchalee Avihingsanon, Margaret Littlejohn, Scott Bowden, Gail Matthews, Christopher K. Fairley, Sharon R. Lewin, Joseph Sasadeusz
620  DETERMINANTS OF LIVER COMPLICATIONS AMONG HIV/HEPATITIS B-COINFECTED PATIENTS

Vincent Lo Re, Craig W. Newcomb, Dena M. Carbonari, Jason A. Roy, Mari Kitahata, Joseph Lim, Michael J. Silverberg, Angel Mayor, Michael A. Horberg, Edward R. Cachay, Mark Hull, Richard D. Moore, Marina Klein, H. Nina Kim, for the North American AIDS Cohort Collaboration on Research and Design of iDEA

621  HIGH PREVALENCE OF ADVANCED LIVER DISEASE AMONG AN HIV/HBV REAL-WORLD COHORT

Mamta K. Jain, Mandana Khalili, Raymond T. Chung, Kranthi Vysyaraju, David Wong, Mauricio Lisker-Melman, Mark Sulkowski, Marc Ghany, Richard K. Sterling

622  HEPATITIS DELTA INFECTION IN PATIENTS WITH HIV/HBV COINFECTION

Giovanni B. Gaeta, Milensu Shanyinde, Giuseppina Brancaccio, Massimo Puoti, Antonella D’Arminio Monforte, Andrea De Luca, Alessandra Vergori, Stefano Rusconi, Antonio Mazzarelli, Antonella Castagna, Andrea Antinori, Alessandro Cozzi-Lepri

623  GAIN OF POSITIVE CHARGES IN HBSAG C-TERMINUS CORRELATES WITH HBV-INDUCED LIVER CANCER

Romina Salpini, Luca Carioti, Marianna Aragri, Domenico Di Carlo, Luna Colagrossi, Giuseppina Cappiello, Pascale Trimoulet, Herve J. Fleury, Simona Francioso, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Francesca Ceccherini Silberstein, Carlo F. Perno, Valentina Svicher

624  SURVIVAL AFTER END-STAGE LIVER DISEASE IN ADULTS WITH HIV: DATA FROM THE NA-ACCORD


Poster P-K10 STEATOSIS AND CIRRHOSIS
Poster Hall D 2:30 PM – 4:00 PM

641  INCREASED RATES OF HEPATIC STEATOSIS IN YOUNG ADULTS WITH LIFE-LONG HIV INFECTION

Julia A. Aepfelbacher, Julia Purdy, Aviva Mattingly, Kirsten Zambell, Chloe S. Chaudhury, Colleen Hadigan

642  CARDIOMETABOLIC RISK PROFILES IN HIV AND NONALCOHOLIC FATTY LIVER

Alyson Kaplan, Donald Chute, Tracey G. Simon, Samson Okello, Hui Zheng, Raymond T. Chung, Kathleen E. Corey

643  UNANTICIPATED INCREASES IN FATTY LIVER IN HIV NAFLD PATIENTS WITH EPSERENONE

Chloe S. Chaudhury, Julia Purdy, Chia-Ying Liu, Caryn G. Morse, Takara L. Stanley, David E. Kleiner, Colleen Hadigan

644  FAILURE RATE OF ULTRASOUND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA IN HIV+ PATIENTS

Nicolás Merchante, Esperanza Merino, Francisco Rodriguez-Arrondo, Boris Revollo, Sofia Ibarra, Maria J. Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Marcial Delgado-Fernández, Francisco Téllez, Maria J. Rios-Villegas, Jose J. Portu, Juan A. Pineda, for the GEHEP-002 Study Group
645 HIV+ PERSONS WITH CIRRHOSIS RECEIVE INADEQUATE SCREENING FOR ESOPHAGEAL VARICES
Chiara Saroli Palumbo, Amine Benmassaoud, Thomas Pembrooke, Bertrand Lebouche, Philip Wong, Marc Deschenes, Marina Klein, Peter Ghali, Giada Sebastiani

646 MEDIUM-TERM EFFECTS OF DAA THERAPY ON HVPG IN PATIENTS WITH HCV-ASSOCIATED CIRRHOSIS
Cristina Diez, Juan Berenguer, Luis Ibáñez, Elba L. Herrera, Leire Pérez Latorre, María V. Catalina, Víctor Hontanon, Diego Rincón, Teresa Aldámiriz-Echevarría, Javier Martínez, José M. Bellón, José L. Calleja, Agustín Albillos, Juan González-García, Rafael Bañares

647 TRANSPLANT FREE SURVIVAL IN HIV ASSOCIATED NON-CIRRHOTIC PORTAL HYPERTENSION
Kathryn Childs, Lauren Hookham, Corinna Psomadakis, Rosa Miquel, Ruth Byrne, Mary Cannon, Kosh Agarwal, Mark Nelson, Chris Taylor, Abid Suddle

648 MR ELASTOGRAPHY DETECTS HIGHER LIVER FIBROSIS IN UNCONTROLLED HIV INFECTION

657 SUPPRESSIVE ART ASSOCIATED WITH EFFECTIVE TREATMENT OF CERVICAL PRECANCER
Christina Carlander, Philippe Wagner, Astrid van Beirs, Aylin Yilmaz, Kristina Elfgren, Joakim Dillner, Anders Sönnerborg, Pär Sparén

658LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN

659 GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEIP IN ART-SUPPRESSED HIV+HPV+
Emmanouil Papasavvas, Andrew V. Kossenkov, Livio Azzone, Nicola M. Zetola, Agneszka Mackiewicz, Brian Ross, Matthew Fair, Surya Vadrevu, Doreen Ramogola-Masire, Cindy Finnhaber, Luis Montaner

660 IMPACT OF SINGLE-DOSE NANOVALENT VACCINE FOR HIV-HPV COINFECTION IN SOUTH AFRICA
Nicholas Tan, Monisha Sharma, Ruanne V. Barnabas

661 COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN WOMEN WITH HIV IN SOUTH AFRICA
Nicole G. Campos, Naomi Lince-Deroche, Carla J. Chibwesha, Cindy Finnhaber, Pamela Michelow, Gesine Meyer-Rath, Lise Jamieson, Suzette Jordaan, Vivien Tsu, Jose Jeronimo, Jane Kim

662 CLEARANCE, PERSISTANCE, AND NEW HPV INFECTIONS IN A MEXICAN MSM - HIV COHORT
Ofelia M. Rosales Del Real, Rocio Mendez Martinez, Yanink Caro-Vega, Norma E. Rivera-Martinez, Alejandro M. García-Carrancá, Juan Sierra-Madero, Brenda Crabtree-Ramírez
663 AGE-SPECIFIC PREVALENCE OF VACCINE-PREVENTABLE ANAL HPV INFECTION IN HIV-INFECTED MSM
Alessandra Latini, Maria Gabriella Dona, Manuela Colafigli, Mauro Zaccarelli, Maria Benevolo, Francesca Rollo, Domenico Moretto, Amalia Giglio, Antonio Cristaudo, Massimo Giuliani

664 ABLATION OUTCOMES FOR HIV INFECTED AND UNINFECTED PATIENTS WITH ANAL DYSPLASIA
Keith M. Sigel, Yuxin Liu, Michael Gaisa

665 PATTERNS OF REPEATED ANAL CYTOLOGY TESTING AMONG HIV-POSITIVE AND HIV-NEGATIVE MSM
Hilary Robbins, Dorothy J. Wiley, Ken Ho, Michael Plankey, Susheel Reddy, Nancy Joste, Teresa Darragh, Elizabeth Breen, Stephen Young, Gypsyamber D’Souza

666 EFFECTIVENESS OF A SCREENING PROGRAM FOR ANAL CANCER PREVENTION IN HIV-INF. PATIENTS
Boris Revollo, Sebastia Videla, Arelyl Ornelas, Roger Paredes, Josep Coll, Marta Piñol, Francesc García-Cuyás, Antoni Tarrats, David Parés, Ross Cranston, Bonaventura Clotet, Guillemer Sirera

Poster P-M4 PREDICTING CARDIOVASCULAR DISEASE RISK AND STATIN USE
Poster Hall D 2:30 PM – 4:00 PM

689 EFFECTS OF PITAVASTATIN ON ATHEROSCLEROTIC-ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV
Angsana Phuphuakrat, Artit Wongs,a, Sirawat Sriratapamik, Boonrat Tassaneenrithep, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph

690 STATIN COVERAGE IN AN HIV COHORT: COMPARISON OF ATP III, ACC/AHA, AND NLA GUIDELINES
Matthew E. Levy, Alan Greenberg, Manya Magnus, Najy Younes, Amanda D. Castel, for the DC Cohort Executive Committee

691 HIV+ MEN MATCHED BY AGE AND FRS WITH CONTROLS HAVE MORE CARDIOVASCULAR EVENTS
Stefan Esser, Marina Arendt, Christina Schulze, Volker Holzendorf, Norbert H. Brockmeyer, Karl-Heinz Jockey, Raimund Erbel, Nico Reinsch, for the HIV HEART Study group and Heinz Nixdorf Recall Investigative group

Poster P-M5 REDUCING CARDIOVASCULAR DISEASE RISK
Poster Hall D 2:30 PM – 4:00 PM

692 COMPARING STRATEGIES FOR REDUCING MYOCARDIAL INFARCTION RATES IN HIV PATIENTS
Priscilla Hsue, Grace A. McComsey, Calvin Cohen, Alejandro Sola, Anne C. Beaubrun

693 ZINC TO REDUCE MORTALITY AND CVD RISK AND HIV DISEASE PROGRESSION IN RUSSIAN DRINKERS
Matthew Freiberg, Natalia Gnatenko, Debbie Cheng, E Blokhina, Sharon Coleman, Margaret F. Doyle, Carly Bridden, Kaku So-Armah, Sally Bendiks, Russell Tracy, Kendall J. Bryant, Evgeny Krupitsky, Jeffrey H. Samet
**Poster P-M6 HEART FAILURE, VENTRICULAR FUNCTION, AND PERIPHERAL ARTERY DISEASE**

**Poster Hall D**

**2:30 PM – 4:00 PM**

694 MYOCARDIAL STEATOSIS IN RELATION TO CARDIAC DYSFUNCTION AMONG WOMEN LIVING WITH HIV

Mabel Toribio, Tomas G. Neilan, Lauren Stone, Adam Rokicki, Corinne Rivard, Jacob C. Calkins, Mary O’Hara, Magid Awadalla, Virginia Triant, Lidia S. Szczepaniak, Markella V. Zanni

695 SUB-CLINICAL CARDIAC SYSTOLIC DYSFUNCTION AMONG WOMEN LIVING WITH HIV

Magid Awadalla, Markella V. Zanni, Mabel Toribio, Lauren Stone, Adam Rokicki, Corinne Rivard, Virginia Triant, Tomas G. Neilan

696 SYSTOLIC HEART FAILURE AND HEART FAILURE OUTCOMES AMONG PERSONS LIVING WITH HIV

Raza M. Alvi, Maryam Afshar, Noor Tariq, Jaime Gerber, Virginia Triant, Markella V. Zanni, Tomas G. Neilan

697 SLEEP APNEA AND HEART FAILURE WITH REDUCED EJECTION FRACTION AMONG HIV PATIENTS

Raza M. Alvi, Magid Awadalla, Atul Malhotra, Noor Tariq, Adam Rokicki, Virginia Triant, Markella V. Zanni, Tomas G. Neilan

698 CARDIAC VENTRICULAR DYSFUNCTION IN YOUNG VERTICALLY INFECTED HIV PATIENTS

Lidia Capotosto, Eugenio Nelson Cavallari, Giuseppina Cusano, Ivano Mezzaroma, Giancarlo Ceccarelli, Luigi Celani, Camilla Ajassa, Gabriella d’Ettorre, Vincenzo Vullo, Antonio Vitarelli

699 ACUTE HIV INFECTION RESULTS IN SUBCLINICAL AND REVERSIBLE INFLAMMATORY CARDIOMYOPATHY

Christopher Schuster, Florian Mayer, Corinna Wohlfahrt, Rodrig Marculescu, Michael Skoll, Robert Strassl, Maximilian Aichelburg, Noemi Pavo, Theresia Popow-Kraup, Martin Hülsmann, Armin Rieger, Georg Goliasch

700 CORONARY WALL THICKENING AND ASSOCIATION WITH MYOCARDIAL DIASTOLIC FUNCTION IN HIV

Julia Purdy, Khaled Z. Abd-Elmoniem, Hwaida Hannoush, Vandana Sachdev, Colleen Hadigan, Ahmed M. Gharib

701 CONTRIBUTION OF HIV, HCV, AND VASCULAR RISK FACTORS TO PERIPHERAL ARTERIAL DISEASE

Emily Cedarbaum, Yifei Ma, Rebecca Scherzer, Jennifer Price, Michael Plankey, Margaret Fischl, Eric C. Seaberg, Mardge H. Cohen, Marcos Bamman, Jason Lazar, Adaora Adimora, Michael T. Yin, Phyllis Tien

702 CARDIAC ABNORMALITIES IN PERINATALLY INFECTED HIV+ SOUTH AFRICAN ADOLESCENTS ON ART

Sana Mahtab, John Lawrenson, Norme J. Luff, Nana Akua Asafu-Agyei, Liesl Zülke, Landon Myer, Heather Zar
Poster P-N02 RENAL DISEASE
Poster Hall D  2:30 PM – 4:00 PM

728  PEOPLE LIVING WITH HIV IN FRANCE HAVE DELAYED ACCESS TO KIDNEY TRANSPLANTATION
Jérôme Tourret, Sophie Abgrall, Mathilde Lassalle, Sophie Grabar, Corinne Isnard-Bagnis, Gilbert Deray, Benoît Barrou, Dominique Costagliola, Cécile Couchoud, Marguerite Guiguet, Sophie Tezenas du Moncel

729  CHRONIC KIDNEY DISEASE RISK FACTORS AND URINE KIDNEY INJURY MARKERS IN HIV+ PERSONS
Anthony Muiru, Michael Shlipak, Rebecca Scherzer, William Zhang, Simon Ascher, Chirag Parikh, Carl Grunfeld, Frank J. Palella, Ruibin Wang, Phyllis Tien, Qibin Qi, Michelle Estrella

730  VALIDATION OF A CHRONIC KIDNEY DISEASE RISK SCORE IN HIV+ PATIENTS IN THE US
Anthony Mills, Kathy L. Schulman, Jennifer Fusco, Ricky Hsu, Andrew Beyer, Girish Prajapati, Karam Mounzer, Gregory Fusco

731  CHRONIC KIDNEY DISEASE IN HIV POPULATIONS OF AFRICAN DESCENT IN THE UK
Sophie Jose, Lisa Hamzah, Rachael Jones, Deborah Williams, Alan Winston, Fiona Burns, Caroline Sabin, Frank Post, for the UK Collaborative HIV Cohort Study Steering Committee

732  SAFETY AND EFFICACY OF E/C/F/TAF IN HIV-INFECTED ADULTS ON CHRONIC HEMODIALYSIS

Poster P-N05 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Poster Hall D  2:30 PM – 4:00 PM

745  PROGRESSION OF QUANTITATIVE EMPHYSEMA IN A HIV-INFECTED SPANISH COHORT
Francisco Fanjul, Gloria Samperiz, Helem Haydee Vilchez, María Leyes, Antoni Campins, Maria Angeles Ribas, María Peñaranda, Javier Murillas, Luisa Martin, Angel Ríos, Meritxell Lopez Zamora, Jose Luis Valera, Melchor Riera

746  SMOKING AND ACCELERATED LUNG FUNCTION DECLINE IN THE START PULMONARY SUBSTUDY
David MacDonald, Gary Collins, Nicholas Ingraham, Anne Melzer, Kristina Crothers, Anchalee Avihingsanon, Henry Mugerwa, Matti Ristola, Jonathan Shuter, Ken Kunisaki

747  MARIJUANA SMOKING IMPACTS PULMONARY DISEASE IN HIV-INFECTED MEN
David Lorenz, Dana H. Gabuzda

748  HIV INFECTION, SYSTEMIC INFLAMMATION AND LUNG FUNCTION IN RURAL UGANDA
Crystal North, Bernard Kakuhikire, Alexander C. Tsai, David C. Christiani, Douglas Kwon, Samson Okello, Mark J. Siedner, Russell Tracy
749 DIFFERENCES IN THE ADENOSINE SIGNALING PATHWAY AMONG HIV+ INDIVIDUALS WITH COPD
Kiran Bandi, Seyed M. Nouraie, Edwin Jackson, Peter Nam, Delbert Gillespie, Cynthia Klamar-Blain, Cathy Kessinger, Sharon Riddler, Alison Morris, Bernard J. Macatangay

750 PREDICTORS OF AIRFLOW OBSTRUCTION IN AN HIV TERTIARY CARE CLINIC
Cecilia Costiniuk, Roy Nitulescu, Christina de Castro, Natale Wasef, Syim Salahuddin, Jean-Pierre Routy, Bertrand Lebouché, Joseph Cox, Benjamin M. Smith, Jason Szabo, Alexandra de Pokomandy, Chris Tsoukas, Mohammad-Ali Jenabian, Jean Bourbeau, Marina Klein

751 HIV IS INDEPENDENTLY ASSOCIATED WITH HIGHER ALPHA-1 ANITTRYPSIN
Rebekka F. Thudium, Jens D. Lundgren, Børge Nordestgaard, Jan Gerstoft, Susanne D. Nielsen, Andreas Ronit

Poster P-N06 DEPRESSION
Poster Hall D 2:30 PM – 4:00 PM

752 DEPRESSION IS INDEPENDENTLY ASSOCIATED WITH NEAR DOUBLING OF HIV VIRAL LOAD
Susan M. Meffert, Thomas C. Neylan, Charles E. McCulloch, Jonah Jonath Maswai, John Owuoth, Francis Kiweewa, Lucas Maganga, Victor Valcour, Julie Ake

753 DEPRESSION IS ASSOCIATED WITH MISSED VISITS, EMERGENCY ROOM UTILIZATION, AND DRUG USE
Mamta K. Jain, Yordanos Tiruneh, Piper Duarte, Amneris Luque, Ank E. Nijhawan

754 DEPRESSIVE SYMPTOMS AND HIV INFECTION IN AN AGING UGANDAN COHORT
Jennifer Manne-Goehler, Bernard Kakuhikire, Alexander C. Tsai, Till Bärnighausen, Samson Okello, Mark J. Siedner

Poster P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS
Poster Hall D 2:30 PM – 4:00 PM

763 NOVEL BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS DURING ART-MEDIATED VIRAL SUPPRESSION
Martin Hoenigl, Carlee Moser, Nicholas Funderburg, Ronald Bosch, Amy Kantor, Yonglong Zhang, Jesper Eugen-Olsen, Malcolm Finkelman, Alan Landay, Michael M. Lederman, Sara Gianella, for the ACTG NWCS 329 study team

764 INFLAMMATION AND IMMUNE ACTIVATION MARKERS ASSOCIATED WITH NON-AIDS CANCERS IN HIV
Muhammad Siddiqui, Elizabeth Breen, Jay Bream, Yue Chen, Dana H. Gabuzda, Eric C. Seaberg

765 SERUM ALBUMIN AS A LONG TERM PREDICTOR OF SERIOUS NON-AIDS EVENTS
Andreas Ronit, Camilla Ingrid Hatleberg, Lene Ryom, Fabrice Bonnet, Wafa M. El-Sadr, Peter Reiss, Rainer Weber, Christian Pradier, Stephane de Wit, Matthew Law, Antonella D'Arminio Monforte, Jens D. Lundgren, Andrew N. Phillips, Caroline Sabin
Poster Sessions

783 DIAGNOSTIC UTILITY OF MULTIPLEX PCR IN AN HIV-INFECTED POPULATION WITH MENINGITIS
Sarah Bridge, Kathy Hoppler Hullsiek, Richard Kwizera, Edwin Nuwagira, Anna Stadelman, Tadeo K. Kiiza, Liberica Ndyatunga, Kenneth Ssebambulidde, James Mwesigye, Edward Mpoza, Mahsa Abassi, David Meya, Conrad Muzoora, David R. Boulware, Joshua Rhein

784 CRAG STATUS AND EFFECT ON BENEFITS FROM ENHANCED PROPHYLAXIS IN THE REALITY TRIAL
Sarah Pett, Lewis Haddow, Ruth Nhema, Moira J. Spyer, Laura Benjamin, Grace Najiuka, Ibrahim Daud, Jay Berkley, Juliet Kitabalgwa, James G. Hakim, Rob Heyderman, Sarah Walker, Diana Gibb, for the REALITY trial team

785 EVALUATION OF A CRYPTOCOCCAL SCREENING AND TREATMENT PROGRAM IN HIV CLINICS IN UGANDA
Elizabeth Nalintya, David Meya, Sarah Lofgren, Kathy Hoppler Hullsiek, David R. Boulware, Radha Rajasingham

786 CLINIC-BASED LATERAL FLOW CRYPTOCOCCAL ANTIGEN TESTING AT HIV DIAGNOSIS, SOUTH AFRICA
Paul K. Drain, Ting Hong, Hilary Thulare, Mahomed-Yunas Moosa, Connor L. Celum

787 SYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA PRESENTING AS EARLY CRYPTOCOCCAL MENINGITIS
Kenneth Ssebambulidde, Mahsa Abassi, Joshua Rhein, Ananta Bangdiwala, Darlisha A. Williams, Edward Mpoza, Lillian Tugume, Richard Kwizera, Abdu Musubire, Fiona Cresswell, Sarah Lofgren, Kathy Hoppler Hullsiek, David R. Boulware, David Meya, for the ASTRO-CM

788 POSTMORTEM CRYPTOCOCCAL MENINGITIS FOLLOWING TREATMENT FOR CRYPTOCOCCAL ANTIGENAEMIA
Rachel M. Wake, Tanvicer Omar, Aaron S. Karat, Joseph N. Jarvis, Nelesh P. Govender, Thomas S. Harrison

789 DECLINING INCIDENCE OF HIV-ASSOCIATED CRYPTOCOCCOSIS IN SOUTH AFRICA, 2005-2015
Nelesh P. Govender, Cheryl Cohen, Phelly Matlapeng, Penny Crowther-Gibson, Susan Meiring, Alan Karstaaedt, Halima Dawood, Kerrigan McCarthy, Graeme Meintjes, Vanessa Quan, for the GERMS-SA surveillance group

790 ETIOLOGIES OF SYMPTOMATIC RECURRENCE OF HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS
Emily Evans, Kathy Hoppler Hullsiek, Edwin Nuwagira, Edward Mpoza, Kenneth Ssebambulidde, Lillian Tugume, Bozena M. Morawski, Sarah Lofgren, Mahsa Abassi, Darlisha A. Williams, Conrad Muzoora, David Meya, David R. Boulware, Joshua Rhein

791 HIGH MORTALITY ASSOCIATED WITH UNMASKING CRYPTOCOCCAL MENINGITIS
Joshua Rhein, Kathy Hoppler Hullsiek, Nathan C. Bahr, Lillian Tugume, Edwin Nuwagira, Kenneth Ssebambulidde, Reuben Kiggundu, Emily Evans, Edward Mpoza, Darlisha A. Williams, Mahsa Abassi, Abdu Musubire, Conrad Muzoora, David Meya, David R. Boulware
Poster Sessions

792 CUSTOMIZED AMPHOTERICIN DURATION FOR CRYPTOCOCCAL MENINGITIS BASED ON FUNGAL BURDEN
Darlisha A. Williams, Kathy Huppler Hullsiek, Andrew Akampurira, Tonny Luggya, Edwin Nuwagira, Lillian Tugume, Edward Mpoza, Reuben Kiggundu, Kenneth Ssebambulidde, Mahsa Abassi, Conrad Muzoora, David Meya, David R. Boulware, Joshua Rhein, for the ASTRO-CM Trial

793 PCR AND URINE ANTIGEN FOR DIAGNOSIS OF DISSEMINATED HISTOPLASMOSIS IN AIDS PATIENTS

794 ANTIFUNGAL DRUG SUSCEPTIBILITY OF TALAROMYCES MARNEFFEI CLINICAL ISOLATES, GUANGDONG
Linghua Li, Wanshan Chen, Fengyu Hu, Xiejie Chen, Weiping Cai, Xiaoping Tang

795 RISK FACTORS FOR IRIS IN HIV-ASSOCIATED PNEUMOCYSTIS PNEUMONIA AFTER ART INITIATION
Gerrit Kann, Hannah Bielke, Philipp De Leuw, Gundolf Schuettfort, Annette E. Haberl, Junaid Owasil, Claus P. Kuepper-Tetzel, Nils Wetzstein, Imke Wieters, Johanna Kessel, Markus Bickel, Pavel Khaykin, Christoph Stephan

Poster P-P3 INFANT HIV INFECTION AND DIAGNOSIS IN THE ERA OF OPTION B+

Poster Hall D
2:30 PM – 4:00 PM

821 MATERNAL VIRAL LOAD SUPPRESSION AND VERTICAL TRANSMISSION IN MALAWI’S PMTCT PROGRAM
Ernest Nkhoma, Monique van Lettow, Beth A. Tippett Barr, Joep J. van Oosterhout, Eunice Mwandira, Lloyd Chilikutali, Annie Kanyemba, Zinenani T. Truwah, Andrew F. Auld, Megan Landes

822 INFANT HIV-FREE SURVIVAL IN THE ERA OF “OPTION B+” SERVICES IN RURAL ZAMBIA
Benjamin H. Chi, Wilbroad Mutale, Jennifer Winston, Winifreda Phiri, Joan T. Price, Charles Y. Msiska, Helen Ayles, Jeffrey S. Stringer

823 HIV-POSITIVITY AMONG HIV-EXPOSED INFANTS IN LESOTHO IN THE ERA OF OPTION B+
Tsigereda G. Belachew, Kieran Hartsough, Andrea Schaaf, Mahlompho Ntholeng, Tiffany G. Harris

824 HIGH HIV BURDEN AMONG CHILDREN IN LESOTHO: FINDINGS FROM A POPULATION BASED SURVEY
Koen Frederix, Stefania Davia, Keletso Ntene-Sealiete, Stephen M. Arpadi, Stephen McCracken, Kyaw Thin, Hetal Patel, Mosilinyane Letsie, Andrea Low

825 IMPACT OF BIRTH TESTING ON EARLY INFANT DIAGNOSIS IN KWAZULU-NATAL, SOUTH AFRICA
Shayla Smith, Louise Kuhn, Moherndran Archary, Pravi Moodley, Phillip LaRussa, Kerusha Govender
AGE AT HIV DIAGNOSIS WITHIN SOUTH AFRICA’S EARLY INFANT DIAGNOSIS PROGRAM, 2010-2015
Ahmad Haeri Mazanderani, William B. MacLeod, Jacob Bor, Gayle G. Sherman

MATERNAL ANTI-HIV-1 NAB RESPONSE ASSOCIATES WITH TRANSMISSION AND INFANT MORBIDITY
Melissa Ghulam-Smith, Alex Olson, Laura F. White, Charles Chasela, Sascha Ellington, Athena Kourtis, Denise Jamieson, Gerald Tegha, Charles van der Horst, Manish Sagar

ROLE OF REGULATORY T CELLS IN MOTHER TO CHILD TRANSMISSION OF HIV
Peter A. Kessler, Surinder P. Gill, Chris C. Ibegbu

VIROLOGIC RESPONSE TO EFAVIRENZ-BASED FIRST-LINE IN CHILDREN BY PMTCT EXPOSURE STATUS
Lee Fairlie, Patience Nyakato, Mary-Ann Davies, Karl Technau, Geoffrey Fatti, Helena Rabie, Frank Tanser, Andrew Boulle, Robin Wood, Brian Eley, Shobna Savry, Janet Giddy, Nosisa Sipambo, Andreas D. Haas, Louise Kuhn, for the iDeA-SA Collaboration

VIRAL SUPPRESSION IN HIV-INFECTED CHILD-CAREGIVER DYADS IN WESTERN KENYA
John M. Humphrey, Beverly Musick, Edith Apondi, Becky L. Genberg, Adrian Gardner, Joseph Hogan, Kara K. Wools-Kaloustian

ARE HIV+ MIGRANT CHILDREN IN EUROPE AT INCREASED RISK OF POOR OUTCOMES ON ART?

BETTER TREATMENT OUTCOMES FOR RWANDAN CHILDREN AFTER "TREAT ALL"

AFRICAN MULTI-SITE 2-YEAR STUDY OF NEUROCOGNITION IN HIV INFECTED/AFFECTED CHILDREN
Michael J. Boivin, Miriam Chernoff, Barbara Laughton, Bonnie Zimmer, Celeste Joyce, Linda Barlow-Mosha, Mutsa Bwakura-Dangarembizi, Mmule Ratswana, Lee Fairlie, Portia Kamthunzi, Katie McCarthy, Patrick Jean-Philippe, Avy Violari, Mark Cotton, Paul Palumbo

CARDIO-ANKLE VASCULAR INDEX AMONG PERINATALLY HIV-INFECTED THAI ADOLESCENTS
Tavitiya Sudjaritruk, Linda Aurpibul, Suvaporn Anuguleunakit, Tawalchaya Chotechoaroentanan, Siwanart Thamsala, Rattika Thummalangka, Kittipan Rerkasem, Thanyawee Puthanakit, for the PAD study team
857 SUBSTANCEAL GENDER DIFFERENCES IN LONGITUDINAL ARTERIAL STIFFNESS IN CHILDREN ON ART
Steve Innes, Mark Cotton, Kennedy N. Otwombe, Barbara Laughton, Philip Herbst, Innocent Karangwa, Sara H. Browne

858 MITOCHONDRIAL DYSFUNCTION IN WELL-SUPPRESSED PERINATALLY HIV-INFECTED CHILDREN ON ART
Jing Shen, Renate Strehlau, Afaaf Liberty, Stephanie Shiau, Faeezah Patel, Megan Burke, Avy Violari, Marc D. Foca, Stephen M. Arpadi, Louise Kuhn, for the Childhood HAART Alterations in Normal Growth, Genes, and aGing Evaluation Study (CHANGES) Team

859 VITAMIN D SUPPLEMENTATION ATTENUATES IMMUNE ACTIVATION IN HIV+ AVIREMIC YOUTH
Allison R. Eckard, Mary Ann O’Riordan, Vin Tangpricha, Danielle Labbato, Ann Chahroudi, Grace A. McComsey

860 SCD163, T CELL ACTIVATION AND HIV PROGRESSION IN PERINATALLY INFECTED HIV+ CHILDREN
Matthew Generoso, Patricia Alvarez, Adam Kravietz, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

Poster P-Q5 RESPONSE TO EARLY INFANT ANTIRETROVIRAL THERAPY
Poster Hall D
2:30 PM – 4:00 PM

861 VIROLOGIC RESPONSE TO ANTIRETROVIRAL THERAPY STARTED AT <12 WEEKS OF AGE
Victoria Iyun, Karl Technau, Brian Eley, Helena Rabie, Andrew Boulle, Geoffrey Fatti, Frank Tanser, Robin Wood, Lee Fairlie, Mary-Ann Davies, for the International epidemiology Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration

862 MATERNAL ANTIRETROVIRAL THERAPY IN PREGNANCY AND NEONATE PRETREATMENT VIRAL LOAD
Faeezah Patel, Stephanie Shiau, Renate Strehlau, Megan Burke, Maria Paximadis, Sharon Shalekoff, Diana Schramm, Caroline Tiemessen, Elaine J. Abrams, Louise Kuhn, for the LEOPARD study team

863 T AND B CELL RESPONSES ASSOCIATE WITH SMALLER HIV RESERVOIR SIZE IN INFANTS AFTER ART
Julie Mitchell, Marta Massanella, Thanyawee Puthanakit, Pope Kosalaraksa, Piyarat Sundaratattivong, Suparat Kanjanavanit, Rawiwan Hansudewechakul, Thitiporn Borkth, Thidarat Jupimai, Panadda Sawangsith, Mark de Souza, Nicolas Chomont, Jintanat Ananworanich, Lydie Trautmann, for the HIVNAT209 and RV254 study groups

864 FACTORS ASSOCIATED WITH HIV DNA LEVELS IN CHILDREN STARTING ART EARLY IN INFANCY
Man Chan, Alfredo Tagarro, Paola Zangari, Bridget Ferns, Caroline Foster, Anita De Rossi, Eleonora Nastouli, M Ángeles Muñoz-Fernández, Diana Gibb, Paolo Rossi, Carlo Giaquinto, Abdel Babiker, Paolo Palma, Pablo Rojo Conejo, for the EPIICAL Consortium

865 EARLY CMV AND EBV ACQUISITION PREDICTS HIV DNA LEVELS IN INFANTS ON SUPPRESSIVE ART
Jennifer Slyker, Brandon Guthrie, Mark D. Pankau, Dalton Wamalwa, Sarah Benki-Nugent, Meei-Li Huang, Grace John-Stewart, Julie Overbaugh, Dara Lehman
866 HIV SPECIFIC IGM MEMORY B CELLS DOMINATE IN SERONEGATIVE EARLY-TREATED CHILDREN
Nicola Cotugno, Elena Morrocchi, Ilaria Pepponi, Salvatore Rocca, Mark Cameron, Stefano Rinaldi, Silvia Di Cesare, Suresh Pallikkuth, Stefania Bernardi, Nigel Klein, Jintanat Ananworanich, Paolo Rossi, Savita Palha, Paolo Palma, for the EPICAL Consortium

867 INTESTINAL DAMAGE AND INFLAMMATION IN PERINATALLY HIV-1-INFECTED AFRICAN INFANTS
Wei Li A. Koay, Jane Lindsey, Priyanka Uprety, Mutsa Bwakura-Dangarembizi, Adriana Weinstein, Myron Levin, Deborah Persaud

868 LASTING IMMUNE IMPACTS OF AGE AT START OF ART IN VERTICALLY HIV-INFECTED ADOLESCENTS
Mark Cameron, Stefano Rinaldi, Brian Richardson, Nicola Cotugno, Sion Williams, Suresh Pallikkuth, Lesley R. de Armas, Cheryl Cameron, Rajendra Palha, Paolo Palma, Savita Palha, for the EPICAL Consortium

Poster P-R3 PHYLOGENETICS IN EPIDEMIOLOGY
Poster Hall B
2:30 PM – 4:00 PM

944 ARE REAL-TIME PHYLOGENY GUIDED INTERVENTIONS FEASIBLE? A LONGITUDINAL ANALYSIS
Larissa V. Mulka, Manon Raggonnet-Cronin, Jaime Vera-Rojas, Jackie Cassell, Anna Tostevin, David Dunn, Andrew Leigh Brown, for the UK HIV Drug Resistance Database

945 DYNAMICS OF THE CRF01AE EPIDEMICS IN THE CITIES OF SHANGHAI, SHENZHEN AND SHENYANG
Xiaoxu Han, Antoine Chaillon, Ping Zhong, Jin Zhao, Bin Zhao, Haibo Ding, Junjie Xu, Yi Lin, Yile Xue, Xuqin Wang, Min Zhang, Lin Wang, Davey M. Smith, Hong Shang

946 PHYLODYNAMIC FEATURES OF ACTIVE LARGE CLUSTERS FUELING THE HIV EPIDEMIC IN QUEBEC MSM
Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Irene Vrbik, Michel Roger, Isabelle Hardy, David Stephens

947 HIV-1 SUPERINFECTION IN THE SWISS HIV COHORT STUDY: A LARGE SCALE SCREEN
Sandra E. Chaudron, Karin Metzner, Alex Marzel, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Roger Koyou, Huldrych F. Günthard, for the Swiss HIV Cohort Study

948 GREATER THAN RANDOM HLA-B HOMOGENEITY IN HIV-1 TRANSMISSION CHAINS
Huyen Nguyen, Christian Thorball, Jacques Fellay, Jürg Böni, Sabine Yerly, Matthieu Perreau, Thomas Klimkait, Huldrych F. Günthard, Roger Koyou, for the Swiss HIV Cohort Study

949 PREDICTING HIV CLUSTER GROWTH USING PHYLODYNAMIC RECONSTRUCTION IN LOS ANGELES COUNTY
Manon Raggonet-Cronin, Yunyin W. Hu, Joel O. Wertheim

950 ASSESSING HIV-1C TRANSMISSION NETWORK IN BOTSWANA AT LOW SAMPLING DENSITY
Vlad Novitsky, Melissa Zahralban-Steele, Sikhuilile Moyo, Dorcas Marapula, Baitshepi Mokaleng, Tapiwa Nkhisang, Mary F. McLane, Sally Madiba, Erik van Widenfelt, Tendani Gaolathe, Etienne Kadima, Shahin Lockman, Joseph Makhema, Simani Gaseitsiwe, Max Essex
951  **HIV-1 GENETIC DIVERSITY AND TRANSMISSION DYNAMICS IN FISHING COMMUNITIES OF UGANDA**  
Nicholas Bbosa, Deogratius Ssemwangwa, Jesus F. Salazar-Gonzalez, Rebecca N. Nsubuga, Maria Nannyonjo, Janet Seeley, Noah Kiwanuka, Bernard Bagaya, Gonzalo Yebra, Andrew Leigh Brown, Pontiano Kaleebu

952  **PHYLOGENETIC AND GEOGRAPHIC SEPARATION IN HIV-INFECTED PEOPLE IN BRITISH COLUMBIA**  
David McVea, Richard Liang, Jeffrey Joy, P. Richard Harrigan, Art Poon

953  **PHYLODYNAMIC METHODS OF IDENTIFYING FOCI OF HIV-1 TRANSMISSION**  
Angela McLaughlin, P. Richard Harrigan, Jean A. Shoveller, Jeffrey Joy

954  **PHYLOGEOGRAPHIC ANALYSIS SUGGESTS GRAavity MODEL OF HIV TRANSMISSION IN MEXICO**  
Antoine Chaillon, Santiago Avila-Rios, Ann M. Dennis, Joel O. Wertheim, Claudia Garcia-Morales, Daniela Tapia-Trejo, Sanjay R. Mehta, Gustavo Reyes-Terán, for the HIV MexNet Group

955  **ASSOCIATION BETWEEN VIRAL SUPPRESSION AND MOLECULAR CLUSTER GROWTH, UNITED STATES**  
Nivedha Panneer, Alexandra M. Oster, Cheryl B. Ocfemia, Sheryl Lyss, Joel O. Wertheim, Anne Marie France

956  **HIGH VIRAL LOAD ACROSS STAGE OF INFECTION ASSOCIATED WITH CLUSTERING IN US NETWORK**  
Joel O. Wertheim, Alexandra M. Oster, Nivedha Panneer, Chenhua Zhang, Neeraja Saduvala, Ellsworth Campbell, Jeffrey A. Johnson, William M. Switzer, Walid Heneine

957  **HIV TRANSMISSION CLUSTER DYNAMICS THAT INFORM PUBLIC HEALTH INTERVENTION IN ILLINOIS**  
Manon Ragonnet-Cronin, Joel O. Wertheim, Christina S. Hayford, Richard D’Aquila, Fangchao Ma, Cheryl Ward, Nanette Benbow

958  **A NEW B/CRF02 CIRCULATING RECOMBINANT SPREADING QUICKLY IN PARIS AREA, FRANCE**  

959  **PREDICTIVE MODEL FOR HIV TRANSMISSION CLUSTER GROWTH IN NORTH CAROLINA**  

960  **AGE DISPARITIES IN EUROPEAN HIV TRANSMISSION PAIRS UNCOVERED WITH VIRAL SEQUENCE DATA**  
Matthew D. Hall, Chris Wyman, Oliver Ratmann, Jan Albert, Norbert Bannert, Anne-Marte Bakken Kren, Marion Cornelissen, Kate Grabowski, Huldrey F. Günthard, Laurence Meyer, Kholoud Porter, Matti Ristola, Guido Vanham, Christophe Fraser, for the BEEHIVE Collaboration
998** HOW LOW CAN YOU GO? DIAGNOSIS OF ACUTE HIV INFECTION AT VERY LOW HIV RNA LEVELS  
Donn Colby, Siriwat Akapirat, Supanit Pattanachaivit, Rapee Trichaviroj, Suteeraporn Pinyakorn, Sasiriwol Ubolyam, Eugène Kroon, Carlo Sacdalan, Nitiya Chomchey, Nittyta Phanuphak, Merlin L. Robb, Praphan Phanunphak, Jintanat Ananworanich, Mark de Souza, for the RV254/SEARCH010 Study Team

999 **VALIDATION OF THE AMSTERDAM RISK SCORE FOR RECENT HIV INFECTION AMONG MSM  
Timothy Lin, Maartje Dijkstra, Godelieve J. de Bree, Maarten F. Schim van der Loeff, Martin Hoenigl

1000 **DEVELOPMENT AND VALIDATION OF THE SAN DIEGO SYMPTOM SCORE FOR ACUTE HIV INFECTION  
Timothy Lin, Tara Tenenbaum, Sara Gianella, Susan J. Little, Martin Hoenigl

1001 **CAN THE LAG-AVIDITY ASSAY MEASURE AN INCIDENCE DIFFERENCE IN EAST AFRICA?  
Oliver Laeyendecker, Ronald H. Gray, Kate Grabowski, Steven J. Reynolds, Anthony Ndyanabo, Joseph Ssekasanvu, Reinaldo Fernandez, Maria Wawer, David Serwadda, Thomas C. Quinn

1002 **PERFORMANCE VALIDATION OF THE SEDIA LAG ASSAY IN SOUTH AFRICAN BLOOD DONORS  
Eduard Grebe, Marion Vermeulen, Tinus Brits, Ronel Swanevelder, Genevieve Jacobs, Michael P. Busch, Alex Welte

1003 **INNATE DYNAMIC RANGE OF ABBOT PRISM HIV O PLUS IS ADEQUATE FOR RECENTY STAGING  
Eduard Grebe, Marion Vermeulen, Tinus Brits, Ronel Swanevelder, Genevieve Jacobs, Michael P. Busch, Alex Welte

1004 **MEASUREMENT OF ANTIBODY EPITOPE SIGNATURES TO DETERMINE RECENTY OF HIV INFECTION  
Kathryn E. Stephenson, Lisa M. Howe, Dan Barouch, Steven G. Deeks, Sheila M. Keating, Christopher D. Pilcher, Timothy J. Henrich

---

**Poster P-T06 ORAL PrEP IN WOMEN**  
Poster Hall B  
2:30 PM – 4:00 PM

1043 **PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN  
Maria Pyra, Elizabeth Brown, Jessica E. Haberer, Renee Heffron, Elizabeth A. Bukusi, Stephen Asiimwe, Connie L. Celum, Elly T. Katabira, Nelly R. Mugo, Jared Baeten, for the Partners Demonstration Project Team

1044 **CHARACTERIZING THE HIV CONTINUUM OF CARE FOR TRANSGENDER WOMEN IN NORTH AMERICA  
1045 **PREDICTORS OF WILLINGNESS TO TAKE PrEP AMONG BLACK AND LATINA TRANSGENDER WOMEN**  
Tonia Poteat, Erin Cooney, Mannat Malik, Thespina Yamanis, Maren Lujan, Andrea L. Wirtz

1046 **PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT**  
Robyn Eakle, Gabriela Gomez, Niven Naicker, Rutendo Bothma, Judie Mbogua, Maria A. Cabrera Escobar, Elaine Saayman, Michelle A. Moorhouse, Willem D. Venter, Helen Rees

1047 **HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PrEP DURING ANTENATAL CARE**  
John Kinuthia, Jillian Pintye, Kenneth K. Mugwanya, Marline Serede, Joseph Sila, Felix Abuna, Harrison Lagat, Julia Dettinger, Tina Schuh, Jared Baeten, Grace John-Stewart

1048 **PREDICTORS OF PrEP ELIGIBILITY AMONG AT−RISK WOMEN IN THE SOUTHERN UNITED STATES**  
Anar S. Patel, Lakshmi Goparaju, Jessica M. Sales, Cyra Christina Mehta, Oni J. Blackstock, Dominika Seidman, Igbo Ofotokun, Mirjam-Colette Kempf, Margaret Fischl, Elizabeth T. Golub, Adaoa Adimora, Audrey French, Gina Wingood, Seble Kassaye, Anandi N. Sheth

1049 **RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082**  

1050 **HIV BIOMEDICAL PREVENTION AMONG US WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES**  

1051 **DEPRESSION AND PrEP ADHERENCE AMONG HIGH−RISK HIV−UNINFECTED WOMEN IN EAST AFRICA**  
Jennifer Velloza, Jared Baeten, Jessica E. Haberer, Kenneth Nquare, Elizabeth M. Irungu, Nelly R. Mugo, Connie L. Celum, Renee Heffron, for the Partners Demonstration Project Team

---

**Poster P-T07 PrEP IN SERODISCORDANT COUPLES**  
**Poster Hall B**  
**2:30 PM − 4:00 PM**

1052 **REPORTED PrEP USE AMONG HIV-NEGATIVE PARTNERS OF US MSM RECEIVING HIV MEDICAL CARE**  
Linda Beer, R. L. Shouse, Dawn K. Smith, Amy R. Baugher, Jennifer Fagan, for the Medical Monitoring Project

1053 **RAPID SCALE-UP OF PrEP FOR HIV SERODISCORDANT COUPLES IN HIV CARE CLINICS IN KENYA**  
1054 NO RISK COMPENSATION BUT HIV EXPOSURE PERSISTS IN HETEROSEXUAL COUPLES USING PrEP
Kenneth K. Mugwanya, Renee Heffron, Nelly R. Mugo, Elizabeth A. Bukusi, Elly T. Katabira, Stephen Asimwe, Kenneth Ngure, Connie L. Celum, Jared Baeten, for the Partners Demonstration Project Team

Poster Session
Tuesday

1061 A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY VRC07-523LS IN HEALTHY ADULTS
Martin R. Gaudinski, Katherine V. Houser, Grace Chen, Ro Shauna Rothwell, Pamela Costner, Lasonji Holman, Ingelise Gordon, Robert Bailor, Margarita G. Lorenzo, Richard A. Koup, Edmund V. Capparelli, Barney S. Graham, John R. Mascola, Julie Ledgerwood, for the VRC 605 Study Team

Poster Session
Tuesday

1062 A PHASE 1 TRIAL OF THE COMBINATION OF 3BNC117 AND 10-1074 IN HIV-UNINFECTED ADULTS

Poster Session
Tuesday

1063 PHASE 1 TRIAL TO ASSESS SAFETY AND ANTIVIRAL ACTIVITY OF MB66 VAGINAL FILM

Poster Session
Tuesday

1064 ACCEPTABILITY OF TETANUS TOXOID VACCINE PRIOR TO SAFE MALE CIRCUMCISION
Anna Lawino, Richard A. Mangwi, Christopher G. Orach

Poster Session
Tuesday

1065 PERCEPTIONS OF AND MOTIVATIONS FOR VMMC AMONG ADOLESCENTS: A MULTICOUNTRY STUDY

Poster Session
Tuesday

1066 NOTIFIABLE ADVERSE EVENTS ASSOCIATED WITH MEDICAL MALE CIRCUMCISION IN KENYA
Elijah Odoyo-June, Kawango Agot, Nandi Ouwor, Cristine Kisia, Boaz Otiemo-Nyunya, Paul K. Musingila, Vincent Ojiambo, Norah Talam, Hellen Muttai, Kennedy Serrem, Martin Sirengo

Poster Session
Tuesday

1067 SAFETY AND ACCEPTABILITY OF PREPEX CIRCUMCISION AMONG ADOLESCENTS IN KISUMU, KENYA
Kawango Agot, Julie Ambia, Risper Bosire, David Muhuaya, Joshua Juma, Abraham Bitok, Spala Ohire, Benard Ayeke, Maurice Onyango

Poster Session
Tuesday
**Poster P-U1 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING IN HIV PREVENTION AND CARE**

**Poster Hall B**

**2:30 PM – 4:00 PM**

**1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA**
Wangui Muthigani, Emily R. Begnel, Dunstan Achwoka, Tai Ho Chen, John Kinuthia, Christine J. McGrath, Alison L. Drake, for the FP Working Group

**1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO**
Shino Arikawa, Cécile Cazes, Anne Thomas, Thierry Tiendrebeogo, Benjamin G. Kariyiare, Vincent Pitche, Didier K. Ekouevi, Renaud Becquet

**1070 CONCEPTION AND PREP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS**
Ingrid V. Bassett, Ai Xu, Sabina Govere, Hilary Thulare, Simone C. Frank, Christina Psaros, Robert A. Parker

**1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI’S PMTCT PROGRAM**
Deus Thindwa, Megan Landes, Monique van Lettow, Annie Kanyemba, Ernest Nkhoma, Thokozani Kalua, Happy Phiri, Joep J. van Oosterhout, for the NEMAPP consortium

---

**Poster P-V1 LINKAGE, ENGAGEMENT, AND RETENTION**

**Poster Hall B**

**2:30 PM – 4:00 PM**

**1076 IDENTIFYING OPERATIONAL CHALLENGES IN ZAMBIAN ART CLINICS: A TIME AND MOTION STUDY**

**1077 EFFECT OF UNDISCLOSED HIV+ STATUS ON LINKAGE TO AND RETENTION IN CARE**
Neena M. Philip, Yingfeng Wu, Margaret McNairy, Averie B. Gachuhi, Matthew R. Lamb, Harriet Nuwagaga-Biribonwoha, Veli M. Madau, Sean Burke, Zandile Mnis, Wafa M. El-Sadr

**1078 INTEGRATED COCAINE & MENTAL HEALTH TREATMENT WITH NAVIGATION RCT FOR HIV+ OUTPATIENTS**

**1079 SINGLE-PILL ART AND RETENTION IN CARE: A REGRESSION DISCONTINUITY STUDY IN S. AFRICA**
Sheryl Kluberg, Matthew P. Fox, Michael LaValley, Denise Evans, Kamban Hirasesh, Mhaiir Maskew, Lawrence Long, Jacob Bor

**1080 HIV CARE DELIVERY BY ID PHYSICIANS, OTHER PHYSICIANS, AND ADVANCED PRACTICE PROVIDERS**
John Weiser, Guangnan Chen, Wendy S. Armstrong, Linda Beer

**1081 BETTER RETENTION AMONG PATIENTS ON ART ARGUES FOR UNIVERSAL TREATMENT IN KENYA**
Irene Mukui, Maureen Kimani, Samuel M. Mwalili, Agnes Natukunda, Evelyne Nguji, Abraham Katana, Lucy Ng'ang'a, Peter W. Young, George Rutherford
1082 • IS DIFFERENTIATED CARE IMPLEMENTED? ANALYSIS OF SEVEN AFRICAN TREATMENT PROGRAMS
Andreas D. Haas, Leigh F. Johnson, Izukanji Sikazwe, Nathan Ford, Matthew P. Fox, Hans Prozesky, Cleophas Chimbetete, Jonathan Euvrard, Matthias Egger, for the IeDEA Southern African collaboration

1083 • LINKAGE, TREATMENT AND SUPPRESSION IN THE BOTSWANA COMBINATION PREVENTION PROJECT

1084 • DISTRIBUTION OF ADVANCED HIV IN 3 HIGH HIV PREVALENCE COUNTRIES IN AFRICA
Menard L. Chihana, Helena Huerga, Gilles van Cutsem, Stephen Wanjala, Charles Masiku, Elisabeth Szumilin, Jean F. Etard, Mary-Ann Davies, David Maman

1085 • CASCADE OF CARE AMONG SERODISCORDANT COUPLES IN 4 HIGH PREVALENCE SETTINGS IN AFRICA
Menard L. Chihana, Nolwenn Conan, Erica Simons, Cyrus Paye, Daniela B. Garone, Reinaldo Ortuno, Helena Huerga, Gilles van Cutsem, Stephen Wanjala, Charles Masiku, Elisabeth Szumilin, Jean F. Etard, Mary-Ann Davies, David Maman

1086 • MULTI-MONTH SCRIPTING (MMS) AND RETENTION ON HIV ANTIRETROVIRAL THERAPY IN HAITI
Nancy Puttkammer, Tricia Rodriguez, Ermane Robin, Gracia Desforges, Canada Parrish, Jean Gabriel Balan, Jean Guy Honore, Joelle Deas Van Onacker, Scott Barnhart, Jane M. Simoni, Kesner Francois

1087 • ROUTINE RETENTION IN CARE AT HOWARD BROWN, 2012-2017: ARE QUARTERLY VISITS TOO MUCH?
Laura Rusie, Carlos Orengeo, Diane Burrell, Magda Houlberg, Arthi Ramachandran, Kristin Keglovitz-Baker, David Munar, John A. Schneider

1088 • POSTPARTUM MOBILITY AND TRANSFER OF CARE AMONG HIV+ WOMEN ON ART IN SOUTH AFRICA
Tamsin K. Phillips, Kate Clouse, Allison Zerbe, Catherine Orrell, Elaine J. Abrams, Landon Myer

1089 • LINKAGE TO CARE AFTER HIV TESTING IN THE COMMUNITY IN A HIGH HIV PREVALENCE SETTING
Sarah Jane Steele, Bernadette Gergonne, Liesbet Ohler, Ellie Ford-Kamara, Gilles van Cutsem, Amir Shroufi

1090 • PHONE CALL FROM CLINICAL OFFICER AT HIV TESTING/RE-CONTACT IMPROVES LINKAGE TO CARE
James Ayieko, Erick Wafula, Wilson Opudo, Craig R. Cohen, Elizabeth A. Bukusi, Tamara D. Clark, Laura B. Balzer, Moses R. Kamya, Edwin D. Charlebois, Maya L. Petersen, Diane V. Havlir

1091 • UNDERSTANDING PATIENT MOBILITY IN HIV +VE ADULTS ACROSS MULTIPLE CLINICS IN ZAMBIA
Kombatende Sikombe, Sandra Simbeza, Jillian L. Kadota, Ingrid Eshun-Wilson, Laura Beres, Carolyn Bolton Moore, Nje kwa Mukamba, Charles B. Holmes, Izukanji Sikazwe, Elvin Geng

1092 • RISK FOR ATTRITION IN HIV-INFECTED CLIENTS ON TREATMENT IN URBAN HIV CLINICS IN KENYA
Emily C. Koech, Sylvia Ojoo, Caroline Ngunu
1093  **TIME TO ART INITIATION IN KENYA, 2003-2013**  
Kenneth Masamaro, Jacques Muthusi, Maureen Kimani, Irene Mukui, Evelyne Ngugi, George Mgomella, Tai Ho Chen

1094  **YOUTH-FOCUSED CARE IN AN ADULT CLINIC IMPROVES RETENTION FOR YOUNG ADULTS WITH HIV**  
David C. Griffith, Shanna Dell, Jeremy Snyder, Samantha Greenblatt, Jeanne C. Keruly, Allison Agwu

1095  **CAN FOOD HELP RETENTION IN HIV CARE: A COHORT STUDY OF ADULTS INITIATING ART IN HAITI**  
Julie Reiff, Stanislas Galbaud, Akanksha Dua, Jean Edouard Mathon, Patrice Joseph, Adias Marcelin, Pierrot Julma, Serena Koenig, Pierre Cremieux, Jean W. Pape, Margaret McNairy

1096  **HIV CASCADE OF CARE IN GREECE: USEFUL INSIGHTS FROM ADDITIONAL STAGES**  
Giota Touloumi, Georgia Vourli, Vasileios Paparizos, Athanasios Skoutelis, Simeon Metallidis, Panagiotis Gargalianos, Antonios Papadopoulos, Maria Chini, Nikolaos Sipsas, Mina Psychogiou, Georgios Chrysos, Helen Sambatakou, Charalambos Gogos, Dimitra Paraskeva, Georgios Nikolopoulos

1097  **IMPACT OF SYSTEMS NAVIGATION AND COUNSELING ON ART, SUT AND DEATH IN PWID: HPTN 074**  
William C. Miller, Irving Hoffman, Brett Hanscom, Tran V. Ha, Kostyantyn Dumchev, Zubairi Djoeberan, Scott M. Rose, Kathryn E. Lancaster, Vivian Go, Sarah Reifeis, Estelle Piwowar-Manning, Carl A. Latkin, David Metzger, David Burns, for the HPTN 074 Protocol Team

1098  **TRENDS IN UNSUPPRESSED HIV RNA AFTER LINKAGE TO CARE AMONG KEY POPULATIONS**  
Fidel A. Desir, Catherine R. Lesko, Richard D. Moore, Michael A. Horberg, Peter F. Rebeiro, Michael John Gill, Mari Kitahata, Michael J. Silverberg, Julie H. Levison, Marina Klein, Angel Mayor, Amy C. Justice, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

1099  **OUTCOMES OF PATIENTS LOST TO FOLLOW-UP IN AFRICAN ART PROGRAMS: MULTI-COHORT STUDY**  

1100  **IMPROVEMENT IN HIV CARE INDICATORS AMONG THE HOMELESS IN SAN FRANCISCO**  
Susan Scheer, Ling Hsu, Darpun Sachdev, Oliver Bacon, Stephanie E. Cohen, Albert Y. Liu, Jennie C. Chin, Susan P. Buchbinder

1101LB  **IMPACT OF SERVICE INTEGRATION ON HIV TESTING UPTAKE AMONG KEY POPULATIONS IN INDIA**  
Sunil S. Solomon, Suniti Solomon, Allison M. McFall, Aylur K. Srikrishnan, Santhanam Anand, Pachamuthu Balakrishnan, Elizabeth Ogburn, Lawrence Moulton, Muniratnam S. Kumar, David D. Celentano, Gregory M. Lucas, Shruti H. Mehta

1102  **SHORT-TERM EFFECTS OF ALTERNATIVE MEDICATION REFILL STRATEGIES IN SOUTH AFRICA**  
Matthew P. Fox, Sophie Pascoe, Amy Huber, Joshua Murphy, Mokgadi Phokojoe, Marelinez Gorgens, **Sydney Rosen**, David Wilson, Yogan Pillay, Nicole Fraser
1103  EFFECT OF FAST TRACK INITIATION COUNSELLING ON ART INITIATION IN SOUTH AFRICA
Sophie Pascoe, Matthew P. Fox, Amy Huber, Joshua Murphy, Mokgadi Phokojo, Marelize Gorgens, Sydney Rosen, David Wilson, Yogan Pillay, Nicole Fraser

1104  ART ELIGIBILITY EXPANSION AND TIMELY ART INITIATION: 22-COUNTRY META-ANALYSIS
Olga Tymejczyk, Ellen Brazier, Constantin T. Yiannoutsos, Kara K. Woolskaloustian, Keri N. Althoff, Brenda Crabtree-Ramirez, Kinh V. Nguyen, Elizabeth Zaniewski, François Dabis, Jean d’Amour Sinayobye, Nanina Anderegg, Nathan Ford, Radhika Wikramanayake, Denis Nash, for the IeDEA Collaboration

1105  A STREAMLINED ART INITIATION ALGORITHM OF CARE REDUCES TIME TO ART
Izukanji Sikazwe, Samuel Bosomprah, Jake Pry, Mpande Mukumbwa-Mwenechanya, Anjali Sharma, Paul Somwe, Nancy Padian, Monika Roy, Carolyn Bolton Moore, Charles B. Holmes, Elvin Geng

1106  SAME-DAY ART INITIATION IN THE SLATE TRIAL IN SOUTH AFRICA: PRELIMINARY RESULTS
Mhairi Maskew, Alana T. Brennan, Matthew P. Fox, Willem D. Venter, Lungisile Velez, Bruce Larson, Isaac Tsikhutsu, Margaret Bii, Sydney Rosen

1107  STARTING ART IN HIV+ DRUG USERS WHILE HOSPITALIZED PREDICTS HIV TREATMENT ENGAGEMENT
Petra Jacobs, Daniel Feaster, Yue Pan, Lauren Gooden, Carlos del Rio, Eric Daar, Gregory M. Lucas, Mamta K. Jain, Eliza Marsh, Lisa Metch

1108  GETTING A JUMP ON HIV: EXPEDITED ARV TREATMENT AT NYC SEXUAL HEALTH CLINICS, 2017
Susan Blank, Christine M. Borges, Michael A. Castro, Kelly Jamison, John Winters, Tarek Mikati, Julie Myers, Demetre C. Daskalakis

1109  A RAPID ENTRY PROGRAM IN THE SOUTH: IMPROVING ACCESS TO CARE AND VIRAL SUPPRESSION
Jonathan Colasanti, Jeri Sumitani, Cyra Christina Mehta, Yiran Zhang, Minh Ly Nguyen, Wendy S. Armstrong, Carlos del Rio

1110  EARLY RETENTION DOES NOT MEDIATE/MODERATE EFFECT OF SEX/SEXUAL BEHAVIOR ON SURVIVAL
Lara Coelho, Peter F. Rebeiro, Jessica L. Castilho, Yanink Caro-Vega, Fernando A. Mejia, Carina Cesar, Claudia P. Cortes, Denise Padgett, Catherine McGowan, Valdielea Veloso, Timothy R. Sterling, Beatriz Grinsztejn, Bryan E. Shepherd, Paula M. Luz, for the CCASAnet

1111LB  SAME-DAY ART INITIATION ASSOCIATED WITH POORER RETENTION BUT HIGHER VIRAL SUPPRESSION
Dvora Joseph Davey, Claire Serrao, Madaline Feinberg, Marlien Prins, Ernest Darkoh
192 INFANT T/F HIV-1 FROM PERIPARTUM TRANSMISSION ARE RESISTANT TO MATERNAL PLASMA

193 ZIKA VIRUS AND HIV-1 INTERPLAY IN HUMAN IMMUNE CELLS
Joel Provost, Corinne Barat, Michel J. Tremblay

194 STRUCTURAL AND RNA BINDING MODEL OF APOBEC3G N-TERMINAL DOMAIN FOR NEW DRUG DESIGNS
Hirofumi Fukuda, Anamaria D. Sarca, Kazuo Yamashita, Song Lin Li, Luca Sardo, Jessica Smith, Hirotaka Ebina, Kotaro Shirakawa, Kei Sato, Daron Standley, Yoshio Koyanagi, Taisuke Izumi, Akifumi Takaori-Kondo

195 SEMINAL CYTOKINE/CHEMOKINE NETWORK AND HIV TRANSMISSION IN MEN WHO HAVE SEX WITH MEN
Christophe Vanpouille, Andrea Lisco, Leonid Margolis, Laura Layman, Martin Hoenigl, Sara Gianella

196 BENEFICIAL IMPACT OF EARLY TREATMENT ON RESTRICTION FACTOR EXPRESSION PROFILE
Clarissa Van Hecke, Magdalena Sips, Eva Malatinova, Ward De Spieghelaere, Karen Vervisch, Chris Verhofstede, Margaret Johnson, Sabine Kinloch-de Loes, Wim Tryptseyn, Linos Vandekeerkhove

197 HOST MICRORNA MIR-382-5P MAY EXERT A PROTECTIVE EFFECT ON HIV CONTROL
Marcial García, Ricardo Ramos, María Ángeles Navarrete, Carlos Cañada, Alfonso Cabello, Juan Carlos López-Bernaldo, Francisco Javier De La Hera, Vicente Estrada, Carlos Barros, Clara Restrepo, Manuel Fernández, Miguel Górgolas, José Miguel Benito, Norma Rallón

198 NEF’S INFERIOR ABILITY TO DOWNREGULATE HLA-B CORRELATES WITH PLASMA VIRAL CONTROL
Francis Mwimanzi, Mako Toyoda, Macdonald Mahiti, Jaclyn Mann, Jeffrey N. Martin, David R. Bangsberg, Mark Brockman, Philip J. Boulder, Frank Kirchhoff, Zabrina Brumme, Thombi Ndungú, Takamasu Ueno

199 MODULATION OF HIV RESTRICTION FACTORS BY BLOCKING CCL2/CCR2 IN VITRO AND IN VIVO
Daniela Angela Covino, Maria Clementina Galluzzo, Jing Lu, Cristina Purificato, Laura Catapano, Matteo Pellegrini, Maria Cristina Gauzzi, Stefano Vella, Eric Lefebvre, Mauro Andreotti, Laura Fantuzzi

200 TRIM21 –CRM-1 INTERACTION: A NOVAL MECHANISM FOR HIV RESTRICTION IN MURINE CELLS
Roqaya Sabbah-Abuadabes, Moshe Kotler, Richard Sutton, Hila Elinav

201 NEF ANTAGONIZES TIM-MEDIATED INHIBITION OF HIV-1 RELEASE: ROLE OF SERINC5
Minghua Li, Abdul A. Waheed, Eric O. Freed, Shan-Lu Liu

202 IMPACT OF NATURAL HIV-1 NEF POLYMORPHISMS ON SERINC5 ANTAGONISM
Steven W. Jin, Nirmin Alsahahi, Xiao Mei T. Kuang, Philip Mwimanzi, Heinrich Gottlinger, Zabrina Brumme, Andrés Finzi, Mark Brockman
252  Fecal microbiota from HIV-infected subjects increases innate immune activation

Charles P. Neff, Owen Krueger, Sam Li, Nichole Nusbacher, Jennifer M. Schneider, Abigail Armstrong, Catherine Lozupone, Brent E. Palmer

253  Isolation of translocating bacteria in progressive SIV infection of rhesus macaques

Jacob Flynn, Alexandra Ortiz, Jason Brenchley

254  Circulating (1→3)-β-D-glucan as a marker of microbial translocation in HIV infection

Vikram Mehraj, Rayoun Ramendra, Cecilia Costiniuk, Bertrand Lebouché, Rosalie Ponte, Réjean Thomas, Jason Szabo, Pierre Coté, Roger LeBlanc, Jean-Guy Baril, Cécile Tremblay, Nicole Bernard, Don C. Sheppard, Jean-Pierre Routy, for the Montreal Primary HIV-infection Study Group

255  Transfer of microbiota and immunophenotypes in HIV-+ MSM to mice by fecal transplant

Sam Li, Sharon Sen, Jennifer M. Schneider, Nichole Nusbacher, Nancy Moreno-Huizar, Catherine Lozupone, Brent E. Palmer

256  Antibiotics disrupt colonic microbiota and mucosal immune function in rhesus macaques

Alexander S. Zevin, Ryan Cheu, Tiffany Hensley-McBain, Jacob Modesitt, Jennifer A. Manuzak, Charlene J. Miller, Ernesto Coronado, Elise Smith, Brian Richardson, Michael Gale, Mark Cameron, Jeremy Smedley, Nichole Klatt

257  Effect of probiotics on gut microbiota and PET/MRI activity in HIV-infected persons

Caroline Arnbjerg, Beate Vestad, Johannes Hov, Karin K. Pedersen, Sofie Jespersen, Helle H. Johannesen, Kristian Holm, Eva Fallentin, Adam E. Hansen, Theis Lange, Andreas Kjær, Marius Troseid, Barbara M. Fischer, Susanne D. Nielsen

258  Investigating the effect of therapeutics on the microbiome of patients with HIV/AIDS

Bryn C. Taylor, David M. Asmuth, Rob Knight

259  TLR9 agonist modulated intestinal glycogene expression impacts microbiome diversity


260  Evolution of the gut microbiome following acute HIV-1 infection

Muntsa Rocafort, Marc Noguera-Julian, Javier Rivera, Lucia Pastor Palomo, Yolanda Guillén, Jost Langhorst, Mariona Parera, Inacio Mandomando, Jorge Carrillo, Bonaventura Clotet, Julià Blanco, Denise Naniche, Roger Paredes
261 HIV-ASSOCIATED CHANGES OF THE GUT MICROBIOME IN ARV-TREATED, UNTREATED, & CONTROLLERS
Jesus M. Luevano, David B. Gootenberg, Zoe Rogers, Jeff Paer, Douglas Kwon

262 TIME BETWEEN HIV ACQUISITION AND ART INITIATION IMPACTS GI MICROBIOME
Douglas Fadrosh, Susan V. Lynch, Javier R. Lama, Ricardo Alfaro, Delia Pinto-Santini, Rachel A. Bender Ignacio, Peter W. Hunt, Jessica Rios, Ann Duerr, for the MERLIN Study Group

263 COMPLEXITIES OF GUT MICROBIOME DYSBIOSIS IN HIV INFECTED AND HIGH RISK POPULATIONS
Abigail Armstrong, Michael Shaffer, Nichole Nusbacher, Thomas Campbell, Brent E. Palmer, Catherine Lozupone

264 ELEVATED FECAL INFLAMMATORY BIOMARKERS IN HIV-/+ MSM ASSOCIATE TO GUT MICROBIOTA
Jennifer M. Schneider, Sam Li, Charles P. Neff, Nichole Nusbacher, Nancy Moreno-Huizar, Catherine Lozupone, Brent E. Palmer

265 EFFECTS OF SUBSTANCE USE AND SEXUAL BEHAVIOR ON THE INTESTINAL MICROBIOME IN HIV
Jennifer A. Fulcher, Ryan Cook, Fan Li, Shehnaz K. Hussain, Nicole Tobin, Amy Ragsdale, Steven Shoptaw, Pamina Gorbach, Grace M. Aldrovandi

266 LIVER BACTERIAL DYSBIOSIS PERSISTS DURING ANTIRETROVIRAL THERAPY IN SIV+ MACAQUES

267 PREGNANCY ASSOCIATED VAGINAL PROTEOME ALTERATIONS LINKED TO HIV ACQUISITION RISK
Christina Farr Zuend, Nicole Tobin, Kenzie Birse, Laura Noël-Romas, Lani Kotyrba, Trisha Vera, Sarah Mutch, Max Abou, Stuart McCorrister, Garrett Westmacott, Grace M. Aldrovandi, Adam Burgener

268 VAGINAL MICROBIOTA AND HIV ACQUISITION RISK AMONG AFRICAN WOMEN
Sujatha Srinivasan, Barbra A. Richardson, Jacqueline Wallis, Tina L. Fiedler, Charlene S. Dezzutti, Z. Mike Chirenje, Edward W. Livant, David N. Fredricks, Sharon L. Hillier, Jeanne Marrazzo

269 THE VAGINAL MICROBIOME IN PREGNANCY DIFFERS BY HIV STATUS, ART EXPOSURE, AND CLASS

270 BACTERIAL VAGINOSIS ASSOCIATED MICROBES INDUCE ALTERED INNATE IMMUNE PROFILES
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>271</td>
<td>Poster P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION</td>
<td>Laura Noël-Romas, Michelle Perner, Alicia Berard, Ann M. Carias, Kenzie Birse, John Schellenberg, Melissa Lemke, Annelie Tjernlund, Garrett Westmacott, Douglas Lauffenburger, Kristina Broliden, Lyle McKinnon, Kelly Arnold, Thomas Hope, Adam Burgener</td>
</tr>
</tbody>
</table>

272 | IMPAIRED GUT TIGHT JUNCTION BUT PRESERVED ΔΑ AND MICROBIAL TRANSLLOCATION IN ACUTE HIV | Elvira S. Cannizzo, Giuseppe Ancona, Delfina Tosi, Federica Savi, Camilla Tincati, Antonella D’Arminio Monforte, Giulia Marchetti |

273 | MICROBIAL DYSBIOSIS DOES NOT ALTER DISEASE PROGRESSION IN SIV-INFECTED ASIAN MACAQUES | Alexandra Ortiz, Sarah DiNapoli, Jacob Flynn, Carly Elizabeth C. Starke, Stephen Lai, Mackenzie Long, Ornella Sortino, Carol Vinton, Joseph Mudd, Jacob D. Estes, Jason Brenchley |

274 | EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S | Rachel Presti, Douglas W. Kitch, Adriana Andrade, Alan Landay, Jeffrey Jacobson, Cara Wilson, Eunice Yeh, Jacob D. Estes, Claire Deleage, Karin L. Klingman, Netanya S. Utay, Edgar T. Overton, Jason Brenchley, Brett Williams, for the A5352S Clinical Trial Team |

275 | THE IMPACT OF SYNBIOTICS IN ADVANCED HIV DISEASE: A RANDOMIZED CLINICAL TRIAL | Sergio Serrano-Villar, Maria Lagarde, Nadia Madrid, Jose I. Bernardino, Alejandro Vallejo, Carolina Gutierrez, Alfonso Cabello, Mariano Matarranz, Judit Villar, Alberto Diaz de Santiago, Jose-Ramon Blanco, Talia Sainz, Federico Pulido, Santiago Moreno, Vicente Estrada |

276 | Poster P-C1 KILLERS: NK AND CD8 CELLS                                  | Carly Elizabeth C. Starke, Jason Brenchley |

277 | TCF-1 EXPRESSION IS ASSOCIATED WITH HIV-SPECIFIC CD8+ T CELL PROLIFERATIVE CAPACITY | Rachel L. Rutishauser, Christian Deo T. Deguit, Rebecca Hoh, Michelle A. Hough, Melissa Krone, Rafick-Pierre Sekaly, Frederick M. Hecht, Christopher D. Pilcher, Jeffrey N. Martin, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt |

278 | LONGITUDINAL T CELL RESPONSES IN HIV-EXPOSED INFANTS WITH CONGENITAL CMV INFECTION | Pamela M. Odorizzi, Rachel L. Rutishauser, Ruth Cortado, Margaret Feeney, Trevor Burt, Karin Nielsen-Saines, Deborah Persaud, Yvonne Bryson, Joseph M. McCune |

279 | PHOSPHORYLATED HIV-1 AS POTENTIAL CYTOTOXIC T LYMPHOCYTE (CTL) TARGETS | Fatema Z. Chowdhury, Shivaali Maddali, Matthew J. Szucs, Rushdy Ahmad, John Sidney, Alessandro Sette, Pratikkumar Rathod, Emmanuel J. Chang, Mathias Lichterfeld, Xu G. Yu |
280  EVALUATING THE LINK BETWEEN MITOCHONDRIAL STATE & HIV-SPECIFIC CD8+ T CELL EXHAUSTION  
Christian Deo T. Deguit, Michelle A. Hough, Rebecca Hoh, Melissa Krone, Christopher D. Pilcher, Jeffrey N. Martin, Steven G. Deeks, Joseph M. McCune, Peter W. Hunt, Rachel L. Rutishauser

281  S100A14, NOVEL NK CROSS TALK PROTEIN FOR MONOCYTE-NK ACTIVATION IN HESN-IDU SUBJECTS  
Krystal Colon-Rivera, Costin Tomescu, David Metzger, David W. Speicher, Luis Montaner

282  FUNCTIONAL MECHANISMS OF MEMORY-LIKE NK CELLS IN SIV-INFECTED MACAQUES  
Spandan Shah, Cordelia Manickam, Daniel Ram, R. Keith Reeves

283  IFN-ALPHA ENHANCES NK CELL AND CD8+ T CELL MEDIATED SUPPRESSION OF HIV REPLICATION  
Abena Kwaa, Joel Blankson

---

Poster P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES  
Poster Hall A  2:30 PM – 4:00 PM

284  FREQUENCIES AND DISTRIBUTION OF ENV-SPECIFIC B CELLS IN BLOOD VERSUS LYMPH NODES  
Alessandra Noto, Andrew McDavid, Phu Van, Madeleine Suffiotti, Agostino Riva, Jean-Marc Corpataux, Song Ding, Craig Fenwick, Raphael Gottardo, Giuseppe Pantaleo

285  T AND B CELL ALTERATIONS IN PERIPHERAL BLOOD AND LYMPH NODE IN ACUTE HIV INFECTION  
Supranee Buranapraditkun, Hiroshi Takata, Carlo Sacdalan, Sopark Manasnyakorn, Suthat Chotchanapund, Pattarawat Thantiworasit, Peeriya Prueksakaw, Khunthalee Benjapornpong, Bessara Nuntapin, Timothy Schacker, Merlin L. Robb, Nelson L. Michael, Jintanat Ananworanich, Lydie Trautmann, for the RV254/SEARCH010

286  CYTOLYTIC CD4+ T CELLS WITH FOLLICULAR HOMING PROPERTIES IN CHRONIC HIV INFECTION  
Enrico Richter, Johanna Eberhard, Marek Korencak, Bruce T. Schultz, Britta Flach, Stefan Esser, Julian Schulze zur Wiesch, Hendrik Streeck

287  TFC CELLS INTERACT WITH OTHER FOLLICULAR T CELLS TO CONTROL SIV VIREMIA  
Mohammad Arif Rahman, Katherine M. McKinnon, Tatiana S. Karpova, David A. Ball, David Venzon, Wenjin Fan, Guobin Kang, Qingsheng Li, Marjorie Robert-Guroff

---

Poster P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS  
Poster Hall A  2:30 PM – 4:00 PM

375  SIV PROVIRAL LANDSCAPE DIFFERS FROM THAT OF HIV-1 AND SHOWS GROSS HYPERMUTATION  
Alexandra J. Murray, Katherine Bruner, Mithra R. Kumar, Andrew Timmons, Po-Ting Liu, Janice E. Clements, Dan Barouch, Janet Siliciano, Robert Siliciano

376  IL-10 SIGNALING IS A KEY MECHANISM OF SIV PERSISTENCE IN ART-TREATED RHESUS MACAQUES  
Justin L. Harper, Maria Pino, Luca Micci, Susan P. Ribeiro, Claire Deleage, Hong Wang, Colin T. King, Daniel Gorman, Jacob D. Estes, Rafick-Pierre Sekaly, Mirko Paiardini
NOVEL SHIVS ENCODING TRANSMITTED/FOUNDER ENVS FOR LATENCY AND CURE RESEARCH

Anya Bauer, Fang-Hua Lee, Hui Li, Ronald Veazey, Meagan Watkins, George Shaw, Katharine J. Bar

CLONES WITH INTACT PROVIRUSES ARE FOUND IN MULTIPLE CD4+ T CELL MATURATION SUBSETS

Andrew Musick, Eli A. Boritz, Jonathan Spindler, Michael J. Bale, Michele Sobolewski, Wei Shao, Stephen H. Hughes, John M. Coffin, John W. Mellors, Frank Maldarelli, Mary F. Kearney

MULTI-COMPARTMENT DISSEMINATION OF GENOME-INTACT HIV-1 RESERVOIR CLONES

Guinevere Q. Lee, Riddhima Banga, Matthias Cavassini, Jean-Marc Corpataux, Xu G. Yu, Giuseppe Pantaleo, Matthieu Perreau, Mathias Lichterfeld

WITHDRAWN

HIV INTEGRATES IN GENES REGULATING CELL CYCLE, DNA DAMAGE, & VIRAL TRANSPORT

Sulggi Lee, Kevin G. Haworth, Cassandra Thanh, Lauren E. Schechter, Zachary K. Norgaard, Christopher D. Pilcher, Frederick M. Hecht, Jeffrey N. Martin, Timothy J. Henrich, Steven G. Deeks, Hans-Peter Kiem

INTEGRATION SITE-INDEPENDENT ENHANCEMENT OF LATENCY REVERSAL BY HIV-1 NEF

Xiao Mei T. Kuang, Steven W. Jin, Tristan M. Markle, Mark Brockman

HIGHER RECTAL P24 LEVELS CORRELATE WITH POOR CD4 RECOVERY IN TREATED HIV INFECTION

Bonnie J. Howell, Guoxin Wu, Shih Lin Goh, Paul Zuck, Montha Pao, Monika Deswal, Rebecca Hoh, Jeffrey N. Martin, Steven G. Deeks, Ma Somsouk, Daria Hazuda, Peter W. Hunt, for the DARE Collaboratory

ALTERED PD-1/PD-L1 INTERACTIONS IN GERMINAL CENTERS OF TREATED HIV-INFECTED SUBJECTS

Riddhima Banga, Caterina Rebecchini, Francesco Procopio, Stephanie D. Georget, Fabio Candotti, Matthias Cavassini, Jean-Marc Corpataux, Laurence de Leval, Giuseppe Pantaleo, Matthieu Perreau

CD32 EXPRESSION IS ASSOCIATED TO T CELL ACTIVATION AND UPREGULATED BY HIV

Roger Badia, Edurne Garcia Vidal, Maria Pujantell, Bonaventura Clotet, Miguel Angel Martinez, Ester Ballana, Eva Riveira-Muñoz, Jose A. Este

HIV-SEROREVERSION DYNAMICS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Maria Salgado, Victoria Gonzalez, Belen Rivaya, Cristina Gálvez, Mi Kwon, Jon Badiola, Alessandra Bandera, Björn Jensen, Linos Vandekerckhove, Kavita Raj, Monique Nijhuis, Jose Luis Diez, Annemarie Wensing, Javier Martinez-Picado, for the IciStem Consortium
**Poster Sessions**

387 **IMMUNE ACTIVATION CORRELATES WITH EXPRESSION OF CD32 ON CD4+ T CELLS OF HIV PATIENTS**
Melanie Wittner, Gabor Dunay, Johanna Eberhard, Julian Schulze zur Wiesch

388 **THE HIV RESERVOIR RESIDES MAINLY IN CD32A–/CD4+ T CELLS IN PERINATAL INFECTION**

389 **CD4+ T CELLS EXPRESSING CD32 FROM HIV-1+ PATIENTS ARE NOT ENRICHED FOR PROVIRAL DNA**
Adam M. Spivak, Racheal Nell, McKenna L. Coletti, Luis Montaner, Vicente Planelles

390 **PRODUCTIVE HIV 1 INFECTION UPREGULATES CD32 IN VITRO AND IN VIVO**
Carla Serra Peinado, Judith Grau-Expósito, Merixtell Genescà, Laura Luque-Ballesteros, Cristina Gálvez, Josep Castellví, Rein Willekens, Luis Montaner, Vicenç Falcó, Javier Martínez-Picardo, María J. Buzón

391 **HIV 1 BURDEN IN PERIPHERAL BLOOD AND GUT CD4+ T CELLS EXPRESSING CD30 AND CD32**
Louise Hogan, Joshua Vasquez, Kristen Hobbs, Emily Hanhauser, Brandon Aguilar-Rodriguez, Cassandra Thanh, Erica Gibson, Alexander Carvidi, Louis Smith, Ma Somsouk, Daniel R. Kuritzkes, Steven G. Deeks, Timothy J. Henrich

392 **HIV ANTIBODY AND T CELL RESPONSES ON ART ARE ASSOCIATED WITH HIV DNA BUT NOT RNA**
Sheila M. Keating, R. Brad Jones, Christina Lalama, Ronald Bosch, Deborah McMahon, Dylan Hampton, Evelyn Hogg, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Michael P. Busch, Rajesh T. Gandhi, for the ACTG 5321 team

**Poster P-D10 QUANTIFYING HIV RESERVOIRS**
Poster Hall A 2:30 PM – 4:00 PM

393 **BLINDED EVALUATION OF ULTRASENSITIVE ASSAYS OF HIV IN PLASMA**
Sheila M. Keating, Mars Stone, Xutao Deng, Sonia Bakkour, John W. Mellors, Douglas D. Richman, Rob Gorelick, Jeffrey D. Lifson, Cheryl Jennings, Martin Stengelin, Guoxin Wu, Bonnie J. Howell, Peter Bacchetti, Michael P. Busch, for the Reservoir Assay Validation and Evaluation Network (RAVEN) Study Group

394 **QUANTIFYING THE TURNOVER OF LATENT HIV: APPLICATIONS TO ANTI-PROLIFERATIVE THERAPY**
Jeffrey Gerold, Michael J. Bale, Zheng Wang, Guinevere Q. Lee, Mathias Lichterfeld, Robert Siliciano, Mary F. Kearney, Alison L. Hill

395 **SINGLE CELL ANALYSIS OF HIV LATENCY REVEALS DIVERSE PROVIRAL AND HOST CELL BEHAVIOR**
Edward P. Browne, Todd Bradley, Guido Ferrari, Barton F. Haynes, David M. Margolis

396 **ULTRASENSITIVE P24 DIGITAL ELISA CAN LEAD TO AN OVERESTIMATE OF HIV RESERVOIR SIZE**
Francesco R. Simonetti, Subul A. Beg, Jun Lai, Purvish Patel, Hao Zhang, Gregory Laird, Lynn N. Bertagnolli, David Kulick, Robert Siliciano, Janet Siliciano
NEXT-GEN VIRAL OUTGROWTH ASSAYS AS PROXIES FOR CLASSIC QVOA TO MEASURE HIV RESERVOIR
Mars Stone, Daniel S. Rosenbloom, Peter Bacchetti, Xutao Deng, Melanie Dimapopoulos, Sheila M. Keating, Douglas D. Richman, John W. Mellors, Steven G. Deeks, Janet Siliciano, Nicolas Chomont, Roger Ptak, Michael P. Busch, for the RAVEN

QVOA COUPLED WITH DIGITAL P24 ANALYSIS ENHANCES HIV RESERVOIR QUANTIFICATION
Elizabeth R. Wonderlich, Yury V. Kuzmichev, Carol Lackman-Smith, Marie K. Mankowski, Christine N. Raney, Hayley P. Madeira, Jiayi Wei, Rebecca M. Bernbaum, Krupa Subramanian, Rachel L. Jarrett, Ellen R. Nordgren, Mars Stone, Michael P. Busch, Roger Ptak, Deanna Kulpa

QUANTIFICATION OF REPLICA COMPETENT LATENT HIV-1 IN GALT AND SEMEN
Anwesha Sanyal, Ian McGowan, Ma Somsouk, Charles Rinaldo, Nicolas Sluis-Cremer, Phalguni Gupta

SINGLE-CELL RNA SEQUENCING TO CHARACTERIZE CSF IN VIROLOGICALLY SUPPRESSED HIV
Shelli Farhadian, Chryssa Zografu, Sameet Mehta, Jennifer Chiarella, Kevin Robertson, Sarah Yosief, Jenna Pappalardo, David Hafler, Serena S. Spudich

HIV-RNA IN THE OLFATORY MUCOSA OF HIV-POSITIVE PATIENTS
Mattia Trunfio, Tiziano Allice, Luca Bertero, Daniele Imperiale, Sebastiano Catera, Veronica Pirriatore, Giovanni Di Perri, Maria Enrica Amasio, Paola Cassoni, Valeria Ghisetti, Stefano Borzoni, Andrea Calcagno

DISTINCT HIV POPULATIONS IN CSF AND BLOOD DURING ACTIVE CRYPTOCOCCAL MENINGITIS
Maura Manion, Camille Lange, Kathy Huppler Hullsiek, Brandon Keele, Helene Highbarger, David Meya, David R. Boulware, Frank Maldarelli, Irini Sereti

NEUROLOGIC STABILITY WITH BRIEF ANALYTIC TREATMENT INTERRUPTION AFTER EARLY ART
Joanna Hellmuth, Donn Colby, Eugene Kroon, Carlo Sacdalan, Phillip Chan, Jintana Intasan, Victor Valcour, Trevor Crowell, Linda Jagodzinski, Khunthalee Benjapornpong, Nelson L. Michael, Jintanat Ananworanich, Robert Paul, Serena S. Spudich, for the SEARCH 010/RV254 Study Group

SPECIFIC CSF VIRAL ESCAPE FINDINGS COMPARED TO PRE-CART HIV ENCEPHALITIS
Valentina De Zan, Francesca Ferretti, Simonetta Gerevini, Laura Passeri, Adriano Lazzarin, Cinque Paola

RISK AND PREDICTORS OF ASYMPTOMATIC AND SYMPTOMATIC CSF VIRAL ESCAPE IN HIV+ PATIENTS
Carmela Pinnetti, Patrizia Lorenzini, Ilaria Mastrorosa, Valentina Fedele, Stefania Carta, Alessandra Vergori, Alberto Giannetti, Massimo Tempestilli, Adriana Ammassari, Susanna Grisetti, Francesco Baldini, Chiara Agrati, Maria R. Capobianchi, Carlo F. Perno, Andrea Antinori
CSF AND BLOOD HIV RNA RELATIONSHIP IN ACUTE HIV IS LINKED TO CD4/CD8 RATIO
Phillip Chan, Payal Patel, Joanna Hellmuth, Donn Colby, Eugène Kroon, Carlo Sacdalan, James L. Fletcher, Suteeraporn Pinyakorn, Linda Jagodzinski, Shelly J. Krebs, Nelson L. Michael, Jintanat Ananworanich, Victor Valcour, Serena S. Spudich, for the RV254/SEARCH 010 Study Team

PERIPHERAL AND CSF IMMUNE ACTIVATION AND INFLAMMATION IN HIV+ PATIENTS STARTING CART
Esther Merlini, Francesca Iannuzzi, Andrea Calcagno, Francesca Bai, Mattia Trunfio, Antonella D’Arminio Monforte, Stefano Bonora, Giulia Marchetti

NOX-4 ASSOCIATED NITROSATIVE STRESS AND INEPT REDOX ADAPTATION IN AGED HIV-1 TG RAT
William Reid, Swati Shah, Frank Denaro, Dragan Maric, Dima A. Hammoud

CEREBROSPINAL FLUID AND SERUM NEPRILYSIN IN PATIENTS INFECTED WITH HIV CLADES C AND B
Sergio M. de Almeida, Clea E. Ribeiro, Indiana Rotta, Mauro Piovesan, Bin Tang, Meire S. Batistella, Scott L. Letendre, Michael Potter, Florin Vaida, Ronald J. Ellis

REGIONAL BRAIN HEME OXYGENASE CORRELATES WITH SIV LOAD IN ACUTE/CHRONIC INFECTION
Rolando Garza, Maria Diaz Ortiz, Analise Gruenewald, Fiorella Rossi, Ferzin Sethna, Guido Silvestri, Michael R. Betts, Dennis L. Kolson

CSF EXTRACELLULAR VESICLES AS BIOMARKERS OF CNS INJURY IN HIV PATIENTS ON ART
Debjani Guha, Sukrutha Chettimada, Vikas Misra, David Lorenz, Dana H. Gabuzda

DELETERIOUS EFFECTS OF HIV-1 LATENCY-REVERSING AGENTS MEDIATED BY ASTROCYTES
Alizé Proust, Corinne Barat, Mathieu Leboeuf, Jean Drouin, Michel J. Tremblay

DESIGN & SYSTEMS PHARMACOLOGY ANALYSIS OF ORAL LONG-ACTING ANTIRETROVIRAL THERAPY
Morgan L. Craig, Alison L. Hill, Christopher D. Bruno, Shirley S. Mo, Ameya Kirtane, Martin A. Nowak, Robert Langer, Carlo G. Traverso

PRECLINICAL EVALUATION OF A REDUCED DOSE DARUNAVIR/RITONAVIR NANO PARTICLE FORMULATION
Helen J. Box, Joanne Sharp, Megan Neary, Darren M. Moss, Lee M. Tatham, Hannah Kinvig, Alison C. Savage, Samantha Ashcroft, David Back, Steve Rannard, Andrew Owen
CHARM-03: SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ORAL AND TOPICAL MARAVIROC
Ian McGowan, Rhonda M. Brand, Jarret C. Engstrom, Aaron Siegel, Ashley Myerski, Cindy Jacobson, Mark A. Marzinke, Craig W. Hendrix, Alex Rinehart, John Steytler, Charlene S. Dezzutti, Nicola Richardson-Harman, Hans M. Spiegel, Ross Cranston, for the Charm-03 team

MARAVIROC SOLID DRUG NANOPARTICLES WITH IMPROVED ORAL PHARMACOKINETICS
Lee M. Tatham, Alison C. Savage, Andrew Dwyer, Marco Siccardi, Steve Rannard, Andrew Owen

TOWARDS A LONG-ACTING INJECTABLE (LAI) FORMULATION FOR MARAVIROC
Lee M. Tatham, Andrew Dwyer, Alison C. Savage, Marco Siccardi, Steve Rannard, Andrew Owen

IN VIVO PHARMACOKINETICS OF NOVEL LONG-ACTING INJECTABLE EMTRICITABINE PRODRUGS
Paul Curley, James J. Hobson, Christopher David, Amer Al-Khouja, David Meyers, Caren Freel Meyers, Charles W. Flexner, Marco Siccardi, Steve Rannard, Andrew Owen

PBPK MODELING OF MICROARRAY PATCHES FOR LONG-ACTING INTRADERMAL DRUG DELIVERY
Rajith Kumar Reddy Rajoli, Charles W. Flexner, Andrew Owen, Ryan Donnelly, Marco Siccardi

PHARMACOKINETICS OF TENOFOVIR ALAFENAMIDE BY SUBCUTANEOUS IMPLANT FOR HIV PREP
Greg Gatto, Natalie Girouard, Rhonda M. Brand, Leah Johnson, Mark A. Marzinke, Sudie Rowshan, Jarret C. Engstrom, Ian McGowan, Zach Demkovich, Ellen Luecke, Ariane van der Straten

LONG-ACTING 3 HIV-DRUGS-IN-ONE NANOPARTICLE FORMULATION INTENDED FOR ADOLESCENTS
Josefin Koehn, John C. Kraft, Lisa McConnachie, Loren Kinman, Sarah Lane, Wonsok Lee, Ann Collier, Rodney J. Ho

LONG-ACTING PHARMACOKINETICS OF 4 HIV DRUGS COFORMULATED IN ONE NANO-FORMULATION
Lisa McConnachie, Loren Kinman, Josefin Koehn, John C. Kraft, Sarah Lane, Wonsok Lee, Ann Collier, Rodney J. Ho, for the NIH-funded UM1 TLC-ART Program

DTG VERSUS LPV/R IN SECOND LINE (DAWNING): OUTCOMES BY WHO-RECOMMENDED NRTI BACKBONE
Michael Aboud, Carlos Brites, Hongzhou Lu, Khuanchai Supparatpinyo, Luis Hercilla, Jörg Sievers, Maria Claudia Nascimento, Judy Hopking, Mark Underwood, Dannae Brown, Martin Gartland, Kim Smith

INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) EFFECTIVENESS IN ART-EXPERIENCED PATIENTS
Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharova, David Wohl, Claire E. Farel, Joseph J. Eron
510 VIROLOGIC RESPONSE TO 2-DRUG ART REGIMENS AMONG TREATMENT-EXPERIENCED HIV+ PATIENTS
Gerald Pierone, Cassidy Henegar, Jennifer Fusco, Vani Vannappagari, Michael Aboud, Leigh Ragone, Gregory Fusco

511 TREATING MULTICLASS-RESISTANT HIV+PATIENTS IN RWANDA USING A PUBLIC HEALTH APPROACH
Sabin Nsanzimana, Muhayimpundu Ribakare, Remera Eric, Amitabh B. Suthar, Riedel J. David, Edward J. Mills, Heiner C. Bucher

Poster P-H5 ANTIRETROVIRAL ADHERENCE
Poster Hall D 2:30 PM – 4:00 PM

512 ADHERENCE IN EARLY VERSUS LATE ART INITIATION IN SUB-SAHARAN AFRICA
Jessica E. Haberer, Bosco M. Bwana, Catherine Orrell, Stephen Asimwe, Gideon Amanyire, Nicholas Musinguzi, Mark J. Siedner, Kathleen Bell, Annet Kembabazi, Stephen Mugisha, Victoria Kibirige, Anna Cross, Nicola Kelly, David R. Bangsberg, for the META team

513 ADHERENCE TO COMBINATION ANTIRETROVIRAL THERAPY (ART) IN SUB-SAHARAN AFRICA
Judith J. Lok, Elisavet Syriopoulou, Dustin J. Rabideau, Beverly Musick, Jeffrey N. Martin, Kara K. Wools-Kaloustian, Ronald Bosch, Ann Mwangi, Constantin T. Yiannoutsos

514 USING INPATIENT DOT TO IDENTIFY TRUE ART FAILURE AND IMPROVE TREATMENT OUTCOMES
Nicole E. Winchester, Safia S. Kuriakose, Frank Maldarelli, Michael Proschan, Yolanda Mejia, Holly Ann Baus, Megan Anderson, Robin L. Dewar, H. Clifford Lane, Alice K. Pau

515 PATTERNS OF WISEPILL DEVICE USE IN AFRICAN ADULTS TAKING ANTIRETROVIRAL THERAPY (ART)
Catherine Orrell, Nicholas Musinguzi, Norma C. Ware, Anna Cross, Bosco M. Bwana, Stephen Asimwe, Gideon Amanyire, David R. Bangsberg, Jessica E. Haberer

Poster P-H6 VIRAL LOAD MONITORING AND SUPPRESSION
Poster Hall D 2:30 PM – 4:00 PM

516 ROUTINE VS TARGETED VIRAL LOAD STRATEGY AMONG PATIENTS STARTING ART IN HANOI, VIETNAM
Todd Pollack, Duong T. Hao, Thuy T. Pham, Thang D. Nguyen, Howard Libman, Long Ngo, Julian Elliot, Cuong D. Do Duy, Donn Colby

517 CLINICAL AND VIROLOGICAL IMPACT OF LOW-LEVEL VIREMIA IN TREATED HIV INFECTED PATIENTS
Enrique Bernal, Inma Jarrin, Alfredo Cano, Antonia Alcaraz, Angeles Muñoz, Pascual Balsalobre, Jorge Romero, Jose-Ramón Blanco, Federico García, Miguel Górgolas, Félix Gutiérrez, for the CoRIS

518 VL SUPPRESSION AT ULTRASENSITIVE LEVELS IS ASSOCIATED WITH INSTI-INITIATION ART
Poster Sessions

519 STIMULANT USERS RECEIVING ART DISPLAY INCREASING RATES OF HIV SUPPRESSION
Adam W. Carrico, Elise D. Riley, Torsten B. Neilands, Samantha E. Dillworth, Jeffrey N. Martin, Steven G. Deeks, Peter W. Hunt

Poster P-H7 IMMUNE RECOVERY AND HIV CONTROL
Poster Hall D  2:30 PM – 4:00 PM

520 FUNCTION OF CD4 RECOVERY AND DECREASING IMMUNE ACTIVATION OF A CHINESE HERB: TWHF
Wei Lu, Yuchao Liu, Yang Han, Zhifeng Qin, Xiaojing Song, Taisheng Li

521 METABOLIC SHUT DOWN OF CD4 T CELL ACTIVITY AND FUNCTION INDUCED BY HAART
Marek Korencak, Enrico Richter, Eva Eilers, Bruce T. Schultz, Patrick Juszczak, Stefan Esser, Hendrik Streeck

522 NATURAL CONTROL OF HIV INFECTION IN A COHORT OF YOUNG WOMEN IN SOUTH AFRICA: HPTN 068
Mariya V. Sivay, Yinfeng Zhang, Jing Wang, Jessica M. Fogel, Estelle Piwowar-Manning, William Clarke, Erica Hamilton, Kathleen Kahn, Amanda Selin, Xavier Gomez-Olive, Catherine MacPhail, James P. Hughes, Audrey Pettifor, Susan H. Eshleman, for the HPTN 068 Study Team

Poster P-I5 PREVALENCE OF ANTIRETROVIRAL THERAPY RESISTANCE: THE POPULATION MATTERS
Poster Hall D  2:30 PM – 4:00 PM

550 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG MSM IN SUB-SAHARAN AFRICA (HPTN 075)
Yinfeng Zhang, Jessica M. Fogel, Xu Guo, William Clarke, Autumn Breaud, Vanessa Cummings, Erica Hamilton, Arthur Ogendo, Noel Kayange, Ravindre Panchia, Karen Dominguez, Ying Q. Chen, Theodorus Sandfort, Susan H. Eshleman, for the HPTN 075 Study Team

551 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG YOUNG WOMEN IN SOUTH AFRICA (HPTN 068)
Yinfeng Zhang, Mariya V. Sivay, Sarah E. Hudelson, Jing Wang, Yaw Agyei, William Clarke, Autumn Breaud, Erica Hamilton, Kathleen Kahn, Xavier Gomez-Olive, Catherine MacPhail, James P. Hughes, Audrey Pettifor, Susan H. Eshleman, for the HPTN 068 Study Team

552 PREVALENCE OF NRTI, NNRTI AND PI MUTATIONS ACROSS BOTSWANA IN 2013 — 2015
Sikhulile Moyo, Simani Gaseitsiwe, Melissa Zahralban- Steele, Dorcas Maruapula, Batshepi Mokaleng, TERENCE Mohammed, Erik van Widenfelt, Madisa Mine, Elliot G. Raizes, Etienne Kadima, Tendani Gaolathe, Joseph Makhma, Shahin Lockman, Max Essex, Vlad Novitsky

553 ARV RESISTANCE AND CO-RECEPTOR TROPISM IN HIV+ DECEASED ORGAN DONORS IN THE US
Gilad Bismut, Christine Durand, Diane M. Brown, Brianna Doby, Shanti Seaman, Michael Seisa, Christos Petropoulos, Reinaldo Fernandez, Dorry Segev, Aaron Tobian, Andrew D. Redd

554 IMPROVED CARE OF SOCIALLY DISADVANTAGED PATIENTS IS NEEDED TO REDUCE DRUG RESISTANCE
Irene A. Abela, Alexandra Scherrer, Jürg Böni, Sabine Yerly, Thomas Klimkait, Matthieu Perreau, Manuel Battegay, Hansjakob Furrer, Alexandra Calmy, Patrick Schmid, Matthias Cavassini, Enos Bernasconi, Huldrych F. Günthard, for the Swiss HIV Cohort Study
Poster Sessions

Poster P-I6 NEW INSIGHTS INTO ANTIRETROVIRAL SUSCEPTIBILITY AND RESISTANCE
Poster Hall D 2:30 PM – 4:00 PM

555 PASEQ: ONE-CLICK, CLOUD-BASED WEB SERVICE FOR NGS-BASED HIV GENOTYPING DATA ANALYSIS
Jordi Herms, Cristina Rodriguez, Maria Casadella, Teresa Puig, Bonaventura Clotet, Roger Paredes, Marc Noguera-Julian

556 SMRT SEQUENCING OF FULL-LENGTH POL AMPLICONS TO INVESTIGATE HIV-1 DRUG RESISTANCE
Sergio Ita, Caroline Ignacio, Sanjay Mohan, Venkatesh Kumar, Benjamin Murrell, Douglas D. Richman, Davey M. Smith, Gabriel A. Wagner

557 POINT-OF-CARE HIV-1 GENOTYPIC RESISTANCE TESTING USING MELT-CURVE ANALYSIS
Dana S. Clutter, Gelareh Mazarei, Justen Manasa, Sara Bolouki, Ruma Sinha, Peter Kuimelis, Robert Kuimelis, Benjamin Pinsky, Gary Schoolnik, Arjang Hassibi, Robert Shafer

558 PROTEASE, GAG AND GP41 MUTATIONS ASSOCIATED WITH VIROLOGICAL RESPONSE TO PI REGIMEN

559 HIV-1 GAG REDUCES PI-SUSCEPTIBILITY IN THE ABSENCE OF PROTEASE RESISTANCE MUTATIONS
Oscar Blanch-Lombarte, José Ramón Santos, Ruth Penya, Alba Ruiz, Esther Jimenez-Moyano, Roger Paredes, Bonaventura Clotet, Julia G Prado, for the VIRIEVAC

560 ACTIVITY OF TENOFOVIR ALAFENAMIDE IN HIV-1 WITH THYMIDINE ANALOG MUTATIONS AND M184V
Nicolas A. Margot, Renee R. Ram, Michael E. Abram, Richard Haubrich, Michael D. Miller, Christian Callebaut

561 IBALIZUMAB SUSCEPTIBILITY IN PATIENT HIV ISOLATES RESISTANT TO ANTIRETROVIRALS
Steven Weinheimer, Zvi Cohen, Christian Marsolais, Stanley Lewis

562 RPV LA DOES NOT INHIBIT RESISTANT HIV TRANSMISSION OR SELECT SIGNIFICANT RESISTANCE
Zandrea Ambrose, Kevin Melody, Chris Kline, Mackenzie L. Cottrell, Brandon Keele, Angela Kashuba, Moses Bility

Poster P-K07 NON-B, NON-C HEPATITIS
Poster Hall D 2:30 PM – 4:00 PM

625 HAV EPIDEMICS AMONG MSM: HIGH PREVALENCE OF HIV INFECTED PATIENTS
Veronique Lemee, Anne-Marie Roque-Afonso, Elodie Alessandri-Gradt, Lina Mouna, Laure Izquierdo, Odile Goria, Hélène Montialoux, Valerie Delbos, Thomas Mourez, Jeremie Leporrier, Jean-Christophe Plantier, Ghassan Riachi
**Poster Sessions**

626  **ACUTE HEPATITIS A AMONG HIV-INFECTED THAI MSM IS LINKED TO MSM IN EUROPE AND TAIWAN**

Donn Colby, Nawarat Posuwan, Carlo Sacdalan, Jintana Intasan, Eugène Kroon, Tanyporn Wansom, Nittaya Phanuphak, Jintanat Ananworanich, Merlin L. Robb, Praphan Phanuphak, Yong Poovorawan, for the RV254/SEARCH010 Study Team

627  **SEROPREVALENCE AND RISK FACTORS OF HEPATITIS E AMONG PLHIV IN SOUTH WESTERN FRANCE**

Marc Vareil, Florence Abravanel, Heidi Wille, Anne-Christine Jaouen, David Leysenne, Jacques Izopet

628  **HEPATITIS C VIRUS AND HUMAN PEGIVIRUS 2 SURVEILLANCE IN A LARGE CAMEROONIAN COHORT**

Mary Rodgers, Vera Holzmayer, Ana Vallari, Ana Olivo, Kenn Forberg, Jill Fuhrman, Kelly Collier, Bih Awazi, Jules Bertrand Kenmegne Sidje, Matthew Frankel, Michael Berg, Dora Mbanya, Nicaise Ndemb, Gavin Cloherty

629  **PREVALENCE AND CORRELATES OF HPGV INFECTION AMONG PWID WITH HIV INFECTION IN INDIA**

Nandagopal Paneerselvam, Thongadi R. Dinesha, Shanmugam Saravanan, Allison M. McFall, Pachamuthu Balakrishnan, Aylur K. Srikrishnan, Sunil S. Solomon, Shruti H. Mehta

Poster P-K08 HEPATITIS BEYOND THE LIVER

**Poster Hall D**  
2:30 PM – 4:00 PM

630  **HEPATITIS C VIRUS AND INCIDENT TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTION IN HIV**


631  **ERADICATION OF HCV: EFFECTS ON CARDIOVASCULAR RISK AND PRECLINICAL ATHEROSCLEROSIS**

Ana Carrero, Juan Berenguer, Victor Hontanon, Jordi Navarro, José Hernández-Quero, María J. Galindo, Carmen Quereda, Ignacio Santos, María J. Téllez, Enrique Ortega, José Sanz, Javier Bermejo, José M. Bellón, Juan González-García, for the GeSIDA 3603b Study Group

632  **RISK OF DIABETES IN HCV-HIV PATIENTS IS ASSOCIATED WITH CIRRHOSIS, NOT WITH HCV**

Aurélien Provost, Moustapha Drame, Laurent Cotte, Lise Cuzin, Rodolphe Garraffo, David Rey, François Raffi, Isabelle Poizot-Martin, Pascal Pugiéssé, Firouze Bani-Sadr

633  **HCV AND LIVER DISEASE INCREASE RISK OF NEUROCOGNITIVE IMPAIRMENT IN HIV+ INDIVIDUALS**

Ilaria Mastorrosa, Carmela Pinnetti, Patrizia Lorenzini, Alessandra Vergori, Gabriele Fabbrì, Pietro Balestra, Maria Maddalena Plazzi, Martina Ricottiini, Rita Bellagamba, Stefania Cicalini, Rita Maddaluno, Mauro Zaccarelli, Adriana Ammassari, Andrea Antinori

634  **PORPHYRIA CUTANEA TARDTA EVOLUTION IN HCV+/HIV+/ PATIENTS POST TREATMENT WITH HCV DAA**

Lucio Jesus García-Fraile Fraile, Pablo Rodríguez, Luisa Consuelo García Buey, Concepción Alonso Cerezo, Ignacio d. Santos Gil
635 INFLAMMATION AND IMMUNE ACTIVATION MARKERS IN HEPATITIS C INFECTION AND CLEARANCE
Ruibin Wang, Chloe Thio, Otoniel Martinez-Maza, Steven Wolinsky, Yue Chen, Eric C. Seaberg

636 IMPACT OF OCCULT HCV INFECTION (OCI) ON SYSTEMIC IMMUNE ACTIVATION AFTER DAA THERAPY
David M. Asmuth, Annie Y. Chen, Netanya S. Utay, Natalie Torok, Patricia L. Poole, Joy Vongsphanich, Kathleen R. Haigh, Anoma D. Sumasunderam, Enkhmaa Byambaa, Xiao-Dong Li, Stuart T. Cohen, Lars Berglund, Mark Holodniy, Tomasz I. Michalak

Poster P-K09 MICRO-RNA: A LOT OF INFORMATION IN A LITTLE BIT OF RNA
Poster Hall D 2:30 PM – 4:00 PM

637 POTENTIAL FOR SERUM MICRO-RNAs TO PREDICT FIBROSIS REGRESSION DURING HBV TREATMENT
Cody Orr, Rob Myers, David Gong, Biao Li, Zhaoshi Jiang, John Flaherty, Anuj Gaggar, G. Mani Subramanian, Eric G. Meissner

638 HEPATIC EXPRESSION OF HSA-MIR-125A-5P AND FIBROSIS IN OVERT AND OCCULT HBV INFECTION
Lorenzo Onorato, Aniello Russo, Giorgio de Stefano, Carmine Minichini, Mario Starace, Pietro Filippini, Loredana Alessio, Nunzia Farella, Nicoletta Potenza, Evangelista Sagnelli, Nicola Coppola

639 CIRCULATING MICRORNAS IN HIV PATIENTS REVEAL SPECIFIC SIGNATURES FOR LIVER DAMAGE
Miguel Angel Martinez, Sandra Franco, Daniela Buccione, Beatriz Mothe, Lidia Ruiz, Maria Nevet, Ana Jordan-Paiz, Raquel Pluvinet, Susanna Aussó, Rosa M. Morillas, Lauro Sumoy, Cristina Tural

640 MIRNA PROFILE OF HCV SPONTANEOUS CLEARANCE INDIVIDUALS SHOW PREVIOUS HCV INFECTION
Óscar Brochado Kith, Alicia Gómez Sanz, Luis M. Real, Javier Crespo, Pablo Ryan, Juan Macías, Joaquina Cabezas, Juan A. Pineda, María T. Arias-Loste, Isabel Cuesta, Sara Monzón-Fernández, Luz M. Medrano, María A. Jimenez-Sousa, Salvador Resino, Amanda Fernández-Rodriguez

Poster P-L3 HIV-RELATED LYMPHOMA AND LIVER CANCER
Poster Hall D 2:30 PM – 4:00 PM

667 ANAPLASTIC LARGE CELL LYMPHOMA IN HIV-INFECTED INDIVIDUALS
Parag Mahale, Dennis D. Weisenburger, Amy R. Kahn, Lou Gonsalves, Karen Pawlish, Lori Koch, Mirabel Tirado-Gomez, Christina A. Clarke, Glenn Copeland, Geogetra Albertson, Meredith S. Shiels, Eric A. Engels

668 CNS-IPI AS RISK MODEL FOR CNS RELAPSE IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
Alessandra Bandera, Davide Dalu, Ilaria De Benedetto, Elisa Colella, Gaia Bombonati, Elisa Doni, Fulvio Crippa, Omar Giglio, Maurizio Mena, Elisa Suardi, Paola Vitiello, Carlo Gambacorti Passerini, Andrea Gori, Luisa Verga, for the Musthal Study Group

669 PRESENTATION AND OUTCOME OF BIOPSY-PROVEN HEPATOCELLULAR CARCINOMA BY HIV STATUS
Jessie Torgersen, Lesley Park, Tamar Taddei, Dena M. Carbonari, Michael J. Kallan, Kisha Mitchell-Richards, Xuchen Zhang, Kathryn D’Addeo, Rajni Mehta, Farah Kidwai-Khan, Amy C. Justice, Vincent Lo Re
670  ANTIRETROVIRAL DRUGS ASSOCIATED WITH SUBCLINICAL CORONARY ARTERY DISEASE
Helen Kovari, Alexandra Calmy, Thanh Doco-Lecompte, René Nkoulou, Alex Marzel, Rainer Weber, Philipp A. Kaufmann, Ronny R. Buechel, Bruno Ledergerber, Philip E. Tarr

671  CAROTID IMT PROGRESSION IS MOST STRIKING IN FIRST 48 WEEKS OF ANTIRETROVIRAL THERAPY
Corrilynn O. Hileman, Grace A. McComsey

672  EFFECTS OF ANTIRETROVIRAL THERAPY ON ALLELE-ASSOCIATED LIPOPROTEIN(A) LEVEL IN HIV

673  COMPARATIVE IMPACT OF ANTIRETROVIRALS ON HUMAN PLATELET ACTIVATION
Kirk A. Taylor, Francesca Rauzi, Erica Smyth, Mark Nelson, Brian Gazzard, Michael Emerson

674  LEUKOCYTES ARE KEY TO THE PRO-THROMBOTIC EFFECTS OF ABACAVIR
Victor Collado-Díaz, Ainhoa Sanchez-Lopez, Samuel Orden, Maria Amparo Blanch-Ruiz, Maria Angeles Martinez-Cuesta, Isabel Andujar, Angeles Alvarez, Juan V. Esplugues

675  EXPLORING CHANGES IN HDL AND MONOCYTE ChOLESTEROL METABOLISM WITH ART INITIATION

676  FUNCTIONAL STATUS ASSOCIATED WITH CARDIOVASCULAR DISEASE AND DIABETES IN HIV+ ADULTS
Sean G. Kelly, Kunling Wu, Katherine Tassiopoulos, Kristine M. Erlandson, Susan L. Koletar, Frank J. Palella

677LB  CHANGE IN SOLUBLE GLYCOPROTEIN VI (SGPVI) WHEN SWITCHING FROM ABC/3TC TO TAF/FTC
Patrick W. Mallon, Robert T. Maughan, Alejandro A. Garcia, Willard Tinago, Aoife Lacey, Andrew Lovell, Eimear Dunne, Elena Alvarez-Barco, Alan Winston, Frank Post, Dermot Kenny, Mingjin Yan, Moupali Das, Martin Rhee, for the GS-US-311-1717 Platelet Sub Study Team
679 **INFLAMMATION ASSOCIATES WITH IMPAIRED ARTERIAL ELASTICITY IN EARLY HIV DISEASE**
Tess Peterson, Kathy Huppler Hullsiek, Nicole Wyman Engen, Nagalingeswaran Kumarasamy, Pamela Schreiner, Jason V. Baker, for the INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group

680 **PERIVASCULAR ADIPOSE INFLAMMATION AND MICROVASCULAR ENDOTHELIAL DYSFUNCTION IN HIV**
Cheng Wang, Tian Li, Philena Sun, Cuwei Wang, Seble Kassaye, Princy Kumar, Jennifer Verbesey, Mary Young, Christopher Wilcox, Dan Wang

681 **PCS K9 LEVELS IN RELATION TO IMMUNE ACTIVATION AND SUBCLINICAL CORONARY PLAQUE IN HIV**
Markella V. Zanni, Lauren Stone, Mabel Toribio, Dodie Rimmelin, Jake A. Robinson, Tricia H. Burdo, Kenneth C. Williams, Kathleen V. Fitch, Janet Lo, Steven K. Grinspoon

682 **AN IMMUNOLOGICAL SIGNATURE FOR SUBCLINICAL ATHEROSCLEROSIS IN HIV-1 INFECTION**
Tomas Raul Wiche Salinas, Yuwei Zhang, Annie Gosselin, Mohamed El-Far, Inna Bacearcinovic, Carl Chartrand-Lefebvre, Madeleine Durand, Cécile Tremblay, Petronela Ancuta

683 **CARDIAC MORBIDITY IN HIV IS ASSOCIATED WITH CHECKPOINT INHIBITOR LAG3**
Suresh Pallikkuth, Bagavathi Kausalya, Rajendra Pawha, Shanmuqam Saravanar, Li Pan, R Vignesh, Syed Iqbal, Sunil S. Solomon, Kailapuri G. Murugavel, Selvamuthu Poongulali, Nagalingeswaran Kumarasamy, Savita Pawha

684LB **IMPACT OF METHOTREXATE ON ARTERIAL INFLAMMATION IN PERSONS WITH TREATED HIV**

**Poster P-M3 RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ROLE OF FAT AND OTHER FACTORS**

**Poster Hall D**
2:30 PM – 4:00 PM

685 **LIPODYSTROPHTHY IS AN IMPORTANT DETERMINANT OF MARKERS OF ARTERIAL INFLAMMATION IN HIV**
Suman Srinivasa, Kathleen V. Fitch, Martin Torriani, Markella V. Zanni, Patrick Maehler, Sara E. Looby, Janet Lo, Steven K. Grinspoon

686 **CARDIAC BNP DEFICIENCY RELATES TO EXCESS ADIPOSEITY AND METABOLIC PERTURBATIONS IN HIV**
Kathleen V. Fitch, Meghan Feldpausch, Patrick Maehler, Martin Torriani, Gail K. Adler, Steven K. Grinspoon, Suman Srinivasa

687 **ASSOCIATION OF SUBCLINICAL CMV DNA AND IMMUNOLOGIC MARKERS OF CARDIOVASCULAR DISEASE**
Ankita Garg, Sara Gianella, Masato Nakazawa, Stephen A. Spector

688 **Cystatin C AND ATHEROSCLEROSIS IMAGING MARKERS IN HIV INFECTED PATIENTS**
Poster Sessions

Poster P-N03 ADIPOSE TISSUE
Poster Hall D 2:30 PM – 4:00 PM

733 CHANGE IN FAT/LEAN MASS IN HIV-POSITIVE AND -NEGATIVE SUBJECTS; DATA FROM HIV UPBEAT
Aoife G. Cotter, Alan Macken, Willard Tinago, Eoin Kavanagh, Geraldine McCarthy, Juliet Compston, Caroline Sabin, Patrick W. Mallon, for the HIV UPBEAT Study Group

734 I-FABP IS ELEVATED AND IS INVERSELY RELATED TO BODY FAT IN HIV
Lediya Cheru, Elli Park, Charles Saylor, Kathleen V. Fitch, Tricia H. Burdo, Jake A. Robinson, Martin Torriani, Steven K. Grinspoon, Janet Lo

735 LOWER PRETREATMENT GUT INTEGRITY ASSOCIATED WITH FAT GAINS ON ANTIRETROVIRALS
Vanessa El Kamari, Carlee Moser, Judith S. Currier, Todd T. Brown, Liz Johnston, Corrilynn O. Hileman, Peter W. Hunt, Grace A. McComsey

736 TESAMORELIN IMPROVES FAT QUALITY INDEPENDENT OF CHANGES IN FAT QUANTITY

737 FAT QUALITY IS INDEPENDENTLY ASSOCIATED WITH CARDIOMETABOLIC RISK IN HIV INFECTION
Jordan E. Lake, Carlee Moser, Liz Johnston, Clara Magyar, Scott D. Nelson, Kristine M. Erlandson, Todd T. Brown, Grace A. McComsey

738 HIV IMMUNE DYSREGULATION PREDICTS LEAN TISSUE AND FAT CHANGES DURING CHRONIC DISEASE
Louie M. Gangcuangco, Dominic Chow, Scott A. Souza, Glen M. Chew, Brooks I. Mitchell, Michelle L. D’Antoni, Jason T. Huynh, Lishomwa C. Ndhlovu, Cecilia Shikuma

Poster P-N04 DIABETES AND DIET
Poster Hall D 2:30 PM – 4:00 PM

739 DISPARITIES IN DIABETES SCREENING AND TREATMENT AMONG PATIENTS RECEIVING HIV CARE
Kassem Bourgi, Peter F. Rebeiro, John R. Koethe, Stephen P. Raffanti, Megan M. Turner, Sally S. Bebawy, Timothy R. Sterling

740 GESTATIONAL DIABETES IN WOMEN ON DOLUTEGRAVIR- OR Efavirenz-Based ART IN BOTSWANA

741 RECOMMENDED ANTIRETROVIRAL REGIMENS AND DIABETES MELLITUS IN THAI HIV-INFECTED ADULTS
Ninutchai Paengsai, Gonzague Jeurdain, Jean-Yves Mary, Nicolas Salvadori, Tim R. Cressy, Apichat Tantravorasin, Romanee Chaiwarith, Chureeratanat Bowonwatanuwong, Sorakij Bhakeecheep, Natapong Kosachununun
742  **GLP-1 AND C-PEPTIDE ARE ASSOCIATED WITH INSULIN RESISTANCE AMONG PLWH IN INDIA**
Ivan Marbaniang, Shashikala Sangle, Dileep Kadam, Vandana Kulkarni, Dhananjay Shere, Nikhil Gupte, Amita Gupta, Vidya Mave

743  **T CELL SUBSETS ASSOCIATED WITH INCIDENT DIABETES RISK IN HIV+ AND HIV— VETERANS**
Wyatt J. McDonnell, Kathleen McGinnis, Kaku So-Arman, Melissa Wellons, Glory Koerbel, Jeffrey Blume, Margaret F. Doyle, Nels C. Olson, Russell Tracy, Amy C. Justice, Simon Mallal, Matthew Freiberg, John R. Koethe

744  **FOOD INSECURITY IS ASSOCIATED WITH INCREASED INFLAMMATION AMONG HIV-POSITIVE WOMEN**
Anna Leddy, Annelys Roque, Lila A. Sheira, Edward A. Frongillo, Alan Landay, Mardeg H. Cohen, Phyllis Tien, Janet M. Turan, Bulent Turan, Sheri Weiser

---

**Poster P-N08 AGING: BIOLOGIC MECHANISMS**
Poster Hall D 2:30 PM – 4:00 PM

757  **REVERSING ACCELERATED AGING IN HIV PATIENTS: METABOLIC AND MITOCHONDRIAL MECHANISMS**
Rajagopal V. Sekhar, Jean W. Hsu, James Suliburk, Ruya Liu, Charles G. Minard, Vijay K. Yeohoor, Farook Jahooh, Chun Liu

758  **BLOOD TELOMERE LENGTH CHANGES AFTER DRV/R + EITHER RAL OR TDF/FTC AS FIRST LINE ART**
Natalia Stella-Ascariz, Rocio Montejoano, Javier Rodriguez-Centeno, Belen Alejos, Christine Schwimmer, Jose I. Bernardino, Berta Rodes, Clotilde Allavena, Christian Hoffmann, Magnus Gisslén, Rosa de Miguel, Cédric Wallet, François Raffi, Jose R. Arribas, for the ANRS 143/NEAT 001 Study Group

759  **THYMUS IS THE BARMETER OF AGING IN HIV PATIENTS, ASSOCIATED WITH FRAILTY AND QOL**
Giovanni Guaraldi, Giulia Besutti, Andrea Malagoli, Iacopo Franconi, Nicoletta Riva, Alessandro Raimondi, Riccardo Scaglioni, Guido Ligabue, Marianna Menozzi, Antonella Santoro, Federica Carli, Stefano Zona, Vanni Borghi, Andrea Cossarizza, Cristina Mussini

760  **METHAMPHETAMINE USE INDEPENDENTLY PREDICTS PREMATURE AGING IN HIV+ INDIVIDUALS**
Sanjay R. Mehta, Jennifer Iudicello, Ronald J. Ellis, Jue Lin, Erin Morgan, Debralee Cookson, Robert K. Heaton, Igor Grant, Scott L. Letendre

---

**Poster P-N09 HOSPITALIZATION AND OUTCOMES**
Poster Hall D 2:30 PM – 4:00 PM

761  **SHORT-TERM OUTCOMES FOR MAJOR NON-CARDIAC SURGERY IN HIV INFECTION**
Keith M. Sigel, Lesley Park, Michael Leapman, Amy C. Justice, Sheldon T. Brown, Joseph T. King, for the VACS Project Team

762  **HOSPITALIZATION RATES AND OUTCOMES IN A SOUTHEASTERN US CLINICAL COHORT, 1996-2016**
Thibaut Davy-Mendez, Sonia Napravnik, Oksana Zakharaov, David Wohl, Claire E. Farel, Joseph J. Eron
Poster P-05 HIV-ASSOCIATED SYPHILIS
Poster Hall D 2:30 PM – 4:00 PM

796 NATURAL EXPERIMENT OF SYPHILIS TREATMENT WITH DOXYCYCLINE IN HIV-INFECTED PATIENTS
Marilia B. Antonio, Ricardo d. Vasconcelos, Gabriel Trova, Vivian I. Avelino-Silva

797 INTRAOCULAR TREPONEMA AND TOXOPLASMA INFECTIONS ASSOCIATED WITH BLINDING CATARACTS
Juliet Ottiti-Sengeri, Colebunders Robert, Lois Bayigga, Rose Nabatanzi, Samuel Kyobe, Damalie Nakanjako

798 PRIOR SYPHILIS PROTECTS AGAINST T. PALLIDUM DISSEMINATION IN REPEAT INFECTION
Christina Marra, Clare Maxwell, Sharon Sahi, Lauren Tantalo, Shelia Dunaway, Sheila Lukehart

Poster P-06 RATES AND RISKS OF OTHER OIs
Poster Hall D 2:30 PM – 4:00 PM

799 HIV REPLICATION AS RISK FACTOR FOR 3 OPPORTUNISTIC INFECTIONS
Hansjakob Furrer, for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

800 HERPES ZOSTER AND ZOSTER VACCINE RATES AMONG HIV-INFECTED AND UNINFECTED IN THE VACS
Kellie L. Hawkins, Kirsha S. Gordon, Myron Levin, Adriana Weinberg, Catherine Battaglia, Maria Rodriguez-Barradas, Sheldon T. Brown, David Rimland, Amy C. Justice, Janet Tate, Kristine M. Erlandson

801 CMV VIREMIA AND DISEASE IN PATIENTS WITH ADVANCED HIV INFECTION: A PROSPECTIVE STUDY
Adaia Albasanz, Juliana Esperalba, Ariadna Torrella, Bibiana Planas, Candela Fernández, Antonio Segura, Adrià Curran, Jordi Navarro, Esteban Ribera, Joaquin Burgos, Rein Willekens, Mario Martin, Vicenç Falcó

802 BLASTOCYSTIS INFECTIONS IN HIV POSITIVE AND NEGATIVE ADULTS IN GHANA
Veronica Di Cristianziano, Federica Berrilli, Rossella D’Alfonso, Fred S. Sarfo, Lavinia Fabeni, Elena Knops, Eva Heger, Albert Dompreh, Rolf Kaiser, Torsten Feldt, Kirsten Eberhardt

Poster P-P4 HIV, ANTIRETROVIRAL THERAPY, AND PREGNANCY OUTCOMES
Poster Hall D 2:30 PM – 4:00 PM

829 BIRTH DEFECTS AMONG OFFSPRING OF HIV-INFECTED & UNINFECTED WOMEN IN KAMPALA, UGANDA
Philippa Musoke, Daniel M. Mumpe, Ayoub Kakande, Jolly Nankunda, Diana Valencia, Joyce Namale, Evelyn Nabunya, Josaphat Byagumisha, Doreen Birabwa-Male, Monica Nolan, Dhelia Williamson, Linda Barlow-Mosh

830 PRECONCEPTIONAL ART AND SPONTANEOUS PRETERM BIRTH IN AN URBAN ZAMBIAN COHORT
Joan T. Price, Bellington Wvalika, Jennifer Winston, Margaret P. Kasaro, Humphrey Mwape, Benjamin H. Chi, Elizabeth M. Stringer, Bethany Freeman, Courtney Gravett, Katelyn J. Rittenhouse, Lungowe Njobvu, Julie A. Nelson, Angela Kashuba, Jeffrey S. Stringer
Prenatal Antiretroviral Exposure and Risk of Low Birth Weight in Lusaka, Zambia
Jennifer Winston, Margaret P. Kasaro, Marie Stoner, Lloyd Mulenga, Joan T. Price, Elizabeth M. Stringer, Benjamin H. Chi, Bellington Vwalika, Jeffrey S. Stringer

Pregnancy Outcomes in the Era of Universal HAART in Africa (the POISE Study)
Sufia Dadabhai, Luis Gadama, Rachel Chamanga, Rachel Kawalazira, Chaplain Katumbi, Dingase E. Dula, Isaac Singini, Leslie Degnan, Melvin C. Kamanga, Taha E. Taha

High Rates of Adverse Birth Outcomes in Syphilis & HIV Coinfected Women in Botswana
Emily Shava, Sikhulile Moyo, Modiegi Diseko, Rebecca Zash, Eldah N. Dintwa, Lucy Mupfumi, Judith Mabuta, Gloria Mayondi, Jennifer Y. Chen, Shahin Lockman, Mompati O. Mmalane, Joseph Makhma, Roger L. Shapiro

Placental Evidence of Maternal Vascular Malperfusion Among HIV-Infected Women

Inflammation in HIV-Infected Pregnant Women Is Associated with Preterm Birth

Markers of Preterm Delivery in HIV+ Women; Role of Protease Inhibitors and Vitamin D
Adriana Weinberg, Yanling Huo, Deborah Kacanek, Kunjal Patel, Heather Watts, Diane Wara, Jelena Klawitter, Uwe Christians, for the IMPAACT Team

Poster P-Q6 Health Outcomes for HIV-Exposed Uninfected Infants, Children, and Adolescents
Poster Hall D 2:30 PM – 4:00 PM

Decreased Diarrheal and Respiratory Disease in HEUs Following RV and PCV Vaccination
Gbolahan Ajibola, Kara Bennett, Kathleen M. Powis, Michael D. Hughes, Jean Leidner, Samuel W. Kgole, Kerapetse Botebele, Oganne Batlang, Chipo Petlo, Mompati O. Mmalane, Joseph Makhma, Shahin Lockman, Roger L. Shapiro

Persistent B Cell Deficiency in HIV-Exposed Uninfected Infants Following Immunization
Liane S. Sadder, Li Yin, Kai-Fen Chang, Bernard Fischer, Maureen Goodenow, John W. Sleasman

Infant HIV Vaccination: Relationship to Childhood Vaccines and Maternal Antibodies
Hannah Itell, Erin McGuire, Meng Chen, Petronella Muresan, Sallie Permar, Genevieve Fouda
872 GROWTH AND BONE MINERAL ACCRETION IN UGANDAN INFANTS EXPOSED TO MATERNAL HIV AND ART
Florence Nabwire, Ann Prentice, Matthew M. Hamill, Adeodata Kekitiinwa, Josaphat Byamugisha, Mary G. Fowler, Gail R. Goldberg

873 INFLAMMATION, CMV AND THE GROWTH HORMONE AXIS IN HIV-EXPOSED UNINFECTED INFANTS
Ceri Evans, Bernard Chasekwa, Sandra Rukobo, Margaret Ghova, Kuda Mutasa, Robert Ntozini, Jean Humphrey, Andrew Prendergast

874 METABOLIC OUTCOMES IN OBESE HIV-EXPOSED UNINFECTED CHILDREN: COMPARISON WITH NHANES
Jennifer Jao, Denise Jacobson, Wendy Yu, Matthew McKenna, William Borkowsky, Mitchell Geffner, Rohan Hazra, Brad Karalus, Elizabeth J. McFarland, Kunjal Patel, Paige L. Williams, Tracie Miller, for the Pediatric HIV/AIDS Cohort Study (PHACS)

875 HIV VIRAEMIA IN PREGNANCY AND NEURODEVELOPMENT OF HIV-EXPOSED UNINFECTED CHILDREN
Stanzi M. le Roux, Elaine J. Abrams, Kirsty Donald, Kirsty Brittain, Tamsin K. Phillips, Allison Zerbe, Max Kroon, Landon Myer

876 DEVELOPMENTAL OUTCOMES AND ARV EXPOSURE IN HIV-EXPOSED UNINFECTED CHILDREN
Micah Piske, Matthew A. Budd, Annie Q. Qiu, Evelyn J. Maan, Laura J. Sauve, John C. Forbes, Ariane Alimenti, Patricia Janssen, Helene C. Cote, for the CIHR Team Grant on Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

877 MENTAL HEALTH DIAGNOSES, SYMPTOMS, AND SERVICE UPTAKE IN US YOUTH WITH PHIV EXPOSURE
Renee Smith, Yanling Huo, Katherine Tassiopoulos, Richard Rutstein, Suad Kapetanovic, Claude A. Mellins, Deborah Kacanek, Kathleen Malee, for the Pediatric HIV/AIDS Cohort Study (PHACS)

878 LOPINAVIR/RITONAVIR INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN
Audrey Monnin, Nicolas Nagot, Marianne Periès, Roselyne Vallo, Nicolas Meda, Mandisa Singata, James Tumwine, Pascal Reynier, Thorkild Tylleskår, Philippe Van de Perre, Jean-Pierre Moles, for the PROMISE PEP consortium ANRS 12174

879 HEU BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)
Abhinav Ajaykumar, Mayanne Zhu, Hugo Soudéyns, Fatima Kakkar, Jason Brophy, Ari Bitnun, Ariane Alimenti, Deborah M. Money, Helene C. Cote, for the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)

880 INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS
Marisa M. Mussi-Pinhata, Adriana Weinberg, Qilu Yu, Rachel A. Cohen, Sahera Dirajal-Fargo, Nicholas Funderburg, Emily Bowman, Nahida Chakhtoura, Grace A. McComsey
Poster Sessions

881  INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA
Pilar Garcia Broncano, Samuel W. Kgole, Gosego Masasa, Terence Mohammed, Sikhulile Moyo, Joseph Makhma, Xu G. Yu, Jennifer Jao, Roger L. Shapiro, Mathias Lichterfeld, Kathleen M. Powis

882 MICROBIAL TRANSLLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS
Charles D. Mitchell, Sady Dominguez, Varghese George, Eddy Perez-Then, Carlos V. Castillo, Juan L. Santanna-Guerrero, Jeannette Baez, Margaret Roach, William Walters, Qiaojuan Shi, Shao-Pei Chou, Ruth Ley, Savita Pahwa

Poster P-Q8 INFANT TESTING AND STRATEGIES
Poster Hall D 2:30 PM – 4:00 PM

883 WILL TARGETED COMMUNITY OUTREACH IMPROVE HIV TESTING UPTAKE AMONG CHILDREN IN KENYA?
Samuel Ndolo, Nicollate A. Okoko, Mary A. Guzé, George Nyanaro, Lenah Nyabiage, Elizabeth A. Bukusi, Craig R. Cohen, Jeremy Penner, Jayne L. Kulzer

884 ENGAGEMENT IN CARE AND INFANT HIV TESTING AMONG LOST TO FOLLOW-UP OPTION B+ PATIENTS
William J. Reidy, Harriet Nuwagaba-Biribonwoha, Siphelehle Shongwe, Ruben Sahabo, Kieran Hartsough, Simangele Mthetwa, Elaine J. Abrams

885LB OPTIMIZING EID: A CLUSTER-RANDOMIZED TRIAL OF THE HIV INFANT TRACKING SYSTEM IN KENYA

Poster P-R4 HIV AND DRUG USE
Poster Hall B 2:30 PM – 4:00 PM

961 RESTART OF THE HIV EPIDEMIC AMONG PWID IN OCCUPIED CRIMEA AND IN THE EAST OF UKRAINE
Marina Kornilova, Yana Sazonova

962 HIV TESTING AND PREVENTION SERVICES AMONG PERSONS WHO INJECT DRUGS—INDIANA, 2016
Mary Tanner, Sharoda Dasgupta, Monita Patel, Julie O’Donnell, Brandon Halleck, Joseph Amlung, Caitlin Conrad, Cameron McAlister, Erika Chapman, Ayriane Bailey, Michael Spiller, Dita Broz, Philip J. Peters, Paul J. Weidle, Joan Duwve

963 AN OUTBREAK OF HIV ASSOCIATED WITH SHARING OPIATE INJECTION PREPARATION EQUIPMENT
Sharon Koivu, L Ball, K Gupta, C Venner, R Tirona, Eric Arts, B Hallam, Ryan Wong, Klajdi Puka, M Speechley, G Hovhannisyan, Michael Silverman

964 IDENTIFYING UNDIAGNOSED HIV-INFECTED PWID IN INDIA USING RESPONDENT-DRIVEN SAMPLING
965 HIV TRANSMISSION RISKS AMONG HIV-POSITIVE ADULTS IN MEDICAL CARE WHO MISUSE OPIOIDS
Ansley Lemons, Nicholas DeGroote, Alejandro Pérez, Jason Craw, Margaret Nyaku, Dita Broz, Christine Mattson, Linda Beer, for the Medical Monitoring Project

966 INDICATORS OF INJECTION DRUG USE — INDIAN HEALTH SERVICE, 2010–2014
Mary Evans, Marissa Person, Brigg Reilley, Jessica Leston, Richard Haverkate, Michelle Van Handel, Michele Bohm, Danae Bixler, Dita Broz, Andrew J. Mitsch, Dana Haberling, Eyasu Teshale, Paul J. Weidle, Philip J. Peters, Kate Buchacz

967 REPORTED DRUG INJECTION BEHAVIORS BEFORE AND AFTER AN HIV OUTBREAK — INDIANA, 2016
Sharoda Dasgupta, Mary Tanner, Monita Patel, Julie O'Donnell, Brandon Halleck, Joseph Amlung, Cameron McAlister, Erika Chapman, Ayriane Bailey, Caitlin Conrad, Michael Spiller, Dita Broz, Philip J. Peters, Paul J. Weidle, Joan Duwve

968 JOINT TRAJECTORIES OF METHAMPHETAMINE USE AND HIV VIRAL LOAD
Chelsea L. Shover, Heather A. Pines, Steven Shoptaw, Marjan Javanbakht, Robert Bolan, Pamina Gorbach

969 TRANSACTIONAL SEX AMONG MEN WHO HAVE SEX WITH MEN: WHAT’S DRUGS GOT TO DO WITH IT?
Marjan Javanbakht, Amy Ragsdale, Steven Shoptaw, Pamina Gorbach

970 HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS — UNITED STATES, 2010–2015
Sheryl Lyss, Tianchi Zhang, Alexandra M. Oster

971 CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US
Johanna Chapin-Bardales, Silvina Masciotra, Amanda Smith, Brooke Hoots, William M. Switzer, Wei Luo, S. Michele Owen, Gabriela Paz-Bailey

972 DISTRIBUTIVE SYRINGE SHARING AND USE OF SYRINGE SERVICES PROGRAMS AMONG PWID
Monica Adams, Qian An, Dita Broz, Janet C. Burnett, Cyprian Wejnert, Gabriela Paz-Bailey

973 NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006–2016
Lucia V. Torian, Jasmine Abdelnabi, Lisa A. Forgione, Joel O. Wertheim

974 DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007–2015
Sarah L. Braunstein, Rebekkah S. Robbins, Demetre C. Daskalakis

975 3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS

976LB HIV TRANSMISSION POTENTIAL DUE TO INJECTION DRUG USE IN RURAL WEST VIRGINIA, US, 2017
Vicki Hogan, Brooke Hoots, Christine Agnew-Brune, Dawn Broussard, Kate Buchacz, Bridget Rose, Scott Cope, Erica Dawson, William Hoffman, Shacara Johnson, Sheryl Lyss, Laura Quilter, Paul J. Weidle, Br unlis White, Heather Bradley
### Poster P-R5 STIs AND HIV
**Poster Hall B**
2:30 PM – 4:00 PM

<table>
<thead>
<tr>
<th>Poster P-R5 STIs AND HIV</th>
<th>977</th>
<th>EVALUATING THE USE OF SYPHILIS PARTNER SERVICES FOR HIV CASE FINDING IN MISSISSIPPI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tigran Avoundjian, James Stewart, David Peyton, Christie Lewis, Kendra Johnson, Sara N. Glick, Matthew R. Golden, Christine M. Khosropour</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster P-R5 STIs AND HIV</th>
<th>978</th>
<th>ESTIMATED PRIMARY &amp; SECONDARY SYPHILIS RATES IN MSM BY HIV STATUS – 34 STATES, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeremy A. Grey, Elizabeth A. Torrone, Sarah E. Kidd, Kyle T. Bernstein, Hillard S. Weinstock</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster P-R5 STIs AND HIV</th>
<th>979</th>
<th>HIGHER RISK AND VULNERABILITY BUT LOWER HIV/SYPHILIS COINFECTION IN THAI TG THAN MSM</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Poster P-R5 STIs AND HIV</th>
<th>980</th>
<th>GAPS IN STI PREVENTION AMONG NIGERIAN MSM ADHERENT TO ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rebecca G. Nowak, Trevor Crowell, Andrew Mitchell, Teclaie Ndomb, Babajide Keshinro Keshinro, Sheila A. Peel, Charlotte A. Gaydos, Julie Ake, William Blattner, Stefan Baral, Man Charurat, for the TRUST/RV368 Study Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Poster P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING
**Poster Hall B**
2:30 PM – 4:00 PM

<table>
<thead>
<tr>
<th>Poster P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING</th>
<th>983</th>
<th>COMMUNITY-BASED SERVICES REACH LARGE VOLUMES OF HIGH RISK MEN IN TANZANIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caterina Casalini, Dorica Boyee, Amasha Mwanansungu, Magnus Ndolichimpa, Yeronimo Mlawa, Peris Urasa, Neema Makyao, Erick Mlanga, Nelson Rutabanzibwa, Benjamin Myoelve, Anike Akridge, Albert Komba, Jason Reed, Kelly Curran</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING</th>
<th>984</th>
<th>MALE AND ADOLESCENT FIRST-TIME HIV TESTERS REACHED BY COMMUNITY HEALTH INITIATIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hong-Ha M. Truong, Dancun O. Obunge, Mary A. Guzé, Esther Wandera, Placide Ntawali, Eliud Akama, Frankline Otieno, Elizabeth A. Bukusi, Patrick Oyaro, Craig R. Cohen</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING</th>
<th>985</th>
<th>DOOR-TO-DOOR HIV TESTING TO INCREASE ANTIRETROVIRAL THERAPY UPTAKE, WESTERN KENYA</th>
</tr>
</thead>
</table>
986 BARRIERS TO HIV TESTING IN SWAZILAND: EFFECT OF FAMILY SUPPORT AND TRAVEL TIME
Harriet Nuwagaba-Biribonwoha, Yingfeng Wu, Averie B. Gachuh, Margaret McNairy, Matthew R. Lamb, Sikhathele Mazibuko, Zandile Mnisi, Veli M. Madau, Sean Burke, Neena M. Philip, Wafa M. El-Sadr

987 HIV TESTING IN PRIMARY CARE CLINICS IN SOUTH AFRICA: A MISSED OPPORTUNITY
Bhakti Hansoti, Tonderai Mabuto, Griffiths Kubeka, Salome Charalambous, Deanne Kerrigan, Chris Hoffmann

988 HIGH PERCENTAGE OF UNDIAGNOSED HIV CASES IN A HYPER-ENDEMIC SOUTH AFRICAN POPULATION
Alain Vandormael, Tulio de Oliveira, Frank Tanser, Till Bärnighausen, Joshua T. Herbeck

989 REDUCING TIME FOR HIV VIRAL LOAD RESULT DELIVERY TO ART FACILITIES IN MALAWI
Natasha Gous, Frank Chirwa, Jeff Takle, Alan Schooley

990 IMPACT OF TESTING DELAY ON LOW-LEVEL VIRAEMIA IN SOUTH AFRICA: A PROGRAMME-WIDE VIEW
Nei-Yuan M. Hsiao, Elton Mukonda, Maia Lesosky, Jean Maritz, Wolfgang Preiser, Landon Myer

991 RAPID VS. STANDARD TESTING FOR HIV AND HCV AT A DRUG DETOX: A RANDOMIZED TRIAL
Sabrina A. Assoumou, Samantha M. Paniagua, Benjamin Linas, Jianing Wang, Jeffrey H. Samet, Jonathan Hall, Curt G. Beckwith

992 HIV SELF-TESTING INCREASES TESTING IN YOUNG SOUTH AFRICAN WOMEN: RESULTS OF AN RCT

993 FEMALE SEX WORKERS’ INTERPRETATIONS OF HIV SELF-TEST RESULTS: A PERFORMANCE STUDY
Katrina F. Ortblad, Daniel K. Musoke, Thomson Ngabirano, Aidah Nakitende, Jessica E. Haberer, Margaret McConnell, Till Bärnighausen, Catherine E. Oldenburg

994 HIV SELF-TESTING AMONG MEN WHO HAVE SEX WITH MEN AND TRANSGENDER WOMEN IN MYANMAR
Andrea L. Wirtz, Soe Naing, Emily Clouse, Hsu Hnin Mon, Aung Zayar Paing, Stefan Baral, Chris Beyrer

995 EVALUATION OF TARGETED HIV SELF-TEST KIT DISTRIBUTION VIA A DIGITAL VENDING MACHINE
Alex Pollard, Gillian Dean, Suneeta Soni, Carrie Llewellyn, Carlos Peralta, Liliana Rodriguez, Jaime Vera-Rojas

996 COST ANALYSIS OF DIFFERENTIATED HIV SELF-TESTING KITS DISTRIBUTION IN ZAMBIA
Nurilign Ahmed, Lawrence Mwenge, Linda Sande, Collin Mangenah, Sarah Kanema, Mutinta Nalubamba, Sepiso Libamba, Euphemia Sibanda, Hendramoorthy Maheswaran, Cheryl Johnson, Karin Hatzold, Elizabeth L. Corbett, Helen Ayles, Fern Terris-Prestholt
Poster Sessions

COMPARING SELF-REPORTED VIRAL LOAD WITH HOME-COLLECTED HIV-RNA AMONG HIGH-RISK MSM

Richard A. Teran, Martin J. Downing, Mary Ann Chiasson, Hong Van Tieu, Laura Dize, Charlotte A. Gaydos, Sabina Hirshfield

Poster P-T02 PreP AND STIs: THE EMERGING STORY
Poster Hall B 2:30 PM – 4:00 PM

Effect of on demand oral PreP with TDF/FTC on HSV-1/2 incidence among MSM

Marie-Laure Chaix Baudier, Isabelle Charreau, Constance Delaquerre, Nadia Mahjoub, Martin Signier, Catherine Capitant, Cécile Tremblay, François Raffi, Eric Cua, Gilles Pialoux, Laurent Cotte, Armelle Pasquet, Laurence Meyer, Jean-Michel Molina, for the ANRS IPERGAY Study Group

Integrating PreP referrals into STD partner services increases PreP use among MSM

David A. Katz, Michael Barry, Julia C. Dombrowski, Teal Bell, Matthew R. Golden

Partners, not condom use, drive STI rates among PreP users in community health center

Sarit A. Golub, Stephanie Pena, Rachel A. Fikslin, Matthew Goldberg, Asa Radix

Incident HIV, Hepatitis C and other STI in Daily and event-driven PreP users

Elke Hoornenborg, Liza N. Coyer, Roel C. Achterbergh, Amy Matser, Udi Davidovich, Maarten F. Schim van der Loeff, Henry J. de Vries, Maria Prins, for the Amsterdam PreP Project team in the HIV Transmission Elimination Amsterdam Initiative

Sexually transmitted infections and adherence to PreP

Claire Bristow, David J. Moore, Michael Dube, Katya Calvo, Eric Ellorin, Jill Blumenthal, Sheldon Morris

Factors impacting appropriate HIV/STI screening and PreP persistence in primary care

Matthew A. Spinelli, Hyman Scott, Eric Vittinghoff, Albert Y. Liu, Alicia Morehead-Gee, Rafael Gonzalez, Monica Gandhi, Susan P. Buchbinder

Poster P-T03 THE INTERSECTION OF DRUG USE AND PreP
Poster Hall B 2:30 PM – 4:00 PM

Chemsex drugs use by hair analysis among MSM in the ANRS IPERGAY trial.

Julie Chas, Gilles Peytavin, Diane Carette, Nicolas Fabresse, Isabelle Charreau, Catherine Capitant, Perrine Roux, Eric Cua, Laurent Cotte, Armelle Pasquet, François Raffi, Laurence Meyer, Gilles Pialoux, Jean-Michel Molina, Jean-Claude Alvarez

Assessing PreP needs among heterosexuals and people who inject drugs, Washington, DC

Irene Kuo, Anya Agopian, Jenevieve Opoku, Anthony Rawls, Rudy Patrick, Manya Magnus, Michael Khafren, Alan Greenberg

Stimulant use and condomless sex with multiple partners: effect on PreP adherence

Poster Session

**Poster P-T04 PrEP AND ON-DEMAND PrEP**

**Poster Hall B**

**2:30 PM – 4:00 PM**

1032 **USE OF HIV PEP BY US COMMERCIAL INSURED PERSONS INCREASED WITH AVAILABILITY OF PrEP**

Ya-Lin A. Huang, Kenneth L. Dominguez, Anne Patala, Karen W. Hoover

1033 **HIV INCIDENCE AMONG MSM GIVEN PEP STARTER PACKS IN NYC SEXUAL HEALTH CLINICS, 2014–16**

Christine M. Borges, Addie Crawley, Michael A. Castro, Susan Blank, Sarah L. Braunstein, Preeti Pathela

1034 **COVERAGE OF SEX EVENTS WITH ON DEMAND PrEP: A MEMS SUB-STUDY OF THE IPERGAY TRIAL**

Rebecca Bauer, Emmanuelle Netzer, Claire Pintado, Catherine Capitant, Eric Cua, Nicolas Etien, Gilles Pialoux, Christian Chidiac, Cedric Etienne, François Raffi, Armelle Pasquet, Veronique Dore, Laurence Meyer, Jean-Michel Molina, for the ANRS Ipergay Study Group

1035 **FEASIBILITY OF SHORT-TERM PrEP UPTAKE FOR MSM WITH EPISODIC HIGH-RISK FOR HIV**

James E. Egan, Ken Ho, Ronald Dean Stall, Morgan T. Drucker, Ryan Tappin, Craig W. Hendrix, Mark A. Marzinke, William Clarke, Kenneth H. Mayer

**Poster P-T05 PrEP AND HIV INCIDENCE**

**Poster Hall B**

**2:30 PM – 4:00 PM**

1036 **PrEP USE HISTORY OF PERSONS NEWLY DIAGNOSED WITH HIV: NEW YORK CITY, 2015-2017**

Kavita Misra, Jamie Huang, Chi-Chi Udeagu

1037 **DECREASES IN HIV INCIDENCE IN A MONTREAL CLINIC COINCIDE WITH EXPANDING PrEP USE**

Marieve Beauchemin, Zoe Greenwald, Jason Szabo, Louise Charest, Judith Fafard, Danièle Longpré, Stéphane Lavoie, Réjean Thomas

1038 **HIGH SEROCONVERSION RATES FOLLOWING PrEP DISCONTINUANCE IN A MONTREAL CLINIC**

Zoe Greenwald, Marieve Beauchemin, Khadija Benomar, Gabrielle Landry, Michel Boissonnault, Louise Charest, Danièle Longpré, Stéphane Lavoie, Réjean Thomas

1039 **USING HIV INCIDENCE ESTIMATES TO INFORM GUIDELINES FOR THE PrEP IMPACT TRIAL**

Martina Furegato, Paula Blomquist, Sarika Desai, Hamish Mohammed, Holly Mitchell, Monica Desai, Owen N. Gill, John Saunders

1040 **PrEP INTEREST AND HIV-1 INCIDENCE AMONG MSM AND TRANSGENDER WOMEN IN COASTAL KENYA**

Makobu Kimani, Elisabeth M. van der Elst, Oscar Chirro, Clifford Oduor, Elizabeth Wahome, Winston Kazungu, Mahmoud Shally, Don Operario, Susan M. Graham, Eduard Sanders

1041 **SEROCONVERSION ON PrEP: A PROTOCOL FOR UNTANGLING ADHERENCE VS RESISTANCE FAILURE**

Joshua T. Thaden, Monica Gandhi, Karen Kuncze, Alexander Louie, Hideaki Okochi, Christopher B. Hurt, Mehri McKellar
A PUBLIC HEALTH APPROACH TO VIREMIC INDIVIDUALS WITH PrEP-RESISTANT VIRUS
Susan E. Buskin, Richard Lechtenberg, Matthew R. Golden, Mark J. Fleming, Julia C. Dombrowski

Poster P-V3 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND COMPLICATIONS

Poster Hall B 2:30 PM – 4:00 PM

1112 HIGH HIV-RELATED TUBERCULOSIS RISK IN COUNTRIES WITH LOW HIV PREVALENCE—KENYA, 2015
Herman O. Weyenga, Abraham Katana, Thomas Achia, Brian Baker, Lucy Ng’ang’a, Evelyne Ngugi, Tai Ho Chen, Maureen Kamene, Emily C. Zielinski-Gutierrez, Enos Masini, Dunstan Achwo, George K. Kadondi, Christine Wambu, Kenneth Masamaro, Kevin M. De Cock

1113 BURSTING MYTHS: PROGRAMMATIC SCALEUP OF ISONIAZID PREVENTIVE THERAPY, KENYA 2014-2016
Evelyn M. Karanja, Herman O. Weyenga, Abraham Katana, Martin Sirengo, Enos Masini, Lucy Ng’ang’a, Evelyne Ngugi, Shobha Vakil, Caroline Olwande, Agnes Langat, Christine Wambu, Brian Baker, Kevin M. De Cock

1114 THE EFFECTS OF HIV TREATMENT ON UPTAKE OF TB AND NCD TREATMENT BY HOUSEHOLD MEMBERS
Suzue Saito, Andrea Howard, Magdalena Cerda, Frank Tanser, Deenan Pillay, Wafaa M. El-Sadr, Tilly Bärnighausen

1115 HYPERTENSION SCREENING AND MANAGEMENT IN TWO PEPFAR-FUNDED CLINICS IN MALAWI
Sam Phiri, Hannock Twya, Alice Maida, Sundeep Gupta, Colin Speight, Denise Giles, Oliver J. Gadabu, Fleetwood Loustalot, Pragna Patel

1116 HISTORICAL & CURRENT ANAL CYTOLOGY, HRHPV-DNA AND -MRNA-E6/E7 TESTS PREDICT ANAL HSIL

1117LB COST-EFFECTIVENESS OF URINE TB SCREENING FOR HOSPITALIZED PEOPLE WITH HIV IN AFRICA

Poster P-V4 ADHERENCE AND TREATMENT OUTCOMES
Poster Hall B 2:30 PM – 4:00 PM

1118 HIGH RATES OF VIRAL RESUPPRESSION ON FIRST-LINE ART AFTER INITIAL VIROLOGICAL FAILURE
Lucas E. Hermans, Hugo Tempelman, Sergio Carmona, Monique Nijhuis, Diederic Grobbee, Douglas D. Richman, Michelle A. Moorhouse, Willem D. Venter, Annemarie Wensing

1119 IS CLINICAL STABILITY STABLE? MULTI-STATE SURVIVAL ANALYSIS OF HIV PATIENTS IN ZAMBIA
Monika Roy, Charles B. Holmes, Izukanji Sikazwe, Theodora Savory, Mwanzia wa Mwanzia, Carolyn Bolton Moore, Nancy Czaicki, David Glidden, Nancy Padian, Elvin Geng
Comparing Time to Viral Suppression Among Acute and Non-Acute HIV in North Carolina
Nicole Dzialowy Adams, Anna Cope, Brad Wheeler, Victoria L. Mobeley, John Barnhart, Joann D. Kuruc, Cynthia L. Gay, Lindsey M. Fillatreau, Rhonda Ashby, Erika Samoff

CD4 Count and HIV Viral Suppression Improve After Housing Program Enrollment, 2013-16
Yaoyu Zhong, Ellen Wiewel, Christopher Beattie, Xiomara Farquhar, Jesse Thomas, Sarah L. Braunstein, John Rojas

Improved Virological Outcomes in a Co-Pay Model Supporting Differentiated Care
Rosalind M. Parkes-Ratanshi, Samuel Lewis, Maria S. Nabaggala, Adeline Twimukye, Tom Kakaire, Noela Owarwo, Barbara Castelnuovo, Agnes Kiragga, Walter Schlech, Mohammed Lamorde

Clinical-Level Factors Associated With Time to Viral Suppression in Washington DC
Anne K. Monroe, Nabil Rayeed, Maria Jaurretche, Lindsey Powers Happ, Kevin Trac, Arpi Terzian, Alan Greenberg, Amanda D. Castel, for the DC Cohort Executive Committee

Predictors of Persistent Low Level Viremia and Transient Viral Blips
Allahna L. Esber, Christina Polyak, Jonah Jonath Maswai, John Owuoth, Lucas Maqangwa, Akindiran Akintunde, Hannah Kibuuka, Julie Ake, Trevor Crowell

Improved Outcomes with Maximum Assistance, Low-Threshold HIV Care (The “Max Clinic”)
Julia C. Dombrowski, Sean Galagan, Meena Ramchandani, Shireesha Dhanireddy, Robert D. Harrington, Matthew R. Golden

Clinical Outcomes of US Young Black Men with HIV Receiving Medical Care, 2009–2014
Pranesh P. Chowdury, Linda Beer, R. L. Shouse, Heather Bradley

Beyond Viral Suppression: Broadening Quality Measures (QM) for Total HIV Patient Care
Michael A. Horberg, Jackie Blank, Kevin Rubenstein, Leo Hurley, Peter Kadlecik, Daniel B. Klein, Michael J. Silverberg

HIV Stigma Is Associated With Retention and Viral Load Among US Patients in Care

High Viremia Among ‘Stable’ Patients Receiving Antiretroviral Therapy in Zambia
Mpande Mukumbwa-Mwenechanya, Emilie Efronson, Paul Somwe, Jillian L. Kadota, Monika Roy, Samuel Bosomprah, Kelvin Kaputula, Jake Pry, Nancy Padian, Elvin Geng, Charles B. Holmes, Izukanji Sikazwe, Anjali Sharma, Carolyn Bolton Moore

Compliance to Guidelines for Routine Viral Load Testing in Resource Limited Settings
Barbara Castelnuovo, Frank Mubiru, Mark Nsumba, Isaac Lwanga, Ivan Lumu, Agnes Kiragga, Steven J. Reynolds
1131 HEALTHCARE PROVIDER TRUST LINKED TO LONG-TERM HIV VIRAL SUPPRESSION
Kate G. Michel, Cuiwei Wang, Tracey Wilson, Kathryn Anastos, Mardge H. Cohen, Ruth Greenblatt, Margaret Fischl, Igho Ofotokun, Mirjam-Colette Kempf, Adaora Adimora, Joel Milam, Joanne Michelle F. Ocampo, Stephen J. Gange, Michael Plankey, Seble Kassaye

1132 CHARACTERIZING HIV CARE TRAJECTORIES AND DIFFERENCES IN PATIENT OUTCOMES
Eva A. Enns, Cavan Reilly, Karen Baker, Keith Henry

1133 FROM PRISON’S GATE TO DEATH’S DOOR: SURVIVAL ANALYSIS OF RELEASED PRISONERS WITH HIV
Kelsey B. Loeliger, Jaimie P. Meyer, Maria M. Ciarleglio, Mayur M. Desai, Colleen Gallagher, Frederick Altice

1134 DISCRIMINATION IN HEALTHCARE SETTINGS AMONG PATIENTS WITH RECENT HIV DIAGNOSES
Amy R. Baugher, Linda Beer, Jennifer Fagan, Christine Mattson, R. L. Shouse, for the Medical Monitoring Project

1135 LONGITUDINAL DIFFERENCES IN POOR ADHERENCE AMONG YOUTH AND ADULTS LIVING WITH HIV
Kalysha Closson, Alexis Palmer, Cathy Puskar, Kate Salters, Surita Parashar, Karyn Gabler, Lateefa Tiamiyu, Wendy Zhang, Angela Kaida, Robert S. Hogg

1136 VIRAL SUPPRESSION AFTER INTERMITTENT VIREMIA: WOMEN’S INTERAGENCY HIV STUDY 1994-2015
Amanda B. Spence, Cuiwei Wang, Tracey Wilson, Kathryn Anastos, Mardge H. Cohen, Ruth Greenblatt, Margaret Fischl, Igho Ofotokun, Mirjam-Colette Kempf, Adaora Adimora, Joel Milam, Joanne Michelle F. Ocampo, Kate G. Michel, Seble Kassaye

1137 EVALUATING CARE OUTCOMES FOR ACUTE HIV INFECTION IN PHILADELPHIA, 2014-2016
Melissa Miller, Tanner Nassau, Coleman Terrell, Kathleen Brady

1138 HIV CARE TRAJECTORIES IN THE ERA OF UNIVERSAL TEST-AND-TREAT IN RURAL SOUTH AFRICA
Delphine Perriat, Hassimiou Diallo, François Dabis, Deenan Pillay, Joanna Orne-Gliemann, Joseph Larmarange, for the ANRS 12249 TasP Study Group

1139 THE IMPACT OF “TREATMENT FOR ALL” ON EARLY GAPS IN ART- A MULTISITE COHORT STUDY
Ingrid Katz, Nicholas Musinguzi, Kathleen Bell, Anna Cross, Bosco M. Bwana, Gideon Amanyire, Stephen Asimwe, Catherine Orrell, David R. Bangsberg, Jessica E. Haberer, for the META Research Group

1140 VIRAL SUPPRESSION EFFECTS OF INTERVENTIONS FOR UNSTABLE ART PATIENTS IN SOUTH AFRICA
Matthew P. Fox, Sophie Pascoe, Amy Huber, Joshua Murphy, Mokgadi Phokojoe, Mareilize Gorgens, Sydney Rosen, David Wilson, Yogan Pillay, Nicole Fraser

1141 SUSTAINABLE VIRAL LOAD MONITORING SCALE-UP: GEOSPATIAL OPTIMIZATION MODEL FOR ZAMBIA
Brooke E. Nichols, Sarah Girdwood, Thomas Crompton, Lynsey E. Stewart-Isherwood, Leigh Berrie, Dorman Chimhamhiwa, Crispin Moyo, John Kuehnle, Sydney Rosen, for the EQUIP Health team
1142  EXPANDING VIRAL LOAD TESTING ACCESS THROUGH EVALUATION OF THE GENEXPERT IN BOTSWANA
Rachel S. Beard, Anikie Mathoma, Mackenzie Hurlston, Naledi Nyepetsi, Christopher Serumola, Joyce Basotli, Ritah Moatlhodi, Unami Mathebula, Otisile Meswele, Charity Ralegoreng, Tefera Agizew, Rosanna Boyd, Madisa Mine, Ishmael Kasvosve

1143  THE ECONOMIES OF SCALE OF TEST AND TREAT: A LONGITUDINAL COSTING STUDY IN SWAZILAND
Shaukat Khan, Cebele Wong, Pascal Geldsetzer, Gerda Asmus, Thomas How, Charlotte Lejeune, Velephi Okello, Till Bärnighausen

1144  DECREASED ALCOHOL USE (EVEN WITHOUT ABSTINENCE) IS ASSOCIATED WITH BETTER VIRAL LOAD
Heidi M. Crane, Robin M. Nance, Andrew Hahn, Judith I. Tsui, Michael J. Mugavero, Bryan Lau, Geetanjali Chander, Sonia Napravnik, Karen Cropsey, Katerina A. Christopoulos, Rob Fredericksen, Dennis Donovan, Jane M. Simoni, Mari Kitahata, Joseph Delaney

1145  DURABILITY OF FINANCIAL INCENTIVES EFFECT ON VIRAL SUPPRESSION AND CONTINUITY IN CARE
Wafaa M. El-Sadr, Geetha Beauchamp, Irene Hall, Lucia V. Torian, Barry S. Zingman, Garret Lum, Richard A. Elion, Kate Buchacz, David Burns, Allison Zerbe, Theresa Gamble, Deborah J. Donnell

Poster P-W1 MODELING HIV TESTING AND PREVENTION STRATEGIES
Poster Hall B
2:30 PM – 4:00 PM

1146  COST-EFFECTIVENESS OF REGULAR HIV SCREENING FOR YOUNG MEN WHO HAVE SEX WITH MEN
Anne M. Neilan, Alexander Bulteel, Kenneth Freedberg, Sybil Hosek, Raphael J. Landovitz, Rochelle P. Walensky, Craig M. Wilson, Andrea L. Ciaranello

1147  REPEAT HIV TESTING DURING PREGNANCY IN KENYA: AN ECONOMIC EVALUATION
Anna Joy Rogers, Janet M. Turan, Ellen F. Eaton, Stephen T. Mennemeyer

1148  PREFERENCES AND WILLINGNESS-TO-PAY FOR BLOOD AND ORAL-FLUID HIV SELF-TESTS IN KENYA
Kristen Little, Nicholas L. Wilson, Patrick Alyward, Hildah Essendi

1149  THE PrEP CARE CONTINUUM AND HIV RACIAL DISPARITIES AMONG MEN WHO HAVE SEX WITH MEN
Samuel Jenness, Kevin Maloney, Dawn K. Smith, Karen W. Hoover, Steven M. Goodreau, Kevin Weiss, Eli Rosenberg, Patrick S. Sullivan

1150  IMPROVING STATEWIDE PRE-EXPOSURE PROPHYLAXIS IMPLEMENTATION AMONG MSM
Jason Gantenberg, Maximilian King, Madeline C. Montgomery, Omar Galarraga, Mattia Prosperi, Brandon D. Marshall, Philip A. Chan

1151  POTENTIAL EFFECTIVENESS OF LONG-ACTING INJECTABLE PrEP IN MSM: A MODELING STUDY
Brandon D. Marshall, William C. Goedel, Maximilian King, David P. Durham, Philip A. Chan, Jeffrey P. Townsend, Alison P. Galvani
1152 QUANTIFYING INDIRECT BENEFITS OF PrEP: MODELING ANALYSIS OF ORAL PrEP IN ZIMBABWE
Zindoga Mukandavire, Daniel J. Klein, Graham F. Medley, Anna Bershteyn, Katharine Kripke, Delivette Castor, Definate Nhamo, Joseph Murungu, Taurai Bhatasara, Lawrance Nyazema, Kudakwashe Takarinda, Kristine Torjesen

1153 DESIGNING HIV VACCINE DELIVERY STRATEGIES IN SOUTH AFRICA: A POLICY ANALYSIS
Blythe J. Adamson, Simon de Montigny, Benoît R. Mâsse, Louis Garrison, James G. Kublin, Peter Gilbert, Dobromir Dimitrov

1154 FINE TUNING SPATIAL RESOLUTION OF HIV EPIDEMIOLOGIC DATA WHILE PROTECTING PRIVACY
Marta M. Jankowska, Tommi O. Gaines, Susan J. Little, Sanjay R. Mehta, Antoine Chaillon
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Poster locations are as follows:

Poster Hall A — Basic Science (categories A to E), posters 167 to 454
Poster Hall B — Epidemiology/Public Health (categories R to W), posters 886 to 1158
Poster Hall D — Clinical (categories F to Q), posters 455 to 885LB

A. VIROLOGY
P-A1 MOLECULAR VIROLOGY (Monday)
P-A2 HOST CELL PATHWAYS AND VIRAL REPLICATION (Tuesday)
P-A3 EARLY EVENTS: METHODS AND MECHANISM (Tuesday)
P-A4 HIV AND HOST DEFENSES (Wednesday)

B. PATHOGENESIS: HUMAN STUDIES AND ANIMAL MODELS
P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION (Monday)
P-B2 IMMUNE ACTIVATION AND SUPPRESSION IN HIV INFECTION (Tuesday)
P-B3 NATURAL AND UNNATURAL CONTROL OF HIV INFECTION (Tuesday)
P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION (Tuesday)
P-B5 COMPARTMENTS FOR HIV REPLICATION (Tuesday)
P-B6 THE MICROBIOME AND HIV: TRANLOCATION AND INTERVENTION (Wednesday)
P-B7 EFFECT OF HIV INFECTION ON THE MICROBIOME (Wednesday)
P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION (Wednesday)

C. HOST IMMUNE RESPONSES TO INFECTION, VACCINES, AND IMMUNOTHERAPY
P-C1 KILLERS: NK AND CD8 CELLS (Wednesday)
P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES (Wednesday)
P-C3 NEUTRALIZING ANTIBODIES (Monday)
P-C4 NON-NEUTRALIZING ANTIBODIES (Monday)
P-C5 VACCINE DESIGN AND TESTING (Tuesday)
P-C6 NOVEL INTERVENTIONAL STRATEGIES (Tuesday)

D. HIV RESERVOIRS, LATENCY, AND ALL CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL (Monday)
P-D02 INSIGHTS FROM HIV REBOUND (Monday)
P-D03 HIV RESERVOIRS IN ACUTE INFECTION (Monday)
P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS (Monday)
P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE (Tuesday)
P-D06 NOVEL INTERVENTIONS TO TARGET HIV RESERVOIRS (Tuesday)
P-D07 CHARACTERIZING HIV RESERVOIRS (Tuesday)
P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS (Wednesday)
P-D09 MARKERS OF HIV RESERVOIRS (Wednesday)
P-D10 QUANTIFYING HIV RESERVOIRS (Wednesday)

E. NEUROPATHOGENESIS AND CNS HIV COMPLICATIONS
P-E1 NEUROCOGNITIVE CORRELATES, INCLUDING ANTIRETROVIRAL THERAPY AND VASCULAR DISEASE (Monday)
P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION (Monday)
P-E3 NEUROCOGNITIVE CORRELATES: TREATMENT STRATEGIES AND ADJUNCTIVE TREATMENT (Monday)
P-E4 NEUROIMAGING AND ASSOCIATED BIOMARKERS (Tuesday)
P-E5 CNS RESERVOIRS, ESCAPE, ANTIRETROVIRAL THERAPY, AND RESPONSES (Wednesday)
P-E6 BASIC NEUROPATHOGENES AND NEUROPATHOLOGY (Wednesday)
F. CLINICAL PHARMACOLOGY
P-F1 ANTIRETROVIRAL, ANTITUBERCULAR, AND ANTIMALARIAL PHARMACOKINETICS (Monday)
P-F2 PHARMACOLOGIC ASSESSMENT OF ADHERENCE (Monday)
P-F3 ANTIRETROVIRAL PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS (Tuesday)
P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS (Tuesday)
P-F5 NOVEL FORMULATIONS FOR ANTIRETROVIRAL DRUG DELIVERY (Wednesday)

G. ANTIRETROVIRAL THERAPY: PRE-CLINICAL AND RANDOMIZED TRIALS AND
H. ANTIRETROVIRAL THERAPY: EFFICACY AND EFFECTIVENESS STUDIES
P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES (Monday)
P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS (Monday)
P-H3 ANTIRETROVIRAL SWITCH STUDIES (Monday)
P-H4 ANTIRETROVIRAL TREATMENT-EXPERIENCED STUDIES (Wednesday)
P-H5 ANTIRETROVIRAL ADHERENCE (Wednesday)
P-H6 VIRAL LOAD MONITORING AND SUPPRESSION (Wednesday)
P-H7 IMMUNE RECOVERY AND HIV CONTROL (Wednesday)

I. HIV DRUG RESISTANCE
P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN (Tuesday)
P-I2 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY (Tuesday)
P-I3 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS! (Tuesday)
P-I4 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF? (Tuesday)
P-I5 PREVALENCE OF ANTIRETROVIRAL THERAPY RESISTANCE: THE POPULATION MATTERS (Wednesday)
P-I6 NEW INSIGHTS INTO ANTIRETROVIRAL SUSCEPTIBILITY AND RESISTANCE (Wednesday)

J. HIV DIAGNOSTICS
P-J1 HIV DIAGNOSTICS (Tuesday)

K. HEPATITIS VIRUSES AND LIVER COMPLICATIONS
P-K01 HCV DIAGNOSIS AND TESTING (Monday)
P-K02 MOLECULAR EPIDEMIOLOGY OF HCV NETWORKS (Monday)
P-K03 NEW HCV INFECTIONS (Monday)
P-K04 HCV CASCADE (Tuesday)
P-K05 HCV CASCADE: TREATMENT AND BEYOND (Tuesday)
P-K06 HEPATITIS B AND DELTA (Tuesday)
P-K07 NON-B, NON-C HEPATITIS (Wednesday)
P-K08 HEPATITIS BEYOND THE LIVER (Wednesday)
P-K09 MICRO-RNA: A LOT OF INFORMATION IN A LITTLE BIT OF RNA (Wednesday)
P-K10 STEATOSIS AND CIRRHOSIS (Tuesday)

L. MALIGNANCIES
P-L1 HIV-ASSOCIATED CANCER: EPIDEMIOLOGY AND OUTCOMES (Monday)
P-L2 CERVICAL AND ANAL CANCER AND HPV (Tuesday)
P-L3 HIV-RELATED LYMPHOMA AND LIVER CANCER (Wednesday)
M. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

P-M1 ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR DISEASE (Wednesday)
P-M2 IMMUNOLOGIC FACTORS AND PATHOGENESIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (Wednesday)
P-M3 RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ROLE OF FAT AND OTHER FACTORS (Wednesday)
P-M4 PREDICTING CARDIOVASCULAR DISEASE RISK AND STATIN USE (Tuesday)
P-M5 REDUCING CARDIOVASCULAR DISEASE RISK (Tuesday)
P-M6 HEART FAILURE, VENTRICULAR FUNCTION, AND PERIPHERAL ARTERY DISEASE (Tuesday)
P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS (Monday)
P-M8 CARDIAC AND PULMONARY COMPLICATIONS IN LOW- AND MIDDLE-INCOME SETTINGS (Monday)

N. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY

P-N01 BONE DISEASE (Monday)
P-N02 RENAL DISEASE (Tuesday)
P-N03 ADIPOSE TISSUE (Wednesday)
P-N04 DIABETES AND DIET (Wednesday)
P-N05 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Tuesday)
P-N06 DEPRESSION (Tuesday)
P-N07 FRAILTY AND FUNCTIONAL STATUS (Monday)
P-N08 AGING: BIOLOGIC MECHANISMS (Wednesday)
P-N09 HOSPITALIZATION AND OUTCOMES (Wednesday)
P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS (Tuesday)

Q. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS

P-O1 TUBERCULOSIS INCIDENCE, SCREENING, AND DIAGNOSIS (Monday)
P-O2 TUBERCULOSIS BIOMARKERS AND INFLAMMATION (Monday)
P-O3 TUBERCULOSIS TRANSMISSION DYNAMICS, DRUG RESISTANCE, AND TREATMENT ISSUES (Monday)
P-O4 CRYPTOCOCCAL MENINGITIS AND OTHER FUNGAL INFECTIONS (Tuesday)
P-O5 HIV-ASSOCIATED SYPHILIS (Wednesday)
P-O6 RATES AND RISKS OF OTHER OIs (Wednesday)

P. MATERNAL/ FETAL HIV

P-P1 ANTIRETROVIRAL PHARMACOKINETICS, SAFETY, AND STRATEGIES DURING PREGNANCY (Monday)
P-P2 ADHERENCE, VIRAL SUPPRESSION, AND RETENTION IN PREGNANT AND POSTPARTUM WOMEN (Monday)
P-P3 INFANT HIV INFECTION AND DIAGNOSIS IN THE ERA OF OPTION B+ (Tuesday)
P-P4 HIV, ANTIRETROVIRAL THERAPY, AND PREGNANCY OUTCOMES (Wednesday)

Q. PEDIATRICS AND ADOLESCENTS

P-Q1 PHARMACOKINETICS, SAFETY, AND UPTAKE OF HIV CO-TREATMENTS IN CHILDREN (Monday)
P-Q2 SOMETHING OLD, SOMETHING NEW: PHARMACOKINETICS AND SAFETY OF ARVs FOR INFANTS, CHILDREN, AND ADOLESCENTS (Monday)
P-Q3 AGING UP WITH HIV INFECTION: HEALTH OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS (Monday)
P-Q4 HIV AND ANTIRETROVIRAL THERAPY OUTCOMES IN CHILDREN AND ADOLESCENTS (Tuesday)
P-Q5 RESPONSE TO EARLY INFANT ANTIRETROVIRAL THERAPY (Tuesday)
P-Q6 HEALTH OUTCOMES FOR HIV-EXPOSED UNINFECTED INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)
P-Q7 HIV-EXPOSED INFANTS: HOW ARE THEY DIFFERENT? (Wednesday)
P-Q8 INFANT TESTING AND STRATEGIES (Wednesday)
R. EPIDEMIOLOGY
P-R1 LATE PRESENTATION AND MORTALITY (Monday)
P-R2 EPIDEMIOLOGY AND RISK FACTORS (Monday)
P-R3 PHYLOGENETICS IN EPIDEMIOLOGY (Tuesday)
P-R4 HIV AND DRUG USE (Wednesday)
P-R5 STIs AND HIV (Wednesday)

S. TESTING
P-S1 IMPROVING COMMUNITY- AND CLINIC-BASED TESTING (Wednesday)
P-S2 ME, MYSELF, AND I: SELF-TESTING FOR HIV DIAGNOSIS (Wednesday)
P-S3 EARLY INFECTION AND RECYCNY ASSAYS (Tuesday)

T. PREVENTION INTERVENTIONS
P-T01 BARRIERS AND FACILITATORS OF PrEP (Monday)
P-T02 PrEP AND STIs: THE EMERGING STORY (Wednesday)
P-T03 THE INTERSECTION OF DRUG USE AND PrEP (Wednesday)
P-T04 PEP AND ON-DEMAND PrEP (Wednesday)
P-T05 PrEP AND HIV INCIDENCE (Wednesday)
P-T06 ORAL PrEP IN WOMEN (Tuesday)
P-T07 PrEP IN SERODISCORDANT COUPLES (Tuesday)
P-T08 MUCOSAL SAFETY STUDIES OF VAGINAL, RECTAL RING, AND ORAL PrEP (Monday)
P-T09 PHASE I STUDIES OF MONOCLONAL ANTIBODIES IN NON-INFECTED ADULTS (Tuesday)
P-T10 SAFETY AND ACCEPTABILITY OF MALE CIRCUMCISION (Tuesday)

U. CONTRACEPTIVE AND REPRODUCTIVE HEALTH IN WOMEN
P-U1 CLOSING THE GAP: INTEGRATION OF FAMILY PLANNING IN HIV PREVENTION AND CARE (Tuesday)
P-U2 CARING FOR WOMEN LIVING WITH HIV: MENOPAUSE AND CONTRACEPTION (Monday)

V. IMPLEMENTATION AND SCALE-UP OF TREATMENT AND CARE
P-V1 LINKAGE, ENGAGEMENT, AND RETENTION (Tuesday)
P-V2 EARLY ANTIRETROVIRAL THERAPY INITIATIVE (Tuesday)
P-V3 TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND COMPLICATIONS (Wednesday)
P-V4 ADHERENCE AND TREATMENT OUTCOMES (Wednesday)

W. POPULATION AND COST MODELING
P-W1 MODELING HIV TESTING AND PREVENTION STRATEGIES (Wednesday)
P-W2 MODELING ANTIRETROVIRAL THERAPY INTERVENTIONS AND OUTCOMES (Monday)
INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that the authors have noted women or women’s issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the full program for other presentations that may address this subject.

MONDAY, MARCH 5, 2018

30LB  RESULTS OF ACTG A5288: A STRATEGY STUDY IN RLS FOR 3RD-LINE ART CANDIDATES (Oral Abstract Session O-02)
45  FEMALE HIV ACQUISITION PER SEX ACT IS ELEVATED IN LATE PREGNANCY AND POSTPARTUM (Oral Abstract Session O-04)
207  CELL RECRUITMENT EVENTS DURING THE MENSTRUAL CYCLE ASSOCIATE WITH SHIV SUSCEPTIBILITY (Poster Session P-B1)
288  CHARACTERIZATION OF THE NEUTRALIZING ANTIBODY RESPONSE IN A LINKED HIV SUPERINFECTION (Poster Session P-C3)
297  THE CODEVELOPMENT OF ANTIBODY GLYCOSYLATION AND FUNCTIONALITY IN HIV INFECTION (Poster Session P-C4)
337  HIV-1 VIRAL REBOUND AND SAFETY OUTCOMES OF POSTPARTUM TREATMENT INTERRUPTION IN WOMEN (Poster Session P-D02)
339  HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION (Poster Session P-D03)
341  HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I (Poster Session P-D03)
401  USE OF NON-ANTIRETROVIRAL MEDICATIONS THAT MAY IMPACT NEUROCOGNITION (Poster Session P-E1)
412  CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT DIFFER BY SEX (Poster Session P-E1)
420  LOW DOSE HYDROCORTISONE ENCHANCES COGNITIVE FUNCTIONING IN HIV-INFECTED WOMEN (Poster Session P-E2)
423  DEPRESSION SYMPTOM CHANGES OF HIV-POSITIVE INDIVIDUALS IN THE RAKAI COHORT (Poster Session P-E3)
461  PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH LOW PROTEASE INHIBITOR LEVELS IN HAIR (Poster Session P-F2)
462  EFAVIRENZ LEVEL IN HAIR PREDICTS VIROLOGIC RESPONSE BETTER THAN LEVEL IN BLOOD (Poster Session P-F2)
500  SWITCHING TO BICTEGRAVIR/EMTRACITABINE/TENOFOVIR ALAFENIMIDE (B/F/TAF) IN WOMEN (Poster Session P-H3)
586  ESTIMATING HIV, HCV AND HSV-2 INCIDENCE FROM EMERGENCY DEPARTMENT SEROSURVEYS (Poster Session P-K03)
658  LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN (Themed Discussion TD-03)
659  GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+ (Themed Discussion TD-03)
719  ARV-NAIVE HIV-INFECTED ADULTS HAD LOWER BONE FORMATION MARKERS THAN HIV-UNINFECTED (Poster Session P-N01)
Index of Studies Related to Women

720 TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY (Poster Session P-N01)

721 OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN (Poster Session P-N01)

727 HYPERKYPHOSIS AND AGING IN THE WOMEN'S INTERAGENCY HIV STUDY (Poster Session P-N01)

803 INCREASED RISK OF HYPERTENSION IN PREGNANCY AMONG WOMEN ON NEVIRAPINE-BASED REGIMENS (Poster Session P-P1)

804 DOES CHANGING ART IN EARLY PREGNANCY FOR FETAL RISKS DESTABILIZE VIRAL SUPPRESSION? (Poster Session P-P1)

805 COMPARISON OF FOUR CLASSICAL PI- AND Raltegravir-BASED REGIMENS DURING PREGNANCY (Poster Session P-P1)

806 Raltegravir in PREGNANCY: PATTERNS OF USE AND BIRTH OUTCOMES IN THE UK AND IRELAND (Poster Session P-P1)

807 DolPHIN-1: Dolutegravir vs Efavirenz When Initiating Treatment in Late Pregnancy (Poster Session P-P1)

808 Dipsticks Proteinuria to Predict Renal Dysfunction in HIV-Infected Pregnant Women (Poster Session P-P1)

809 Concentrations of TFV-DP During Pregnancy Among Women Using PrEP (Poster Session P-P1)

810 Ex Vivo Cotyledon Perfusion Fairly predicts in Vivo ARV Human Placental Transfer (Poster Session P-P1)

811 Cabergoline for Lactation Suppression Among HIV+ and HIV- Women (Poster Session P-P2)

812 Predictors of Virologic Failure in Postpartum Women on ART in Promise 1077HS (Poster Session P-P2)

813 Disparities in Antenatal Virologic Failure Among Women Receiving Option B+ in Kenya (Poster Session P-P2)

814 ART Adherence Among Pregnant and Non-Pregnant Women in South Africa and Uganda (Poster Session P-P2)

815 Early Clinical Events After Art Initiation in Pregnancy Influence Viral Load Outcomes (Poster Session P-P2)

817 Quantifying Visit Adherence in Pregnant Women Initiating Art in Swaziland (Poster Session P-P2)

818 Text Messaging for Retention in PMTCT: A Stepped-Wedge Cluster-Randomized Trial (Poster Session P-P2)

819 Does QI Improve PMTCT Processes in Rural South Africa? A Stepped-Wedge Cluster RCT (Poster Session P-P2)

820 Improved Postpartum HIV Outcomes After Care Coordination Team Intervention (Poster Session P-P2)

903 Life Expectancy in Key Populations of Adults with HIV in the US and Canada (Poster Session P-R1)

911 HIV Transmission Between Men Who Have Sex with Men and Heterosexual Women (Poster Session P-R2)

917 HIV Diagnoses Among Women in Rural vs Non-Rural Areas, United States, 2010-2016 (Poster Session P-R2)
920 HIV PREVALENCE AMONG WOMEN WHO EXCHANGE SEX RECRUITED IN 4 US CITIES, 2016 (Poster Session P-R2)
921 TRANSACTIONAL SEX MEASUREMENT AND ASSOCIATION WITH HIV INCIDENCE AMONG WOMEN (Poster Session P-R2)
922 VIOLENCE AND HIV RISK FACTORS AMONG WOMEN WHO EXCHANGE SEX FOR MONEY OR DRUGS (Poster Session P-R2)
924 AN AGE-STRATIFIED RISK SCORE TO PREDICT HIV ACQUISITION IN YOUNG SOUTH AFRICAN WOMEN (Poster Session P-R2)
933 NO CHANGE IN THE FREQUENCY OF AGE DISPARATE RELATIONSHIPS OR IMPACT ON HIV STATUS (Poster Session P-R2)
942 CONCOMITANTLY SUPPRESSED SYSTEMIC AND IMBALANCED MUCOSAL IMMUNITY INCREASE HIV RISK (Poster Session P-R2)
1059LB EARLY TERMINATION OF A PHASE 1 TRIAL OF TENOFUROVIR DISOPROXIL FUMARATE VAGINAL RING (Poster Session P-T08)
1072 HIV-1 RESERVOIR DYNAMICS IN MENOPAUSAL WOMEN DURING HORMONE THERAPY (Poster Session P-U2)
1073 ASSOCIATION OF HIV STATUS WITH SEXUAL FUNCTION IN WOMEN AGED 45-60 (Poster Session P-U2)
1074 MENOPAUSAL SYMPTOMS ARE ASSOCIATED WITH PSYCHOLOGICAL DISTRESS IN HIV+ WOMEN (Poster Session P-U2)
1075 REPRODUCTIVE TRACT INFECTION RISK-BASED SCREENING FOR IUD INSERTION IN HIV+ WOMEN (Poster Session P-U2)

TUESDAY, MARCH 6, 2018

67 CD8+ T CELL RESPONSES IN TREATED HYPERACUTE HIV INFECTION LIMIT HIV RESERVOIR SIZE (Oral Abstract Session O-05)
246 INNATE LYMPHOID CELLS IN ENDOCERVICAL MUCOSA OF HIV INFECTED WOMEN (Poster Session P-B5)
249 NEUTROPHIL EXTRACELLULAR TRAPS PREVENT HIV INFECTION IN THE GENITAL TRACT (Poster Session P-B5)
271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN (Themed Discussion TD-06)
361 SEX-BASED DIFFERENCES IN TRANSCRIPTOMIC PROFILES AND HIV RESERVOIR CORRELATES (Poster Session P-D07)
464 HIGHER NRTI METABOLITE:ENDOGENOUS NUCLEOTIDE RATIOS IN OLDER HIV+ WOMEN ON TDF/FTC (Poster Session P-F3)
466 CYP2B6 VARIANTS ALTER ETIONOGESTREL PHARMACOKINETICS WHEN COMBINED WITH EFAVIRENZ (Poster Session P-F3)
469 PHARMACOKINETICS (PK) OF ETHINYLESTRADIOL/LEVONORGESTREL WITH ATAZANAVIR/COBICISTAT (Poster Session P-F3)
568 INCREASING POSITIVITY FOR NON-PLASMA SAMPLES USING THE ABBOTT REALTIME HIV-1 ASSAY (Poster Session P-J1)
648 MR ELASTOGRAPHY DETECTS HIGHER LIVER FIBROSIS IN UNCONTROLLED HIV INFECTION (Poster Session P-K10)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>657</td>
<td>SUPPRESSIVE ART ASSOCIATED WITH EFFECTIVE TREATMENT OF CERVICAL PRECANCER</td>
<td>P-L2</td>
</tr>
<tr>
<td>658</td>
<td>LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN</td>
<td>P-L2</td>
</tr>
<tr>
<td>659</td>
<td>GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+</td>
<td>P-L2</td>
</tr>
<tr>
<td>660</td>
<td>IMPACT OF SINGLE-DOSE NANOVALENT VACCINE FOR HIV-HPV COINFECTION IN SOUTH AFRICA</td>
<td>P-L2</td>
</tr>
<tr>
<td>661</td>
<td>COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN WOMEN WITH HIV IN SOUTH AFRICA</td>
<td>P-L2</td>
</tr>
<tr>
<td>694</td>
<td>MYOCARDIAL STEATOSIS IN RELATION TO CARDIAC DYSFUNCTION AMONG WOMEN LIVING WITH HIV</td>
<td>P-M6</td>
</tr>
<tr>
<td>695</td>
<td>SUB-CLINICAL CARDIAC SYSTOLIC DYSFUNCTION AMONG WOMEN LIVING WITH HIV</td>
<td>P-M6</td>
</tr>
<tr>
<td>701</td>
<td>CONTRIBUTION OF HIV, HCV, AND VASCULAR RISK FACTORS TO PERIPHERAL ARTERIAL DISEASE</td>
<td>P-M6</td>
</tr>
<tr>
<td>720</td>
<td>TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY</td>
<td>TD-09</td>
</tr>
<tr>
<td>721</td>
<td>OPTION B-PLUS ART, PREGNANCY, LACTATION AND BONE HEALTH IN UGANDAN WOMEN</td>
<td>TD-09</td>
</tr>
<tr>
<td>821</td>
<td>MATERNAL VIRAL LOAD SUPPRESSION AND VERTICAL TRANSMISSION IN MALAWI’S PMTCT PROGRAM</td>
<td>P-P3</td>
</tr>
<tr>
<td>822</td>
<td>INFANT HIV-FREE SURVIVAL IN THE ERA OF “OPTION B+” SERVICES IN RURAL ZAMBA</td>
<td>P-P3</td>
</tr>
<tr>
<td>827</td>
<td>MATERNAL ANTI-HIV-1 NAB RESPONSE ASSOCIATES WITH TRANSMISSION AND INFANT MORBIDITY</td>
<td>P-P3</td>
</tr>
<tr>
<td>903</td>
<td>LIFE EXPECTANCY IN KEY POPULATIONS OF ADULTS WITH HIV IN THE US AND CANADA</td>
<td>TD-11</td>
</tr>
<tr>
<td>1043</td>
<td>PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN</td>
<td>P-T06</td>
</tr>
<tr>
<td>1043</td>
<td>PATTERNS OF ORAL PrEP ADHERENCE AND HIV RISK AMONG EASTERN AFRICAN WOMEN</td>
<td>TD-10</td>
</tr>
<tr>
<td>1046</td>
<td>PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT</td>
<td>P-T06</td>
</tr>
<tr>
<td>1046</td>
<td>PrEP AND EARLY ART FOR FEMALE SEX WORKERS IN SOUTH AFRICA: THE TAPS PROJECT</td>
<td>TD-10</td>
</tr>
<tr>
<td>1047</td>
<td>HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PREP DURING ANTENATAL CARE</td>
<td>P-T06</td>
</tr>
<tr>
<td>1047</td>
<td>HIGH PrEP UPTAKE AMONG KENYAN PREGNANT WOMEN OFFERED PREP DURING ANTENATAL CARE</td>
<td>TD-10</td>
</tr>
<tr>
<td>1048</td>
<td>PREDICTORS OF PrEP ELIGIBILITY AMONG AT—RISK WOMEN IN THE SOUTHERN UNITED STATES</td>
<td>P-T06</td>
</tr>
<tr>
<td>1048</td>
<td>PREDICTORS OF PrEP ELIGIBILITY AMONG AT—RISK WOMEN IN THE SOUTHERN UNITED STATES</td>
<td>TD-10</td>
</tr>
<tr>
<td>1049</td>
<td>RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082</td>
<td>P-T06</td>
</tr>
<tr>
<td>1049</td>
<td>RISK BEHAVIOR, PERCEPTION, AND REASONS FOR PrEP AMONG YOUNG AFRICAN WOMEN IN HPTN 082</td>
<td>TD-10</td>
</tr>
</tbody>
</table>
1050 HIV BIOMEDICAL PREVENTION AMONG US WOMEN: KNOWLEDGE, BELIEFS, AND PRACTICES (Poster Session P-T06)

1051 DEPRESSION AND PrEP ADHERENCE AMONG HIGH-RISK HIV-UNINFECTED WOMEN IN EAST AFRICA (Poster Session P-T06)

1063 PHASE 1 TRIAL TO ASSESS SAFETY AND ANTIVIRAL ACTIVITY OF MB66 VAGINAL FILM (Poster Session P-T09)

1068 INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA (Poster Session P-U1)

1069 MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO (Poster Session P-U1)

1070 CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS (Poster Session P-U1)

1071 PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI’S PMTCT PROGRAM (Poster Session P-U1)

1088 POSTPARTUM MOBILITY AND TRANSFER OF CARE AMONG HIV+ WOMEN ON ART IN SOUTH AFRICA (Poster Session P-V1)

1098 TRENDS IN UNSUPPRESSED HIV RNA AFTER LINKAGE TO CARE AMONG KEY POPULATIONS (Poster Session P-V1)

1111LB SAME-DAY ART INITIATION ASSOCIATED WITH POORER RETENTION BUT HIGHER VIRAL SUPPRESSION (Poster Session P-V2)

**WEDNESDAY, MARCH 7, 2018**

131 ITAP TRIAL: MATERNAL AND INFANT EFFICACY AND SAFETY RESULTS 12 MONTHS AFTER DELIVERY (Oral Abstract Session O-11)

134 ACTG 5282: HPV TEST&TREAT VS CYTOLOGY-BASED CERVICAL CANCER PREVENTION IN HIV+ WOMEN (Oral Abstract Session O-11)

138 SIMILAR CLINICAL OUTCOMES BETWEEN FORMULA AND BREASTFEEDING WOMEN IN PROMISE (Oral Abstract Session O-12)

139 PROMISE TRIAL: RESULTS OF CONTINUED VS DISCONTINUED ART AFTER END OF BREASTFEEDING (Oral Abstract Session O-12)

140 ART DETECTION AND RESISTANCE DURING VIRAEMIC EPISODES IN PREGNANCY AND BREASTFEEDING (Oral Abstract Session O-12)

141 VAGINAL CONTRACEPTIVE HORMONE EXPOSURE PROFOUNDLY ALTERED BY EFV- AND ATV/R-BASED ART (Oral Abstract Session O-12)

142LB RANDOMIZED TRIAL OF SAFETY OF ISONIAZID PREVENTIVE THERAPY DURING OR AFTER PREGNANCY (Oral Abstract Session O-12)

143LB HIGH UPTAKE AND REDUCED HIV-1 INCIDENCE IN AN OPEN-LABEL TRIAL OF THE DAPIVIRINE RING (Oral Abstract Session O-13)

144LB HIV INCIDENCE AND ADHERENCE IN DREAM: AN OPEN-LABEL TRIAL OF DAPIVIRINE VAGINAL RING (Oral Abstract Session O-13)

148 EFFECT OF HIV SELF-TESTING ON SEXUAL PARTNER NUMBERS FOR ZAMBIAN FEMALE SEX WORKERS (Oral Abstract Session O-13)

192 INFANT T/F HIV-1 FROM PERIPARTUM TRANSMISSION ARE RESISTANT TO MATERNAL PLASMA (Poster Session P-A4)

267 PREGNANCY ASSOCIATED VAGINAL PROTEOME ALTERATIONS LINKED TO HIV ACQUISITION RISK (Poster Session P-B7)
268 VAGINAL MICROBIOTA AND HIV ACQUISITION RISK AMONG AFRICAN WOMEN (Poster Session P-B7)

269 THE VAGINAL MICROBIOME IN PREGNANCY DIFFERS BY HIV STATUS, ART EXPOSURE, AND CLASS (Poster Session P-B7)

270 BACTERIAL VAGINOSIS ASSOCIATED MICROBES INDUCE ALTERED INNATE IMMUNE PROFILES (Poster Session P-B7)

271 MICROBIOME-ASSOCIATED EPITHELIAL DISRUPTION MODIFIES HIV ACQUISITION RISK IN WOMEN (Poster Session P-B8)

512 ADHERENCE IN EARLY VERSUS LATE ART INITIATION IN SUB-SAHARAN AFRICA (Poster Session P-H5)

522 NATURAL CONTROL OF HIV INFECTION IN A COHORT OF YOUNG WOMEN IN SOUTH AFRICA: HPTN 068 (Poster Session P-H7)

551 ARV DRUG USE AND HIV DRUG RESISTANCE AMONG YOUNG WOMEN IN SOUTH AFRICA (HPTN 068) (Poster Session P-I5)

672 EFFECTS OF ANTIRETROVIRAL THERAPY ON ALLELE-ASSOCIATED LIPOPROTEIN(A) LEVEL IN HIV (Poster Session P-M1)

678 ELEVATED MICROPARTICLE TISSUE FACTOR ACTIVITY AND CAROTID ARTERY PLAQUE IN HIV+ WOMEN (Poster Session P-M2)

740 GESTATIONAL DIABETES IN WOMEN ON DOLUTEGRAVIR- OR EFAVIRENZ-BASED ART IN BOTSWANA (Poster Session P-N04)

744 FOOD INSECURITY IS ASSOCIATED WITH INCREASED INFLAMMATION AMONG HIV-POSITIVE WOMEN (Poster Session P-N04)

829 BIRTH DEFECTS AMONG OFFSPRING OF HIV-INFECTED & UNINFECTED WOMEN IN KAMPALA, UGANDA (Poster Session P-P4)

830 PRECONCEPTIONAL ART AND SPONTANEOUS PRETERM BIRTH IN AN URBAN ZAMBIAN COHORT (Poster Session P-P4)

831 PRENATAL ANTIRETROVIRAL EXPOSURE AND RISK OF LOW BIRTH WEIGHT IN LUSAKA, ZAMBIA (Poster Session P-P4)

832 PREGNANCY OUTCOMES IN THE ERA OF UNIVERSAL HAART IN AFRICA (THE POISE STUDY) (Poster Session P-P4)

833 HIGH RATES OF ADVERSE BIRTH OUTCOMES IN SYPHILIS & HIV COINFECTED WOMEN IN BOTSWANA (Poster Session P-P4)

834 PLACENTAL EVIDENCE OF MATERNAL VASCULAR MALPERFUSION AMONG HIV-INFECTED WOMEN (Poster Session P-P4)

835 INFLAMMATION IN HIV-INFECTED PREGNANT WOMEN IS ASSOCIATED WITH PRETERM BIRTH (Poster Session P-P4)

836 MARKERS OF PRETERM DELIVERY IN HIV+ WOMEN; ROLE OF PROTEASE INHIBITORS AND VITAMIN D (Poster Session P-P4)

884 ENGAGEMENT IN CARE AND INFANT HIV TESTING AMONG LOST TO FOLLOW-UP OPTION B+ PATIENTS (Poster Session P-Q8)

885LB OPTIMIZING EID: A CLUSTER-RANDOMIZED TRIAL OF THE HIV INFANT TRACKING SYSTEM IN KENYA (Poster Session P-Q8)

993 FEMALE SEX WORKERS’ INTERPRETATIONS OF HIV SELF-TEST RESULTS: A PERFORMANCE STUDY (Poster Session P-S2)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1068</td>
<td>INTEGRATION OF FAMILY PLANNING INTO HIV CARE AND TREATMENT PROGRAM IN KENYA</td>
<td>Themed Discussion TD-16</td>
</tr>
<tr>
<td>1069</td>
<td>MISSED OPPORTUNITY FOR FAMILY PLANNING IN HIV-INFECTED WOMEN ON ART IN TOGO</td>
<td>Themed Discussion TD-16</td>
</tr>
<tr>
<td>1070</td>
<td>CONTRACEPTION AND PrEP IN SOUTH AFRICAN HAIR SALONS: OWNER, STYLIST, AND CLIENT VIEWS</td>
<td>Themed Discussion TD-16</td>
</tr>
<tr>
<td>1071</td>
<td>PREGNANCY INTENTION AND CONTRACEPTIVE USE IN MALAWI’S PMTCT PROGRAM</td>
<td>Themed Discussion TD-16</td>
</tr>
<tr>
<td>1131</td>
<td>HEALTHCARE PROVIDER TRUST LINKED TO LONG-TERM HIV VIRAL SUPPRESSION</td>
<td>Poster Session P-V4</td>
</tr>
<tr>
<td>1136</td>
<td>VIRAL SUPPRESSION AFTER INTERMITTENT VIREMIA: WOMEN’S INTERAGENCY HIV STUDY 1994-2015</td>
<td>Poster Session P-V4</td>
</tr>
<tr>
<td>1147</td>
<td>REPEAT HIV TESTING DURING PREGNANCY IN KENYA: AN ECONOMIC EVALUATION</td>
<td>Poster Session P-W1</td>
</tr>
<tr>
<td>1152</td>
<td>QUANTIFYING INDIRECT BENEFITS OF PREP: MODELING ANALYSIS OF ORAL PrEP IN ZIMBABWE</td>
<td>Poster Session P-W1</td>
</tr>
</tbody>
</table>
### INDEX OF PRESENTING AUTHORS

The following index list presenting authors as of February 8, 2018. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook.

<table>
<thead>
<tr>
<th>Aamer, Hadega</th>
<th>370</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel-Mohsen, Mohamed</td>
<td>158, 259</td>
</tr>
<tr>
<td>Abgrall, Sophie</td>
<td>728</td>
</tr>
<tr>
<td>About, Michael</td>
<td>508</td>
</tr>
<tr>
<td>Abrams, Elaine J.</td>
<td>846</td>
</tr>
<tr>
<td>Achwoke, Dunstan</td>
<td>1068, 1112</td>
</tr>
<tr>
<td>Adamson, Blythe J.</td>
<td>1153</td>
</tr>
<tr>
<td>Adu-Gyamfi, Clement G.</td>
<td>773</td>
</tr>
<tr>
<td>Aepfelbacher, Julia A.</td>
<td>641</td>
</tr>
<tr>
<td>Agnew-Brune, Christine</td>
<td>922</td>
</tr>
<tr>
<td>Aguirre, Alfredo</td>
<td>461</td>
</tr>
<tr>
<td>Ajaykumar, Abhinav</td>
<td>879</td>
</tr>
<tr>
<td>Ajibola, Gbolahan</td>
<td>869</td>
</tr>
<tr>
<td>Akapirat, Siriwat</td>
<td>306</td>
</tr>
<tr>
<td>Akiyama, Hisashi</td>
<td>216</td>
</tr>
<tr>
<td>Aldrovandi, Anna</td>
<td>209</td>
</tr>
<tr>
<td>Althoff, Keri N.</td>
<td>103, 903, 904</td>
</tr>
<tr>
<td>Alvarez, Angeles</td>
<td>674</td>
</tr>
<tr>
<td>Alvarez, Jean-Claude</td>
<td>1029</td>
</tr>
<tr>
<td>Alvi, Raza M.</td>
<td>696, 697</td>
</tr>
<tr>
<td>Ambia, Julie</td>
<td>1067</td>
</tr>
<tr>
<td>Ambrose, Zandrea</td>
<td>562</td>
</tr>
<tr>
<td>Amelio, Patrizia</td>
<td>774</td>
</tr>
<tr>
<td>Anderson, Elizabeth M.</td>
<td>365</td>
</tr>
<tr>
<td>Anderson, Motswedi</td>
<td>615, 616</td>
</tr>
<tr>
<td>Andreatta, Kristen</td>
<td>506, 546</td>
</tr>
<tr>
<td>Andrieux-Meyer, Isabelle</td>
<td>842</td>
</tr>
<tr>
<td>Antonio, Marinilla B.</td>
<td>796</td>
</tr>
<tr>
<td>Apondi, Edith</td>
<td>852</td>
</tr>
<tr>
<td>Arikawa, Shino</td>
<td>1069</td>
</tr>
<tr>
<td>Arinaminpathy, Nimalan</td>
<td>56</td>
</tr>
<tr>
<td>Armstrong, Abigail</td>
<td>263</td>
</tr>
<tr>
<td>Arpinadi, Stephen M.</td>
<td>854</td>
</tr>
<tr>
<td>Arthos, James</td>
<td>50</td>
</tr>
<tr>
<td>Asmuth, David M.</td>
<td>636</td>
</tr>
<tr>
<td>Assoumou, Sabrina A.</td>
<td>991</td>
</tr>
<tr>
<td>Atewa, Daniel W.</td>
<td>456</td>
</tr>
<tr>
<td>Audsley, Jennifer</td>
<td>619</td>
</tr>
<tr>
<td>Auld, Andrew F.</td>
<td>31</td>
</tr>
<tr>
<td>Avihingsanon, Anchalee</td>
<td>718, 719</td>
</tr>
<tr>
<td>Awadalla, Magid</td>
<td>695</td>
</tr>
<tr>
<td>Ayieko, James</td>
<td>1090</td>
</tr>
<tr>
<td>Bakken, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balogun, Kayode</td>
<td>428</td>
</tr>
<tr>
<td>Bandera, Alessandra</td>
<td>668</td>
</tr>
<tr>
<td>Band, Kishan</td>
<td>749</td>
</tr>
<tr>
<td>Banga, Riddhima</td>
<td>384</td>
</tr>
<tr>
<td>Bar, Katharine J.</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
<tr>
<td>Baker, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balkan, John D.</td>
<td>527</td>
</tr>
<tr>
<td>Banda, Rachel S.</td>
<td>1142</td>
</tr>
<tr>
<td>Banyard, Roger</td>
<td>133</td>
</tr>
<tr>
<td>Bao, Yangming</td>
<td>553</td>
</tr>
<tr>
<td>Bao, Yan</td>
<td>1042</td>
</tr>
<tr>
<td>Bar, Katharine</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
<tr>
<td>Baker, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balkan, John D.</td>
<td>527</td>
</tr>
<tr>
<td>Banda, Rachel S.</td>
<td>1142</td>
</tr>
<tr>
<td>Banyard, Roger</td>
<td>133</td>
</tr>
<tr>
<td>Bao, Yangming</td>
<td>553</td>
</tr>
<tr>
<td>Bao, Yan</td>
<td>1042</td>
</tr>
<tr>
<td>Bar, Katharine</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
<tr>
<td>Baker, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balkan, John D.</td>
<td>527</td>
</tr>
<tr>
<td>Banda, Rachel S.</td>
<td>1142</td>
</tr>
<tr>
<td>Banyard, Roger</td>
<td>133</td>
</tr>
<tr>
<td>Bao, Yangming</td>
<td>553</td>
</tr>
<tr>
<td>Bao, Yan</td>
<td>1042</td>
</tr>
<tr>
<td>Bar, Katharine</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
<tr>
<td>Baker, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balkan, John D.</td>
<td>527</td>
</tr>
<tr>
<td>Banda, Rachel S.</td>
<td>1142</td>
</tr>
<tr>
<td>Banyard, Roger</td>
<td>133</td>
</tr>
<tr>
<td>Bao, Yangming</td>
<td>553</td>
</tr>
<tr>
<td>Bao, Yan</td>
<td>1042</td>
</tr>
<tr>
<td>Bar, Katharine</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
<tr>
<td>Baker, Jason V.</td>
<td>74, 104</td>
</tr>
<tr>
<td>Balkan, John D.</td>
<td>527</td>
</tr>
<tr>
<td>Banda, Rachel S.</td>
<td>1142</td>
</tr>
<tr>
<td>Banyard, Roger</td>
<td>133</td>
</tr>
<tr>
<td>Bao, Yangming</td>
<td>553</td>
</tr>
<tr>
<td>Bao, Yan</td>
<td>1042</td>
</tr>
<tr>
<td>Bar, Katharine</td>
<td>338</td>
</tr>
<tr>
<td>Barouch, Dan</td>
<td>73LB</td>
</tr>
<tr>
<td>Barrenes, Fredrik</td>
<td>233LB</td>
</tr>
<tr>
<td>Basset, Ingrid Valerie.</td>
<td>769, 1070</td>
</tr>
<tr>
<td>Batista, Cynthia Julia B.</td>
<td>494</td>
</tr>
<tr>
<td>Bauer, Annya</td>
<td>377</td>
</tr>
<tr>
<td>Bauer, Rebecca</td>
<td>1034</td>
</tr>
<tr>
<td>Baeten, Jared</td>
<td>143LB</td>
</tr>
<tr>
<td>Baiyegunhi, Omolara</td>
<td>341</td>
</tr>
</tbody>
</table>
Tanner, Mary 962
Tariq, Shema 1073, 1074
Tatham, Lee M. 482, 483
Tawakol, Ahmed 684LB
Taylor, Bryn C. 258
Taylor, Ian A. 100
Taylor, Kirk A. 673
Teasdale, Chloe A. 839, 898
Telwate, Sumashma 320
Tembo, Taniya 1076
Teran, Richard A. 997
Thao, Vu Phuong. 525
Thiébaut, Rodolphe 507
Thielman, Nathan 503
Thienemann, Friedrich 714
Thin, Kyaw 91
Thirdwa, Deus 1071
Thirumurthy, Harsha 95
Thomas, Réjean 1037, 1038
Thrift, Aaron P. 653, 654
Thudium, Rebekka F. 751
Tiraboschi, Juan M. 726
Tobin, Nicole 267
Tolstrup, Martin 359
Uldrick, Thomas S. 656LB
Underwood, Jonathan 125, 436
Urasa, Peris 983
Van Bilsen, Ward P. H. 905
Van Duyne, Rachel 111
Van Hecke, Clarissa 196
Vandormael, Alain 46, 988
Varell, Marc 627
Vargas, Benni S. 328
Vasan, Sandhya 204
Velásquez, Gustavo E. 39LB
Velloza, Jennifer 1051
Venter, Willem Daniel 1046
Vestad, Beate 257
Vianu Puglisi, Elisabetta 99
Vibholm, Line K. 357
Villiguer, Francois 1060LB
Visseaux, Benoit 958
Vo, Quynh 595
Vos, Alinda 716
Votteler, Joerg 3
Vucicevic, Katarina 460
Waitt, Catriona 55
Walimbwa, Stephen Ian. 459
Walker-Sperling, Victoria 836
Wang, Dan 680
Wang, Qi 247
Wang, Ruibin 635
Wang, Zheng 68
Watson, Meg 907
Webb, Nicholas E. 290
Weinberg, Adriana 836
Weinheimer, Steven 561
Weiser, John 1080
Weiss, Helen A. 110
Weiss, Kevin 1006
Wertheim, Joel O. 956
Wesolowski, Laura 572
White, Kirsten Lofgren. 532
White, Lisa Diane 2
Whitney, James 157
Wicke Salinas, Tomas 630
Winchester, Nicole Eve. 514
Winston, Jennifer 831
Wirtz, Andrea L. 994
Withers, Keenan 564
Wittner, Melanie 387
Wonderlich, Elizabeth R. 398
Wu, Helen 352
Wyles, David L. 127
Yapa, H. Manisha Namalee. 819
Yende-Zuma, Nonhlanhla 924
Youn, Christine 223
Yu, Wen-Han 303, 304
Zaikos, Thomas D. 374LB
Zangerle, Robert 596
Zarwell, Meagan 914
Zash, Rebecca 803, 834
Zhang, Peng 16LB
Zhang, Yinfeng 550, 551
Zhao, Connie Ann. 112
Zhong, Yaoyu 1121
Zhou, Shuntai 175LB
Zielinski-Gutierrez, Emily C. 928
Wagner, Thor A. 351
<table>
<thead>
<tr>
<th>Time</th>
<th>Sunday, March 4, 2018</th>
<th>Monday, March 5, 2018</th>
<th>Tuesday, March 6, 2018</th>
<th>Wednesday, March 7, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td></td>
<td>PLENARY SESSION</td>
<td>Auditorium / Hall C / Balcony</td>
<td>PLENARY SESSION</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEESS</td>
<td>8:30 AM</td>
<td>THE EARLY DAYS OF AIDS: LOOKING BACK AND THINKING AHEAD</td>
<td>8:30 AM</td>
</tr>
<tr>
<td>9:30 AM</td>
<td></td>
<td>9:00 AM</td>
<td>PATHOGENESIS OF TUBERCULOSIS AND VACCINE PREVENTION</td>
<td>9:00 AM</td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>WELCOME RECEPTION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PLAZA LEVEL
Poster Sessions ........................................ Poster Hall A, B
Registration, Bag and Coat Check, Cafeteria

2ND FLOOR
Opening Session, Plenaries .......................... Auditorium/Hall C
Poster Sessions ........................................ Poster Hall D
Speaker Ready Room ................................. 200
IAS–USA Office ........................................ 203

3RD FLOOR
Opening Session, Plenaries ....................... Auditorium Balcony
New Mother's Room ..................................... 307
Personal Considerations Room...................... 308
Overflow Rooms ..................................... Rooms 302, 311, 312

Networking Areas: 303, 305, 309, 310, Cafeteria, Poster Halls A, B, D